Tenon Medical, Inc.

0001575872-22-001085.txt : 20221110 0001575872-22-001085.hdr.sgml : 20221110 20221110164151 ACCESSION NUMBER: 0001575872-22-001085 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 61 CONFORMED PERIOD OF REPORT: 20220930 FILED AS OF DATE: 20221110 DATE AS OF CHANGE: 20221110 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Tenon Medical, Inc. CENTRAL INDEX KEY: 0001560293 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 455574718 STATE OF INCORPORATION: DE FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-41364 FILM NUMBER: 221378010 BUSINESS ADDRESS: STREET 1: 104 COOPER CT. CITY: LOS GATOS STATE: CA ZIP: 95032 BUSINESS PHONE: (408) 649-5760 MAIL ADDRESS: STREET 1: 104 COOPER CT. CITY: LOS GATOS STATE: CA ZIP: 95032 10-Q 1 tnon-20220930.htm FORM 10-Q Tenon Medical, Inc.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

Form

10-Q

(Mark One)

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2022

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

FOR THE TRANSITION PERIOD FROM _________ to __________

COMMISSION FILE NUMBER 001-41364

TENON MEDICAL, INC.

(Exact name of registrant as specified in its charter)

Delaware		45-5574718
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)

104 Cooper Court Los Gatos, CA 95032		(408) 649-5760
(Address of principal executive offices) (Zip Code)		(Registrant’s telephone number, including area code)

___________________________________

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value $0.001 per share	TNON	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	¨	Accelerated filer	¨
Non-accelerated filer	x	Smaller reporting company	x
		Emerging growth company	x

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act) Yes

As of November

2022, the registrant had a total of 11,236,801 shares of its common stock, par value $0.001 per share, issued and outstanding.

INDEX

		Page
	PART I. FINANCIAL INFORMATION	1
Item 1.	Condensed Consolidated Financial Statements (unaudited)	1
	Condensed Consolidated Balance Sheets	1
	Condensed Consolidated Statements of Operations and Comprehensive Loss	2
	Condensed Consolidated Statements of Convertible Preferred Stock and Stockholders’ Equity (Deficit)	3
	Condensed Consolidated Statements of Cash Flows	5
	Notes to Condensed Consolidated Financial Statements	6
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	17
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	23
Item 4.	Controls and Procedures	23
	PART II. OTHER INFORMATION	24
Item 1.	Legal Proceedings	24
Item 1A.	Risk Factors	24
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	24
Item 3.	Defaults Upon Senior Securities	24
Item 4.	Mine Safety Disclosures	24
Item 5.	Other Information	24
Item 6.	Exhibits	25
	SIGNATURES	26

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS

This Quarterly Report on Form 10-Q contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends impacting the financial condition of our business. Forward-looking statements should not be read as a guarantee of future performance or results and will not necessarily be accurate indications of the times at, or by, which such performance or results will be achieved. Forward-looking statements are based on information available at the time those statements are made and/or management’s good faith belief as of that time with respect to future events and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in or suggested by the forward-looking statements.

Forward-looking statements include all statements that are not historical facts. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “could,” “would,” “expect,” “intend,” “seek,” “plan,” “anticipate,” “believe,” “estimate,” “project,” “predict,” “potential,” “might,” “forecast,” “continue,” or the negative of those terms, and similar expressions and comparable terminology intended to reference future periods. Forward-looking statements include, but are not limited to, statements about:

Our ability to effectively operate our business segments;

Our ability to manage our research, development, expansion, growth and operating expenses;

Our ability to evaluate and measure our business, prospects and performance metrics;

Our ability and our national distributor’s ability to compete, directly and indirectly, and succeed in the highly competitive medical devices industry;

Our ability to respond and adapt to changes in technology and customer behavior;

Our ability to protect our intellectual property and to develop, maintain and enhance a strong brand; and

Should one or more of these risks or uncertainties materialize, or should the underlying assumptions prove incorrect, actual results may differ significantly from those anticipated, believed, estimated, expected, intended or planned.

Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We cannot guarantee future results, levels of activity, performance or achievements. Accordingly, the forward-looking statements in this Quarterly Report on Form 10-Q should not be regarded as representations that the results or conditions described in such statements will occur or that our objectives and plans will be achieved, and we do not assume any responsibility for the accuracy or completeness of any of these forward-looking statements.

PART I – FINANCIAL INFORMATION

ITEM 1. Condensed Consolidated Financial Statements

Tenon Medical, Inc.

Condensed Consolidated Balance Sheets

(In thousands, except share data)

	September 30,			December31,
	2022			2021
	(Unaudited)
Assets
Current assets:
Cash and cash equivalents	$	3,153		$	2,917
Short-term investments		9,381			4,404
Accounts receivable		144			76
Inventory		810			188
Prepaid expenses		177			87
Total current assets		13,665			7,672
Fixed assets, net		294			101
Deposits		51			41
Operating lease right-of-use asset		927			1,084
Deferred offering costs		—			374
TOTAL ASSETS	$	14,937		$	9,272

Liabilities, Convertible Preferred Stock, and Stockholders’ EQUITY (DEFICIT)
Current liabilities:
Accounts payable	$	422		$	478
Accrued expenses		603			1,088
Current portion of operating lease liability		241			202
Convertible notes payable and accrued interest, net of debt discount of $0 and $31 at September 30, 2022 and December 31, 2021, respectively		—			12,857
Convertible notes payable and accrued interest due to related parties, net of debt discount of $0 and $2 at September 30, 2022 and December 31, 2021, respectively		—			649
Total current liabilities		1,266			15,274
Operating lease liability, net of current portion		724			911
Total liabilities		1,990			16,185

Commitments and contingencies (Notes 6 and 9)
Convertible preferred stock:
Series A convertible preferred stock, $0.001 par value; 4,500,000 and 2,805,839 shares authorized at September 30, 2022 and December 31, 2021, respectively; 0 and 2,550,763 shares issued and outstanding at September 30, 2022 and December 31, 2021, respectively		—			12,367
Series B convertible preferred stock, $0.001 par value; 491,222 shares authorized; 0and 491,222 shares issued and outstanding at September 30, 2022 and December 31, 2021, respectively		—			1,272
Stockholders’ equity (deficit):
Common stock, $0.001 par value; 130,000,000 and 10,487,904 shares authorized at September 30, 2022 and December 31, 2021, respectively; 11,236,801 and 989,954 shares issued and outstanding at September 30, 2022 and December 31, 2021, respectively		11			1
Additional paid-in capital		44,691			113
Accumulated deficit		(31,587	)		(20,575	)
Accumulated other comprehensive income (loss)		(168	)		(91	)
Total stockholders’ equity (deficit)		12,947			(20,552	)
TOTAL LIABILITIES, CONVERTIBLE PREFERRED STOCK, AND STOCKHOLDERS' EQUITY (DEFICIT)	$	14,937		$	9,272

The accompanying notes are an integral part of these consolidated financial statements.

Tenon Medical, Inc.

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)

(In thousands, except per share data)

	Three Months Ended September 30,						Nine Months Ended September 30,
	2022			2021			2022			2021
Revenue	$	208		$	70		$	414		$	107
Cost of sales		302			18			848			38
Gross (Loss) Profit		(94	)		52			(434	)		69

Operating Expenses
Research and development		797			601			2,016			925
Sales and marketing		645			556			2,864			1,473
General and administrative		1,726			992			5,483			1,570
Total Operating Expenses		3,168			2,149			10,363			3,968

Loss from Operations		(3,262	)		(2,097	)		(10,797	)		(3,899	)

Other Income (Expense)
Gain on investments		72			1			108			1
Interest expense		—			(267	)		(362	)		(340	)
Other income (expense)		19			—			39			(1	)
Total Other Income (Expense), net		91			(266	)		(215	)		(340	)
Net Loss		(3,171	)		(2,363	)		(11,012	)		(4,239	)
Loss attributable to non-controlling interest		—			(22	)		—			(33	)
Net Loss Attributable to Tenon Medical, Inc.	$	(3,171	)	$	(2,341	)	$	(11,012	)	$	(4,206	)
Net Loss Attributable to Tenon Medical, Inc. Per Share of Common Stock
Basic and diluted	$	(0.28	)	$	(2.55	)	$	(1.59	)	$	(4.85	)

Weighted-Average Shares of Common Stock Outstanding
Basic and diluted		11,237			919			6,920			868

Consolidated Statements of Comprehensive Loss:
Net loss	$	(3,171	)	$	(2,363	)	$	(11,012	)	$	(4,239	)
Unrealized loss on investments		(10	)		—			(37	)		—
Foreign currency translation adjustment		(19	)		1			(40	)		1
Total Comprehensive Loss		(3,200	)		(2,362	)		(11,089	)		(4,238	)
Comprehensive loss attributable to non-controlling interest		—			(22	)		—			(33	)
Total comprehensive loss attributable to Tenon Medical, Inc.	$	(3,200	)	$	(2,340	)	$	(11,089	)	$	(4,205	)

The accompanying notes are an integral part of these consolidated financial statements.

Tenon Medical, Inc.

Condensed Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) (Unaudited)

(In thousands, except share data)

Three months ended September 30, 2022 and 2021:

	Series A Convertible Preferred Stock				Series B Convertible Preferred Stock				Common Stock				Additional Paid-In		Accumulated			Accumulated Other Comprehensive			Non- Controlling
	Shares		Amount		Shares		Amount		Shares		Amount		Capital		Deficit			Income			Interest			Total
Balance at June 30, 2022		—	$	—		—	$	—		11,236,801	$	11	$	43,657	$	(28,416	)	$	(139	)	$	—		$	15,113
Stock-based compensation expense		—		—		—		—		—		—		1,034		—			—			—			1,034
Other comprehensive income		—		—		—		—		—		—		—		—			(29	)		—			(29	)
Net loss		—		—		—		—		—		—		—		(3,171	)		—			—			(3,171	)
Balance at September 30, 2022		—	$	—		—	$	—		11,236,801	$	11	$	44,691	$	(31,587	)	$	(168	)	$	—		$	12,947


Balance at June 30, 2021		—	$	—		491,222	$	1,272		883,757	$	1	$	571	$	(6,351	)	$	(57	)	$	1,696		$	(4,140	)
Stock-based compensation expense		—		—		—		—		—		—		143		—			—			—			143
Common stock issued for services		—		—		—		—		61,750		—		436		—			—			—			436
Other comprehensive income		—		—		—		—		—		—		—		—			1			—			1
Net loss		—		—		—		—		—		—		—		(2,341	)		—			(22	)		(2,363	)
Balance at September 30, 2021		—	$	—		491,222	$	1,272		945,507	$	1	$	1,150	$	(8,692	)	$	(56	)	$	1,674		$	(5,923	)

Nine months ended September 30, 2022 and 2021:

	Series A Convertible Preferred Stock						Series B Convertible Preferred Stock						Common Stock				Additional Paid-In		Accumulated			Accumulated Other Comprehensive			Non- Controlling
	Shares			Amount			Shares			Amount			Shares		Amount		Capital		Deficit			Income			Intere st			Total
Balance at December 31, 2021		2,550,763		$	12,367			491,222		$	1,272			989,954	$	1	$	113	$	(20,575	)	$	(91	)	$	—		$	(20,552	)
Stock-based compensation expense		—			—			—			—			—		—		1,755		—			—			—			1,755
Issuance of common stock and warrants, net of issuance costs		—			—			—			—			3,200,000		3		13,762		—			—			—			13,765
Common stock issued upon conversion of Series A preferred stock		(2,550,763	)		(12,367	)		—			—			2,447,728		2		12,365		—			—			—			12,367
Common stock issued upon conversion of Series B preferred stock		—			—			(491,222	)		(1,272	)		245,614		—		1,272		—			—			—			1,272
Common stock issued upon conversion of debt		—			—			—			—			3,955,415		4		13,864		—			—			—			13,868
Common stock issued for services		—			—			—			—			398,090		1		1,560		—			—			—			1,561
Other comprehensive income		—			—			—			—			—		—		—		—			(77	)		—			(77	)
Net loss		—			—			—			—			—		—		—		(11,012	)		—			—			(11,012	)
Balance at September 30, 2022		—		$	—			—		$	—			11,236,801	$	11	$	44,691	$	(31,587	)	$	(168	)	$	—		$	12,947


Balance at December 31, 2020		—		$	—			491,222		$	1,272			830,000	$	1	$	126	$	(4,486	)	$	(57	)	$	1,707		$	(2,709	)
Stock-based compensation expense		—			—			—			—			—		—		208		—			—			—			208
Common stock issued for services		—			—			—			—			115,507		—		816		—			—			—			816
Other comprehensive income		—			—			—			—			—		—		—		—			1			—			1
Net loss		—			—			—			—			—		—		—		(4,206	)		—			(33	)		(4,239	)
Balance at September 30, 2021		—		$	—			491,222		$	1,272			945,507	$	1	$	1,150	$	(8,692	)	$	(56	)	$	1,674		$	(5,923	)

The accompanying notes are an integral part of these consolidated financial statements.

Tenon Medical, Inc.

Condensed Consolidated Statements of Cash Flows (Unaudited)

(In thousands)

	Nine Months Ended September 30,
	2022			2021
Cash Flows from Operating Activities
Net loss	$	(11,012	)	$	(4,239	)
Adjustments to reconcile net loss to net cash used in operating activities:
Unrealized loss on investments		(37	)		(1	)
Non-cash interest expense		362			340
Stock-based compensation expense		1,755			208
Common stock issued for services		1,561			816
Depreciation and amortization		53			1
Amortization of operating right-of-use asset		157			62
Increase (decrease) in cash resulting from changes in:
Accounts receivable		(68	)		(56	)
Inventory		(622	)		21
Prepaid expenses and other assets		(100	)		(129	)
Accounts payable		(56	)		242
Accrued expenses		(485	)		168
Operating lease liability		(148	)		(35	)
Net cash used in operating activities		(8,640	)		(2,602	)

Cash Flows from Investing Activities
Sales of short-term investments		4,404			—
Purchases of short-term investments		(9,381	)		(7,861	)
Purchases of property and equipment		(246	)		(18	)
Net cash used in investing activities		(5,223	)		(7,879	)

Cash Flows from Financing Activities
Proceeds from issuance of common stock, net of issuance costs		14,139			—
Proceeds from issuance of convertible notes payable		—			12,072
Repayment of notes payable		—			(131	)
Debt issuance costs		—			(71	)
Deferred offering costs		—			(222	)
Net cash provided by financing activities		14,139			11,648

Effect of foreign currency translation on cash flow		(40	)		(4	)
Net Increase in Cash and Cash Equivalents		236			1,163

Cash and Cash Equivalents at Beginning of Period		2,917			245
Cash and Cash Equivalents at End of Period	$	3,153		$	1,409

Supplemental Disclosures of Cash Flow Information
Cash paid during the year for:
Interest	$	—		$	1
Income taxes	$	—		$	1

Non-cash investment and financing activities:
Common stock issued upon conversion of preferred stock	$	13,639		$	—
Common stock issued upon conversion of debt	$	13,868		$	—
Right-of-use assets obtained in exchange for lease liability	$	—		$	1,195
Conversion of trade payable to law firm to note payable	$	—		$	556

The accompanying notes are an integral part of these consolidated financial statements.

Notes to Financial Statements (unaudited)(in thousands, except share and per-share data)

1. Organization and Business

Nature of operations

Tenon Medical, Inc. (the “Company”), was incorporated in the State of Delaware on June 19, 2012 and was headquartered in San Ramon, California until June 2021 when it relocated to Los Gatos, California. The Company is a medical device company that has developed a novel, less invasive, inferior-posterior approach to the sacroiliac joint using a single, robust, titanium implant for treatment of the most common types of sacroiliac joint (the “SI Joint”) disorders that cause lower back pain. The Company received U.S. Food and Drug Administration (“FDA”) clearance in 2018 for its primary product, The Catamaran

SI Joint Fusion System (“The Catamaran System”) which is designed to transfix and stabilize the SI Joint. The Company is in the early stages of its commercial launch with its primary focus being on the US market.

Basis of consolidation

The consolidated financial statements of the Company include the accounts of the Company and its wholly-owned subsidiary, Tenon Technology AG (“TTAG”), a Swiss company. TTAG was a majority-owned subsidiary until October 28, 2021, at which date the Company acquired the remaining non-controlling interest of TTAG (see Note 8). All intercompany balances and transactions have been eliminated in consolidation.

2. Summary of Significant Accounting Principles

Basis of presentation

We have prepared the accompanying unaudited condensed consolidated financial statements pursuant to the rules and regulations of the SEC. As permitted under these rules and regulations, we have condensed or omitted certain financial information and footnote disclosures we normally include in our annual consolidated financial statements prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”).

The unaudited condensed consolidated balance sheet as of December 31, 2021 has been derived from our audited consolidated financial statements, which are included in our amended Registration Statement on Form S-1 filed with the SEC on April 20, 2022 (our “amended Registration Statement”).

These condensed consolidated financial statements have been prepared on the same basis as our annual consolidated financial statements and, in management’s opinion, reflect all adjustments consisting only of normal recurring adjustments that are necessary for a fair presentation of our financial information. Our interim period operating results do not necessarily indicate the results that may be expected for any other interim period or for the full fiscal year.

The financial statements of the subsidiary are prepared for the same reporting period as the parent, using consistent accounting policies in all material respects. The amount of consolidated net loss attributable to the Company and ownership interests in TTAG held by parties other than the Company are both presented on the face of the Consolidated Statements of Operations. As TTAG is a wholly-owned subsidiary as of September 30, 2022, this separate presentation has been discontinued for the three and nine months then ended. Further, as the Company purchased the non-controlling interest in TTAG as of October 28, 2021, the amount of consolidated net loss attributable to the Company and the non-controlling interest are both presented on the face of the Consolidated Statements of Operations and Comprehensive Loss.

These unaudited condensed consolidated financial statements and accompanying notes should be read in conjunction with the Company’s audited consolidated financial statements as of and for the years ended December 31, 2021 and 2020 included in our amended Registration Statement.

The Company’s significant accounting policies are disclosed in the audited consolidated financial statements as of and for the years ended December 31, 2021 and 2020 included in our amended Registration Statement. There have been no material changes in the Company’s significant accounting policies during the nine months ended September 30, 2022.

Going concern uncertainty and liquidity requirements

The accompanying consolidated financial statements have been prepared assuming the Company will continue as a going concern, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business.

There is substantial doubt about the Company’s ability to continue as a going concern for one year after the date that these financial statements are issued.

Since inception, the Company has incurred losses and negative cash flows from operations. Management expects to incur additional operating losses and negative cash flows from operations in the foreseeable future as the Company continues its product development programs and starts the commercial launch of The Catamaran System. On April 29, 2022, the Company closed an initial public offering (the “IPO”) of its common stock for proceeds of $13,765, net of issuance costs. Based on the Company’s current level of revenues and expenditures, the Company believes that its existing cash and cash equivalents and short-term investments as of September 30, 2022 will

not provide sufficient funds to enable it to meet its obligations for a period of at least twelve months from the date of the filing of these consolidated financial statements. The Company plans to raise the necessary additional capital through one or a combination of public or private equity offerings, debt financings, and collaborations or licensing arrangements. The condensed consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.

Use of estimates

The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect certain reported amounts and disclosures. Accordingly, actual results could differ from those estimates. Significant estimates made by management include, but are not limited to, realization of deferred tax assets, accrued liabilities, obsolescence of inventory, stock-based compensation and the fair value of the Company’s common stock and preferred stock.

Income Taxes

The Company accounts for income taxes utilizing ASC 740, “Income Taxes”. ASC 740 requires the measurement of deferred tax assets for deductible temporary differences and operating loss carry forwards, and of deferred tax liabilities for taxable temporary differences. Measurement of current and deferred tax liabilities and assets is based on provisions of enacted tax law. The effects of future changes in tax laws or rates are not included in the measurement. The Company recognizes the amount of taxes payable or refundable for the current year and recognizes deferred tax liabilities and assets for the expected future tax consequences of events and transactions that have been recognized in the Company’s financial statements or tax returns. The Company currently has substantial net operating loss carry forwards. The Company has recorded a 100% valuation allowance against net deferred tax assets due to uncertainty of their ultimate realization. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized.

Impact of COVID-19

In March 2020, the World Health Organization declared the coronavirus (“COVID-19”) outbreak to be a pandemic. During the years ended December 31, 2021 and 2020 and the nine months ended September 30, 2022, the Company’s financial results were not significantly affected by the COVID-19 outbreak. The Company has considered all information available as of the date of issuance of these consolidated financial statements and the Company is not aware of any specific events or circumstances that would require an update to its estimates or judgments, or a revision to the carrying value of its assets or liabilities. These estimates may change as new events occur and additional information becomes available. The extent to which the COVID-19 outbreak affects the Company’s future financial results and operations will depend on future developments which are highly uncertain and cannot be predicted, including new information which may emerge concerning the severity of the outbreak, and current or future domestic and international actions to contain and treat it.

Net loss per share

Basic net loss per share is based upon the weighted-average number of common shares outstanding. Diluted net loss per share is based on the assumption that all potential common stock equivalents (convertible preferred stock, stock options, and warrants) are converted or exercised. The calculation of diluted net loss per share excludes potential common stock equivalents if the effect is anti-dilutive. The Company’s weighted-average common shares outstanding for basic and diluted are the same because the effect of the potential common stock equivalents is anti-dilutive.

The Company had the following dilutive common stock equivalents as of September 30, 2022 and 2021 which were excluded from the calculation because their effect was anti-dilutive.

	September 30, 2022		September 30, 2021
Outstanding restricted stock units		1,318,530		—
Outstanding stock options		841,344		705,394
Outstanding warrants		121,000		25,000
Common shares convertible from notes payable		—		2,079,510
Common shares convertible from preferred stock		—		245,611
Total		2,280,874		3,055,515

Recent Accounting Pronouncements

There have been no accounting pronouncements or changes in accounting pronouncements in the nine months ended September 30, 2022 that are significant or potentially significant to the Company.

Investments

The following table sets forth by level, within the fair value hierarchy, the Company’s investments at fair value as of September 30, 2022 and December 31, 2021:

	Level 2
Corporate debt securities:
September 30, 2022	$	9,381
December 31, 2021	$	4,404

Cost and fair value of available-for-sale investments as of September 30, 2022 and December 31, 2021 are as follows:

	Amortized ‎Cost		Gross ‎Unrealized ‎Gains		Gross Unrealized Losses			Fair ‎Value
Corporate debt securities:
September 30, 2022	$	9,418	$	—	$	(37	)	$	9,381
December 31, 2021	$	4,404	$	—	$	—		$	4,404

All of the investments with gross unrealized losses have been in a continuous loss position for less than 12 months.

During the three and nine months ended September 30, 2022 and 2021, the Company did not recognize any significant other-than-temporary impairment losses because the Company does not intend to sell the investments before recovery of their amortized cost bases.

During the three and nine months ended September 30, 2022, there were net gains of approximately $72 and $108, respectively, included in the Company’s net loss. During the three and nine months ended September 30, 2021, there were no such gains included in the Company’s net loss. Accrued interest as of September 30, 2022 and December 31, 2021 was approximately $6 and $18, respectively, and is included in prepaid expenses in the Company’s consolidated balance sheet.

Fixed Assets

Fixed assets, net, consisted of the following:

	September 30, 2022			December 31,2021
Catamaran Tray Sets	$	270		$	77
IT Equipment		56			17
Lab Equipment		14			—
Office Furniture		9			9
Fixed assets, gross		349			103
Less: accumulated depreciation		(55	)		(2	)
Fixed assets, net	$	294		$	101

Depreciation expense was approximately $24 and $1 for the three months ended September 30, 2022 and 2021, respectively. Depreciation expense was approximately $53 and $1 for the nine months ended September 30, 2022 and 2021, respectively.

5. Accrued Expenses

Accrued expenses consisted of the following:

	September 30, 2022		December 31, 2021
Accrued compensation	$	339	$	846
Accrued commissions		49		14
Other accrued expenses		215		228
Total accrued expenses	$	603	$	1,088

6. Debt

Convertible notes payable – parent company

During 2015, the Company issued a $53 convertible promissory note to a consultant that, along with accrued interest at an annual rate of 8.0%, was automatically convertible upon a preferred stock financing of at least $500, at a conversion price equal to 90% of the price per share paid by the other cash purchasers in the future financing. In June 2019, the note and its accrued interest to date was replaced by a $68 convertible promissory note that, along with accrued interest at an annual rate of 8.0%, was automatically convertible upon a preferred stock financing of at least $1,000, at a conversion price equal to 90% of the price per share paid by the other cash purchasers in the future financing. The note had a maturity date of June 12, 2021. In May 2021, the note was again replaced by a $68 convertible promissory note with a maturity date of May 7, 2022 that, along with accrued interest at an annual rate of 8.0%, was automatically convertible upon an IPO or a capital stock financing of at least $5,000. The conversion price was equal to 80% of the IPO price or $1.9565 per share in the event of a capital stock financing of at least $5,000. Accrued interest at September 30, 2022 and December 31, 2021 totaled approximately $0 and $14, respectively.

During 2016, the Company issued a $118 convertible promissory note to a vendor that, along with accrued interest at an annual rate of 8.0%, was automatically convertible upon a preferred stock financing of at least $500, at a conversion price equal to 90% of the price per share paid by the other cash purchasers in the future financing. The note had a maturity date of January 1, 2019 and remained unpaid during 2019 and 2020. In April 2021, the note was replaced by a $118 convertible promissory note with a maturity date of April 30, 2022 that, along with accrued interest at an annual rate of 8.0%, was automatically convertible upon an IPO or a capital stock financing of at least $5,000. The conversion price was equal to 80% of the IPO price or $1.9565 per share in the event of a capital stock financing of at least $5,000. Accrued interest at September 30, 2022 and December 31, 2021 totaled approximately $0 and $56, respectively.

In October 2019, the Company issued a $70 convertible promissory note to the Company’s former Chief Executive Officer that, along with accrued interest at an annual rate of 8.0%, was automatically convertible upon a preferred stock financing of at least $500, at a conversion price equal to 80% of the price per share paid by the other cash purchasers in the future financing. The note had a maturity date of October 12, 2022. In April 2021, the note was replaced by a $70 convertible promissory note with a maturity date of April 30, 2022 that, along with accrued interest at an annual rate of 8.0%, was automatically convertible upon an IPO or a capital stock financing of at least $5,000. The conversion price was equal to 70% of the IPO price or $1.9565 per share in the event of a capital stock financing of at least $5,000. Accrued interest at September 30, 2022 and December 31, 2021 totaled approximately $0 and $12, respectively.

In October 2019, the Company issued a $50 convertible promissory note to an investor that, along with accrued interest at an annual rate of 8.0%, was automatically convertible upon a preferred stock financing of at least $500, at a conversion price equal to 80% of the price per share paid by the other cash purchasers in the future financing. The note had a maturity date of October 21, 2022. In May 2021, the note was replaced by a $50 convertible promissory note with a maturity date of May 3, 2022 that, along with accrued interest at an annual rate of 8.0%, was automatically convertible upon an IPO or a capital stock financing of at least $5,000. The conversion price was equal to 70% of the IPO price or $1.9565 per share in the event of a capital stock financing of at least $5,000. Accrued interest at September 30, 2022 and December 31, 2021 totaled approximately $0 and $9, respectively.

In November 2020, the Company issued a $200 convertible promissory note to the same investor that, along with accrued interest at an annual rate of 8.0%, was automatically convertible upon a preferred stock financing of at least $2,000, at a conversion price equal to 80% of the price per share paid by the other cash purchasers in the future financing. The note had a maturity date of November 16, 2022. In May 2021, the note was replaced by a $200 convertible promissory note with a maturity date of May 3, 2022 that, along with accrued interest at an annual rate of 8.0%, was automatically convertible upon an IPO or a capital stock financing of at least $5,000. The conversion price was equal to 70% of the IPO price or 70% of the price per share paid by the other cash purchasers in the future financing. Accrued interest at September 30, 2022 and December 31, 2021 was approximately $0 and $18, respectively.

In January 2021, the Company issued a promissory note of $131 to a law firm. The note bore interest at 3.0% per annum and had a maturity date of the earlier of July 27, 2021, the closing of a debt or equity financing, or the closing of a change in control transaction. The interest rate was to increase to 5.0% if all principal and interest had not been paid by the maturity date. The Company repaid this note and accrued interest in May 2021.

In April 2021, the Company issued two convertible promissory notes of $40 and $170 to the vendor described in the second paragraph above that, along with accrued interest at an annual rate of 8.0%, were automatically convertible upon an IPO or a capital stock financing of at least $5,000. The conversion price was equal to 70% of the IPO price or 70% of the price per share paid by the other cash purchasers in the future financing. Accrued interest at September 30, 2022 and December 31, 2021 totaled approximately $0 and $11, respectively.

From May through July 2021, in multiple rounds of closings the Company issued convertible promissory notes to multiple investors for aggregate proceeds of approximately $12,177, with maturity dates twelve months from the issuance dates. Of this amount, $620 of notes were issued to related officers, directors, and their family members, and a $50 note was issued to the Chief Executive Officer of the Representative described in Note 9. The notes, along with accrued interest at an annual rate of 8.0%, were automatically convertible upon an IPO, a capital stock financing of at least $5,000, or a change of control transaction. The conversion price upon an IPO or a capital stock financing was equal to the lesser of 70% of the price per share paid by the other cash purchasers, or the price per share at a Company valuation of $22,500. The Company recorded debt issuance costs of approximately $71 as a discount on the convertible notes payable balance. Accrued interest at September 30, 2022 and December 31, 2021 was approximately $0 and $527, respectively.

On April 29, 2022, as a result of the completion of the IPO and as required under the terms of the convertible notes payable described above, the Company converted the entirety of the outstanding principal and accrued interest of the outstanding convertible notes payable to 3,955,415 shares of the Company’s common stock at the conversion price detailed above and issued the common stock to the noteholders, fully satisfying the Company’s obligations.

Convertible notes payable – subsidiary

In June 2021, the Company’s subsidiary issued a convertible promissory note for approximately $107 to TTAG’s minority shareholder. This note, along with accrued interest at an annual rate of 8.0%, could be applied to future TTAG capital increases. The Company purchased this note and accrued interest of approximately $114 in October 2021 from TTAG’s minority shareholder.

7. Leases

In June 2021, the Company entered into a facility lease agreement for its company headquarters in Los Gatos, California. This non-cancelable operating lease expires in June 2026. The Company includes options that are reasonably certain to be exercised as part of the determination of lease terms. The Company may negotiate termination clauses in anticipation of any changes in market conditions, but generally these termination options are not exercised. Residual value guarantees are generally not included within operating leases. In addition to base rent payments, leases may require the Company to pay directly for taxes and other non-lease components, such as insurance, maintenance, and other operating expenses, which may be dependent on usage or vary month-to-month. Non-lease components were considered and determined not to be material. The Company determined if an arrangement is a lease at inception of the contract in accordance with guidance detailed in the new standard and performed the lease classification test as of the lease commencement date. ROU assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent the obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at the lease’s commencement date based on the present value of lease payments over the lease term. When a lease did not provide an implicit rate, the Company used its estimated incremental borrowing rate based on the information available at the commencement date in determining the present value of future payments.

Operating lease costs for the facility lease were $73 and $73 for the three months ended September 30, 2022 and 2021, respectively, and $219 and $85 for the nine months ended September 30, 2022 and 2021, respectively. Lease costs are included in general and administrative expenses in the consolidated statements of operations and comprehensive loss.

Supplemental balance sheet information related to leases was as follows:

	September 30,			December 31,
	2022			2021
Operating lease right-of-use assets	$	927		$	1,084

Operating lease liability, current	$	(241	)	$	(202	)
Operating lease liability, noncurrent		(724	)		(911	)
Total operating lease liabilities	$	(965	)	$	(1,113	)

Future maturities of operating lease liabilities as of September 30, 2022 were as follows:

2022	$	73
2023		293
2024		301
2025		310
2026		144
Total lease payments		1,121
Less: imputed interest		(156	)
Present value of operating lease liabilities	$	965

Other information:

Cash paid for operating leases for the nine months ended September 30, 2022	$	212
Cash paid for operating leases for the nine months ended September 30, 2021	$	58
Remaining lease term - operating leases (in years)		3.75
Average discount rate - operating leases		8.0	%

8. Stockholders’ Equity

The Amended and Restated Certificate of Incorporation dated February 18, 2014 authorized the issuance of 3,937,550 shares of common stock and 2,099,525 shares of preferred stock, with a par value of $0.001 per share.

April 2021 the Company increased the number of authorized shares to 7,000,000 shares of common stock and 2,460,802 shares of preferred stock, and increased the number of authorized shares of Series A Convertible Preferred Stock (“Series A Preferred Stock”) to 1,798,905.

October 2021 the Company increased the number of authorized shares to 10,487,904 shares of common stock and 3,297,061 shares of preferred stock.

February 2022, the Company increased the number of authorized shares to 130,000,000 shares of common stock and 20,000,000 shares of preferred stock.

Reverse Stock Split

On April 6, 2022, the Company effected a 1:2 reverse stock split (the “Reverse Stock Split”) by filing an amendment to the Company’s Amended and Restated Certificate Incorporation, as amended, with the Delaware Secretary of State. The Reverse Stock Split combined every two shares of our common stock issued and outstanding immediately prior to effecting the Reverse Stock Split into one share of common stock. Similarly, shares of Series A and Series B Preferred Stock became convertible into common stock at a conversion rate of one-to-0.5, subject to adjustments for stock dividends, splits, combinations, and similar events. No fractional shares were issued in connection with the Reverse Stock Split. All historical and per share amounts reflected throughout this document have been adjusted to reflect the Reverse Stock Split. The authorized number of shares and the par value per share of the Company’s common stock were not affected by the Reverse Stock Split.

Initial Public Offering

On April 26, 2022, the Company’s Registration Statement relating to the IPO was declared effective by the SEC. The IPO consisted of 3,200,000 shares of common stock, par value $0.001 per share at a public offering price of $5.00 per share. Pursuant to the Underwriting Agreement dated April 26, 2022, between the Company, The Benchmark Company, LLC (“Benchmark”) and Valuable Capital Limited (together with Benchmark, the “Underwriters”), the Company granted the Underwriters warrants to purchase a total of 96,000 shares of the Company’s common stock at an exercise price of $5.00 per share. The warrants expire on the fifth anniversary of the commencement of sales under the IPO. On April 27, 2022, the shares of the Company’s common stock began trading on the Nasdaq Capital Market LLC under the symbol “TNON.”

On April 29, 2022, the IPO closed, and the Company received approximately $13.8 million in net proceeds from the IPO after deducting the underwriting discount and commission and other estimated IPO expenses payable by the Company. As a result of the completion of the IPO and as required under the terms of the convertible notes payable described in Note 6, the Company converted the entirety of the related outstanding principal and accrued interest to 3,955,415 shares of the Company’s common stock at the conversion price detailed in Note 6 and issued the common stock to the noteholders, fully satisfying the Company’s obligations.

On April 29, 2022, as result of the completion of the IPO, the Company converted all shares of Series A and Series B Preferred Stock to 2,693,342 shares of the Company’s common stock at the conversion rate detailed below and issued the common stock to the preferred stockholders, fully satisfying the Company’s obligations. This includes 1,172,346 shares issued to TTAG’s minority shareholder in accordance with the anti-dilution protection provisions of the Exchange Agreement.

Concurrent with the completion of the IPO and in accordance with the Amended and Restated Exclusive Sales Representative Agreement executed in May 2021, the counterparty to the agreement received anti-dilution protections to maintain ownership of 3.0% of the fully diluted equity of the Company through the date of an initial public offering and was issued 312,351 shares of the Company’s common stock to the Representative, fully satisfying the Company’s obligations. Also, as a result of the completion of the IPO, the Company issued 85,739 shares of its common stock to a consultant. The value of these shares issued at the IPO price of $5.00 per share was charged to operating expenses in the Company’s financial statements.

Preferred Stock

On October 28, 2021, the Company entered into an Agreement (the “Exchange Agreement”) with TTAG’s minority shareholder. Pursuant to the Exchange Agreement, TTAG’s minority shareholder agreed to exchange 574,033 shares of Series A Convertible Preferred Stock issued by TTAG, representing its entire ownership interest in TTAG, for the Company’s Series A Preferred Stock, representing a 24% ownership interest in the Company’s fully-diluted capital, which includes the pro forma conversion of all outstanding convertible preferred stock and promissory notes, options, and warrants. Pursuant to the terms of the Exchange Agreement, the Company issued TTAG’s minority shareholder 2,550,763 shares of Series A Preferred Stock. These shares were subject to anti-dilution protection to maintain TTAG’s minority shareholder’s 24% ownership interest in the Company, excluding any shares issued by the Company in an IPO or a qualified offering of at least $5,000 at a per share price of at least $3.3737. Upon conversion of the Company’s convertible notes payable as described in Note 6, the Company issued 1,172,346 shares of its common stock to TTAG’s minority shareholder.

In accordance with ASC 810-10-45-23, the Company did not recognize any gain or loss in the consolidated statements of operations and comprehensive loss in conjunction with the Exchange Agreement. The carrying value of the non-controlling interest in TTAG was reduced to zero, and the value of the Company’s investment in TTAG increased accordingly. The shares of Series A Preferred Stock issued were recorded at fair value. The difference between the increase in the Company’s investment and the fair value of the Series A Preferred Stock issued was recorded as a decrease in Additional Paid in Capital (“APIC”). The resulting negative APIC was then reclassified to accumulated deficit.

In a series of closings from 2012 through 2015, the Company issued an aggregate of 491,222 shares of Series B Convertible Preferred Stock (“Series B Preferred Stock”) at $2.795 per share for proceeds of $1,272, net of stock issuance costs.

The Company classified the convertible preferred stock outside of total stockholders’ deficit because, in the event of certain deemed liquidation events that are not solely within the control of the Company, the shares would become redeemable at the option of the holders. The Company did not adjust the carrying values of the convertible preferred stock to the deemed liquidation values of such shares since a liquidation event was not probable of occurring.

Conversion

At the option of the holder, shares of Series A and Series B Preferred Stock were convertible into common stock at a conversion rate of one-to-0.5, subject to adjustments for stock dividends, splits, combinations, and similar events. Automatic conversion will occur in the event of a firmly underwritten public offering of common stock of the Company at a price of at least $4.00 per share, subject to appropriate adjustments for stock dividends, splits, combinations, and similar events, and with total gross proceeds to the Company of at least $15,000, before deduction of underwriters’ commissions and expenses. As noted above, the Series A and Series B Preferred Stock were converted to common stock at the time of the Company’s IPO.

Redemption

The shares of the Series A and Series B Preferred Stock were redeemable only upon acquisition or liquidation of the Company.

Liquidation preference

With respect to any distributions in connection with a liquidation, dissolution or winding up of the Company, or in connection with the sale of voting control of all or substantially all of the assets of the Company, by way of merger, acquisition, consolidation or similar transaction, prior to any distribution to common stockholders, the holders of Series A and Series B Preferred Stock were entitled to receive $1.526 and $4.981 per share, respectively, plus any declared but unpaid dividends, adjusted to reflect any dividends previously paid. If, upon the occurrence of such event, the assets and funds distributed among the holders of Series A and Series B Preferred Stock shall be insufficient to permit the payment to such holders of the full liquidation preference amounts, the entire assets and funds of the Company legally available shall be distributed ratably among the preferred stockholders in proportion to the preferential amount to which each holder is entitled.

After payment of the liquidation preferences, the holders of common stock are entitled to receive the remaining assets of the Company available for distribution to its stockholders pro rata based on the number of shares of common stock held by each holder.

Voting rights

The holders of vested shares of common stock shall be entitled to vote on any matter submitted to a vote of the stockholders and each such holder shall be entitled to one vote per share of common stock held. The holders of Series A and Series B Preferred Stock were entitled to vote together with the common stock as a single class on any matter submitted to a vote of the stockholders. Holders of Series A and Series B Preferred Stock were entitled to the number of votes equal to the number of common stock issuable upon conversion of their respective Series A and Series B Preferred Stock at the time such shares are voted. The holders of a majority of the preferred stock had additional voting rights as specified in the Company’s Amended and Restated Certificate of Incorporation, as amended.

Equity awards

In 2012, the Board of Directors of the Company (the “Board”) approved the Tenon Medical, Inc. 2012 Equity Incentive Plan (the “2012 Plan”). The 2012 Plan provides for the issuance of common stock options, appreciation rights, and other awards to employees, directors, and consultants. Options issued under the 2012 Plan generally vest over a period of two to four years and have a 10-year expiration date. In April 2021, the Board increased the number of shares of common stock reserved for issuance under the 2012 Plan to 662,516. In July 2021, the Board increased the number of shares of common stock reserved for issuance under the 2012 Plan to 737,516. In August 2021, the Board increased the number of shares of common stock reserved for issuance under the 2012 Plan from 737,516 shares to 799,266 shares and approved the form of a 2022 Equity Incentive Plan.

On January 10, 2022 and February 2, 2022, the Board and stockholders, respectively, of the Company approved the Tenon Medical, Inc. 2022 Equity Incentive Plan (the “2022 Plan”), which was effective on April 25, 2022. The number of shares of common stock that may be subject to awards and sold under the 2022 Plan is equal to 1,600,000. Automatic annual increases in number of shares available for issuance under the 2022 Plan is equal to the least of (a) 1,100,000 shares, (b) 4% of the total number of shares of all classes of common stock outstanding on the last day of the immediately preceding fiscal year, or (c) such number determined by the 2022 Plan administrator no later than the last day of the immediately preceding fiscal year. Annual increases will continue until the tenth anniversary of the earlier of the Board or stockholder approval of the 2022 Plan, which is January 10, 2032. Upon the effective date of the 2022 Plan, the Board terminated the 2012 Plan such that no new equity awards will be issued by the 2012 Plan.

The Company adopted the fair value recognition provisions in accordance with authoritative guidance related to equity-based payments. Compensation expense in 2022 and 2021 includes the portion of awards vested in the periods for all equity-based awards granted, based on the grant date fair value estimated using a Black-Scholes option valuation model, consistent with authoritative guidance.

A summary of the Company’s share option and restricted stock unit activity under its plans is as follows:

	Number of Shares Subject to Outstanding Stock Options		Weighted Average Exercise Price Per Share		Number of Outstanding Restricted Stock Units		Weighted-average Grant Date Fair Value per Share
Outstanding at December 31, 2021		727,394	$	5.32		—	$	—
Granted		113,950	$	2.47		1,318,530	$	7.93
Forfeited		—	$	—		—	$	—
Outstanding at September 30, 2022		841,344	$	4.93		1,318,530	$	7.93

The following table sets forth stock-based compensation expense recognized for the three and nine months ended September 30, 2022 and 2021:

	Three months ended September 30,				Nine months ended September 30,
	2022		2021		2022		2021
Research and development	$	374	$	23	$	581	$	36
Sales and marketing		37		10		61		18
General, and administrative		623		110		1,113		154
Total stock-based compensation expense	$	1,034	$	143	$	1,755	$	208

At September 30, 2022, there were 167,520 shares available for issuance under the 2022 Plan.

Warrants

During 2020, the Company issued warrants to purchase 25,000 shares of common stock to a consultant. The warrants, which are equity-classified, are immediately exercisable at an exercise price of $5.20 per share. The fair value of the warrants on the grant date was $2.30 per warrant, which was calculated based on the following weighted-average assumptions, using a Black-Scholes option valuation model: expected term of 5.00 years; expected volatility of 51.88%; dividend yield of 0%, and risk-free interest rate of 0.30%. The Company recorded deferred offering costs of approximately $58 associated with these warrants during 2020

which was recorded in additional paid-in capital in 2022

In April 2022, as noted above, the Company granted the Underwriters warrants to purchase a total of 96,000 shares of the Company’s common stock. The warrants are immediately exercisable at an exercise price of $5.00 per share and expire on the fifth anniversary of the commencement of sales under the IPO. The fair value of the warrants on the grant date was $2.75 per warrant, which was calculated based on the following weighted-average assumptions, using a Black-Scholes option valuation model: expected term of 5.00 years; expected volatility of 62.55%; dividend yield of 0%, and risk-free interest rate of 2.92%. The Company recorded the fair value of these warrants of approximately $264 as an issuance cost to additional paid-in capital in 2022. As the IPO issuance costs were also recorded to additional paid-in capital, the net impact was $0.

9. Commitments and Contingencies

Sales Representative Agreement

In April 2020, the Company entered into an Exclusive Sales Representative Agreement, under which the counterparty to the agreement (the “Representative”) received exclusive rights to market, promote, and distribute The Catamaran

System in the United States and Puerto Rico. The agreement is for an initial period of five years, and automatically renews for an additional five years unless written notice is given by either party prior to April 27, 2023. The agreement provides for a bonus to be paid to the Representative upon an acquisition or IPO. In May 2021 the Company entered into an Amended and Restated Exclusive Sales Representative Agreement (the “Restated Sales Agreement”). In connection with the amended agreement, the Company paid $500 cash and issued 53,757 shares of common stock to the Representative, for which the Company recorded a combined total of approximately $880 as sales and marketing expense. In addition, the Representative received anti-dilution protections to maintain ownership of 3.0% of the fully diluted equity of the Company through the date of an initial public offering. In October, 2021, the Company issued 44,447 shares with a fair value of approximately $333 to the Representative in accordance with the anti-dilution provision. In April 2022, the Company issued 312,351 shares to the Representative in accordance with the anti-dilution provision, fully satisfying the Company’s obligations.

The amended agreement restructured the calculation of the bonus paid to the Representative upon an acquisition, removed the bonus payable upon an IPO, and allows the Company to terminate the amended agreement as long as the bonus paid to the Representative is at least $6,000.

In June 2021, the Company issued a $50 convertible note payable to the Chief Executive Officer of the Representative, as part of the convertible debt offering described in Note 6.

In October 2022, the Company entered into the Terminating Amended and Restated Exclusive Sales Representative Agreement with the Representative. See Note 12.

Litigation

In the normal course of business, the Company may possibly be named as a defendant in various lawsuits.

On September 2, 2021, Khalid Mentak, a former director and Chief Executive Officer of the Company filed an arbitration claim with the American Arbitration Association (“AAA”) against the Company, asserting damages in excess of $3,000, plus attorneys’ fees and other costs, for alleged unpaid wages, defamation, and other claims. The services provided by Mr. Mentak were governed by a Consulting Agreement between the Company and Key Medical Technologies, Inc (“Key Medical”), a company which Mr. Mentak served as Chief Executive Officer. The AAA proceeding was also initiated pursuant to the arbitration provision in the Consulting Agreement. The parties selected an arbitrator and the Company filed a motion to dismiss the proceeding as currently pled because the proper parties should be Key Medical and the Company, and not Mr. Mentak as an individual. The arbitrator ruled that Mr. Mentak was the real-party-in-interest and denied the motion, without prejudice to any arguments on the merits of the underlying claims. On March 1, 2022, Mr. Mentak filed a more detailed Statement of Claims, which the Company responded to on March 16, 2022. The Company also filed a cross-complaint for declaratory relief seeking to establish its rights and obligations under the Consulting Agreement with respect to the claimant and Key Medical, which was formally named a defendant in the cross complaint. The claimant objected to the cross-complaint as unnecessary. On July 21, 2022, the Company entered into a Settlement Agreement and General Release of All Claims (the “Settlement Agreement”) with Key Medical and Mr. Mentak to settle all claims and counterclaims. Pursuant to the Settlement Agreement, the Company has agreed to pay Key Medical the total sum of $1,200.

The

settlement amount was fully paid as of September 30, 2022.

10. Concentrations of Risk

Credit risk

Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash and cash equivalents.

The Company maintains cash balances at financial institutions located in California and Switzerland. Accounts at the U.S. financial institutions are secured by the Federal Deposit Insurance Corporation. At times, balances may exceed federally insured limits. The Company has not experienced any losses in such accounts. Management believes that the Company is not exposed to any significant credit risk with respect to its cash and cash equivalents.

The Company grants unsecured credit to its customers based on an evaluation of the customer’s financial condition and a cash deposit is generally not required. Management believes its credit policies do not result in significant adverse risk and historically has not experienced significant credit-related losses.

Currency risk

The Company’s subsidiary, Tenon Technology AG, realizes a portion of its expenses in Swiss francs. Consequently, certain assets and liabilities are exposed to foreign currency fluctuations. At September 30, 2022 and December 31, 2021, approximately $8 and $21, respectively, of the Company’s net monetary assets were denominated in Swiss francs. The Company has not entered into any hedging transactions to reduce the exposure to currency risk.

11. Related Party Transactions

During 2018 through 2020, the Company’s subsidiary issued convertible promissory notes to TTAG’s minority shareholder. In November 2020, these notes payable and accrued interest were converted into TTAG shares. In June 2021, the Company’s subsidiary issued a convertible promissory note for approximately $107 to TTAG’s minority shareholder. The Company purchased this note and accrued interest of $114 in October 2021 from TTAG’s minority shareholder. See Note 6.

The Company had a consulting agreement with a company owned by the former Chief Executive Officer of the Company. Under this consulting agreement, the Chief Executive Officer was to provide services from 2015 through June 1, 2021. Total payments under the consulting agreement of $600 are to be paid as follows: (a) $300 paid upon closing of financing round of at least $5,000, followed by twelve monthly payments of $25 per month; (b) $300 paid upon achieving at least $3,000 of annual revenue and a financing round of less than $5,000; or (c) the entire $600 payable immediately upon an acquisition of the Company. During the three months ended September 30, 2022 and 2021, the Company recorded consulting expense of $0 and $8, respectively, related to this agreement. During the nine months ended September 30, 2022 and 2021, the Company recorded expense of $574 and $25, respectively, related to this agreement. As of September 30, 2022 and December 31, 2021, approximately $0 and $600, respectively, owed to this party was included in accrued expenses with respect of these services. See Note 9.

During 2021, the Company issued convertible promissory notes totaling $620 to officers, directors, and their family members. See Note 6. In addition, a note was issued to the Chief Executive Officer of the Representative described in Note 9.

On October 28, 2021, the Company entered into an agreement with TTAG’s minority shareholder. See Note 8. Pursuant to the terms of the Exchange Agreement, the Company purchased the convertible note and accrued interest between TTAG and Zuhlke Ventures AG (“ZVAG”), TTAG’s minority shareholder, in the amount of approximately $114.

On December 31, 2021, the Company and TTAG entered into the IP Sale and Purchase Agreement, whereby TTAG transferred certain patents and trademarks to the Company. In connection with this transfer, the Company issued an unsecured promissory note to TTAG in the amount of $818 which eliminates in consolidation.

12. Subsequent Events

On October 6, 2022, the Company entered into the Terminating Amended and Restated Exclusive Sales Representative Agreement (the “Termination Agreement”) with the Representative, which terminated the Restated Sales Agreement. In accordance with the Termination Agreement, (i) the Company paid the Representative $1,000 in cash; and (ii) the Company agreed to pay the Representative (a) $85 per month during the six months after the date of the Termination Agreement

in return for efforts by the Representative to transition operations to the Company,

(b) 20% of net sales of the Product sold in the United States and Puerto Rico until December 31, 2023 and (c) after December 31, 2023, a commission in an amount equal to 10% of net sales until such time as the aggregate amount paid to the Representative under this clause (c) and clause (b) above equal $3,600. In the event of an acquisition of the Company, the Company will pay the Representative $3,600 less previous amounts paid pursuant to clause (b) and clause (c) above

In connection with the above terms, the Company will record a charge of $4,600 to sales and marketing expenses in the fourth quarter of 2022.

Simultaneously with the execution of the Termination Agreement, the Company entered into a Consulting Agreement dated October 6, 2022, with the Representative (the “Consulting Agreement”). Under the terms and conditions of the Consulting Agreement, the Representative is tasked with organizing, recruiting, training, and coordinating the Company’s Clinical Specialist program, Physician Education program and Sales Education program as more specifically described in the Consulting Agreement.

The term of the Consulting Agreement is from October 6, 2022, until October 05, 2023, unless extended by mutual agreement of the parties in writing for additional one-year terms, or terminated in accordance with the terms of the Consulting Agreement. In consideration for the services to be provided, the Company shall pay the Representative a base consulting fee of $700 per year, payable in monthly instalments, along with additional compensation of $62.5 per quarter, if certain sales targets are met, for four quarters; along with any travel and related out-of-pocket expenses incurred by the Representative in connection with the performance of the services.

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The following discussion and analysis is intended as a review of significant factors affecting our financial condition and results of operations for the periods indicated. The discussion should be read in conjunction with our unaudited condensed consolidated financial statements and the related notes included elsewhere in this Quarterly Report on Form 10-Q and the audited financial statements and the other information set forth in the Registration Statement. In addition to historical information, the following Management’s Discussion and Analysis of Financial Condition and Results of Operations contains forward-looking statements that involve risks and uncertainties. Our actual results could differ significantly from those anticipated in these forward-looking statements as a result of certain factors discussed herein and any other periodic reports filed and to be filed with the SEC.

Overview

Tenon Medical, Inc., a medical device company formed in 2012, has developed a proprietary, U.S. Food and Drug Administration (“FDA”) approved surgical implant-system, which we call The Catamaran

SI Joint Fusion System (“The Catamaran System”). The Catamaran System offers a novel, less invasive inferior-posterior approach to the sacroiliac joint (“SI Joint”) using a single, robust titanium implant to treat SI Joint dysfunction that often causes severe lower back pain. The system features the Catamaran™ Fixation Device which passes through both the axial and sagittal planes of the ilium and sacrum, transfixing the SI Joint along its longitudinal axis. Published clinical studies have shown that 15% to 30% of all chronic lower back pain is associated with the SI Joint.

With an entry similar to the SI Joint injection, the surgical approach is direct to the joint. The angle and trajectory of the Inferior-Posterior approach is designed to point away from critical neural and vascular structures and into the strongest cortical bone. Joined by a patented osteotome bridge, the implant design consists of two hollow fenestrated pontoons with an open framework to facilitate bony in-growth through the SI Joint. One pontoon fixates into the ilium and the other into the sacrum. The osteotome is designed to disrupt the articular portion of the joint to help facilitate a fusion response.

Our initial clinical results indicate that The Catamaran System implant is promoting fusion across the joint as evidenced by CT scans which is the gold standard widely accepted by the clinical community. We had our national launch of The Catamaran System in October 2022 and are building a sales and marketing infrastructure to market our product and address the greatly underserved market opportunity that exists.

We believe that the implant design and procedure we have developed, along with the 2D and 3D protocols for proper implantation will be received well by the clinician community who have been looking for a next generation device.

We have incurred net losses since our inception in 2012. During the first nine months of 2022 we had net losses of approximately $11,012,000, and

for the year ended December 31,

2021 we had net losses of approximately $7,081,000. As of September 30, 2022, we had an accumulated deficit of approximately $31.6 million. To date, we have financed our operations primarily through private placements of equity securities, certain debt-related financing arrangements, and sales of our product. We have devoted substantially all of our resources to research and development, regulatory matters and sales and marketing of our product.

Reverse Stock Split

On April 6, 2022, we effected the Reverse Stock Split. Any fractional shares that would have resulted from the Reverse Stock Split were rounded up to the nearest whole share. Our authorized common stock was not impacted by the Reverse Stock Split. Immediately after the Reverse Stock Split there were 989,954 shares of our common stock outstanding. Profit per share and share amounts for the condensed consolidated financial statements as of and for the periods ended September 30, 2022 and 2021 reflect the impact of the Reverse Stock Split. Further, we have retrospectively adjusted the 2021 and 2020 financial statements for profit per share and share amounts as a result of the Reverse Stock Split.

Components of Results of Operations

Revenue

We derive substantially all our revenue from sales of The Catamaran System to a limited number of clinicians. Revenue from sales of The Catamaran System fluctuates based on volume of cases (procedures performed), discounts, and the number of implants used for a particular patient. Similar to other orthopedic companies, our revenue can also fluctuate from quarter to quarter due to a variety of factors, including reimbursement, changes in independent sales representatives and physician activities.

Cost of Goods Sold, Gross Profit, and Gross Margin

We utilize contract manufacturers for production of The Catamaran System implants and instrument sets. Cost of goods sold consists primarily of costs of the components of The Catamaran System implants and instruments, quality inspection, packaging, scrap and inventory obsolescence, as well as distribution-related expenses such as logistics and shipping costs. We anticipate that our cost of goods sold will increase in absolute dollars as case levels increase.

Our gross margins have been and will continue to be affected by a variety of factors, including the cost to have our product manufactured for us, pricing pressure from increasing competition, and the factors described above impacting our revenue.

Operating Expenses

Our operating expenses consist of sales and marketing, research and development, and general and administrative expenses. Personnel costs are the most significant component of operating expenses and consist of consulting expenses, salaries, sales commissions and other cash and stock-based compensation related expenses. We expect operating expenses to increase in absolute dollars as we continue to invest and grow our business.

Sales and Marketing Expenses

Sales and marketing expenses primarily consist of independent sales representative training and commissions in addition to salaries and stock-based compensation expense. Starting in May 2021, commissions to our national distributor have been based on a percentage of sales and we anticipate that these commissions will make up a significant portion of our sales and marketing expenses. We expect our sales and marketing expenses to increase in absolute dollars with the commercial launch of The Catamaran System resulting in higher commissions, increased The Catamaran System clinician and sales representative training, and the start of clinical studies to gain wider clinician adoption of The Catamaran System. Our sales and marketing expenses may fluctuate from period to period due to timing of sales and marketing activities related to the commercial launch of our product.

Research and Development Expenses

Our research and development expenses primarily consist of engineering, product development, regulatory expenses, and consulting services, outside prototyping services, outside research activities, materials, and other costs associated with development of our product. Research and development expenses also include related personnel and consultants’ compensation and stock-based compensation expense. We expense research and development costs as they are incurred. We expect research and development expense to increase in absolute dollars as we improve The Catamaran System, develop new products, add research and development personnel, and undergo clinical activities that may be required for regulatory clearances of future products.

General and Administrative Expenses

General and administrative expenses primarily consist of salaries, consultants’ compensation, stock-based compensation expense, and other costs for finance, accounting, legal, compliance, and administrative matters. We expect our general and administrative expenses to increase in absolute dollars as we add personnel and IT infrastructure to support the growth of our business. We also expect to incur additional general and administrative expenses as a result of operating as a public company, including but not limited to: expenses related to compliance with the rules and regulations of the SEC and those of The Nasdaq Capital Market LLC on which our securities will be traded; additional insurance expenses; investor relations activities; and other administrative and professional services. While we expect the general and administrative expenses to increase in absolute dollars, we anticipate that it will decrease as a percentage of revenue over time.

Gain (Loss) on Investments, Interest Expense and Other Income (Expense), Net

Gain (loss) on investments consists of interest income and realized gains and losses from the sale of our investments in money market and corporate debt securities. Interest expense is related to borrowings and includes deemed interest derived from the beneficial conversion prices of notes payable. Other income and expenses have not been significant to date.

Results of Operations

The following table sets forth our results of operations for the periods presented (in thousands):

	Three Months Ended September 30,						Nine Months Ended September 30,
Consolidated Statements of Operations Data:	2022			2021			2022			2021
Revenue	$	208		$	70		$	414		$	107
Cost of goods sold		302			18			848			38
Gross (loss) profit		(94	)		52			(434	)		69
Operating expenses:
Research and development		797			601			2,016			925
Sales and marketing		645			556			2,864			1,473
General and administrative		1,726			992			5,483			1,570
Total operating expenses		3,168			2,149			10,363			3,968
Loss from operations		(3,262	)		(2,097	)		(10,797	)		(3,899	)
Interest and other income (expense), net:
Gain on investments		72			1			108			1
Interest expense		—			(267	)		(362	)		(340	)
Other income (expense)		19			—			39			(1	)
Net loss		(3,171	)		(2,363	)		(11,012	)		(4,239	)
Loss attributable to non-controlling interest		—			(22	)		—			(33	)
Net loss attributable to Tenon Medical, Inc.	$	(3,171	)	$	(2,341	)	$	(11,012	)	$	(4,206	)

The following table sets forth our results of operations as a percentage of revenue:

	Three Months Ended September 30,						Nine Months Ended September 30,
Consolidated Statements of Operations Data:	2022			2021			2022			2021
Revenue		100	%		100	%		100	%		100	%
Cost of goods sold		145			26			205			36
Gross profit		(45	)		74			(105	)		64
Operating expenses:
Research and development		383			859			487			864
Sales and marketing		310			794			692			1,377
General and administrative		830			1,417			1,324			1,467
Total operating expenses		1,523			3,070			2,503			3,708
Loss from operations		(1,568	)		(2,996	)		(2,608	)		3,644
Interest and other income (expense), net:
Gain on investments		35			1			26			1
Interest expense		—			(381	)		(87	)		(318	)
Other expense		9			—			9			(1	)
Net loss		(1,525	)		(3,376	)		(2,660	)		(3,962	)
Loss attributable to non-controlling interest		—			(31	)		—			(31	)
Net loss attributable to Tenon Medical, Inc.		(1,525	)%		(3,344	)%		(2,660	)%		(3,931	)%

Comparison of the Three and Nine Months Ended September 30, 2022 and 2021 (in thousands, except percentages)

Revenue, Cost of Goods Sold, Gross Profit, and Gross Margin

	Three Months Ended September 30,
	2022			2021			$ Change			% Change
Revenue	$	208		$	70		$	138			197	%
Cost of goods sold		302			18			284			1,578	%
Gross (loss) profit	$	(94	)	$	52		$	(146	)		(281	)%
Gross (loss) profit percentage		(45	)%		74	%

	Nine Months Ended September 30,
	2022			2021			$ Change			% Change
Revenue	$	414		$	107		$	307			287	%
Cost of goods sold		848			38			810			2,132	%
Gross (loss) profit	$	(434	)	$	69		$	(503	)		(729	)%
Gross (loss) profit percentage		(105	)%		64	%

Revenue.

The increase in revenue for the three and nine months ended September 30, 2022 as compared to the same periods in 2021 was primarily due to increases of 200% and 345%, respectively, in the number of surgical procedures in which The Catamaran System was used, combined with lower revenue per procedure due to a national distribution agreement in effect for sales from July 2020 through April of 2021 that decreased the amount of revenue that the Company was able to recognize per surgical procedure.

Cost of Goods Sold, Gross Profit, and Gross Margin.

The increase in cost of goods sold for the three and nine months ended September 30, 2022 as compared to the same periods in 2021 was due to a 7,844% year-over-year increase in operations overhead spending as the Company progressed toward commercial launch of The Catamaran System, combined with a 345% year-over-year increase in the number of surgical procedures. Gross (loss) profit decreased due to the increases in overhead spending and the number of surgical procedures. Gross margin percentage decreased due to higher operations overhead spending, and partially offset by higher revenue per procedure from resulting from an amended and restated national distribution agreement.

Operating Expenses

	Three Months Ended September 30,
	2022		2021		$ Change		% Change
Research and development	$	797	$	601	$	196		33	%
Sales and marketing		645		556		89		16	%
General and administrative		1,726		992		734		74	%
Total operating expenses	$	3,168	$	2,149	$	1,019

	Nine Months Ended September 30,
	2022		2021		$ Change		% Change
Research and development	$	2,016	$	925	$	1,091		118	%
Sales and marketing		2,864		1,473		1,391		94	%
General and administrative		5,483		1,570		3,913		249	%
Total operating expenses	$	10,363	$	3,968	$	6,395

Research and Development Expenses.

Research and development expenses for the three months ended September 30, 2022 increased as compared to the same period in 2021 primarily due to increased stock-based compensation ($361), payroll expenses ($143), partially offset by decreased professional fees ($63). Research and development expenses for the nine months ended September 30, 2022 increased as compared to the same period in 2021 primarily due to increased payroll expenses ($801), stock-based compensation ($545) and professional fees ($86). The increase in consulting expenses in 2022 relates to a quality/regulatory consulting group hired in May 2021 to upgrade our quality system. The increase in payroll expenses in 2022 reflects the fact that we did not have any employees during the first three months of 2021.

Sales and Marketing Expenses.

Sales and marketing expenses for the three months ended September 30, 2022 increased as compared to the same period in 2021 primarily due to increased payroll expenses ($176), sales commissions ($83), clinical and marketing collateral expenses ($80), and sales training expenses ($41), partially offset by decreases in consulting fees ($357). Sales and marketing expenses for the nine months ended September 30, 2022 increased as compared to the same period in 2021 primarily due to increased consulting fees ($276), payroll expenses ($347), sales training expenses ($185), sales commissions ($197), and clinical and marketing collateral expenses ($138). The increase in consulting fees in 2022 is primarily due to the common stock issued for services in the second quarter of 2022.

General and Administrative Expenses

. General and administrative expenses for the three months ended September 30, 2022 increased as compared to the same period in 2021 primarily due to increased stock-based compensation ($512), insurance expense ($313) and payroll expenses ($118), partially offset by decreased consulting fees ($143), and legal fees ($60). General and administrative expenses for the nine months ended September 30, 2022 increased as compared to the same period in 2021 primarily due to the legal settlement accrual ($574), increased stock-based compensation ($959), payroll expenses ($763), insurance expense ($733), consulting fees ($434), and legal fees ($256). The significant increase in general and administrative expenses in 2022 was a result of the Company’s ongoing transition to an operating company with formalization and amendment of consulting and sales representative agreements, an audit of our 2021 consolidated financial statements and reviews of our quarterly results by our outside accounting firm and by legal representatives, and the creation of an infrastructure to support future growth through the hiring of employees and establishment of a facility lease.

Gain (Loss) on Investments, Interest Expense and Other Income (Expense), Net

Gain on investments for the three and nine months ended September 30, 2022 increased approximately $71 and $107 as compared to the three and nine months ended September 30, 2021 due to interest on our investments in money market and corporate debt securities. We did not have significant investments in corporate debt securities during the first nine months of 2021. We had no interest expense for the three months ended September 30, 2022 and interest expense increased approximately $22 or 6% for the nine months ended September 30, 2022 compared to the nine months ended September 30, 2021, primarily due to an $12.2 million increase in the level of borrowings associated with closing a new convertible debt offering during May through July 2021.

Liquidity and Capital Resources

As of September 30, 2022, we had cash and cash equivalents and short-term investments of $12.5 million. Since inception, we have financed our operations through private placements of preferred stock, debt financing arrangements, our initial public offering and the sale of our products. As of September 30, 2022, we had no outstanding debt.

As of September 30, 2022, we had an accumulated deficit of $31.6 million. During the nine months ended September 30, 2022, we incurred net losses of $11.0 million and

during the year ended December 31,

2021, we incurred net losses of $7.1 million, and expect to incur additional losses in the future. We have not achieved positive cash flow from operations to date. On April 29, 2022, the Company closed an initial public offering of its common stock. Based upon our current operating plan, we believe that the net proceeds from this initial public offering, together with our existing cash and cash equivalents, will

not be sufficient

to fund our operating expenses and capital expenditure requirements through at least the next 12 months from the date these consolidated financial statements were available to be released.

We plan to raise the necessary additional capital through one or a combination of public or private equity offerings, debt financings, and collaborations or licensing arrangements

We continue to face challenges and uncertainties and, as a result, our available capital resources may be consumed more rapidly than currently expected due to (a) the uncertainty of future revenues from The Catamaran System; (b) changes we may make to the business that affect ongoing operating expenses; (c) changes we may make in our business strategy; (d) regulatory developments affecting our existing products; (e) changes we may make in our research and development spending plans; and (f) other items affecting our forecasted level of expenditures and use of cash resources.

As we

attempt

to raise additional capital to fund our operations, funding may not be available to us on acceptable terms, or at all. If we are unable to obtain adequate financing when needed, we may have to delay, reduce the scope of or suspend one or more of our sales and marketing efforts, research and development activities, or other operations. We may seek to raise any necessary additional capital through a combination of public or private equity offerings, debt financings, and collaborations or licensing arrangements. If we do raise additional capital through public or private equity offerings, the ownership interest of our existing stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect our stockholders’ rights. If we raise additional capital through debt financing, we may be subject to covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures, or declaring dividends. If we are unable to raise capital, we will need to delay, reduce, or terminate planned activities to reduce costs. Doing so will likely harm our ability to execute our business plans.

Contractual Obligations

The following table summarizes our contractual obligations as of September 30, 2022:

	Payments Due By Period (In thousands)
			Less than						More than
	Total		1 year		1-3 years		4-5 years		5 years
Operating leases	$	1,121	$	73	$	594	$	454	$	—
Purchase obligations		—		—		—		—		—
Total	$	1,121	$	73	$	594	$	454	$	—

Cash Flows (in thousands, except percentages)

The following table sets forth the primary sources and uses of cash for each of the periods presented below:

	Nine Months Ended September 30,
	2022			2021			$ Change			% Change
Net cash (used in) provided by:
Operating activities	$	(8,640	)	$	(2,602	)	$	(6,037	)		232	%
Investing activities		(5,223	)		(7,879	)		2,656			-34	%
Financing activities		14,139			11,648			2,491			21	%
Effect of foreign currency translation on cash flow		(40	)		(4	)		(37	)		900	%
Net increase in cash and cash equivalents	$	236		$	1,163		$	(927	)		(80	)%

The increase in net cash used in operating activities for the nine months ended September 30, 2022 as compared to the nine months ended September 30, 2021 was primarily attributable to our increased net loss of $6.8 million as we continued to utilize the cash received from our convertible debt offering during May through July of 2021, adjusted for increases in non-cash stock-based compensation expenses ($1,547) and common stock issued for services ($746), in addition to increases in inventory ($643) and decreases in accrued expenses ($654) and accounts payable ($298).

Cash used in investing activities for the nine months ended September 30, 2022 consisted primarily of the net purchase of short-term investments of approximately $5.0 million as we invested a portion of our IPO proceeds, in addition to purchases of property and equipment of $0.2 million. Cash used in investing activities for the nine months ended September 30, 2021 consisted primarily of the net purchase of short-term investments of $7.9 million.

Cash provided by financing activities for the nine months ended September 30, 2022 consisted of the $14.1 million cash received from our initial public offering in April 2022, net of relevant expenses. Cash provided by financing activities for the nine months ended September 30, 2021 consisted of the issuance of $12.1 million in convertible notes payable.

Critical Accounting Policies, Significant Judgments, and Use of Estimates

Our management’s discussion and analysis of our financial condition and results of operations is based on our financial statements, which have been prepared in accordance with U.S. GAAP. The preparation of these financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported results of operations during the reporting periods. Our estimates are based on our historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from three other sources. Actual results could differ from these estimates under different assumptions or conditions. For the nine months ended September 30, 2022, there were no significant changes to our existing critical accounting policies which are included in the Registration Statement.

Off-Balance Sheet Arrangements

As of September 30, 2022 and December 31, 2021, we did not have any relationships with unconsolidated organizations or financial partnerships, such as structured finance or special purpose entities that would have been established for the purpose of facilitating off-balance sheet arrangements or other contractually narrow or limited purposes.

ITEM 3. Quantitative and Qualitative Disclosures about Market Risk

Not required under Regulation S-K for “smaller reporting companies.”

ITEM 4. Controls and Procedures. Disclosure Controls and Procedures

Evaluation of Disclosure Controls and Procedures

We maintain disclosure controls and procedures that are designed to provide reasonable assurance that the information required to be disclosed by us in reports that we file or submit under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), is recorded, processed, summarized and reported within the time periods specified in the rules and forms promulgated by the Securities and Exchange Commission, and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure. Because of the inherent limitations to the effectiveness of any system of disclosure controls and procedures, no evaluation of disclosure controls and procedures can provide absolute assurance that all control issues and instances of fraud, if any, with a company have been prevented or detected on a timely basis. Even disclosure controls and procedures determined to be effective can only provide reasonable assurance that their objectives are achieved.

As of September 30, 2022, we carried out an evaluation, under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Exchange Act Rule 13a-15(e)) pursuant to Rule 13a-15 of the Exchange Act. Based upon that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures are not effective at the reasonable assurance level.

Our size has prevented us from being able to employ sufficient resources to enable us to have an adequate level of supervision and segregation of duties. Therefore, it is difficult to effectively segregate accounting duties which comprises a material weakness in internal controls. This lack of segregation of duties leads management to conclude that the Company’s disclosure controls and procedures are not effective to give reasonable assurance that the information required to be disclosed in reports that the Company files under the Exchange Act is recorded, processed, summarized and reported as and when required.

To the extent reasonably possible given our limited resources, we intend to take measures to cure the aforementioned weaknesses, including, but not limited to, increasing the capacity of our qualified financial personnel to ensure that accounting policies and procedures are consistent across the organization and that we have adequate control over our Exchange Act reporting disclosures.

Changes in Internal Control over Financial Reporting

There have been no changes in our internal control procedures over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) of the Exchange Act) during our fiscal quarter ended September 30, 2022 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II. OTHER INFORMATION

ITEM 1. LEGAL PROCEDINGS

On September 2, 2021, Khalid Mentak, a former director and Chief Executive Officer of the Company filed an arbitration claim with the American Arbitration Association (“AAA”) against us, asserting damages in excess of $3 million, plus attorneys’ fees and other costs, for alleged unpaid wages, defamation, and other claims. The services provided by Mr. Mentak were governed by a Consulting Agreement between us and Key Medical Technologies, Inc (“Key Medical”), a company which Mr. Mentak served as Chief Executive Officer. The AAA proceeding was also initiated pursuant to the arbitration provision in the Consulting Agreement. The parties selected an arbitrator and we filed a motion to dismiss the proceeding as currently pled because the proper parties should be Key Medical and the Company, and not Mr. Mentak as an individual. The arbitrator ruled that Mr. Mentak was the real-party-in-interest and denied the motion, without prejudice to any arguments on the merits of the underlying claims. On March 1, 2022, Mr. Mentak filed a more detailed Statement of Claims, which we responded to on March 16, 2022. We also filed a cross-complaint for declaratory relief seeking to establish our rights and obligations under the Consulting Agreement with respect to the claimant and Key Medical, which was formally named a defendant in the cross complaint. The claimant objected to the cross-complaint as unnecessary. On July 21, 2022, we entered into a Settlement Agreement and General Release of All Claims (the “Settlement Agreement”) with Key Medical and Mr. Mentak to settle all claims and counterclaims. Pursuant to the Settlement Agreement, we agreed to pay Key Medical the total sum of $1

.2 million

ITEM 1A. RISK FACTORS

As a smaller reporting company as defined by Rule 12b-2 of the Securities Exchange Act of 1934, as amended, and in item 10(f)(1) of Regulation S-K, we are electing scaled disclosure reporting obligations and therefore are not required to provide the information requested by this item. In any event, there have been no material changes in our risk factors as previously disclosed in the Registration Statement on Form S-1 (File No. 333-260931), as amended, originally filed with the U.S. Securities and Securities Exchange Commission (“SEC”) on November 10, 2021 (the “Registration Statement”).

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

(A) Unregistered Sales of Equity Securities

None.

(B) Use of Proceeds

Not applicable.

None

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

None.

ITEM 4. MINE SAFETY DISCLOSURES

Not Applicable.

ITEM 5. OTHER INFORMATION

None.

ITEM 6. EXHIBITS

EXHIBIT INDEX

Exhibit Number		Description

3.1#		Amended and Restated Certificate of Incorporation of the Registrant.

3.2#		Amended and Restated Bylaws of the Registrant.

3.3#		Certificate of Amendment of Amended and Restated Certificate of Incorporation of the Registrant.

3.4#		Certificate of Amendment of Amended and Restated Certificate of Incorporation of the Registrant.

3.5#		Certificate of Amendment of Amended and Restated Certificate of Incorporation of the Registrant.

3.6#		Certificate of Amendment of Amended and Restated Certificate of Incorporation of the Registrant.

3.7#		Certificate of Amendment of Amended and Restated Certificate of Incorporation of the Registrant.

3.8#		Certificate of Amendment of Amended and Restated Certificate of Incorporation of the Registrant.

10.1##†		Consulting Agreement, by and between Tenon Medical, Inc., and SpineSource, Inc.; dated October 06, 2022.

10.2##		Agreement Terminating Amended and Restated Exclusive Sales Representative Agreement, by and between Tenon Medical, Inc., and SpineSource, Inc.; dated October 06, 2022.

31.1*		Rule 13a-14(a)/15d-14(a) Certification of the President and Chief Executive Officer of Tenon Medical, Inc.

31.2*		Rule 13a-14(a)/15d-14(a) Certification of the Chief Financial Officer of Tenon Medical, Inc.

32.1**		Section 1350 Certification of the President and Chief Executive Officer of Tenon Medical, Inc.

32.2**		Section 1350 Certification of the Chief Financial Officer of Tenon Medical, Inc.

101.INS***		Inline XBRL Instance Document

101.SCH***		Inline XBRL Taxonomy Extension Schema Document

101.CAL***		Inline XBRL Taxonomy Extension Calculation Linkbase Document

101.DEF***		Inline XBRL Taxonomy Extension Definition Linkbase Document

101.LAB***		Inline XBRL Taxonomy Extension Label Linkbase Document

101.PRE***		Inline XBRL Taxonomy Extension Presentation Linkbase Document

104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

Incorporated by reference to the same exhibit number in the Company’s Registration Statement No. 333-260931, filed with the Securities and Exchange Commission on April 20, 2022.

Incorporated by reference to the same exhibit number in the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on October 11, 2022.

†

Portions of this exhibit have been omitted.

Filed herewith

Exhibits 32.1 and 32.2 are being furnished and shall not be deemed to be “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the liability of that section, nor shall such exhibits be deemed to be incorporated by reference in any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as otherwise specifically stated in such filing.

***

Pursuant to Rule 406T of Regulation S-T, the interactive data files on Exhibit 101 hereto are deemed not filed or part of a registration statement or prospectus for purposes of Sections 11 or 12 of the Securities Act of 1933, as amended, and otherwise are not subject to liability under those sections.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	TENON MEDICAL, INC.

Dated: November 10, 2022	/s/ Steven M. Foster
	Steven M. Foster
	Chief Executive Officer and President, Director
	(Principal Executive Officer)

Dated: November 10, 2022	/s/ Steven Van Dick
	Steven Van Dick
	Chief Financial Officer
	(Principal Financial and Accounting Officer)

EX-31.1 2 cm177_ex31-1.htm EXHIBIT 31.1

EXHIBIT 31.1

CERTIFICATION OF PRINCIPAL EXECTUIVE OFFICER

PURSUANT TO RULE 13a-14(a)/15d-14(a), AS ADOPTED

PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Steven Foster, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of Tenon Medical, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

	(a)	Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

	(b)	Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

	(c)	Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

	(d)	Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

	(a)	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

	(b)	Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: November 10, 2022	By:	/s/ Steven Foster
	Name:	Steven Foster
	Title:	Chief Executive Officer and President
		(Principal Executive Officer)

EX-31.2 3 cm177_ex31-2.htm EXHIBIT 31.2

EXHIBIT 31.2

CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER

PURSUANT TO RULE 13a-14(a)/15d-14(a), AS ADOPTED

PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Steven Van Dick, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of Tenon Medical, Inc.;

	(a)	Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

	(b)	Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

	(c)	Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

	(d)	Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

	(a)	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

	(b)	Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: November 10, 2022	By:	/s/ Steven Van Dick
	Name:	Steven Van Dick
	Title:	Chief Financial Officer
		(Principal Financial Officer)
		(Principal Accounting Officer)

EX-32.1 4 cm177_ex32-1.htm EXHIBIT 32.1

EXHIBIT 32.1

CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER

PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, I, Steven Foster, the Chief Executive Officer and President of Tenon Medical, Inc. (the “Company”), hereby certify, that, to my knowledge:

1. The Quarterly Report on Form 10-Q for the period ended September 30, 2022 (the “Report”) of the Company fully complies with the requirements of Section 13(a) and 15(d) of the Securities Exchange Act of 1934; and

2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: November 10, 2022	By:	/s/ Steven Foster
	Name:	Steven Foster
	Title:	Chief Executive Officer and President
		(Principal Executive Officer)

EX-32.2 5 cm177_ex32-2.htm EXHIBIT 32.2

EXHIBIT 32.2

CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER

PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, I, Steven Van Dick, the Chief Financial Officer of Tenon Medical, Inc. (the “Company”), hereby certify, that, to my knowledge:

1. The Quarterly Report on Form 10-Q for the period ended September 30, 2022 (the “Report”) of the Company fully complies with the requirements of Section 13(a)/15(d) of the Securities Exchange Act of 1934; and

2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: November 10, 2022	By:	/s/ Steven Van Dick
	Name:	Steven Van Dick
	Title:	Chief Financial Officer
		(Principal Financial Officer)
		(Principal Accounting Officer)

EX-101.SCH 6 tnon-20220930.xsd XBRL SCHEMA FILE 1001 - Document - Cover Page link:presentationLink link:definitionLink link:calculationLink 1002 - Statement - Condensed Consolidated Balance Sheets link:presentationLink link:definitionLink link:calculationLink 1003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) link:presentationLink link:definitionLink link:calculationLink 1004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss link:presentationLink link:definitionLink link:calculationLink 1005 - Statement - Condensed Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) link:presentationLink link:definitionLink link:calculationLink 1006 - Statement - Condensed Consolidated Statements of Cash Flows link:presentationLink link:definitionLink link:calculationLink 1007 - Disclosure - Organization and Business link:presentationLink link:definitionLink link:calculationLink 1008 - Disclosure - Summary of Significant Accounting Principles link:presentationLink link:definitionLink link:calculationLink 1009 - Disclosure - Investments link:presentationLink link:definitionLink link:calculationLink 1010 - Disclosure - Fixed Assets link:presentationLink link:definitionLink link:calculationLink 1011 - Disclosure - Accrued Expenses link:presentationLink link:definitionLink link:calculationLink 1012 - Disclosure - Debt link:presentationLink link:definitionLink link:calculationLink 1013 - Disclosure - Leases link:presentationLink link:definitionLink link:calculationLink 1014 - Disclosure - Stockholders' Equity link:presentationLink link:definitionLink link:calculationLink 1015 - Disclosure - Commitments and Contingencies link:presentationLink link:definitionLink link:calculationLink 1016 - Disclosure - Concentrations of Risk link:presentationLink link:definitionLink link:calculationLink 1017 - Disclosure - Related Party Transactions link:presentationLink link:definitionLink link:calculationLink 1018 - Disclosure - Subsequent Events link:presentationLink link:definitionLink link:calculationLink 1019 - Disclosure - Summary of Significant Accounting Principles (Policies) link:presentationLink link:definitionLink link:calculationLink 1020 - Disclosure - Summary of Significant Accounting Principles (Tables) link:presentationLink link:definitionLink link:calculationLink 1021 - Disclosure - Investments (Tables) link:presentationLink link:definitionLink link:calculationLink 1022 - Disclosure - Fixed Assets (Tables) link:presentationLink link:definitionLink link:calculationLink 1023 - Disclosure - Accrued Expenses (Tables) link:presentationLink link:definitionLink link:calculationLink 1024 - Disclosure - Leases (Tables) link:presentationLink link:definitionLink link:calculationLink 1025 - Disclosure - Stockholders' Equity (Tables) link:presentationLink link:definitionLink link:calculationLink 1026 - Disclosure - Summary of Significant Accounting Principles - Schedule of Securities Excluded Due To Anti Dilutive Effect (Detail) link:presentationLink link:definitionLink link:calculationLink 1027 - Disclosure - Summary of Significant Accounting Principles - Additional Information (Detail) link:presentationLink link:definitionLink link:calculationLink 1028 - Disclosure - Investments - Schedule of Investments At Fair Value in Fair Value Hierarchy Level (Detail) link:presentationLink link:definitionLink link:calculationLink 1029 - Disclosure - Investments - Schedule of Cost And Fair Value of Available For Sale Investments (Detail) link:presentationLink link:definitionLink link:calculationLink 1030 - Disclosure - Investments - Additional Information (Detail) link:presentationLink link:definitionLink link:calculationLink 1031 - Disclosure - Fixed Assets - Summary of Fixed Assets and Equipment Net (Detail) link:presentationLink link:definitionLink link:calculationLink 1032 - Disclosure - Fixed Assets - Additional Information (Detail) link:presentationLink link:definitionLink link:calculationLink 1033 - Disclosure - Accrued Expenses - Schedule of Accrued Expenses (Detail) link:presentationLink link:definitionLink link:calculationLink 1034 - Disclosure - Debt - Additional Information (Detail) link:presentationLink link:definitionLink link:calculationLink 1035 - Disclosure - Leases - Summary of Supplemental Balance Sheet Information Related to Leases (Detail) link:presentationLink link:definitionLink link:calculationLink 1036 - Disclosure - Leases - Summary of Future Maturities of Operating Lease Liabilities (Detail) link:presentationLink link:definitionLink link:calculationLink 1037 - Disclosure - Leases - Additional Information (Detail) link:presentationLink link:definitionLink link:calculationLink 1038 - Disclosure - Stockholders' Equity - Additional Information (Detail) link:presentationLink link:definitionLink link:calculationLink 1039 - Disclosure - Stockholders' Equity - Summary of Share Based Compensation Arrangements By Share Based Payment Award (Detail) link:presentationLink link:definitionLink link:calculationLink 1040 - Disclosure - Stockholders' Equity - Summary of Employee Service Share Based Compensation Allocation of Recognized Period Costs (Detail) link:presentationLink link:definitionLink link:calculationLink 1041 - Disclosure - Commitments and Contingencies - Additional Information (Detail) link:presentationLink link:definitionLink link:calculationLink 1042 - Disclosure - Concentrations of Risk - Additional Information (Detail) link:presentationLink link:definitionLink link:calculationLink 1043 - Disclosure - Related Party Transactions - Additional Information (Detail) link:presentationLink link:definitionLink link:calculationLink 1044 - Disclosure - Subsequent Events - Additional Information (Detail) link:presentationLink link:definitionLink link:calculationLink EX-101.CAL 7 tnon-20220930_cal.xml XBRL CALCULATION FILE EX-101.DEF 8 tnon-20220930_def.xml XBRL DEFINITION FILE EX-101.LAB 9 tnon-20220930_lab.xml XBRL LABEL FILE Cover [Abstract] Document Type Document Quarterly Report Document Period End Date Document Fiscal Year Focus Entity Tax Identification Number Trading Symbol Security Exchange Name Entity Current Reporting Status Document Fiscal Period Focus Document Transition Report Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Entity Ex Transition Period Entity Address, Address Line One Entity File Number Entity Incorporation, State or Country Code Entity Registrant Name Entity Central Index Key Entity Address, City or Town Entity Address, Country Entity Address, Postal Zip Code City Area Code Local Phone Number Title of 12(b) Security Entity Shell Company Entity Common Stock, Shares Outstanding Current Fiscal Year End Date Amendment Flag Statement of Financial Position [Abstract] Statement [Table] Class of Stock [Axis] Class of Stock [Domain] Series B Convertible Preferred Stock [Member] Series B Convertible Preferred Stock [Member] Series B Convertible Preferred Stock [Member] Series A Convertible Preferred Stock [Member] Series A Convertible Preferred Stock [Member] Series A Convertible Preferred Stock [Member] Statement [Line Items] Stockholders' Equity Attributable to Parent [Abstract] Stockholders' equity (deficit): Common Stock, Value, Issued Common stock, $0.001 par value; 130,000,000 and 10,487,904 shares authorized at September 30, 2022 and December 31, 2021, respectively; 11,236,801 and 989,954 shares issued and outstanding at September 30, 2022 and December 31, 2021, respectively Additional Paid in Capital Additional paid-in capital Retained Earnings (Accumulated Deficit) Accumulated deficit Accumulated Other Comprehensive Income (Loss), Net of Tax Accumulated other comprehensive income (loss) Stockholders' Equity Attributable to Parent Total stockholders' equity (deficit) Beginning Balance Ending Balance Liabilities and Equity [Abstract] LIABILITIES, CONVERTIBLE PREFERRED STOCK, AND STOCKHOLDERS' EQUITY (DEFICIT) Liabilities, Current [Abstract] Current liabilities: Operating Lease, Liability, Current Current portion of operating lease liability Operating lease liability, current Accrued Liabilities, Current Accrued expenses Accounts Payable, Current Accounts payable Convertible Notes Payable And Accrued Interest Net Of Debt Discount Current Convertible notes payable and accrued interest, net of debt discount of $0 and $31 at June 30, 2022 and December 31, 2021, respectively Convertible notes payable and accrued interest net of debt discount current. Convertible Notes Payable And Accrued Interest Due To Related Parties Net Of Debt Discount Current Convertible notes payable and accrued interest due to related parties, net of debt discount of $0 and $2 at June 30, 2022 and December 31, 2021, respectively Convertible notes payable and accrued interest due to related parties net of debt discount current. Liabilities, Current Total current liabilities Liabilities Total liabilities Operating Lease, Liability, Noncurrent Operating lease liability, net of current portion Operating lease liability, noncurrent Commitments and Contingencies Commitments and contingencies (Notes 6 and 9) Assets [Abstract] Assets Deferred Costs, Noncurrent Deferred offering costs Property, Plant and Equipment, Net Fixed assets - net Fixed Assets, net Deposits Assets, Noncurrent Deposits Operating Lease, Right-of-Use Asset Operating lease right-of-use asset Operating lease right-of-use assets Assets TOTAL ASSETS Assets, Current [Abstract] Current assets Assets, Current Total current assets Short-term Investments Short-term investments Cash and Cash Equivalents, at Carrying Value Cash and cash equivalents Prepaid Expense, Current Prepaid expenses Inventory, Net Inventory Accounts Receivable, after Allowance for Credit Loss, Current Accounts receivable Temporary Equity [Abstract] Convertible preferred stock Temporary Equity, Carrying Amount, Attributable to Parent Convertible Preferred Stock Liabilities and Equity TOTAL LIABILITIES, CONVERTIBLE PREFERRED STOCK, AND STOCKHOLDERS' EQUITY (DEFICIT) Debt Instrument, Unamortized Discount, Current Debt discount Common Stock, Shares, Issued Common stock shares issued Common Stock, Shares, Outstanding Common stock shares outstanding Temporary Equity, Shares Authorized Temporary equity shares authorized Temporary equity, Shares authorized Temporary Equity, Shares Issued Temporary equity shares issued Debt Discount Related To Related Parties Debt discount related to related parties Debt Discount Related To Related Parties Temporary Equity, Par or Stated Value Per Share Temporary equity par or stated value per share Common Stock, Par or Stated Value Per Share Common stock par or stated value per share Common stock, Par or stated value per share Common Stock, Shares Authorized Common stock shares authorized Common stock, Shares authorized Temporary Equity, Shares Outstanding Temporary equity shares outstanding Income Statement [Abstract] Operating Income (Loss) Loss from Operations Nonoperating Income (Expense) [Abstract] Other Income (Expense) Interest Expense, Debt Interest expense Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Net Loss Net loss Nonoperating Income (Expense) Total Other Income (Expense), net Gain (Loss) on Investments Gain on investments Net gain on investments Other Nonoperating Income (Expense) Other income (expense) Gross Profit Gross (Loss) Profit Operating Expenses [Abstract] Operating Expenses Research and Development Expense Research and development Operating Expenses Total Operating Expenses Selling and Marketing Expense Sales and marketing Sales and marketing expense Selling and marketing expense General and Administrative Expense General and administrative Net Income (Loss) Attributable to Noncontrolling Interest Loss attributable to non-controlling interest Net Income (Loss) Attributable to Parent Net Loss Attributable to Tenon Medical, Inc. Earnings Per Share [Abstract] Net Loss Attributable to Tenon Medical, Inc. Per Share of Common Stock Earnings Per Share, Basic Basic Earnings Per Share, Diluted Diluted Revenues Revenue Revenues Cost of Revenue Cost of sales Weighted Average Number of Shares Outstanding, Diluted [Abstract] Weighted-Average Shares of Common Stock Outstanding Weighted Average Number of Shares Outstanding, Diluted Diluted Weighted Average Number of Shares Outstanding, Basic Basic Statement of Comprehensive Income [Abstract] Other than Temporary Impairment Losses, Investments, Portion in Other Comprehensive Loss, Net of Tax, Portion Attributable to Parent, Available-for-sale Securities Unrealized loss on investments Other than temporary impairment losses Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent Foreign currency translation adjustment Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest Total Comprehensive Loss Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest Comprehensive loss attributable to non-controlling interest Comprehensive Income (Loss), Net of Tax, Attributable to Parent Total comprehensive loss attributable to Tenon Medical, Inc. Statement of Stockholders' Equity [Abstract] Shares, Outstanding Beginning Balance (in shares) Ending Balance (in shares) Stock Issued During Period, Value, Conversion of Units Common stock issued upon conversion Temporary Equity, Carrying Amount, Including Portion Attributable to Noncontrolling Interests Beginning Balance Ending Balance Stock Issued During Period, Value, Conversion of Convertible Securities Common stock issued upon conversion of debt Stock Issued During Period, Shares, Conversion of Convertible Securities Common stock issued upon conversion of debt, Share Stock Issued During Period, Shares, Conversion of Convertible Securities Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent Other comprehensive income Share-based Payment Arrangement, Expense Stock-based compensation expense Temporary Equity, Outstanding Ending Balance (in shares) Beginning Balance (in shares) Temporary equity, outstanding. Stock Issued During Period, Shares, New Issues Issuance of common stock and warrants, net of issuance costs, Share Stock issued during period, Shares, New issues Stock issued during period shares new issues Stock Issued During Period, Value, Issued for Services Common stock issued for services Stock Issued During Period, Shares, Issued for Services Common stock issued for services, Share Stock issued during period, shares, issued for services to consultant Temporary Equity Conversion Of Stock Amount Converted1 Common stock issued upon conversion of debt Temporary Equity Conversion Of Stock Amount Converted1 Temporary Equity Conversion Of Stock Shares Converted1 Common stock issued upon conversion of debt, Share Temporary Equity Conversion Of Stock Shares Converted1. Stock Issued During Period, Shares, Conversion of Units Common stock issued upon conversion, Share Stock Issued During Period, Value, New Issues Issuance of common stock and warrants, net of issuance costs Stock issued during period value new issues Equity Components [Axis] Equity Component [Domain] AOCI Attributable to Parent [Member] Accumulated Other Comprehensive Income [Member] Noncontrolling Interest [Member] Noncontrolling Interest [Member] Additional Paid-in Capital [Member] Additional Paid-in Capital [Member] Retained Earnings [Member] Accumulated Deficit [Member] Common Stock [Member] Common Stock [Member] Statement of Cash Flows [Abstract] Net Cash Provided by (Used in) Operating Activities [Abstract] Cash Flows from Operating Activities Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Adjustments to reconcile net loss to net cash used in operating activities: Paid-in-Kind Interest Non-cash interest expense Share-based Payment Arrangement, Noncash Expense Stock-based compensation expense Depreciation, Depletion and Amortization Depreciation and amortization Operating Lease, Right-of-Use Asset, Amortization Expense Amortization of operating right-of-use asset Increase (Decrease) in Operating Capital [Abstract] Increase (decrease) in cash resulting from changes in: Increase (Decrease) in Prepaid Expense and Other Assets Prepaid expenses and other assets Increase (Decrease) in Accounts Payable Accounts payable Increase (Decrease) in Accrued Liabilities Accrued expenses Increase (Decrease) in Operating Lease Liability Operating lease liability Increase (Decrease) in Accounts Receivable Accounts receivable Increase (Decrease) in Inventories Inventory Unrealized Gain (Loss) on Investments Unrealized loss on investments Issuance of Stock and Warrants for Services or Claims Common stock issued for services Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Cash and Cash Equivalents at End of Period Cash and Cash Equivalents at Beginning of Period Net Cash Provided by (Used in) Investing Activities [Abstract] Cash Flows from Investing Activities Proceeds from Sale, Maturity and Collection of Investments Sales of short-term investments Payments to Acquire Property, Plant, and Equipment Purchases of property and equipment Payments to Acquire Investments Purchases of short-term investments Net Cash Provided by (Used in) Financing Activities Net cash provided by financing activities Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Effect of foreign currency translation on cash flow Supplemental Cash Flow Information [Abstract] Supplemental Disclosures of Cash Flow Information Interest Paid, Excluding Capitalized Interest, Operating Activities Interest Income Taxes Paid, Net Income taxes Net Cash Provided by (Used in) Investing Activities Net cash used in investing activities Net Cash Provided by (Used in) Financing Activities [Abstract] Cash Flows from Financing Activities Payments For Deferred Offering Costs Deferred offering costs Payments for deferred offering costs. Repayments of Convertible Debt Repayment of notes payable Payments of Debt Issuance Costs Debt issuance costs Proceeds from Issuance of Common Stock Proceeds from issuance of common stock, net of issuance costs Proceeds from Convertible Debt Proceeds from issuance of convertible notes payable Net Cash Provided by (Used in) Operating Activities Net cash used in operating activities Noncash Investing and Financing Items [Abstract] Non-cash investment and financing activities: Common Stock Issued Upon Conversion Of Preferred Stock Common stock issued upon conversion of preferred stock Common stock issued upon conversion of preferred stock. Common Stock Issued Upon Conversion Of Debt Common stock issued upon conversion of debt Common stock issued upon conversion of debt. Right of use Assets Obtained In Exchange For Lease Liability Right-of-use assets obtained in exchange for lease liability Right-of-use assets obtained in exchange for lease liability. Conversion Of Trade Payable To Law Firm To Note Payable Conversion of trade payable to law firm to note payable Conversion of trade payable to law firm to note payable. Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Net Increase in Cash and Cash Equivalents Organization And Business Disclosure [Abstract] Organization and business disclosure. Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block] Organization and Business Accounting Policies [Abstract] Significant Accounting Policies [Text Block] Summary of Significant Accounting Principles Investments [Abstract] Investment [Text Block] Investments Property, Plant and Equipment [Abstract] Fixed Assets [Abstract] Property, Plant and Equipment Disclosure [Text Block] Fixed Assets Payables and Accruals [Abstract] Accounts Payable and Accrued Liabilities Disclosure [Text Block] Accrued Expenses Debt Disclosure [Abstract] Debt Disclosure [Text Block] Debt Leases [Abstract] Lessee, Operating Leases [Text Block] Leases Equity [Abstract] Stockholders' Equity Note Disclosure [Text Block] Stockholders' Equity Commitments and Contingencies Disclosure [Abstract] EX-101.PRE 10 tnon-20220930_pre.xml XBRL PRESENTATION FILE XML 11 R1.htm IDEA: XBRL DOCUMENT

Cover Page - shares	9 Months Ended
Cover Page - shares	Sep. 30, 2022	Nov. 10, 2022
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Period End Date	Sep. 30, 2022
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	Q3
Document Transition Report	false
Current Fiscal Year End Date	--12-31
Entity File Number	001-41364
Entity Registrant Name	TENON MEDICAL, INC.
Entity Central Index Key	0001560293
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	45-5574718
Entity Address, Address Line One	104 Cooper Court
Entity Address, City or Town	Los Gatos
Entity Address, Country	CA
Entity Address, Postal Zip Code	95032
City Area Code	408
Local Phone Number	649-5760
Title of 12(b) Security	Common Stock, par value $0.001 per share
Trading Symbol	TNON
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		11,236,801

XML 12 R2.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Current assets
Cash and cash equivalents	$ 3,153	$ 2,917
Short-term investments	9,381	4,404
Accounts receivable	144	76
Inventory	810	188
Prepaid expenses	177	87
Total current assets	13,665	7,672
Fixed assets - net	294	101
Deposits	51	41
Operating lease right-of-use asset	927	1,084
Deferred offering costs	0	374
TOTAL ASSETS	14,937	9,272
Current liabilities:
Accounts payable	422	478
Accrued expenses	603	1,088
Current portion of operating lease liability	241	202
Convertible notes payable and accrued interest, net of debt discount of $0 and $31 at June 30, 2022 and December 31, 2021, respectively	0	12,857
Convertible notes payable and accrued interest due to related parties, net of debt discount of $0 and $2 at June 30, 2022 and December 31, 2021, respectively	0	649
Total current liabilities	1,266	15,274
Operating lease liability, net of current portion	724	911
Total liabilities	1,990	16,185
Commitments and contingencies (Notes 6 and 9)
Stockholders' equity (deficit):
Common stock, $0.001 par value; 130,000,000 and 10,487,904 shares authorized at September 30, 2022 and December 31, 2021, respectively; 11,236,801 and 989,954 shares issued and outstanding at September 30, 2022 and December 31, 2021, respectively	11	1
Additional paid-in capital	44,691	113
Accumulated deficit	(31,587)	(20,575)
Accumulated other comprehensive income (loss)	(168)	(91)
Total stockholders' equity (deficit)	12,947	(20,552)
TOTAL LIABILITIES, CONVERTIBLE PREFERRED STOCK, AND STOCKHOLDERS' EQUITY (DEFICIT)	14,937	9,272
Series A Convertible Preferred Stock [Member]
Convertible preferred stock
Convertible Preferred Stock	0	12,367
Series B Convertible Preferred Stock [Member]
Convertible preferred stock
Convertible Preferred Stock	$ 0	$ 1,272

XML 13 R3.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Debt discount	$ 0	$ 31
Debt discount related to related parties	$ 0	$ 2
Common stock par or stated value per share	$ 0.001	$ 0.001
Common stock shares authorized	130,000,000	10,487,904
Common stock shares issued	11,236,801	989,954
Common stock shares outstanding	11,236,801	989,954
Series A Convertible Preferred Stock [Member]
Temporary equity par or stated value per share	$ 0.001	$ 0.001
Temporary equity shares authorized	4,500,000	2,805,839
Temporary equity shares issued	0	2,550,763
Temporary equity shares outstanding	0	2,550,763
Series B Convertible Preferred Stock [Member]
Temporary equity par or stated value per share	$ 0.001	$ 0.001
Temporary equity shares authorized	491,222	491,222
Temporary equity shares issued	0	491,222
Temporary equity shares outstanding	0	491,222

XML 14 R4.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Income Statement [Abstract]
Revenue	$ 208	$ 70	$ 414	$ 107
Cost of sales	302	18	848	38
Gross (Loss) Profit	(94)	52	(434)	69
Operating Expenses
Research and development	797	601	2,016	925
Sales and marketing	645	556	2,864	1,473
General and administrative	1,726	992	5,483	1,570
Total Operating Expenses	3,168	2,149	10,363	3,968
Loss from Operations	(3,262)	(2,097)	(10,797)	(3,899)
Other Income (Expense)
Gain on investments	72	1	108	1
Interest expense	0	(267)	(362)	(340)
Other income (expense)	19	0	39	(1)
Total Other Income (Expense), net	91	(266)	(215)	(340)
Net Loss	(3,171)	(2,363)	(11,012)	(4,239)
Loss attributable to non-controlling interest		(22)	0	(33)
Net Loss Attributable to Tenon Medical, Inc.	$ (3,171)	$ (2,341)	$ (11,012)	$ (4,206)
Net Loss Attributable to Tenon Medical, Inc. Per Share of Common Stock
Basic	$ (0.28)	$ (2.55)	$ (1.59)	$ (4.85)
Diluted	$ (0.28)	$ (2.55)	$ (1.59)	$ (4.85)
Weighted-Average Shares of Common Stock Outstanding
Basic	11,237	919	6,920	868
Diluted	11,237	919	6,920	868
Statement of Comprehensive Income [Abstract]
Net loss	$ (3,171)	$ (2,363)	$ (11,012)	$ (4,239)
Unrealized loss on investments	(10)	0	(37)	0
Foreign currency translation adjustment	(19)	1	(40)	1
Total Comprehensive Loss	(3,200)	(2,362)	(11,089)	(4,238)
Comprehensive loss attributable to non-controlling interest	0	(22)	0	(33)
Total comprehensive loss attributable to Tenon Medical, Inc.	$ (3,200)	$ (2,340)	$ (11,089)	$ (4,205)

XML 15 R5.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) - USD ($) $ in Thousands	Total	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Deficit [Member]	Accumulated Other Comprehensive Income [Member]	Noncontrolling Interest [Member]	Series A Convertible Preferred Stock [Member]	Series A Convertible Preferred Stock [Member] Common Stock [Member]	Series A Convertible Preferred Stock [Member] Additional Paid-in Capital [Member]	Series B Convertible Preferred Stock [Member]	Series B Convertible Preferred Stock [Member] Common Stock [Member]	Series B Convertible Preferred Stock [Member] Additional Paid-in Capital [Member]
Beginning Balance at Dec. 31, 2020							$ 0			$ 1,272
Beginning Balance (in shares) at Dec. 31, 2020							0			491,222
Beginning Balance at Dec. 31, 2020	$ (2,709)	$ 1	$ 126	$ (4,486)	$ (57)	$ 1,707
Beginning Balance (in shares) at Dec. 31, 2020		830,000
Stock-based compensation expense	208		208
Common stock issued for services	816		816
Common stock issued for services, Share		115,507
Other comprehensive income	1				1
Net loss	(4,239)			(4,206)		(33)
Ending Balance at Sep. 30, 2021							$ 0			$ 1,272
Ending Balance (in shares) at Sep. 30, 2021							0			491,222
Ending Balance at Sep. 30, 2021	(5,923)	$ 1	1,150	(8,692)	(56)	1,674
Ending Balance (in shares) at Sep. 30, 2021		945,507
Beginning Balance at Jun. 30, 2021							$ 0			$ 1,272
Beginning Balance (in shares) at Jun. 30, 2021							0			491,222
Beginning Balance at Jun. 30, 2021	(4,140)	$ 1	571	(6,351)	(57)	1,696
Beginning Balance (in shares) at Jun. 30, 2021		883,757
Stock-based compensation expense	143		143
Common stock issued upon conversion							$ 436	$ 0	$ 436
Common stock issued upon conversion, Share								61,750
Common stock issued upon conversion of debt							$ 0
Common stock issued upon conversion of debt, Share							0
Other comprehensive income	1				1
Net loss	(2,363)			(2,341)		(22)
Ending Balance at Sep. 30, 2021							$ 0			$ 1,272
Ending Balance (in shares) at Sep. 30, 2021							0			491,222
Ending Balance at Sep. 30, 2021	(5,923)	$ 1	1,150	(8,692)	(56)	1,674
Ending Balance (in shares) at Sep. 30, 2021		945,507
Beginning Balance at Dec. 31, 2021							$ 12,367			$ 1,272
Beginning Balance (in shares) at Dec. 31, 2021							2,550,763			491,222
Beginning Balance at Dec. 31, 2021	(20,552)	$ 1	113	(20,575)	(91)	0
Beginning Balance (in shares) at Dec. 31, 2021		989,954
Stock-based compensation expense	1,755		1,755
Issuance of common stock and warrants, net of issuance costs	13,765	$ 3	13,762
Issuance of common stock and warrants, net of issuance costs, Share		3,200,000
Common stock issued upon conversion							$ 12,367	$ 2	$ 12,365	$ 1,272		$ 1,272
Common stock issued upon conversion, Share								2,447,728			245,614
Common stock issued upon conversion of debt							$ (12,367)			$ (1,272)
Common stock issued upon conversion of debt, Share							(2,550,763)			(491,222)
Common stock issued upon conversion of debt	13,868	$ 4	13,864
Common stock issued upon conversion of debt, Share		3,955,415
Common stock issued for services	1,561	$ 1	1,560
Common stock issued for services, Share		398,090
Other comprehensive income	(77)				(77)
Net loss	(11,012)			(11,012)
Ending Balance at Sep. 30, 2022							$ 0			$ 0
Ending Balance (in shares) at Sep. 30, 2022							0			0
Ending Balance at Sep. 30, 2022	12,947	$ 11	44,691	(31,587)	(168)	0
Ending Balance (in shares) at Sep. 30, 2022		11,236,801
Beginning Balance at Jun. 30, 2022							$ 0			$ 0
Beginning Balance (in shares) at Jun. 30, 2022							0			0
Beginning Balance at Jun. 30, 2022	15,113	$ 11	43,657	(28,416)	(139)	0
Beginning Balance (in shares) at Jun. 30, 2022		11,236,801
Stock-based compensation expense	1,034		1,034
Other comprehensive income	(29)				(29)
Net loss	(3,171)			(3,171)
Ending Balance at Sep. 30, 2022							$ 0			$ 0
Ending Balance (in shares) at Sep. 30, 2022							0			0
Ending Balance at Sep. 30, 2022	$ 12,947	$ 11	$ 44,691	$ (31,587)	$ (168)	$ 0
Ending Balance (in shares) at Sep. 30, 2022		11,236,801

XML 16 R6.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Cash Flows from Operating Activities
Net loss	$ (11,012)	$ (4,239)
Adjustments to reconcile net loss to net cash used in operating activities:
Unrealized loss on investments	(37)	(1)
Non-cash interest expense	362	340
Stock-based compensation expense	1,755	208
Common stock issued for services	1,561	816
Depreciation and amortization	53	1
Amortization of operating right-of-use asset	157	62
Increase (decrease) in cash resulting from changes in:
Accounts receivable	(68)	(56)
Inventory	(622)	21
Prepaid expenses and other assets	(100)	(129)
Accounts payable	(56)	242
Accrued expenses	(485)	168
Operating lease liability	(148)	(35)
Net cash used in operating activities	(8,640)	(2,602)
Cash Flows from Investing Activities
Sales of short-term investments	4,404	0
Purchases of short-term investments	(9,381)	(7,861)
Purchases of property and equipment	(246)	(18)
Net cash used in investing activities	(5,223)	(7,879)
Cash Flows from Financing Activities
Proceeds from issuance of common stock, net of issuance costs	14,139	0
Proceeds from issuance of convertible notes payable	0	12,072
Repayment of notes payable	0	(131)
Debt issuance costs	0	(71)
Deferred offering costs	0	(222)
Net cash provided by financing activities	14,139	11,648
Effect of foreign currency translation on cash flow	(40)	(4)
Net Increase in Cash and Cash Equivalents	236	1,163
Cash and Cash Equivalents at Beginning of Period	2,917	245
Cash and Cash Equivalents at End of Period	3,153	1,409
Supplemental Disclosures of Cash Flow Information
Interest	0	1
Income taxes	0	1
Non-cash investment and financing activities:
Common stock issued upon conversion of preferred stock	13,639	0
Common stock issued upon conversion of debt	13,868	0
Right-of-use assets obtained in exchange for lease liability	0	1,195
Conversion of trade payable to law firm to note payable	$ 0	$ 556

XML 17 R7.htm IDEA: XBRL DOCUMENT

Organization and Business	9 Months Ended
Organization and Business	Sep. 30, 2022
Organization And Business Disclosure [Abstract]
Organization and Business	1. Organization and Business Nature of operations Tenon Medical, Inc. (the “Company”), was incorporated in the State of Delaware on June 19, 2012 and was headquartered in San Ramon, California until June 2021 when it relocated to Los Gatos, California. The Company is a medical device company that has developed a novel, less invasive, inferior-posterior approach to the sacroiliac joint using a single, robust, titanium implant for treatment of the most common types of sacroiliac joint (the “SI Joint”) disorders that cause lower back pain. The Company received U.S. Food and Drug Administration (“FDA”) clearance in 2018 for its primary product, The Catamaran TM SI Joint Fusion System (“The Catamaran System”) which is designed to transfix and stabilize the SI Joint. The Company is in the early stages of its commercial launch with its primary focus being on the US market. Basis of consolidation The consolidated financial statements of the Company include the accounts of the Company and its wholly-owned subsidiary, Tenon Technology AG (“TTAG”), a Swiss company. TTAG was a majority-owned subsidiary until October 28, 2021, at which date the Company acquired the remaining non-controlling interest of TTAG (see Note 8). All intercompany balances and transactions have been eliminated in consolidation.

XML 18 R8.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Principles

9 Months Ended

Sep. 30, 2022

Accounting Policies [Abstract]

Summary of Significant Accounting Principles

2. Summary of Significant Accounting Principles

Basis of presentation

Going concern uncertainty and liquidity requirements

There is substantial doubt about the Company’s ability to continue as a going concern for one year after the date that these financial statements are issued.

Use of estimates

Income Taxes

Impact of COVID-19

Net loss per share

The Company had the following dilutive common stock equivalents as of September 30, 2022 and 2021 which were excluded from the calculation because their effect was anti-dilutive.

	September 30, 2022		September 30, 2021
Outstanding restricted stock units		1,318,530		—
Outstanding stock options		841,344		705,394
Outstanding warrants		121,000		25,000
Common shares convertible from notes payable		—		2,079,510
Common shares convertible from preferred stock		—		245,611
Total		2,280,874		3,055,515

Recent Accounting Pronouncements

There have been no accounting pronouncements or changes in accounting pronouncements in the nine months ended September 30, 2022 that are significant or potentially significant to the Company.

XML 19 R9.htm IDEA: XBRL DOCUMENT

Investments

9 Months Ended

Sep. 30, 2022

Investments [Abstract]

Investments

The following table sets forth by level, within the fair value hierarchy, the Company’s investments at fair value as of September 30, 2022 and December 31, 2021:

	Level 2
Corporate debt securities:
September 30, 2022	$	9,381
December 31, 2021	$	4,404

Cost and fair value of available-for-sale investments as of September 30, 2022 and December 31, 2021 are as follows:

	Amortized ‎Cost		Gross ‎Unrealized ‎Gains		Gross Unrealized Losses			Fair ‎Value
Corporate debt securities:
September 30, 2022	$	9,418	$	—	$	(37	)	$	9,381
December 31, 2021	$	4,404	$	—	$	—		$	4,404

All of the investments with gross unrealized losses have been in a continuous loss position for less than 12 months.

XML 20 R10.htm IDEA: XBRL DOCUMENT

Fixed Assets

9 Months Ended

Sep. 30, 2022

Property, Plant and Equipment [Abstract]

Fixed Assets

Fixed assets, net, consisted of the following:

	September 30, 2022			December 31,2021
Catamaran Tray Sets	$	270		$	77
IT Equipment		56			17
Lab Equipment		14			—
Office Furniture		9			9
Fixed assets, gross		349			103
Less: accumulated depreciation		(55	)		(2	)
Fixed assets, net	$	294		$	101

XML 21 R11.htm IDEA: XBRL DOCUMENT

Accrued Expenses

9 Months Ended

Sep. 30, 2022

Payables and Accruals [Abstract]

Accrued Expenses

5. Accrued Expenses

Accrued expenses consisted of the following:

	September 30, 2022		December 31, 2021
Accrued compensation	$	339	$	846
Accrued commissions		49		14
Other accrued expenses		215		228
Total accrued expenses	$	603	$	1,088

XML 22 R12.htm IDEA: XBRL DOCUMENT

Debt	9 Months Ended
Debt	Sep. 30, 2022
Debt Disclosure [Abstract]
Debt	6. Debt Convertible notes payable – parent company During 2015, the Company issued a $53 convertible promissory note to a consultant that, along with accrued interest at an annual rate of 8.0%, was automatically convertible upon a preferred stock financing of at least $500, at a conversion price equal to 90% of the price per share paid by the other cash purchasers in the future financing. In June 2019, the note and its accrued interest to date was replaced by a $68 convertible promissory note that, along with accrued interest at an annual rate of 8.0%, was automatically convertible upon a preferred stock financing of at least $1,000, at a conversion price equal to 90% of the price per share paid by the other cash purchasers in the future financing. The note had a maturity date of June 12, 2021. In May 2021, the note was again replaced by a $68 convertible promissory note with a maturity date of May 7, 2022 that, along with accrued interest at an annual rate of 8.0%, was automatically convertible upon an IPO or a capital stock financing of at least $5,000. The conversion price was equal to 80% of the IPO price or $1.9565 per share in the event of a capital stock financing of at least $5,000. Accrued interest at September 30, 2022 and December 31, 2021 totaled approximately $0 and $14, respectively. During 2016, the Company issued a $118 convertible promissory note to a vendor that, along with accrued interest at an annual rate of 8.0%, was automatically convertible upon a preferred stock financing of at least $500, at a conversion price equal to 90% of the price per share paid by the other cash purchasers in the future financing. The note had a maturity date of January 1, 2019 and remained unpaid during 2019 and 2020. In April 2021, the note was replaced by a $118 convertible promissory note with a maturity date of April 30, 2022 that, along with accrued interest at an annual rate of 8.0%, was automatically convertible upon an IPO or a capital stock financing of at least $5,000. The conversion price was equal to 80% of the IPO price or $1.9565 per share in the event of a capital stock financing of at least $5,000. Accrued interest at September 30, 2022 and December 31, 2021 totaled approximately $0 and $56, respectively. In October 2019, the Company issued a $70 convertible promissory note to the Company’s former Chief Executive Officer that, along with accrued interest at an annual rate of 8.0%, was automatically convertible upon a preferred stock financing of at least $500, at a conversion price equal to 80% of the price per share paid by the other cash purchasers in the future financing. The note had a maturity date of October 12, 2022. In April 2021, the note was replaced by a $70 convertible promissory note with a maturity date of April 30, 2022 that, along with accrued interest at an annual rate of 8.0%, was automatically convertible upon an IPO or a capital stock financing of at least $5,000. The conversion price was equal to 70% of the IPO price or $1.9565 per share in the event of a capital stock financing of at least $5,000. Accrued interest at September 30, 2022 and December 31, 2021 totaled approximately $0 and $12, respectively. In October 2019, the Company issued a $50 convertible promissory note to an investor that, along with accrued interest at an annual rate of 8.0%, was automatically convertible upon a preferred stock financing of at least $500, at a conversion price equal to 80% of the price per share paid by the other cash purchasers in the future financing. The note had a maturity date of October 21, 2022. In May 2021, the note was replaced by a $50 convertible promissory note with a maturity date of May 3, 2022 that, along with accrued interest at an annual rate of 8.0%, was automatically convertible upon an IPO or a capital stock financing of at least $5,000. The conversion price was equal to 70% of the IPO price or $1.9565 per share in the event of a capital stock financing of at least $5,000. Accrued interest at September 30, 2022 and December 31, 2021 totaled approximately $0 and $9, respectively. In November 2020, the Company issued a $200 convertible promissory note to the same investor that, along with accrued interest at an annual rate of 8.0%, was automatically convertible upon a preferred stock financing of at least $2,000, at a conversion price equal to 80% of the price per share paid by the other cash purchasers in the future financing. The note had a maturity date of November 16, 2022. In May 2021, the note was replaced by a $200 convertible promissory note with a maturity date of May 3, 2022 that, along with accrued interest at an annual rate of 8.0%, was automatically convertible upon an IPO or a capital stock financing of at least $5,000. The conversion price was equal to 70% of the IPO price or 70% of the price per share paid by the other cash purchasers in the future financing. Accrued interest at September 30, 2022 and December 31, 2021 was approximately $0 and $18, respectively. In January 2021, the Company issued a promissory note of $131 to a law firm. The note bore interest at 3.0% per annum and had a maturity date of the earlier of July 27, 2021, the closing of a debt or equity financing, or the closing of a change in control transaction. The interest rate was to increase to 5.0% if all principal and interest had not been paid by the maturity date. The Company repaid this note and accrued interest in May 2021. In April 2021, the Company issued two convertible promissory notes of $40 and $170 to the vendor described in the second paragraph above that, along with accrued interest at an annual rate of 8.0%, were automatically convertible upon an IPO or a capital stock financing of at least $5,000. The conversion price was equal to 70% of the IPO price or 70% of the price per share paid by the other cash purchasers in the future financing. Accrued interest at September 30, 2022 and December 31, 2021 totaled approximately $0 and $11, respectively. From May through July 2021, in multiple rounds of closings the Company issued convertible promissory notes to multiple investors for aggregate proceeds of approximately $12,177, with maturity dates twelve months from the issuance dates. Of this amount, $620 of notes were issued to related officers, directors, and their family members, and a $50 note was issued to the Chief Executive Officer of the Representative described in Note 9. The notes, along with accrued interest at an annual rate of 8.0%, were automatically convertible upon an IPO, a capital stock financing of at least $5,000, or a change of control transaction. The conversion price upon an IPO or a capital stock financing was equal to the lesser of 70% of the price per share paid by the other cash purchasers, or the price per share at a Company valuation of $22,500. The Company recorded debt issuance costs of approximately $71 as a discount on the convertible notes payable balance. Accrued interest at September 30, 2022 and December 31, 2021 was approximately $0 and $527, respectively. On April 29, 2022, as a result of the completion of the IPO and as required under the terms of the convertible notes payable described above, the Company converted the entirety of the outstanding principal and accrued interest of the outstanding convertible notes payable to 3,955,415 shares of the Company’s common stock at the conversion price detailed above and issued the common stock to the noteholders, fully satisfying the Company’s obligations. Convertible notes payable – subsidiary In June 2021, the Company’s subsidiary issued a convertible promissory note for approximately $107 to TTAG’s minority shareholder. This note, along with accrued interest at an annual rate of 8.0%, could be applied to future TTAG capital increases. The Company purchased this note and accrued interest of approximately $114 in October 2021 from TTAG’s minority shareholder.

- Definition

The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-URI https://asc.fasb.org/topic&trid=2208564

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1B
-Subparagraph (h)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1C
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1I
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1I
-Subparagraph (d)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(c))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1B
-Subparagraph (g)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1C
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1C
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1E
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1B
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1I
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1B
-Subparagraph (i)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611

+ Details

XML 23 R13.htm IDEA: XBRL DOCUMENT

Leases

9 Months Ended

Sep. 30, 2022

Leases [Abstract]

Leases

7. Leases

Supplemental balance sheet information related to leases was as follows:

	September 30,			December 31,
	2022			2021
Operating lease right-of-use assets	$	927		$	1,084

Operating lease liability, current	$	(241	)	$	(202	)
Operating lease liability, noncurrent		(724	)		(911	)
Total operating lease liabilities	$	(965	)	$	(1,113	)

Future maturities of operating lease liabilities as of September 30, 2022 were as follows:

2022	$	73
2023		293
2024		301
2025		310
2026		144
Total lease payments		1,121
Less: imputed interest		(156	)
Present value of operating lease liabilities	$	965

Other information:

Cash paid for operating leases for the nine months ended September 30, 2022	$	212
Cash paid for operating leases for the nine months ended September 30, 2021	$	58
Remaining lease term - operating leases (in years)		3.75
Average discount rate - operating leases		8.0	%

XML 24 R14.htm IDEA: XBRL DOCUMENT

Stockholders' Equity

9 Months Ended

Sep. 30, 2022

Equity [Abstract]

Stockholders' Equity

8. Stockholders’ Equity

October 2021 the Company increased the number of authorized shares to 10,487,904 shares of common stock and 3,297,061 shares of preferred stock.

February 2022, the Company increased the number of authorized shares to 130,000,000 shares of common stock and 20,000,000 shares of preferred stock.

Reverse Stock Split

Initial Public Offering

Preferred Stock

Conversion

Redemption

The shares of the Series A and Series B Preferred Stock were redeemable only upon acquisition or liquidation of the Company.

Liquidation preference

Voting rights

Equity awards

A summary of the Company’s share option and restricted stock unit activity under its plans is as follows:

	Number of Shares Subject to Outstanding Stock Options		Weighted Average Exercise Price Per Share		Number of Outstanding Restricted Stock Units		Weighted-average Grant Date Fair Value per Share
Outstanding at December 31, 2021		727,394	$	5.32		—	$	—
Granted		113,950	$	2.47		1,318,530	$	7.93
Forfeited		—	$	—		—	$	—
Outstanding at September 30, 2022		841,344	$	4.93		1,318,530	$	7.93

The following table sets forth stock-based compensation expense recognized for the three and nine months ended September 30, 2022 and 2021:

	Three months ended September 30,				Nine months ended September 30,
	2022		2021		2022		2021
Research and development	$	374	$	23	$	581	$	36
Sales and marketing		37		10		61		18
General, and administrative		623		110		1,113		154
Total stock-based compensation expense	$	1,034	$	143	$	1,755	$	208

At September 30, 2022, there were 167,520 shares available for issuance under the 2022 Plan.

Warrants

which was recorded in additional paid-in capital in 2022

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-URI https://asc.fasb.org/topic&trid=2208762

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 14
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 14
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (d)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (g)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (h)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 14
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 16
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (i)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(e)(1))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 50
-Paragraph 6
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008

+ Details

XML 25 R15.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies	9 Months Ended
Commitments and Contingencies	Sep. 30, 2022
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	9. Commitments and Contingencies Sales Representative Agreement In April 2020, the Company entered into an Exclusive Sales Representative Agreement, under which the counterparty to the agreement (the “Representative”) received exclusive rights to market, promote, and distribute The Catamaran System in the United States and Puerto Rico. The agreement is for an initial period of five years, and automatically renews for an additional five years unless written notice is given by either party prior to April 27, 2023. The agreement provides for a bonus to be paid to the Representative upon an acquisition or IPO. In May 2021 the Company entered into an Amended and Restated Exclusive Sales Representative Agreement (the “Restated Sales Agreement”). In connection with the amended agreement, the Company paid $500 cash and issued 53,757 shares of common stock to the Representative, for which the Company recorded a combined total of approximately $880 as sales and marketing expense. In addition, the Representative received anti-dilution protections to maintain ownership of 3.0% of the fully diluted equity of the Company through the date of an initial public offering. In October, 2021, the Company issued 44,447 shares with a fair value of approximately $333 to the Representative in accordance with the anti-dilution provision. In April 2022, the Company issued 312,351 shares to the Representative in accordance with the anti-dilution provision, fully satisfying the Company’s obligations. The amended agreement restructured the calculation of the bonus paid to the Representative upon an acquisition, removed the bonus payable upon an IPO, and allows the Company to terminate the amended agreement as long as the bonus paid to the Representative is at least $6,000. In June 2021, the Company issued a $50 convertible note payable to the Chief Executive Officer of the Representative, as part of the convertible debt offering described in Note 6. In October 2022, the Company entered into the Terminating Amended and Restated Exclusive Sales Representative Agreement with the Representative. See Note 12. Litigation In the normal course of business, the Company may possibly be named as a defendant in various lawsuits. On September 2, 2021, Khalid Mentak, a former director and Chief Executive Officer of the Company filed an arbitration claim with the American Arbitration Association (“AAA”) against the Company, asserting damages in excess of $3,000, plus attorneys’ fees and other costs, for alleged unpaid wages, defamation, and other claims. The services provided by Mr. Mentak were governed by a Consulting Agreement between the Company and Key Medical Technologies, Inc (“Key Medical”), a company which Mr. Mentak served as Chief Executive Officer. The AAA proceeding was also initiated pursuant to the arbitration provision in the Consulting Agreement. The parties selected an arbitrator and the Company filed a motion to dismiss the proceeding as currently pled because the proper parties should be Key Medical and the Company, and not Mr. Mentak as an individual. The arbitrator ruled that Mr. Mentak was the real-party-in-interest and denied the motion, without prejudice to any arguments on the merits of the underlying claims. On March 1, 2022, Mr. Mentak filed a more detailed Statement of Claims, which the Company responded to on March 16, 2022. The Company also filed a cross-complaint for declaratory relief seeking to establish its rights and obligations under the Consulting Agreement with respect to the claimant and Key Medical, which was formally named a defendant in the cross complaint. The claimant objected to the cross-complaint as unnecessary. On July 21, 2022, the Company entered into a Settlement Agreement and General Release of All Claims (the “Settlement Agreement”) with Key Medical and Mr. Mentak to settle all claims and counterclaims. Pursuant to the Settlement Agreement, the Company has agreed to pay Key Medical the total sum of $1,200. The settlement amount was fully paid as of September 30, 2022.

XML 26 R16.htm IDEA: XBRL DOCUMENT

Concentrations of Risk	9 Months Ended
Concentrations of Risk	Sep. 30, 2022
Risks and Uncertainties [Abstract]
Concentrations of Risk	10. Concentrations of Risk Credit risk Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash and cash equivalents. The Company maintains cash balances at financial institutions located in California and Switzerland. Accounts at the U.S. financial institutions are secured by the Federal Deposit Insurance Corporation. At times, balances may exceed federally insured limits. The Company has not experienced any losses in such accounts. Management believes that the Company is not exposed to any significant credit risk with respect to its cash and cash equivalents. The Company grants unsecured credit to its customers based on an evaluation of the customer’s financial condition and a cash deposit is generally not required. Management believes its credit policies do not result in significant adverse risk and historically has not experienced significant credit-related losses. Currency risk The Company’s subsidiary, Tenon Technology AG, realizes a portion of its expenses in Swiss francs. Consequently, certain assets and liabilities are exposed to foreign currency fluctuations. At September 30, 2022 and December 31, 2021, approximately $8 and $21, respectively, of the Company’s net monetary assets were denominated in Swiss francs. The Company has not entered into any hedging transactions to reduce the exposure to currency risk.

XML 27 R17.htm IDEA: XBRL DOCUMENT

Related Party Transactions	9 Months Ended
Related Party Transactions	Sep. 30, 2022
Related Party Transactions [Abstract]
Related Party Transactions	11. Related Party Transactions During 2018 through 2020, the Company’s subsidiary issued convertible promissory notes to TTAG’s minority shareholder. In November 2020, these notes payable and accrued interest were converted into TTAG shares. In June 2021, the Company’s subsidiary issued a convertible promissory note for approximately $107 to TTAG’s minority shareholder. The Company purchased this note and accrued interest of $114 in October 2021 from TTAG’s minority shareholder. See Note 6. The Company had a consulting agreement with a company owned by the former Chief Executive Officer of the Company. Under this consulting agreement, the Chief Executive Officer was to provide services from 2015 through June 1, 2021. Total payments under the consulting agreement of $600 are to be paid as follows: (a) $300 paid upon closing of financing round of at least $5,000, followed by twelve monthly payments of $25 per month; (b) $300 paid upon achieving at least $3,000 of annual revenue and a financing round of less than $5,000; or (c) the entire $600 payable immediately upon an acquisition of the Company. During the three months ended September 30, 2022 and 2021, the Company recorded consulting expense of $0 and $8, respectively, related to this agreement. During the nine months ended September 30, 2022 and 2021, the Company recorded expense of $574 and $25, respectively, related to this agreement. As of September 30, 2022 and December 31, 2021, approximately $0 and $600, respectively, owed to this party was included in accrued expenses with respect of these services. See Note 9. During 2021, the Company issued convertible promissory notes totaling $620 to officers, directors, and their family members. See Note 6. In addition, a note was issued to the Chief Executive Officer of the Representative described in Note 9. On October 28, 2021, the Company entered into an agreement with TTAG’s minority shareholder. See Note 8. Pursuant to the terms of the Exchange Agreement, the Company purchased the convertible note and accrued interest between TTAG and Zuhlke Ventures AG (“ZVAG”), TTAG’s minority shareholder, in the amount of approximately $114. On December 31, 2021, the Company and TTAG entered into the IP Sale and Purchase Agreement, whereby TTAG transferred certain patents and trademarks to the Company. In connection with this transfer, the Company issued an unsecured promissory note to TTAG in the amount of $818 which eliminates in consolidation.

XML 28 R18.htm IDEA: XBRL DOCUMENT

Subsequent Events	9 Months Ended
Subsequent Events	Sep. 30, 2022
Subsequent Events [Abstract]
Subsequent Events	12. Subsequent Events On October 6, 2022, the Company entered into the Terminating Amended and Restated Exclusive Sales Representative Agreement (the “Termination Agreement”) with the Representative, which terminated the Restated Sales Agreement. In accordance with the Termination Agreement, (i) the Company paid the Representative $1,000 in cash; and (ii) the Company agreed to pay the Representative (a) $85 per month during the six months after the date of the Termination Agreement in return for efforts by the Representative to transition operations to the Company, (b) 20% of net sales of the Product sold in the United States and Puerto Rico until December 31, 2023 and (c) after December 31, 2023, a commission in an amount equal to 10% of net sales until such time as the aggregate amount paid to the Representative under this clause (c) and clause (b) above equal $3,600. In the event of an acquisition of the Company, the Company will pay the Representative $3,600 less previous amounts paid pursuant to clause (b) and clause (c) above In connection with the above terms, the Company will record a charge of $4,600 to sales and marketing expenses in the fourth quarter of 2022. Simultaneously with the execution of the Termination Agreement, the Company entered into a Consulting Agreement dated October 6, 2022, with the Representative (the “Consulting Agreement”). Under the terms and conditions of the Consulting Agreement, the Representative is tasked with organizing, recruiting, training, and coordinating the Company’s Clinical Specialist program, Physician Education program and Sales Education program as more specifically described in the Consulting Agreement. The term of the Consulting Agreement is from October 6, 2022, until October 05, 2023, unless extended by mutual agreement of the parties in writing for additional one-year terms, or terminated in accordance with the terms of the Consulting Agreement. In consideration for the services to be provided, the Company shall pay the Representative a base consulting fee of $700 per year, payable in monthly instalments, along with additional compensation of $62.5 per quarter, if certain sales targets are met, for four quarters; along with any travel and related out-of-pocket expenses incurred by the Representative in connection with the performance of the services.

XML 29 R19.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Principles (Policies)

9 Months Ended

Sep. 30, 2022

Accounting Policies [Abstract]

Basis of presentation

Going concern uncertainty and liquidity requirements

There is substantial doubt about the Company’s ability to continue as a going concern for one year after the date that these financial statements are issued.

The Company had the following dilutive common stock equivalents as of September 30, 2022 and 2021 which were excluded from the calculation because their effect was anti-dilutive.

	September 30, 2022		September 30, 2021
Outstanding restricted stock units		1,318,530		—
Outstanding stock options		841,344		705,394
Outstanding warrants		121,000		25,000
Common shares convertible from notes payable		—		2,079,510
Common shares convertible from preferred stock		—		245,611
Total		2,280,874		3,055,515

Recent Accounting Pronouncements

There have been no accounting pronouncements or changes in accounting pronouncements in the nine months ended September 30, 2022 that are significant or potentially significant to the Company.

- Definition

Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.

+ References + Details

XML 30 R20.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Principles (Tables)

9 Months Ended

Sep. 30, 2022

Accounting Policies [Abstract]

Schedule of Securities Excluded Due To Anti Dilutive Effect

The Company had the following dilutive common stock equivalents as of September 30, 2022 and 2021 which were excluded from the calculation because their effect was anti-dilutive.

	September 30, 2022		September 30, 2021
Outstanding restricted stock units		1,318,530		—
Outstanding stock options		841,344		705,394
Outstanding warrants		121,000		25,000
Common shares convertible from notes payable		—		2,079,510
Common shares convertible from preferred stock		—		245,611
Total		2,280,874		3,055,515

XML 31 R21.htm IDEA: XBRL DOCUMENT

Investments (Tables)

9 Months Ended

Sep. 30, 2022

Investments [Abstract]

Schedule of Investments At Fair Value in Fair Value Hierarchy Level

The following table sets forth by level, within the fair value hierarchy, the Company’s investments at fair value as of September 30, 2022 and December 31, 2021:

	Level 2
Corporate debt securities:
September 30, 2022	$	9,381
December 31, 2021	$	4,404

Schedule of Cost And Fair Value of Available For Sale Investments

Cost and fair value of available-for-sale investments as of September 30, 2022 and December 31, 2021 are as follows:

	Amortized ‎Cost		Gross ‎Unrealized ‎Gains		Gross Unrealized Losses			Fair ‎Value
Corporate debt securities:
September 30, 2022	$	9,418	$	—	$	(37	)	$	9,381
December 31, 2021	$	4,404	$	—	$	—		$	4,404

- Definition

Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.

+ References + Details

XML 32 R22.htm IDEA: XBRL DOCUMENT

Fixed Assets (Tables)

9 Months Ended

Sep. 30, 2022

Property, Plant and Equipment [Abstract]

Summary of Fixed Assets

Fixed assets, net, consisted of the following:

	September 30, 2022			December 31,2021
Catamaran Tray Sets	$	270		$	77
IT Equipment		56			17
Lab Equipment		14			—
Office Furniture		9			9
Fixed assets, gross		349			103
Less: accumulated depreciation		(55	)		(2	)
Fixed assets, net	$	294		$	101

XML 33 R23.htm IDEA: XBRL DOCUMENT

Accrued Expenses (Tables)

9 Months Ended

Sep. 30, 2022

Payables and Accruals [Abstract]

Schedule of Accrued Expenses

Accrued expenses consisted of the following:

	September 30, 2022		December 31, 2021
Accrued compensation	$	339	$	846
Accrued commissions		49		14
Other accrued expenses		215		228
Total accrued expenses	$	603	$	1,088

XML 34 R24.htm IDEA: XBRL DOCUMENT

Leases (Tables)

9 Months Ended

Sep. 30, 2022

Leases [Abstract]

Summary of Supplemental Balance Sheet Information Related To Leases

Supplemental balance sheet information related to leases was as follows:

	September 30,			December 31,
	2022			2021
Operating lease right-of-use assets	$	927		$	1,084

Operating lease liability, current	$	(241	)	$	(202	)
Operating lease liability, noncurrent		(724	)		(911	)
Total operating lease liabilities	$	(965	)	$	(1,113	)

Summary of Future Maturities of Operating Lease Liabilities

Future maturities of operating lease liabilities as of September 30, 2022 were as follows:

2022	$	73
2023		293
2024		301
2025		310
2026		144
Total lease payments		1,121
Less: imputed interest		(156	)
Present value of operating lease liabilities	$	965

Other information:

Cash paid for operating leases for the nine months ended September 30, 2022	$	212
Cash paid for operating leases for the nine months ended September 30, 2021	$	58
Remaining lease term - operating leases (in years)		3.75
Average discount rate - operating leases		8.0	%

XML 35 R25.htm IDEA: XBRL DOCUMENT

Stockholders' Equity (Tables)

9 Months Ended

Sep. 30, 2022

Equity [Abstract]

Summary of Share Based Compensation Arrangements By Share Based Payment Award

A summary of the Company’s share option and restricted stock unit activity under its plans is as follows:

	Number of Shares Subject to Outstanding Stock Options		Weighted Average Exercise Price Per Share		Number of Outstanding Restricted Stock Units		Weighted-average Grant Date Fair Value per Share
Outstanding at December 31, 2021		727,394	$	5.32		—	$	—
Granted		113,950	$	2.47		1,318,530	$	7.93
Forfeited		—	$	—		—	$	—
Outstanding at September 30, 2022		841,344	$	4.93		1,318,530	$	7.93

Summary of Employee Service Share Based Compensation Allocation of Recognized Period Costs

The following table sets forth stock-based compensation expense recognized for the three and nine months ended September 30, 2022 and 2021:

	Three months ended September 30,				Nine months ended September 30,
	2022		2021		2022		2021
Research and development	$	374	$	23	$	581	$	36
Sales and marketing		37		10		61		18
General, and administrative		623		110		1,113		154
Total stock-based compensation expense	$	1,034	$	143	$	1,755	$	208

XML 36 R26.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Principles - Schedule of Securities Excluded Due To Anti Dilutive Effect (Detail) - shares	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	2,280,874	3,055,515
Outstanding restricted stock units [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	1,318,530	0
Outstanding stock options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	841,344	705,394
Outstanding warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	121,000	25,000
Common shares convertible from notes payable [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	0	2,079,510
Common shares convertible from preferred stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	0	245,611

XML 37 R27.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Principles - Additional Information (Detail) - USD ($) $ in Thousands		9 Months Ended
	Apr. 29, 2022	Sep. 30, 2022	Sep. 30, 2021
Accounting Policies [Abstract]
Percentage of valuation allowance in deferred tax assets		100.00%
Proceeds from Issuance of Common Stock	$ 13,765	$ 14,139	$ 0

XML 38 R28.htm IDEA: XBRL DOCUMENT

Investments - Schedule of Investments At Fair Value in Fair Value Hierarchy Level (Detail) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Corporate Debt Securities [Member] \| Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	$ 9,381	$ 4,404

XML 39 R29.htm IDEA: XBRL DOCUMENT

Investments - Schedule of Cost And Fair Value of Available For Sale Investments (Detail) - Corporate Debt Securities [Member] - USD ($) $ in Thousands	9 Months Ended	12 Months Ended
	Sep. 30, 2022	Dec. 31, 2021
Debt Securities, Available-for-sale [Line Items]
Amortized Cost	$ 9,418	$ 4,404
Unrealized ‎Gains	0	0
Unrealized Losses	(37)	0
Fair Value	$ 9,381	$ 4,404

XML 40 R30.htm IDEA: XBRL DOCUMENT

Investments - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021
Other than temporary impairment losses	$ 10	$ 0	$ 37	$ 0
Net gain on investments	72	$ 1	108	$ 1
Prepaid Expenses and Other Current Assets [Member]
Accrued interest	$ 6		$ 6		$ 18

XML 41 R31.htm IDEA: XBRL DOCUMENT

Fixed Assets - Summary of Fixed Assets and Equipment Net (Detail) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Fixed Assets [Line Items]
Fixed Assets, gross	$ 349	$ 103
Less: accumulated depreciation	(55)	(2)
Fixed Assets, net	294	101
Catamaran Tray Sets [Member]
Fixed Assets [Line Items]
Fixed Assets, gross	270	77
IT Equipment [Member]
Fixed Assets [Line Items]
Fixed Assets, gross	56	17
Lab Equipment [Member]
Fixed Assets [Line Items]
Fixed Assets, gross	14	0
Office Equipment [Member]
Fixed Assets [Line Items]
Fixed Assets, gross	$ 9	$ 9

XML 42 R32.htm IDEA: XBRL DOCUMENT

Fixed Assets - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Property, Plant and Equipment [Abstract]
Depreciation	$ 24	$ 1	$ 53	$ 1

XML 43 R33.htm IDEA: XBRL DOCUMENT

Accrued Expenses - Schedule of Accrued Expenses (Detail) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Payables and Accruals [Abstract]
Accrued compensation	$ 339	$ 846
Accrued commissions	49	14
Other accrued expenses	215	228
Total accrued expenses	$ 603	$ 1,088

XML 44 R34.htm IDEA: XBRL DOCUMENT

Debt - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Thousands									1 Months Ended	12 Months Ended
	Apr. 29, 2022	May 31, 2021	Apr. 30, 2021	Jan. 31, 2021	Nov. 30, 2020	Oct. 31, 2019	Jun. 30, 2019	Dec. 31, 2016	May 31, 2021	Dec. 31, 2021	Sep. 30, 2022	Oct. 28, 2021	Jul. 31, 2021	Jun. 30, 2021	Dec. 31, 2015
IPO [Member]
Debt Disclosure [Line Items]
Stock Issued During Period, Shares, Conversion of Convertible Securities	3,955,415
Convertible Promissory Notes [Member]
Debt Disclosure [Line Items]
Proceeds from related party debt										$ 620
Convertible Promissory Notes [Member] \| Consultant [Member]
Debt Disclosure [Line Items]
Debt instrument principal amount		$ 68					$ 68		$ 68						$ 53
Interest rate		8.00%					8.00%		8.00%						8.00%
Percentage Of Debt Conversion Price Equal To Price Per Share Paid By The Other Cash Purchasers In The Future Financing							90.00%								90.00%
Maturity date		May 07, 2022					Jun. 12, 2021
Debt Conversion Convertible Automatically Upon The Minimum Amount Of Initial Public Offering Or Capital Stock Financing		$ 5,000							$ 5,000
Debt Instrument Conversion Price Equal To Percentage Of IPO Price		80.00%							80.00%
Debt instrument conversion price per share		$ 1.9565							$ 1.9565
Minimum Threshold Amount Of Capital Stock Financing Required For Conversion Of Convertible Instrument		$ 5,000							$ 5,000
Accrued Interest										14	$ 0
Minimum Threshold Amount Of Preferred Stock Financing Required For Conversion Of Convertible Debt							$ 1,000								$ 500
Convertible Promissory Notes [Member] \| Entity Minority Shareholder [Member]
Debt Disclosure [Line Items]
Debt instrument principal amount														$ 107
Interest rate														8.00%
Debt instrument convertible note and accrued interest												$ 114
Convertible Promissory Notes [Member] \| Vendor [Member]
Debt Disclosure [Line Items]
Debt instrument principal amount			$ 118					$ 118
Interest rate			8.00%					8.00%
Percentage Of Debt Conversion Price Equal To Price Per Share Paid By The Other Cash Purchasers In The Future Financing								90.00%
Maturity date			Apr. 30, 2022					Jan. 01, 2019
Debt Instrument Conversion Price Equal To Percentage Of IPO Price			80.00%
Debt instrument conversion price per share			$ 1.9565
Minimum Threshold Amount Of Capital Stock Financing Required For Conversion Of Convertible Instrument			$ 5,000
Accrued Interest										56	0
Minimum Threshold Amount Of Preferred Stock Financing Required For Conversion Of Convertible Debt			500
Convertible Promissory Notes [Member] \| Chief Executive Officer [Member]
Debt Disclosure [Line Items]
Debt instrument principal amount			$ 70			$ 70
Interest rate			8.00%			8.00%
Percentage Of Debt Conversion Price Equal To Price Per Share Paid By The Other Cash Purchasers In The Future Financing						80.00%
Maturity date			Apr. 30, 2022			Oct. 12, 2022
Debt Instrument Conversion Price Equal To Percentage Of IPO Price			70.00%
Debt instrument conversion price per share			$ 1.9565
Minimum Threshold Amount Of Capital Stock Financing Required For Conversion Of Convertible Instrument			$ 5,000
Accrued Interest										12	0
Minimum Threshold Amount Of Preferred Stock Financing Required For Conversion Of Convertible Debt			500
Convertible Promissory Notes [Member] \| Investor [Member]
Debt Disclosure [Line Items]
Debt instrument principal amount		$ 50				$ 50			$ 50
Interest rate		8.00%				8.00%			8.00%
Percentage Of Debt Conversion Price Equal To Price Per Share Paid By The Other Cash Purchasers In The Future Financing						80.00%
Maturity date		May 03, 2022				Oct. 21, 2022
Debt Instrument Conversion Price Equal To Percentage Of IPO Price		70.00%							70.00%
Debt instrument conversion price per share		$ 1.9565							$ 1.9565
Minimum Threshold Amount Of Capital Stock Financing Required For Conversion Of Convertible Instrument		$ 5,000							$ 5,000
Accrued Interest										9	0
Minimum Threshold Amount Of Preferred Stock Financing Required For Conversion Of Convertible Debt		500							500
Convertible Promissory Notes [Member] \| Investor One [Member]
Debt Disclosure [Line Items]
Debt instrument principal amount		$ 200			$ 200				$ 200
Interest rate		8.00%			8.00%				8.00%
Percentage Of Debt Conversion Price Equal To Price Per Share Paid By The Other Cash Purchasers In The Future Financing					80.00%
Maturity date		May 03, 2022			Nov. 16, 2022
Debt Instrument Conversion Price Equal To Percentage Of IPO Price		70.00%							70.00%
Minimum Threshold Amount Of Capital Stock Financing Required For Conversion Of Convertible Instrument		$ 5,000							$ 5,000
Accrued Interest										18	0
Minimum Threshold Amount Of Preferred Stock Financing Required For Conversion Of Convertible Debt					$ 2,000
Convertible Promissory Notes [Member] \| Officers, Directors, and their Family [Member]
Debt Disclosure [Line Items]
Debt instrument principal amount													$ 620
Interest rate													8.00%
Percentage Of Debt Conversion Price Equal To Price Per Share Paid By The Other Cash Purchasers In The Future Financing													70.00%
Minimum Threshold Amount Of Capital Stock Financing Required For Conversion Of Convertible Instrument													$ 5,000
Accrued Interest										527	0
Proceeds from related party debt									$ 12,177
Valuation amount													22,500
Debt issuance costs													71
Convertible Promissory Notes [Member] \| Chief Executive Officer of the Representative [Member]
Debt Disclosure [Line Items]
Debt instrument principal amount													$ 50
Promissory Notes [Member] \| Law Firm [Member]
Debt Disclosure [Line Items]
Debt instrument principal amount				$ 131
Interest rate				3.00%
Maturity date				Jul. 27, 2021
Percentage Of Increase IN Interest Rate If Principal And Interest Not Been Paid By Maturity Date				5.00%
Convertible Promissory Notes One [Member] \| Vendor [Member]
Debt Disclosure [Line Items]
Debt instrument principal amount			40
Convertible Promissory Notes Two [Member] \| Vendor [Member]
Debt Disclosure [Line Items]
Debt instrument principal amount			$ 170
Convertible Promissory Notes One and Two [Member] \| Vendor [Member]
Debt Disclosure [Line Items]
Interest rate			8.00%
Percentage Of Debt Conversion Price Equal To Price Per Share Paid By The Other Cash Purchasers In The Future Financing			70.00%
Debt Instrument Conversion Price Equal To Percentage Of IPO Price			70.00%
Minimum Threshold Amount Of Capital Stock Financing Required For Conversion Of Convertible Instrument			$ 5,000
Accrued Interest										$ 11	$ 0

XML 45 R35.htm IDEA: XBRL DOCUMENT

Leases - Summary of Supplemental Balance Sheet Information Related to Leases (Detail) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Lessee Disclosure [Abstract]
Operating lease right-of-use assets	$ 927	$ 1,084
Operating lease liability, current	(241)	(202)
Operating lease liability, noncurrent	(724)	(911)
Total operating lease liabilities	$ (965)	$ (1,113)

XML 46 R36.htm IDEA: XBRL DOCUMENT

Leases - Summary of Future Maturities of Operating Lease Liabilities (Detail) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021
Lessee Disclosure [Abstract]
2022	$ 73
2023	293
2024	301
2025	310
2026	144
Total lease payments	1,121
Less: imputed interest	(156)
Present value of operating lease liabilities	965		$ 1,113
Cash paid for operating leases	$ 212	$ 58
Remaining lease term - operating leases (in years)	3 years 9 months
Average discount rate - operating leases	8.00%

XML 47 R37.htm IDEA: XBRL DOCUMENT

Leases - Additional Information (Detail) - USD ($) $ in Thousands	1 Months Ended	3 Months Ended		9 Months Ended
	Jun. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Lessee, Operating lease, Expiration, Month and Year	2026-06
General and Administrative Expense [Member]
Operating lease costs		$ 73	$ 73	$ 219	$ 85

XML 48 R38.htm IDEA: XBRL DOCUMENT

Stockholders' Equity - Additional Information (Detail) $ / shares in Units, $ in Thousands			1 Months Ended			9 Months Ended		12 Months Ended	48 Months Ended
	Apr. 29, 2022 USD ($) $ / shares shares	Oct. 28, 2021 USD ($) $ / shares shares	Apr. 30, 2022 USD ($) yr $ / shares shares	Oct. 31, 2021 shares	May 31, 2021 shares	Sep. 30, 2022 USD ($) $ / shares shares	Sep. 30, 2021 shares	Dec. 31, 2020 USD ($) yr $ / shares shares	Dec. 31, 2015 USD ($) $ / shares shares	Apr. 26, 2022 $ / shares shares	Apr. 25, 2022 shares	Feb. 28, 2022 shares	Dec. 31, 2021 $ / shares shares	Aug. 31, 2021 shares	Jul. 31, 2021 shares	Apr. 30, 2021 shares	Feb. 18, 2014 $ / shares shares
Common stock, Shares authorized				10,487,904		130,000,000						130,000,000	10,487,904			7,000,000	3,937,550
Common stock, Par or stated value per share \| $ / shares						$ 0.001							$ 0.001				$ 0.001
Common stock, Voting rights						one vote
Stock issued during period, shares, issued for services to consultant	85,739
Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs \| $			$ 0
Representative [Member] \| Other [Member]
Ownership Percentage	3.00%
IPO [Member]
Common stock, Par or stated value per share \| $ / shares										$ 0.001
Common stock shares subscribed but unissued										3,200,000
Sale of stock, price per share \| $ / shares	$ 5									$ 5
Net proceeds from the IPO after deducting expenses \| $	$ 13,800
Common Stock Warrants [Member] \| Consultant [Member]
Class of warrant or right, number of common stock called by warrants or rights			96,000					25,000
Class of warrants or rights exercise price \| $ / shares			$ 5					$ 5.2
Class of warrants of rights grant date fair value of warrants \| $ / shares			$ 2.75					$ 2.3
Deferred costs associated with warrants \| $			$ 264					$ 58
Common Stock Warrants [Member] \| Consultant [Member] \| Measurement Input, Expected Term [Member]
Warrants and Rights Outstanding, Measurement Input \| yr			5					5
Common Stock Warrants [Member] \| Consultant [Member] \| Measurement Input, Price Volatility [Member]
Warrants and Rights Outstanding, Measurement Input			62.55					51.88
Common Stock Warrants [Member] \| Consultant [Member] \| Measurement Input, Expected Dividend Rate [Member]
Warrants and Rights Outstanding, Measurement Input			0					0
Common Stock Warrants [Member] \| Consultant [Member] \| Measurement Input, Risk Free Interest Rate [Member]
Warrants and Rights Outstanding, Measurement Input			2.92					0.3
Conversion of Convertible Notes to Common Stock [Member]
Number of shares issued during the period on conversion of convertible notes	3,955,415
Conversion of Series A and Series B Preferred Stock to Common Stock [Member]
Conversion of stock, Shares issued	2,693,342
Two Thousand And Twelve Plan [Member]
Common Stock, Capital Shares Reserved for Future Issuance															737,516	662,516
Two Thousand and Twenty Two Equity Incentive Plan [Member]
Share based compensation by share based payment award number of shares available for grant											1,600,000
Share based compensation arrangement by share based payment award cumulative annual increase shares											1,100,000
Share based compensation arrangement by share based payment award cumulative annual increase percentage											4.00%
Employee Stock Option [Member] \| Two Thousand And Twelve Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period						10 years
Minimum [Member] \| Two Thousand And Twelve Plan [Member]
Common Stock, Capital Shares Reserved for Future Issuance														737,516
Minimum [Member] \| Employee Stock Option [Member] \| Two Thousand And Twelve Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period						2 years
Maximum [Member] \| Two Thousand And Twelve Plan [Member]
Common Stock, Capital Shares Reserved for Future Issuance														799,266
Maximum [Member] \| Employee Stock Option [Member] \| Two Thousand And Twelve Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period						4 years
Common Stock [Member]
Stock issued during period, Shares, New issues						3,200,000
Stock issued during period, shares, issued for services to consultant						398,090	115,507
Common Stock [Member] \| Event Triggering Automatic Conversion [Member]
Minimum price per share at which shares are issued under firmly underwritten public offering \| $ / shares						$ 4
Minimum gross proceeds from firmly underwritten public offering \| $						$ 15,000
Noncontrolling Interest [Member] \| Conversion of Series A and Series B Preferred Stock to Common Stock [Member]
Conversion of stock, Shares issued	1,172,346	1,172,346
TTAG [Member]
Carrying value of the non controlling interest \| $						0
Shares Subject To Anti Dilution Protection [Member]
Minimum threshold amount of shares issued in an initial public offering or a qualified offering that were excluded \| $		$ 5,000
Minimum threshold price per share of shares issued in an initial public offering or a qualified offering that were excluded \| $ / shares		$ 3.3737
Shares Subject To Anti Dilution Protection [Member] \| Other [Member]
Ownership Percentage		24.00%
Exchange Agreement [Member]
Gain loss on agreement \| $						$ 0
Underwriting Agreement [Member]
Class of warrant or right, number of common stock called by warrants or rights										96,000
Class of warrants or rights exercise price \| $ / shares										$ 5
Amended and Restated Exclusive Sales Representative Agreement [Member] \| Representative [Member]
Stock issued during period, Shares, New issues	312,351			44,447	53,757
Amended and Restated Exclusive Sales Representative Agreement [Member] \| Representative [Member] \| Other [Member]
Ownership Percentage					3.00%
Convertible Preferred Stock [Member]
Temporary equity, Shares authorized				3,297,061								20,000,000				2,460,802	2,099,525
Series A Convertible Preferred Stock [Member]
Temporary equity, Shares authorized						4,500,000							2,805,839			1,798,905
Temporary equity, Liquidation preference per share \| $ / shares						$ 1.526
Series A Convertible Preferred Stock [Member] \| Exchange Agreement [Member] \| Shares Converted By TTAG s Minority Shareholder For Company Shares [Member]
Conversion of stock, Shares converted		574,033
Conversion of stock, Shares issued		2,550,763
Series A Convertible Preferred Stock [Member] \| Exchange Agreement [Member] \| Shares Converted By TTAG s Minority Shareholder For Company Shares [Member] \| Other [Member]
Ownership Percentage		24.00%
Series B Convertible Preferred Stock [Member]
Temporary equity, Shares authorized						491,222							491,222
Stock issued during period, Shares, New issues									491,222
Shares issued, Price per share \| $ / shares									$ 2.795
Proceeds from issuance of convertible preferred stock \| $									$ 1,272
Temporary equity, Liquidation preference per share \| $ / shares						$ 4.981
Series A Series B Convertible Preferred Stock [Member]
Conversion ratio						0.5

XML 49 R39.htm IDEA: XBRL DOCUMENT

Stockholders' Equity - Summary of Share Based Compensation Arrangements By Share Based Payment Award (Detail)	9 Months Ended
	Sep. 30, 2022 $ / shares shares
Number of Shares Subject to Outstanding Stock Options (Beginning Balance) \| shares	727,394
Number of Shares Subject to Outstanding Stock Options Granted \| shares	113,950
Number of Shares Subject to Outstanding Stock Options Forfeited \| shares	0
Number of Shares Subject to Outstanding Stock Options Outstanding (Ending Balance) \| shares	841,344
Weighted Average Exercise Price Per Share Outstanding (Beginning Balance) \| $ / shares	$ 5.32
Weighted Average Exercise Price Per Share Granted \| $ / shares	2.47
Weighted Average Exercise Price Per Share Forfeited \| $ / shares	0
Weighted Average Exercise Price Per Share Outstanding (Ending Balance) \| $ / shares	$ 4.93
Restricted Stock Units (RSUs) [Member]
Number of Outstanding Restricted Stock Units (Beginning Balance) \| shares	0
Number of Outstanding Restricted Stock Units Granted \| shares	1,318,530
Number of Outstanding Restricted Stock Units Forfeited \| shares	0
Number of Outstanding Restricted Stock Units (Ending Balance) \| shares	1,318,530
Share-based Payment Arrangement, Option [Member]
Weighted-average Grant Date Fair Value per Share (Beginning Balance) \| $ / shares	$ 0
Weighted-average Grant Date Fair Value per Share Granted \| $ / shares	7.93
Weighted-average Grant Date Fair Value per Share Forfeited \| $ / shares	0
Weighted-average Grant Date Fair Value per Share (Ending Balance) \| $ / shares	$ 7.93

XML 50 R40.htm IDEA: XBRL DOCUMENT

Stockholders' Equity - Summary of Employee Service Share Based Compensation Allocation of Recognized Period Costs (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Share-based Payment Arrangement, Expense	$ 1,034	$ 143	$ 1,755	$ 208
Research and development
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Share-based Payment Arrangement, Expense	374	23	581	36
Sales and marketing
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Share-based Payment Arrangement, Expense	37	10	61	18
General, and administrative
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Share-based Payment Arrangement, Expense	$ 623	$ 110	$ 1,113	$ 154

XML 51 R41.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies - Additional Information (Detail) - USD ($) $ in Thousands				1 Months Ended			3 Months Ended		9 Months Ended
	Jul. 21, 2022	Apr. 29, 2022	Sep. 02, 2021	Oct. 31, 2021	May 31, 2021	Apr. 30, 2020	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Jun. 30, 2021
Other Commitments [Line Items]
Sales and marketing expense							$ 645	$ 556	$ 2,864	$ 1,473
Stock issued during period value new issues									$ 13,765
Key Medical [Member]
Other Commitments [Line Items]
Litigation Settlement	$ 1,200
Representative [Member] \| Other [Member]
Other Commitments [Line Items]
Ownership Percentage		3.00%
Representative [Member] \| Convertible Notes Payable [Member]
Other Commitments [Line Items]
Debt instrument principal amount											$ 50
Khalid Mentak [Member] \| Arbitration Claim [Member]
Other Commitments [Line Items]
Loss Contingency, Damages Sought, Value			$ 3,000
Sales Representative Agreement [Member]
Other Commitments [Line Items]
Agreement term						5 years
Agreement additional extension term						5 years
Amended and Restated Exclusive Sales Representative Agreement [Member] \| Representative [Member]
Other Commitments [Line Items]
Payment of representative bonus					$ 500
Stock issued during period shares new issues		312,351		44,447	53,757
Sales and marketing expense					$ 880
Stock issued during period value new issues				$ 333
Minimum representative bonus payable				$ 6,000
Amended and Restated Exclusive Sales Representative Agreement [Member] \| Representative [Member] \| Other [Member]
Other Commitments [Line Items]
Ownership Percentage					3.00%

XML 52 R42.htm IDEA: XBRL DOCUMENT

Concentrations of Risk - Additional Information (Detail) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Switzerland, Francs [Member] \| Net Assets, Geographic Area [Member]
Concentration Risk [Line Items]
Net assets	$ 8	$ 21

XML 53 R43.htm IDEA: XBRL DOCUMENT

Related Party Transactions - Additional Information (Detail) - USD ($) $ in Thousands		3 Months Ended		9 Months Ended		12 Months Ended
	Jun. 01, 2021	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021	Oct. 28, 2021	Jun. 30, 2021
Related Party Transaction [Line Items]
Revenues		$ 208	$ 70	$ 414	$ 107
Convertible Promissory Notes [Member]
Related Party Transaction [Line Items]
Proceeds from related party debt						$ 620
IP Sale and Purchase Agreement [Member] \| Unsecured Promissory Note [Member]
Related Party Transaction [Line Items]
Debt instrument principal amount						818
Entity Minority Shareholder [Member] \| Convertible Promissory Notes [Member]
Related Party Transaction [Line Items]
Debt instrument principal amount								$ 107
Debt instrument convertible note and accrued interest							$ 114
Former Chief Executive Officer [Member] \| Consulting Agreement [Member]
Related Party Transaction [Line Items]
Related party transaction amounts of payments	$ 600
Related party transaction, expenses from transactions with related party		0	$ 8	574	$ 25
Due to Related Parties		$ 0		$ 0		$ 600
Former Chief Executive Officer [Member] \| Consulting Agreement Tranche One [Member]
Related Party Transaction [Line Items]
Related party transaction amounts of payments	300
Minimum threshold financing	5,000
Consulting agreement monthly payments	25
Former Chief Executive Officer [Member] \| Consulting Agreement Tranche Two [Member]
Related Party Transaction [Line Items]
Related party transaction amounts of payments	300
Minimum threshold financing	5,000
Revenues	$ 3,000

XML 54 R44.htm IDEA: XBRL DOCUMENT

Subsequent Events - Additional Information (Detail) - USD ($)		3 Months Ended			9 Months Ended
	Oct. 06, 2022	Dec. 31, 2022	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Subsequent Event [Line Items]
Selling and marketing expense			$ 645,000	$ 556,000	$ 2,864,000	$ 1,473,000
Subsequent Event [Member] \| Termination Agreement [Member] \| Representative [Member]
Subsequent Event [Line Items]
Payment to representative as per agreement	$ 1,000,000
As per agreement value agreed to pay the representative per month	$ 85,000
Percentage of net sales of the product sold agreed to pay the representative	20.00%
Percentage of commission to net sales agreed to pay the representative until aggregate amount paid	10.00%
Value of commission agreed to pay as per agreement	$ 3,600,000
As per agreement value to pay the representative in the event of acquisition net of previous amount paid	$ 3,600,000
Selling and marketing expense		$ 4,600,000
Subsequent Event [Member] \| Consulting Agreement [Member]
Subsequent Event [Line Items]
Term of agreement	October 6, 2022, until October 05, 2023
Additional term of agreement by mutual agreement of the parties in writing	1 year
Subsequent Event [Member] \| Consulting Agreement [Member] \| Representative [Member]
Subsequent Event [Line Items]
Consulting fee per year payable in monthly installments	$ 700,000
Additional compensation payable per quarter	$ 62,500

XML 55 tnon-20220930_htm.xml IDEA: XBRL DOCUMENT 0001560293 2022-01-01 2022-09-30 0001560293 2021-12-31 0001560293 2022-09-30 0001560293 2021-01-01 2021-09-30 0001560293 2021-07-01 2021-09-30 0001560293 2022-07-01 2022-09-30 0001560293 2021-06-01 2021-06-30 0001560293 2022-02-28 0001560293 2021-10-31 0001560293 2021-04-30 0001560293 2014-02-18 0001560293 2022-11-10 0001560293 2022-04-29 2022-04-29 0001560293 2022-04-01 2022-04-30 0001560293 2020-12-31 0001560293 2021-06-30 0001560293 2022-06-30 0001560293 2021-09-30 0001560293 tnon:SeriesBConvertiblePreferredStockMember 2022-09-30 0001560293 tnon:SeriesAConvertiblePreferredStockMember 2022-09-30 0001560293 tnon:ItEquipmentMember 2022-09-30 0001560293 tnon:LabEquipmentMember 2022-09-30 0001560293 us-gaap:OfficeEquipmentMember 2022-09-30 0001560293 tnon:CatamaranTraySetsMember 2022-09-30 0001560293 tnon:ConsultingAgreementMember tnon:FormerChiefExecutiveOfficerMember 2022-09-30 0001560293 currency:CHF us-gaap:NetAssetsGeographicAreaMember 2022-09-30 0001560293 us-gaap:FairValueInputsLevel2Member us-gaap:CorporateDebtSecuritiesMember 2022-09-30 0001560293 us-gaap:CorporateDebtSecuritiesMember 2022-09-30 0001560293 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember 2022-09-30 0001560293 tnon:TtagMember 2022-09-30 0001560293 tnon:SeriesASeriesBConvertiblePreferredStockMember 2022-09-30 0001560293 us-gaap:CommonStockMember tnon:EventTriggeringAutomaticConversionMember 2022-09-30 0001560293 tnon:ConvertiblePromissoryNotesMember tnon:OfficersDirectorsAndTheirFamilyMember 2022-09-30 0001560293 tnon:ConvertiblePromissoryNotesOneAndTwoMember tnon:VendorMember 2022-09-30 0001560293 tnon:ConvertiblePromissoryNotesMember tnon:InvestorOneMember 2022-09-30 0001560293 tnon:ConvertiblePromissoryNotesMember us-gaap:InvestorMember 2022-09-30 0001560293 tnon:ConvertiblePromissoryNotesMember srt:ChiefExecutiveOfficerMember 2022-09-30 0001560293 tnon:ConvertiblePromissoryNotesMember tnon:VendorMember 2022-09-30 0001560293 tnon:ConvertiblePromissoryNotesMember tnon:ConsultantMember 2022-09-30 0001560293 tnon:SeriesBConvertiblePreferredStockMember 2021-12-31 0001560293 tnon:SeriesAConvertiblePreferredStockMember 2021-12-31 0001560293 tnon:ItEquipmentMember 2021-12-31 0001560293 tnon:LabEquipmentMember 2021-12-31 0001560293 us-gaap:OfficeEquipmentMember 2021-12-31 0001560293 tnon:CatamaranTraySetsMember 2021-12-31 0001560293 tnon:UnsecuredPromissoryNoteMember tnon:IpSaleAndPurchaseAgreementMember 2021-12-31 0001560293 tnon:ConsultingAgreementMember tnon:FormerChiefExecutiveOfficerMember 2021-12-31 0001560293 currency:CHF us-gaap:NetAssetsGeographicAreaMember 2021-12-31 0001560293 us-gaap:FairValueInputsLevel2Member us-gaap:CorporateDebtSecuritiesMember 2021-12-31 0001560293 us-gaap:CorporateDebtSecuritiesMember 2021-12-31 0001560293 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember 2021-12-31 0001560293 tnon:ConvertiblePromissoryNotesMember tnon:OfficersDirectorsAndTheirFamilyMember 2021-12-31 0001560293 tnon:ConvertiblePromissoryNotesOneAndTwoMember tnon:VendorMember 2021-12-31 0001560293 tnon:ConvertiblePromissoryNotesMember tnon:InvestorOneMember 2021-12-31 0001560293 tnon:ConvertiblePromissoryNotesMember us-gaap:InvestorMember 2021-12-31 0001560293 tnon:ConvertiblePromissoryNotesMember srt:ChiefExecutiveOfficerMember 2021-12-31 0001560293 tnon:ConvertiblePromissoryNotesMember tnon:VendorMember 2021-12-31 0001560293 tnon:ConvertiblePromissoryNotesMember tnon:ConsultantMember 2021-12-31 0001560293 tnon:ConsultingAgreementMember tnon:FormerChiefExecutiveOfficerMember 2022-07-01 2022-09-30 0001560293 us-gaap:GeneralAndAdministrativeExpenseMember 2022-07-01 2022-09-30 0001560293 us-gaap:ResearchAndDevelopmentExpenseMember 2022-07-01 2022-09-30 0001560293 us-gaap:SellingAndMarketingExpenseMember 2022-07-01 2022-09-30 0001560293 us-gaap:AdditionalPaidInCapitalMember 2022-07-01 2022-09-30 0001560293 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-07-01 2022-09-30 0001560293 us-gaap:RetainedEarningsMember 2022-07-01 2022-09-30 0001560293 tnon:ConsultingAgreementMember tnon:FormerChiefExecutiveOfficerMember 2021-07-01 2021-09-30 0001560293 us-gaap:GeneralAndAdministrativeExpenseMember 2021-07-01 2021-09-30 0001560293 us-gaap:ResearchAndDevelopmentExpenseMember 2021-07-01 2021-09-30 0001560293 us-gaap:SellingAndMarketingExpenseMember 2021-07-01 2021-09-30 0001560293 us-gaap:AdditionalPaidInCapitalMember 2021-07-01 2021-09-30 0001560293 tnon:SeriesAConvertiblePreferredStockMember us-gaap:CommonStockMember 2021-07-01 2021-09-30 0001560293 tnon:SeriesAConvertiblePreferredStockMember us-gaap:AdditionalPaidInCapitalMember 2021-07-01 2021-09-30 0001560293 tnon:SeriesAConvertiblePreferredStockMember 2021-07-01 2021-09-30 0001560293 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-07-01 2021-09-30 0001560293 us-gaap:RetainedEarningsMember 2021-07-01 2021-09-30 0001560293 us-gaap:NoncontrollingInterestMember 2021-07-01 2021-09-30 0001560293 tnon:ConsultingAgreementMember tnon:FormerChiefExecutiveOfficerMember 2022-01-01 2022-09-30 0001560293 us-gaap:ConvertiblePreferredStockMember 2022-01-01 2022-09-30 0001560293 us-gaap:ConvertibleNotesPayableMember 2022-01-01 2022-09-30 0001560293 us-gaap:WarrantMember 2022-01-01 2022-09-30 0001560293 us-gaap:EmployeeStockOptionMember 2022-01-01 2022-09-30 0001560293 us-gaap:RestrictedStockMember 2022-01-01 2022-09-30 0001560293 us-gaap:GeneralAndAdministrativeExpenseMember 2022-01-01 2022-09-30 0001560293 us-gaap:CorporateDebtSecuritiesMember 2022-01-01 2022-09-30 0001560293 tnon:ExchangeAgreementMember 2022-01-01 2022-09-30 0001560293 us-gaap:CommonStockMember tnon:EventTriggeringAutomaticConversionMember 2022-01-01 2022-09-30 0001560293 srt:MinimumMember us-gaap:EmployeeStockOptionMember tnon:TwoThousandAndTwelvePlanMember 2022-01-01 2022-09-30 0001560293 srt:MaximumMember us-gaap:EmployeeStockOptionMember tnon:TwoThousandAndTwelvePlanMember 2022-01-01 2022-09-30 0001560293 us-gaap:EmployeeStockOptionMember tnon:TwoThousandAndTwelvePlanMember 2022-01-01 2022-09-30 0001560293 us-gaap:ResearchAndDevelopmentExpenseMember 2022-01-01 2022-09-30 0001560293 us-gaap:SellingAndMarketingExpenseMember 2022-01-01 2022-09-30 0001560293 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-09-30 0001560293 us-gaap:CommonStockMember 2022-01-01 2022-09-30 0001560293 tnon:SeriesAConvertiblePreferredStockMember us-gaap:CommonStockMember 2022-01-01 2022-09-30 0001560293 tnon:SeriesAConvertiblePreferredStockMember us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-09-30 0001560293 tnon:SeriesAConvertiblePreferredStockMember 2022-01-01 2022-09-30 0001560293 tnon:SeriesBConvertiblePreferredStockMember us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-09-30 0001560293 tnon:SeriesBConvertiblePreferredStockMember 2022-01-01 2022-09-30 0001560293 tnon:SeriesBConvertiblePreferredStockMember us-gaap:CommonStockMember 2022-01-01 2022-09-30 0001560293 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-01-01 2022-09-30 0001560293 us-gaap:RetainedEarningsMember 2022-01-01 2022-09-30 0001560293 us-gaap:RestrictedStockUnitsRSUMember 2022-01-01 2022-09-30 0001560293 us-gaap:EmployeeStockOptionMember 2022-01-01 2022-09-30 0001560293 tnon:ConsultingAgreementMember tnon:FormerChiefExecutiveOfficerMember 2021-01-01 2021-09-30 0001560293 us-gaap:ConvertiblePreferredStockMember 2021-01-01 2021-09-30 0001560293 us-gaap:ConvertibleNotesPayableMember 2021-01-01 2021-09-30 0001560293 us-gaap:WarrantMember 2021-01-01 2021-09-30 0001560293 us-gaap:EmployeeStockOptionMember 2021-01-01 2021-09-30 0001560293 us-gaap:RestrictedStockMember 2021-01-01 2021-09-30 0001560293 us-gaap:GeneralAndAdministrativeExpenseMember 2021-01-01 2021-09-30 0001560293 us-gaap:ResearchAndDevelopmentExpenseMember 2021-01-01 2021-09-30 0001560293 us-gaap:SellingAndMarketingExpenseMember 2021-01-01 2021-09-30 0001560293 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-09-30 0001560293 us-gaap:CommonStockMember 2021-01-01 2021-09-30 0001560293 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-01-01 2021-09-30 0001560293 us-gaap:RetainedEarningsMember 2021-01-01 2021-09-30 0001560293 us-gaap:NoncontrollingInterestMember 2021-01-01 2021-09-30 0001560293 tnon:ConvertiblePromissoryNotesMember 2021-01-01 2021-12-31 0001560293 us-gaap:CorporateDebtSecuritiesMember 2021-01-01 2021-12-31 0001560293 tnon:SeriesBConvertiblePreferredStockMember 2015-12-31 0001560293 tnon:ConvertiblePromissoryNotesMember tnon:ConsultantMember 2015-12-31 0001560293 tnon:ConvertiblePromissoryNotesMember tnon:ConsultantMember 2019-06-30 2019-06-30 0001560293 tnon:ConvertiblePromissoryNotesMember tnon:ConsultantMember 2019-06-30 0001560293 tnon:ConvertiblePromissoryNotesMember tnon:InvestorOneMember 2021-05-31 2021-05-31 0001560293 tnon:ConvertiblePromissoryNotesMember us-gaap:InvestorMember 2021-05-31 2021-05-31 0001560293 tnon:ConvertiblePromissoryNotesMember tnon:ConsultantMember 2021-05-31 2021-05-31 0001560293 tnon:RepresentativeMember tnon:OtherMember tnon:AmendedAndRestatedExclusiveSalesRepresentativeAgreementMember 2021-05-31 0001560293 tnon:ConvertiblePromissoryNotesMember tnon:InvestorOneMember 2021-05-31 0001560293 tnon:ConvertiblePromissoryNotesMember us-gaap:InvestorMember 2021-05-31 0001560293 tnon:ConvertiblePromissoryNotesMember tnon:ConsultantMember 2021-05-31 0001560293 tnon:ConvertiblePromissoryNotesMember tnon:VendorMember 2016-12-31 2016-12-31 0001560293 tnon:ConvertiblePromissoryNotesMember tnon:VendorMember 2016-12-31 0001560293 tnon:ConvertiblePromissoryNotesMember srt:ChiefExecutiveOfficerMember 2021-04-30 2021-04-30 0001560293 tnon:ConvertiblePromissoryNotesMember tnon:VendorMember 2021-04-30 2021-04-30 0001560293 tnon:SeriesAConvertiblePreferredStockMember 2021-04-30 0001560293 us-gaap:ConvertiblePreferredStockMember 2021-04-30 0001560293 tnon:TwoThousandAndTwelvePlanMember 2021-04-30 0001560293 tnon:ConvertiblePromissoryNotesTwoMember tnon:VendorMember 2021-04-30 0001560293 tnon:ConvertiblePromissoryNotesOneMember tnon:VendorMember 2021-04-30 0001560293 tnon:ConvertiblePromissoryNotesMember srt:ChiefExecutiveOfficerMember 2021-04-30 0001560293 tnon:ConvertiblePromissoryNotesMember tnon:VendorMember 2021-04-30 0001560293 tnon:ConvertiblePromissoryNotesOneAndTwoMember tnon:VendorMember 2021-04-30 0001560293 tnon:ConvertiblePromissoryNotesMember us-gaap:InvestorMember 2019-10-31 2019-10-31 0001560293 tnon:ConvertiblePromissoryNotesMember srt:ChiefExecutiveOfficerMember 2019-10-31 2019-10-31 0001560293 tnon:ConvertiblePromissoryNotesMember us-gaap:InvestorMember 2019-10-31 0001560293 tnon:ConvertiblePromissoryNotesMember srt:ChiefExecutiveOfficerMember 2019-10-31 0001560293 tnon:ConvertiblePromissoryNotesMember tnon:InvestorOneMember 2020-11-30 2020-11-30 0001560293 tnon:ConvertiblePromissoryNotesMember tnon:InvestorOneMember 2020-11-30 0001560293 tnon:PromissoryNotesMember tnon:LawFirmMember 2021-01-31 2021-01-31 0001560293 tnon:PromissoryNotesMember tnon:LawFirmMember 2021-01-31 0001560293 tnon:RepresentativeMember tnon:AmendedAndRestatedExclusiveSalesRepresentativeAgreementMember 2021-05-01 2021-05-31 0001560293 tnon:ConvertiblePromissoryNotesMember tnon:OfficersDirectorsAndTheirFamilyMember 2021-05-01 2021-05-31 0001560293 tnon:TwoThousandAndTwelvePlanMember 2021-07-31 0001560293 tnon:ConvertiblePromissoryNotesMember tnon:ChiefExecutiveOfficerOfTheRepresentativeMember 2021-07-31 0001560293 tnon:ConvertiblePromissoryNotesMember tnon:OfficersDirectorsAndTheirFamilyMember 2021-07-31 0001560293 tnon:RepresentativeMember tnon:AmendedAndRestatedExclusiveSalesRepresentativeAgreementMember 2022-04-29 2022-04-29 0001560293 tnon:ConversionOfSeriesAAndSeriesBPreferredStockToCommonStockMember us-gaap:NoncontrollingInterestMember 2022-04-29 2022-04-29 0001560293 tnon:ConversionOfSeriesAAndSeriesBPreferredStockToCommonStockMember 2022-04-29 2022-04-29 0001560293 us-gaap:IPOMember 2022-04-29 2022-04-29 0001560293 tnon:ConversionOfConvertibleNotesToCommonStockMember 2022-04-29 2022-04-29 0001560293 tnon:ConvertiblePromissoryNotesMember tnon:EntityMinorityShareholderMember 2021-06-30 0001560293 tnon:RepresentativeMember us-gaap:ConvertibleNotesPayableMember 2021-06-30 0001560293 tnon:ConvertiblePromissoryNotesMember tnon:EntityMinorityShareholderMember 2021-10-28 0001560293 tnon:OtherMember tnon:SharesSubjectToAntiDilutionProtectionMember 2021-10-28 0001560293 tnon:OtherMember tnon:SharesConvertedByTtagSMinorityShareholderForCompanySharesMember tnon:SeriesAConvertiblePreferredStockMember tnon:ExchangeAgreementMember 2021-10-28 0001560293 tnon:SharesSubjectToAntiDilutionProtectionMember 2021-10-28 0001560293 us-gaap:ConvertiblePreferredStockMember 2014-02-18 0001560293 tnon:RepresentativeMember tnon:AmendedAndRestatedExclusiveSalesRepresentativeAgreementMember 2021-10-31 0001560293 us-gaap:ConvertiblePreferredStockMember 2021-10-31 0001560293 us-gaap:ConvertiblePreferredStockMember 2022-02-28 0001560293 us-gaap:IPOMember 2022-04-26 0001560293 tnon:UnderwritingAgreementMember 2022-04-26 0001560293 tnon:RepresentativeMember tnon:OtherMember 2022-04-29 0001560293 us-gaap:IPOMember 2022-04-29 0001560293 tnon:SharesConvertedByTtagSMinorityShareholderForCompanySharesMember tnon:SeriesAConvertiblePreferredStockMember tnon:ExchangeAgreementMember 2021-10-28 2021-10-28 0001560293 tnon:ConversionOfSeriesAAndSeriesBPreferredStockToCommonStockMember us-gaap:NoncontrollingInterestMember 2021-10-28 2021-10-28 0001560293 tnon:SeriesBConvertiblePreferredStockMember 2012-01-01 2015-12-31 0001560293 srt:MaximumMember tnon:TwoThousandAndTwelvePlanMember 2021-08-31 0001560293 srt:MinimumMember tnon:TwoThousandAndTwelvePlanMember 2021-08-31 0001560293 tnon:TwoThousandAndTwentyTwoEquityIncentivePlanMember 2022-04-25 0001560293 tnon:ConsultantMember tnon:CommonStockWarrantsMember 2020-01-01 2020-12-31 0001560293 tnon:ConsultantMember tnon:CommonStockWarrantsMember 2020-12-31 0001560293 tnon:ConsultantMember tnon:CommonStockWarrantsMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2020-12-31 0001560293 tnon:ConsultantMember tnon:CommonStockWarrantsMember us-gaap:MeasurementInputExpectedDividendRateMember 2020-12-31 0001560293 tnon:ConsultantMember tnon:CommonStockWarrantsMember us-gaap:MeasurementInputPriceVolatilityMember 2020-12-31 0001560293 tnon:ConsultantMember tnon:CommonStockWarrantsMember us-gaap:MeasurementInputExpectedTermMember 2020-12-31 0001560293 tnon:ConsultantMember tnon:CommonStockWarrantsMember 2022-04-01 2022-04-30 0001560293 tnon:ConsultantMember tnon:CommonStockWarrantsMember 2022-04-30 0001560293 tnon:ConsultantMember tnon:CommonStockWarrantsMember us-gaap:MeasurementInputPriceVolatilityMember 2022-04-30 0001560293 tnon:ConsultantMember tnon:CommonStockWarrantsMember us-gaap:MeasurementInputExpectedTermMember 2022-04-30 0001560293 tnon:ConsultantMember tnon:CommonStockWarrantsMember us-gaap:MeasurementInputExpectedDividendRateMember 2022-04-30 0001560293 tnon:ConsultantMember tnon:CommonStockWarrantsMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2022-04-30 0001560293 tnon:RepresentativeMember tnon:AmendedAndRestatedExclusiveSalesRepresentativeAgreementMember 2021-10-01 2021-10-31 0001560293 tnon:KhalidMentakMember tnon:ArbitrationClaimMember 2021-09-02 2021-09-02 0001560293 tnon:KeyMedicalMember 2022-07-21 2022-07-21 0001560293 tnon:ConsultingAgreementMember tnon:FormerChiefExecutiveOfficerMember 2021-06-01 2021-06-01 0001560293 tnon:ConsultingAgreementTrancheOneMember tnon:FormerChiefExecutiveOfficerMember 2021-06-01 2021-06-01 0001560293 tnon:ConsultingAgreementTrancheTwoMember tnon:FormerChiefExecutiveOfficerMember 2021-06-01 2021-06-01 0001560293 tnon:ConsultingAgreementTrancheOneMember tnon:FormerChiefExecutiveOfficerMember 2021-06-01 0001560293 tnon:ConsultingAgreementTrancheTwoMember tnon:FormerChiefExecutiveOfficerMember 2021-06-01 0001560293 tnon:SalesRepresentativeAgreementMember 2020-04-01 2020-04-30 0001560293 tnon:RepresentativeMember us-gaap:SubsequentEventMember tnon:TerminationAgreementMember 2022-10-06 0001560293 tnon:RepresentativeMember us-gaap:SubsequentEventMember tnon:ConsultingAgreementMember 2022-10-06 0001560293 tnon:RepresentativeMember us-gaap:SubsequentEventMember tnon:TerminationAgreementMember 2022-10-06 2022-10-06 0001560293 us-gaap:SubsequentEventMember tnon:ConsultingAgreementMember 2022-10-06 2022-10-06 0001560293 tnon:RepresentativeMember us-gaap:SubsequentEventMember tnon:TerminationAgreementMember 2022-10-01 2022-12-31 0001560293 tnon:SeriesAConvertiblePreferredStockMember 2022-06-30 0001560293 tnon:SeriesBConvertiblePreferredStockMember 2022-06-30 0001560293 us-gaap:NoncontrollingInterestMember 2022-06-30 0001560293 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-06-30 0001560293 us-gaap:RetainedEarningsMember 2022-06-30 0001560293 us-gaap:AdditionalPaidInCapitalMember 2022-06-30 0001560293 us-gaap:CommonStockMember 2022-06-30 0001560293 us-gaap:CommonStockMember 2022-09-30 0001560293 us-gaap:AdditionalPaidInCapitalMember 2022-09-30 0001560293 us-gaap:RetainedEarningsMember 2022-09-30 0001560293 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-09-30 0001560293 us-gaap:NoncontrollingInterestMember 2022-09-30 0001560293 tnon:SeriesAConvertiblePreferredStockMember 2021-06-30 0001560293 tnon:SeriesBConvertiblePreferredStockMember 2021-06-30 0001560293 us-gaap:NoncontrollingInterestMember 2021-06-30 0001560293 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-06-30 0001560293 us-gaap:RetainedEarningsMember 2021-06-30 0001560293 us-gaap:AdditionalPaidInCapitalMember 2021-06-30 0001560293 us-gaap:CommonStockMember 2021-06-30 0001560293 tnon:SeriesAConvertiblePreferredStockMember 2021-09-30 0001560293 tnon:SeriesBConvertiblePreferredStockMember 2021-09-30 0001560293 us-gaap:CommonStockMember 2021-09-30 0001560293 us-gaap:AdditionalPaidInCapitalMember 2021-09-30 0001560293 us-gaap:RetainedEarningsMember 2021-09-30 0001560293 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-09-30 0001560293 us-gaap:NoncontrollingInterestMember 2021-09-30 0001560293 us-gaap:RetainedEarningsMember 2021-12-31 0001560293 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-12-31 0001560293 us-gaap:NoncontrollingInterestMember 2021-12-31 0001560293 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001560293 us-gaap:CommonStockMember 2021-12-31 0001560293 us-gaap:RestrictedStockUnitsRSUMember 2021-12-31 0001560293 us-gaap:RestrictedStockUnitsRSUMember 2022-09-30 0001560293 us-gaap:EmployeeStockOptionMember 2021-12-31 0001560293 us-gaap:EmployeeStockOptionMember 2022-09-30 0001560293 tnon:SeriesAConvertiblePreferredStockMember 2020-12-31 0001560293 tnon:SeriesBConvertiblePreferredStockMember 2020-12-31 0001560293 us-gaap:CommonStockMember 2020-12-31 0001560293 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001560293 us-gaap:RetainedEarningsMember 2020-12-31 0001560293 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-12-31 0001560293 us-gaap:NoncontrollingInterestMember 2020-12-31 iso4217:USD shares utr:Year pure iso4217:USD shares utr:Y false Q3 --12-31 0001560293 CA

P2Y

10-Q true 2022-09-30 2022 false 001-41364 TENON MEDICAL, INC. DE 45-5574718 104 Cooper Court Los Gatos 95032 408 649-5760 Common Stock, par value $0.001 per share TNON NASDAQ Yes Yes Non-accelerated Filer true true false false 11236801

3153000

2917000

9381000

4404000

144000

76000

810000

188000

177000

87000

13665000

7672000

294000

101000

51000

41000

927000

1084000

374000

14937000

9272000

422000

478000

603000

1088000

241000

202000

31000

0 12857000 0 2000 0 649000

1266000

15274000

724000

911000

1990000

16185000

0.001

4500000

2805839

2550763

12367000

0.001

491222

1272000

0.001

130000000

10487904

11236801

989954

11000

1000

44691000

113000

-31587000

-20575000

-168000

-91000

12947000

-20552000

14937000

9272000

208000

70000

414000

107000

302000

18000

848000

38000

-94000

52000

-434000

69000

797000

601000

2016000

925000

645000

556000

2864000

1473000

1726000

992000

5483000

1570000

3168000

2149000

10363000

3968000

-3262000

-2097000

-10797000

-3899000

72000

1000

108000

1000

267000

362000

340000

19000

39000

-1000

91000

-266000

-215000

-340000

-3171000

-2363000

-11012000

-4239000

-22000

-33000

-3171000

-2341000

-11012000

-4206000

-0.28

-2.55

-1.59

-4.85

11237

919

6920

868

-3171000

-2363000

-11012000

-4239000

10000

37000

-19000

1000

-40000

1000

-3200000

-2362000

-11089000

-4238000

-22000

-33000

-3200000

-2340000

-11089000

-4205000

11236801

11000

43657000

-28416000

-139000

15113000

1034000

-29000

-3171000

11236801

11000

44691000

-31587000

-168000

12947000

491222

1272000

883757

1000

571000

-6351000

-57000

1696000

-4140000

143000

0 0

61750

436000

1000

-2341000

-22000

-2363000

491222

1272000

945507

1000

1150000

-8692000

-56000

1674000

-5923000

2550763

12367000

491222

1272000

989954

1000

113000

-20575000

-91000

-20552000

1755000

3200000

3000

13762000

13765000

-2550763 -12367000

2447728

2000

12365000

12367000

-491222 -1272000

245614

1272000

3955415

4000

13864000

13868000

398090

1000

1560000

1561000

-77000

-11012000

11236801

11000

44691000

-31587000

-168000

12947000

491222

1272000

830000

1000

126000

-4486000

-57000

1707000

-2709000

208000

115507

816000

1000

-4206000

-33000

-4239000

491222

1272000

945507

1000

1150000

-8692000

-56000

1674000

-5923000

-11012000

-4239000

37000

1000

362000

340000

1755000

208000

1561000

816000

53000

1000

157000

62000

68000

56000

622000

-21000

100000

129000

-56000

242000

-485000

168000

-148000

-35000

-8640000

-2602000

4404000

9381000

7861000

246000

18000

-5223000

-7879000

14139000

12072000

131000

71000

0 222000

14139000

11648000

-40000

-4000

236000

1163000

2917000

245000

3153000

1409000

1000

13639000 0 13868000 0 0 1195000 0 556000

<div style="margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; line-height: 12pt; background: none;;text-indent: 0px;"><div style="font-weight:bold;display:inline;">1. Organization and Business</div></div> <div style="margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; line-height: 12pt; background: none;;text-indent: 0px;"> </div> <div style="margin: 0px 0px 0px 0in; text-align: justify; font-family: "Times New Roman", Times, serif; font-size: 10pt; line-height: 12pt; background: none;;text-indent: 0px;"><div style="font-style:italic;display:inline;">Nature of operations</div></div> <div style="margin: 0px 0px 0px 0in; text-align: justify; font-family: "Times New Roman", Times, serif; font-size: 10pt; line-height: 12pt; background: none;;text-indent: 0px;"> </div> <div style="margin: 0px 0px 0px 0in; text-align: justify; font-family: "Times New Roman", Times, serif; font-size: 10pt; line-height: 12pt; background: none;;text-indent: 0px;">Tenon Medical, Inc. (the “Company”), was incorporated in the State of Delaware on June 19, 2012 and was headquartered in San Ramon, California until June 2021 when it relocated to Los Gatos, California. The Company is a medical device company that has developed a novel, less invasive, inferior-posterior approach to the sacroiliac joint using a single, robust, titanium implant for treatment of the most common types of sacroiliac joint (the “SI Joint”) disorders that cause lower back pain. The Company received U.S. Food and Drug Administration (“FDA”) clearance in 2018 for its primary product, The Catamaran<div style=";display:inline;vertical-align: super;;font-size:9.2px">TM </div>SI Joint Fusion System (“The Catamaran System”) which is designed to transfix and stabilize the SI Joint. The Company is in the early stages of its commercial launch with its primary focus being on the US market.</div> <div style="margin: 0px 0px 0px 0in; text-align: justify; font-family: "Times New Roman", Times, serif; font-size: 10pt; line-height: 12pt; background: none;;text-indent: 0px;"> </div> <div style="margin: 0px 0px 0px 0in; text-align: justify; font-family: "Times New Roman", Times, serif; font-size: 10pt; line-height: 12pt; background: none;;text-indent: 0px;"><div style="font-style:italic;display:inline;">Basis of consolidation</div></div> <div style="margin: 0px 0px 0px 0in; text-align: justify; font-family: "Times New Roman", Times, serif; font-size: 10pt; line-height: 12pt; background: none;;text-indent: 0px;"> </div> <div style="margin: 0px 0px 0px 0in; text-align: justify; font-family: "Times New Roman", Times, serif; font-size: 10pt; line-height: 12pt; background: none;;text-indent: 0px;">The consolidated financial statements of the Company include the accounts of the Company and its wholly-owned subsidiary, Tenon Technology AG (“TTAG”), a Swiss company. TTAG was a majority-owned subsidiary until October 28, 2021, at which date the Company acquired the remaining non-controlling interest of TTAG (see Note 8). All intercompany balances and transactions have been eliminated in consolidation.</div>

<div style="margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; line-height: 12pt; background: none;;text-indent: 0px;"><div style="font-weight:bold;display:inline;">2. Summary of Significant Accounting Principles</div></div> <div style="margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; line-height: 12pt; background: none;;text-indent: 0px;"> </div> <div style="margin: 0px 0px 0px 0in; text-align: justify; font-family: "Times New Roman", Times, serif; font-size: 10pt; line-height: 12pt; background: none;;text-indent: 0px;"><div style="font-style:italic;display:inline;">Basis of presentation</div></div> <div style="margin: 0px 0px 0px 0in; text-align: justify; font-family: "Times New Roman", Times, serif; font-size: 10pt; line-height: 12pt; background: none;;text-indent: 0px;"> </div> <div style="margin: 0px 0px 0px 0in; text-align: justify; font-family: "Times New Roman", Times, serif; font-size: 10pt; line-height: 12pt; background: none;;text-indent: 0px;">We have prepared the accompanying unaudited condensed consolidated financial statements pursuant to the rules and regulations of the SEC. As permitted under these rules and regulations, we have condensed or omitted certain financial information and footnote disclosures we normally include in our annual consolidated financial statements prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”).<div style="font-style:italic;display:inline;"> </div>The unaudited condensed consolidated balance sheet as of December 31, 2021 has been derived from our audited consolidated financial statements, which are included in our amended Registration Statement on Form S-1 filed with the SEC on April 20, 2022 (our “amended Registration Statement”).</div> <div style="margin: 0px 0px 0px 0in; text-align: justify; font-family: "Times New Roman", Times, serif; font-size: 10pt; line-height: 12pt; background: none;;text-indent: 0px;"> </div> <div style="margin: 0px 0px 0px 0in; text-align: justify; font-family: "Times New Roman", Times, serif; font-size: 10pt; line-height: 12pt; background: none;;text-indent: 0px;">These condensed consolidated financial statements have been prepared on the same basis as our annual consolidated financial statements and, in management’s opinion, reflect all adjustments consisting only of normal recurring adjustments that are necessary for a fair presentation of our financial information. Our interim period operating results do not necessarily indicate the results that may be expected for any other interim period or for the full fiscal year.</div> <div style="margin: 0px 0px 0px 0in; text-align: justify; font-family: "Times New Roman", Times, serif; font-size: 10pt; line-height: 12pt; background: none;;text-indent: 0px;"> </div> <div style="margin: 0px 0px 0px 0in; text-align: justify; font-family: "Times New Roman", Times, serif; font-size: 10pt; line-height: 12pt; background: none;;text-indent: 0px;">The financial statements of the subsidiary are prepared for the same reporting period as the parent, using consistent accounting policies in all material respects. The amount of consolidated net loss attributable to the Company and ownership interests in TTAG held by parties other than the Company are both presented on the face of the Consolidated Statements of Operations. As TTAG is a wholly-owned subsidiary as of September 30, 2022, this separate presentation has been discontinued for the three and nine months then ended. Further, as the Company purchased the non-controlling interest in TTAG as of October 28, 2021, the amount of consolidated net loss attributable to the Company and the non-controlling interest are both presented on the face of the Consolidated Statements of Operations and Comprehensive Loss.</div> <div style="margin: 0px 0px 0px 0in; text-align: justify; font-family: "Times New Roman", Times, serif; font-size: 10pt; line-height: 12pt; background: none;;text-indent: 0px;"> </div> <div style="margin: 0px 0px 0px 0in; text-align: justify; font-family: "Times New Roman", Times, serif; font-size: 10pt; line-height: 12pt; background: none;;text-indent: 0px;">These unaudited condensed consolidated financial statements and accompanying notes should be read in conjunction with the Company’s audited consolidated financial statements as of and for the years ended December 31, 2021 and 2020 included in our amended Registration Statement.</div> <div style="margin: 0px 0px 0px 0in; text-align: justify; font-family: "Times New Roman", Times, serif; font-size: 10pt; line-height: 12pt; background: none;;text-indent: 0px;"> </div> <div style="margin: 0px 0px 0px 0in; text-align: justify; font-family: "Times New Roman", Times, serif; font-size: 10pt; line-height: 12pt; background: none;;text-indent: 0px;">The Company’s significant accounting policies are disclosed in the audited consolidated financial statements as of and for the years ended December 31, 2021 and 2020 included in our amended Registration Statement. There have been no material changes in the Company’s significant accounting policies during the nine months ended September 30, 2022.</div> <div style="margin: 0px 0in; break-after: avoid; font-family: "Times New Roman", serif; font-size: 10pt;;text-indent: 0px;"><div style="font-style:italic;display:inline;">Going concern uncertainty and liquidity requirements</div></div> <div style="margin: 0px 0in; break-after: avoid; font-family: "Times New Roman", serif; font-size: 10pt;;text-indent: 0px;"> </div> <div style="margin: 0px 0px 0px 0in; text-align: justify; font-family: "Times New Roman", Times, serif; font-size: 10pt; line-height: 12pt; background: none;;text-indent: 0px;">The accompanying consolidated financial statements have been prepared assuming the Company will continue as a going concern, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business.<div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div>There is substantial doubt about the Company’s ability to continue as a going concern for one year after the date that these financial statements are issued. </div> <div style="margin: 0px 0px 0px 0in; text-align: justify; font-family: "Times New Roman", Times, serif; font-size: 10pt; line-height: 12pt; background: none;;text-indent: 0px;"> </div> <div style="margin: 0px 0px 0px 0in; text-align: justify; font-family: "Times New Roman", Times, serif; font-size: 10pt; line-height: 12pt; background: none;;text-indent: 0px;">Since inception, the Company has incurred losses and negative cash flows from operations. Management expects to incur additional operating losses and negative cash flows from operations in the foreseeable future as the Company continues its product development programs and starts the commercial launch of The Catamaran System. On April 29, 2022, the Company closed an initial public offering (the “IPO”) of its common stock for proceeds of $13,765, net of issuance costs. Based on the Company’s current level of revenues and expenditures, the Company believes that its existing cash and cash equivalents and short-term investments as of September 30, 2022 will<div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div>not provide sufficient funds to enable it to meet its obligations for a period of at least twelve months from the date of the filing of these consolidated financial statements. The Company plans to raise the necessary additional capital through one or a combination of public or private equity offerings, debt financings, and collaborations or licensing arrangements. The condensed consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty. <div style="font-size: 10pt; font-family: "Times New Roman", Times, serif; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"/></div> <div style="margin: 0px 0px 0px 0in; text-align: justify; font-family: "Times New Roman", Times, serif; font-size: 10pt; line-height: 12pt; background: none;;text-indent: 0px;"> </div> <div style="margin: 0px 0px 0px 0in; text-align: justify; font-family: "Times New Roman", Times, serif; font-size: 10pt; line-height: 12pt; background: none;;text-indent: 0px;"><div style="font-style:italic;display:inline;">Use of estimates</div></div> <div style="margin: 0px 0px 0px 0in; text-align: justify; font-family: "Times New Roman", Times, serif; font-size: 10pt; line-height: 12pt; background: none;;text-indent: 0px;"> </div> <div style="margin: 0px 0px 0px 0in; text-align: justify; font-family: "Times New Roman", Times, serif; font-size: 10pt; line-height: 12pt; background: none;;text-indent: 0px;">The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect certain reported amounts and disclosures. Accordingly, actual results could differ from those estimates. Significant estimates made by management include, but are not limited to, realization of deferred tax assets, accrued liabilities, obsolescence of inventory, stock-based compensation and the fair value of the Company’s common stock and preferred stock.</div> <div style="margin: 0px 0px 0px 0in; text-align: justify; font-family: "Times New Roman", Times, serif; font-size: 10pt; line-height: 12pt; background: none;;text-indent: 0px;"> </div> <div style="margin: 0px 0px 0px 0in; text-align: justify; font-family: "Times New Roman", Times, serif; font-size: 10pt; line-height: 12pt; background: none;;text-indent: 0px;"><div style="font-style:italic;display:inline;">Income Taxes</div></div> <div style="margin: 0px 0px 0px 0in; text-align: justify; font-family: "Times New Roman", Times, serif; font-size: 10pt; line-height: 12pt; background: none;;text-indent: 0px;"> </div> <div style="margin: 0px 0px 0px 0in; text-align: justify; font-family: "Times New Roman", Times, serif; font-size: 10pt; line-height: 12pt; background: none;;text-indent: 0px;">The Company accounts for income taxes utilizing ASC 740, “Income Taxes”. ASC 740 requires the measurement of deferred tax assets for deductible temporary differences and operating loss carry forwards, and of deferred tax liabilities for taxable temporary differences. Measurement of current and deferred tax liabilities and assets is based on provisions of enacted tax law. The effects of future changes in tax laws or rates are not included in the measurement. The Company recognizes the amount of taxes payable or refundable for the current year and recognizes deferred tax liabilities and assets for the expected future tax consequences of events and transactions that have been recognized in the Company’s financial statements or tax returns. The Company currently has substantial net operating loss carry forwards. The Company has recorded a 100% valuation allowance against net deferred tax assets due to uncertainty of their ultimate realization. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized.</div> <div style="margin: 0px 0px 0px 0in; text-align: justify; font-family: "Times New Roman", Times, serif; font-size: 10pt; line-height: 12pt; background: none;;text-indent: 0px;"> </div> <div style="margin: 0px 0px 0px 0in; text-align: justify; font-family: "Times New Roman", Times, serif; font-size: 10pt; line-height: 12pt; background: none;;text-indent: 0px;"><div style="font-style:italic;display:inline;">Impact of COVID-19</div></div> <div style="margin: 0px 0px 0px 0in; text-align: justify; font-family: "Times New Roman", Times, serif; font-size: 10pt; line-height: 12pt; background: none;;text-indent: 0px;"> </div> <div style="margin: 0px 0px 0px 0in; text-align: justify; font-family: "Times New Roman", Times, serif; font-size: 10pt; line-height: 12pt; background: none;;text-indent: 0px;">In March 2020, the World Health Organization declared the coronavirus (“COVID-19”) outbreak to be a pandemic. During the years ended December 31, 2021 and 2020 and the nine months ended September 30, 2022, the Company’s financial results were not significantly affected by the COVID-19 outbreak. The Company has considered all information available as of the date of issuance of these consolidated financial statements and the Company is not aware of any specific events or circumstances that would require an update to its estimates or judgments, or a revision to the carrying value of its assets or liabilities. These estimates may change as new events occur and additional information becomes available. The extent to which the COVID-19 outbreak affects the Company’s future financial results and operations will depend on future developments which are highly uncertain and cannot be predicted, including new information which may emerge concerning the severity of the outbreak, and current or future domestic and international actions to contain and treat it.</div> <div style="margin: 0px 0px 0px 0in; text-align: justify; font-family: "Times New Roman", Times, serif; font-size: 10pt; line-height: 12pt; background: none;;text-indent: 0px;"> </div> <div style="margin: 0px 0px 0px 0in; text-align: justify; font-family: "Times New Roman", Times, serif; font-size: 10pt; line-height: 12pt; background: none;;text-indent: 0px;"><div style="font-style:italic;display:inline;">Net loss per share</div></div> <div style="margin: 0px 0px 0px 0in; text-align: justify; font-family: "Times New Roman", Times, serif; font-size: 10pt; line-height: 12pt; background: none;;text-indent: 0px;"> </div> <div style="margin: 0px 0px 0px 0in; text-align: justify; font-family: "Times New Roman", Times, serif; font-size: 10pt; line-height: 12pt; background: none;;text-indent: 0px;">Basic net loss per share is based upon the weighted-average number of common shares outstanding. Diluted net loss per share is based on the assumption that all potential common stock equivalents (convertible preferred stock, stock options, and warrants) are converted or exercised. The calculation of diluted net loss per share excludes potential common stock equivalents if the effect is anti-dilutive. The Company’s weighted-average common shares outstanding for basic and diluted are the same because the effect of the potential common stock equivalents is anti-dilutive.</div> <div style="margin: 0px 0in; text-align: justify; break-after: avoid; font-family: "Times New Roman", serif; font-size: 10pt;;text-indent: 0px;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, serif; line-height: 12pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The Company had the following dilutive common stock equivalents as of September 30, 2022 and 2021 which were excluded from the calculation because their effect was anti-dilutive.</div></div> <div style="margin: 0px 0in; text-align: justify; break-after: avoid; font-family: "Times New Roman", serif; font-size: 10pt;;text-indent: 0px;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, serif; white-space: pre-wrap; line-height: 12pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;;white-space:pre-wrap;"> </div></div> <table cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;;margin-right : auto;;margin-left : 0;margin-right : auto;"> <tr> <td style="width: 74%; padding: 0px 0in 0.5pt; font-family: "Times New Roman", Times, serif; font-size: 10pt; vertical-align: bottom; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="padding: 0in 0in 0.5pt; font-family: "Times New Roman", Times, serif; font-size: 10pt; vertical-align: bottom; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td colspan="2" style="border-top: none; border-image: initial; border-bottom: 1pt solid windowtext; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; vertical-align: bottom; width: 11%; line-height: 10pt;"> <div style="text-align: center; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; white-space: nowrap; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; font-size: 10pt; line-height: 10pt;;font-weight:bold;display:inline;"><div style="font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">September 30, <br/> 2022</div></div></div></div> </td> <td style="padding: 0in 0in 0.5pt; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; vertical-align: bottom; line-height: 10pt;"> <div style="text-align: center; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; white-space: nowrap; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"><div style="line-height: 10pt; font-size: 10pt;;font-weight:bold;display:inline;width:100%;"> </div></div></div></div> </td> <td style="padding: 0in 0in 0.5pt; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; vertical-align: bottom; line-height: 10pt;"> <div style="text-align: center; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; white-space: nowrap; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"><div style="line-height: 10pt; font-size: 10pt;;font-weight:bold;display:inline;width:100%;"> </div></div></div></div> </td> <td colspan="2" style="border-top: none; border-image: initial; border-bottom: 1pt solid windowtext; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; vertical-align: bottom; width: 11%; line-height: 10pt;"> <div style="text-align: center; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; white-space: nowrap; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; font-size: 10pt; line-height: 10pt;;font-weight:bold;display:inline;"><div style="font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">September 30, <br/> 2021</div></div></div></div> </td> <td style="padding: 0in 0in 0.5pt; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; vertical-align: bottom; line-height: 10pt;"> <div style="text-align: center; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; white-space: nowrap; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"><div style="line-height: 10pt; font-size: 10pt;;font-weight:bold;display:inline;width:100%;"> </div></div></div></div> </td> </tr> <tr> <td style="width: 74%; padding: 0px 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255); vertical-align: bottom; line-height: 10pt;"> <div style="margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Outstanding restricted stock units</div></div></div> </td> <td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255); vertical-align: bottom; line-height: 10pt;"> <div style="margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> </td> <td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255); border-bottom: none; border-top: 0px solid windowtext; text-align: left; vertical-align: bottom; line-height: 10pt;"> <div style="margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; text-indent: 0in; text-align: left; white-space: nowrap; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> </td> <td style="border-bottom: none; border-image: initial; width: 10%; border-top: 0px solid windowtext; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); text-align: right; vertical-align: bottom; line-height: 10pt;"> <div style="margin: 0px 0in; text-align: right; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; white-space: nowrap; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">1,318,530</div></div></div> </td> <td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); text-align: left; vertical-align: bottom; line-height: 10pt;"> <div style="margin: 0px 0px 0px 0in; text-align: left; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; white-space: nowrap; text-indent: 0in; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div></div> </td> <td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; line-height: 10pt;"> <div style="margin: 0px 0px 0px 0in; text-align: right; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; white-space: nowrap; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div></div> </td> <td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); border-bottom: none; border-top: 0px solid windowtext; text-align: left; vertical-align: bottom; line-height: 10pt;"> <div style="margin: 0px 0px 0px 0in; text-align: left; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; white-space: nowrap; text-indent: 0in; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div></div> </td> <td style="border-bottom: none; border-image: initial; width: 10%; border-top: 0px solid windowtext; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; line-height: 10pt;"> <div style="text-align: right; margin: 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; white-space: nowrap; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">—</div></div></div> </td> <td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); text-align: left; vertical-align: bottom; line-height: 10pt;"> <div style="text-align: left; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; white-space: nowrap; text-indent: 0in; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div></div> </td> </tr> <tr> <td style="width: 74%; padding: 0px 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgba(255, 255, 255, 0); vertical-align: bottom; line-height: 10pt;"> <div style="margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Outstanding stock options</div></div></div> </td> <td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgba(255, 255, 255, 0); vertical-align: bottom; line-height: 10pt;"> <div style="margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> </td> <td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgba(255, 255, 255, 0); text-align: left; vertical-align: bottom; line-height: 10pt;"> <div style="margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; text-indent: 0in; text-align: left; white-space: nowrap; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> </td> <td style="width: 10%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); text-align: right; vertical-align: bottom; line-height: 10pt;"> <div style="margin: 0px 0in; text-align: right; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; white-space: nowrap; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">841,344</div></div></div> </td> <td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); text-align: left; vertical-align: bottom; line-height: 10pt;"> <div style="margin: 0px 0px 0px 0in; text-align: left; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; white-space: nowrap; text-indent: 0in; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div></div> </td> <td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); vertical-align: bottom; line-height: 10pt;"> <div style="margin: 0px 0px 0px 0in; text-align: right; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; white-space: nowrap; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div></div> </td> <td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); text-align: left; vertical-align: bottom; line-height: 10pt;"> <div style="margin: 0px 0px 0px 0in; text-align: left; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; white-space: nowrap; text-indent: 0in; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div></div> </td> <td style="width: 10%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); text-align: right; vertical-align: bottom; line-height: 10pt;"> <div style="text-align: right; margin: 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; white-space: nowrap; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">705,394</div></div></div> </td> <td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); text-align: left; vertical-align: bottom; line-height: 10pt;"> <div style="text-align: left; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; white-space: nowrap; text-indent: 0in; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div></div> </td> </tr> <tr> <td style="width: 74%; padding: 0px 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255); vertical-align: bottom; line-height: 10pt;"> <div style="margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Outstanding warrants</div></div></div> </td> <td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255); vertical-align: bottom; line-height: 10pt;"> <div style="margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> </td> <td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255); text-align: left; vertical-align: bottom; line-height: 10pt;"> <div style="margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; text-indent: 0in; text-align: left; white-space: nowrap; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> </td> <td style="width: 10%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); text-align: right; vertical-align: bottom; line-height: 10pt;"> <div style="margin: 0px 0in; text-align: right; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; white-space: nowrap; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">121,000</div></div></div> </td> <td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); text-align: left; vertical-align: bottom; line-height: 10pt;"> <div style="margin: 0px 0px 0px 0in; text-align: left; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; white-space: nowrap; text-indent: 0in; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div></div> </td> <td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; line-height: 10pt;"> <div style="margin: 0px 0px 0px 0in; text-align: right; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; white-space: nowrap; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div></div> </td> <td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); text-align: left; vertical-align: bottom; line-height: 10pt;"> <div style="margin: 0px 0px 0px 0in; text-align: left; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; white-space: nowrap; text-indent: 0in; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div></div> </td> <td style="width: 10%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); text-align: right; vertical-align: bottom; line-height: 10pt;"> <div style="text-align: right; margin: 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; white-space: nowrap; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">25,000</div></div></div> </td> <td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); text-align: left; vertical-align: bottom; line-height: 10pt;"> <div style="text-align: left; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; white-space: nowrap; text-indent: 0in; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div></div> </td> </tr> <tr> <td style="width: 74%; padding: 0px 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgba(255, 255, 255, 0); vertical-align: bottom; line-height: 10pt;"> <div style="margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Common shares convertible from notes payable</div></div></div> </td> <td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgba(255, 255, 255, 0); vertical-align: bottom; line-height: 10pt;"> <div style="margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> </td> <td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgba(255, 255, 255, 0); text-align: left; vertical-align: bottom; line-height: 10pt;"> <div style="margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; text-indent: 0in; text-align: left; white-space: nowrap; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> </td> <td style="width: 10%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); vertical-align: bottom; line-height: 10pt;"> <div style="margin: 0px 0in; text-align: right; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; white-space: nowrap; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">—</div></div></div> </td> <td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); text-align: left; vertical-align: bottom; line-height: 10pt;"> <div style="margin: 0px 0px 0px 0in; text-align: left; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; white-space: nowrap; text-indent: 0in; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div></div> </td> <td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); vertical-align: bottom; line-height: 10pt;"> <div style="margin: 0px 0px 0px 0in; text-align: right; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; white-space: nowrap; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div></div> </td> <td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); text-align: left; vertical-align: bottom; line-height: 10pt;"> <div style="margin: 0px 0px 0px 0in; text-align: left; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; white-space: nowrap; text-indent: 0in; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div></div> </td> <td style="width: 10%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); text-align: right; vertical-align: bottom; line-height: 10pt;"> <div style="text-align: right; margin: 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; white-space: nowrap; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">2,079,510</div></div></div> </td> <td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); text-align: left; vertical-align: bottom; line-height: 10pt;"> <div style="text-align: left; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; white-space: nowrap; text-indent: 0in; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div></div> </td> </tr> <tr> <td style="width: 74%; padding: 0px 0in 0.5pt; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255); vertical-align: bottom; line-height: 10pt;"> <div style="margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Common shares convertible from preferred stock</div></div></div> </td> <td style="width: 1%; padding: 0in 0in 0.5pt; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255); vertical-align: bottom; line-height: 10pt;"> <div style="margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> </td> <td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255); border-bottom: 1pt solid windowtext; border-top: none; text-align: left; vertical-align: bottom; line-height: 10pt;"> <div style="margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; text-indent: 0in; text-align: left; white-space: nowrap; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> </td> <td style="border-top: none; border-image: initial; border-bottom: 1pt solid windowtext; width: 10%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; line-height: 10pt;"> <div style="margin: 0px 0in; text-align: right; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; white-space: nowrap; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">—</div></div></div> </td> <td style="width: 1%; padding: 0in 0in 0.5pt; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); text-align: left; vertical-align: bottom; line-height: 10pt;"> <div style="margin: 0px 0px 0px 0in; text-align: left; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; white-space: nowrap; text-indent: 0in; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div></div> </td> <td style="width: 1%; padding: 0in 0in 0.5pt; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; line-height: 10pt;"> <div style="margin: 0px 0px 0px 0in; text-align: right; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; white-space: nowrap; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div></div> </td> <td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); border-bottom: 1pt solid windowtext; border-top: none; text-align: left; vertical-align: bottom; line-height: 10pt;"> <div style="margin: 0px 0px 0px 0in; text-align: left; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; white-space: nowrap; text-indent: 0in; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div></div> </td> <td style="border-top: none; border-image: initial; border-bottom: 1pt solid windowtext; width: 10%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); text-align: right; vertical-align: bottom; line-height: 10pt;"> <div style="text-align: right; margin: 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; white-space: nowrap; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">245,611</div></div></div> </td> <td style="width: 1%; padding: 0in 0in 0.5pt; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); text-align: left; vertical-align: bottom; line-height: 10pt;"> <div style="text-align: left; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; white-space: nowrap; text-indent: 0in; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div></div> </td> </tr> <tr> <td style="width: 74%; padding: 0px 0in 1.25pt 10pt; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgba(255, 255, 255, 0); vertical-align: bottom; line-height: 10pt;"> <div style="margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div></div> </td> <td style="width: 1%; padding: 0in 0in 1.25pt; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgba(255, 255, 255, 0); vertical-align: bottom; line-height: 10pt;"> <div style="margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> </td> <td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgba(255, 255, 255, 0); border-bottom: 2.5pt double black; border-top: 0px none; text-align: left; vertical-align: bottom; line-height: 10pt;"> <div style="margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; text-indent: 0in; text-align: left; white-space: nowrap; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> </td> <td style="border-bottom: 2.5pt double black; width: 10%; border-top: 0px none; border-image: initial; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); text-align: right; vertical-align: bottom; line-height: 10pt;"> <div style="margin: 0px 0in; text-align: right; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; white-space: nowrap; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">2,280,874</div></div></div> </td> <td style="width: 1%; padding: 0in 0in 1.25pt; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); text-align: left; vertical-align: bottom; line-height: 10pt;"> <div style="margin: 0px 0px 0px 0in; text-align: left; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; white-space: nowrap; text-indent: 0in; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div></div> </td> <td style="width: 1%; padding: 0in 0in 1.25pt; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); vertical-align: bottom; line-height: 10pt;"> <div style="margin: 0px 0px 0px 0in; text-align: right; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; white-space: nowrap; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div></div> </td> <td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); border-bottom: 2.5pt double black; border-top: 0px none; text-align: left; vertical-align: bottom; line-height: 10pt;"> <div style="margin: 0px 0px 0px 0in; text-align: left; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; white-space: nowrap; text-indent: 0in; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div></div> </td> <td style="border-bottom: 2.5pt double black; width: 10%; border-top: 0px none; border-image: initial; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); text-align: right; vertical-align: bottom; line-height: 10pt;"> <div style="text-align: right; margin: 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; white-space: nowrap; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">3,055,515</div></div></div> </td> <td style="width: 1%; padding: 0in 0in 1.25pt; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); text-align: left; vertical-align: bottom; line-height: 10pt;"> <div style="text-align: left; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; white-space: nowrap; text-indent: 0in; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"/> <div style="clear: both; max-height: 0px; text-indent: 0px;"/> <div style="margin: 0px 0in; text-align: justify; break-after: avoid; font-family: "Times New Roman", serif; font-size: 10pt;;text-indent: 0px;"> </div> <div style="margin: 0px 0in; text-align: justify; break-after: avoid; font-family: "Times New Roman", serif; font-size: 10pt;;text-indent: 0px;"><div style="font-style:italic;display:inline;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, serif; line-height: 12pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Recent Accounting Pronouncements</div></div></div> <div style="margin: 0px 0in; text-align: justify; break-after: avoid; font-family: "Times New Roman", serif; font-size: 10pt;;text-indent: 0px;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, serif; white-space: pre-wrap; line-height: 12pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;;white-space:pre-wrap;"> </div></div> <div style="margin: 0px 0px 0px 0in; text-align: justify; font-family: "Times New Roman", Times, serif; font-size: 10pt; line-height: 12pt; background: none;;text-indent: 0px;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, serif; line-height: 12pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">There have been no accounting pronouncements or changes in accounting pronouncements in the nine months ended September 30, 2022 that are significant or potentially significant to the Company.</div></div>

<div style="margin: 0px 0px 0px 0in; text-align: justify; font-family: "Times New Roman", Times, serif; font-size: 10pt; line-height: 12pt; background: none;;text-indent: 0px;"><div style="font-style:italic;display:inline;">Basis of presentation</div></div> <div style="margin: 0px 0px 0px 0in; text-align: justify; font-family: "Times New Roman", Times, serif; font-size: 10pt; line-height: 12pt; background: none;;text-indent: 0px;"> </div> <div style="margin: 0px 0px 0px 0in; text-align: justify; font-family: "Times New Roman", Times, serif; font-size: 10pt; line-height: 12pt; background: none;;text-indent: 0px;">We have prepared the accompanying unaudited condensed consolidated financial statements pursuant to the rules and regulations of the SEC. As permitted under these rules and regulations, we have condensed or omitted certain financial information and footnote disclosures we normally include in our annual consolidated financial statements prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”).<div style="font-style:italic;display:inline;"> </div>The unaudited condensed consolidated balance sheet as of December 31, 2021 has been derived from our audited consolidated financial statements, which are included in our amended Registration Statement on Form S-1 filed with the SEC on April 20, 2022 (our “amended Registration Statement”).</div> <div style="margin: 0px 0px 0px 0in; text-align: justify; font-family: "Times New Roman", Times, serif; font-size: 10pt; line-height: 12pt; background: none;;text-indent: 0px;"> </div> <div style="margin: 0px 0px 0px 0in; text-align: justify; font-family: "Times New Roman", Times, serif; font-size: 10pt; line-height: 12pt; background: none;;text-indent: 0px;">These condensed consolidated financial statements have been prepared on the same basis as our annual consolidated financial statements and, in management’s opinion, reflect all adjustments consisting only of normal recurring adjustments that are necessary for a fair presentation of our financial information. Our interim period operating results do not necessarily indicate the results that may be expected for any other interim period or for the full fiscal year.</div> <div style="margin: 0px 0px 0px 0in; text-align: justify; font-family: "Times New Roman", Times, serif; font-size: 10pt; line-height: 12pt; background: none;;text-indent: 0px;"> </div> <div style="margin: 0px 0px 0px 0in; text-align: justify; font-family: "Times New Roman", Times, serif; font-size: 10pt; line-height: 12pt; background: none;;text-indent: 0px;">The financial statements of the subsidiary are prepared for the same reporting period as the parent, using consistent accounting policies in all material respects. The amount of consolidated net loss attributable to the Company and ownership interests in TTAG held by parties other than the Company are both presented on the face of the Consolidated Statements of Operations. As TTAG is a wholly-owned subsidiary as of September 30, 2022, this separate presentation has been discontinued for the three and nine months then ended. Further, as the Company purchased the non-controlling interest in TTAG as of October 28, 2021, the amount of consolidated net loss attributable to the Company and the non-controlling interest are both presented on the face of the Consolidated Statements of Operations and Comprehensive Loss.</div> <div style="margin: 0px 0px 0px 0in; text-align: justify; font-family: "Times New Roman", Times, serif; font-size: 10pt; line-height: 12pt; background: none;;text-indent: 0px;"> </div> <div style="margin: 0px 0px 0px 0in; text-align: justify; font-family: "Times New Roman", Times, serif; font-size: 10pt; line-height: 12pt; background: none;;text-indent: 0px;">These unaudited condensed consolidated financial statements and accompanying notes should be read in conjunction with the Company’s audited consolidated financial statements as of and for the years ended December 31, 2021 and 2020 included in our amended Registration Statement.</div> <div style="margin: 0px 0px 0px 0in; text-align: justify; font-family: "Times New Roman", Times, serif; font-size: 10pt; line-height: 12pt; background: none;;text-indent: 0px;"> </div> <div style="margin: 0px 0px 0px 0in; text-align: justify; font-family: "Times New Roman", Times, serif; font-size: 10pt; line-height: 12pt; background: none;;text-indent: 0px;">The Company’s significant accounting policies are disclosed in the audited consolidated financial statements as of and for the years ended December 31, 2021 and 2020 included in our amended Registration Statement. There have been no material changes in the Company’s significant accounting policies during the nine months ended September 30, 2022.</div>

<div style="margin: 0px 0in; break-after: avoid; font-family: "Times New Roman", serif; font-size: 10pt;;text-indent: 0px;"><div style="font-style:italic;display:inline;">Going concern uncertainty and liquidity requirements</div></div> <div style="margin: 0px 0in; break-after: avoid; font-family: "Times New Roman", serif; font-size: 10pt;;text-indent: 0px;"> </div> <div style="margin: 0px 0px 0px 0in; text-align: justify; font-family: "Times New Roman", Times, serif; font-size: 10pt; line-height: 12pt; background: none;;text-indent: 0px;">The accompanying consolidated financial statements have been prepared assuming the Company will continue as a going concern, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business.<div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div>There is substantial doubt about the Company’s ability to continue as a going concern for one year after the date that these financial statements are issued. </div> <div style="margin: 0px 0px 0px 0in; text-align: justify; font-family: "Times New Roman", Times, serif; font-size: 10pt; line-height: 12pt; background: none;;text-indent: 0px;"> </div> <div style="margin: 0px 0px 0px 0in; text-align: justify; font-family: "Times New Roman", Times, serif; font-size: 10pt; line-height: 12pt; background: none;;text-indent: 0px;">Since inception, the Company has incurred losses and negative cash flows from operations. Management expects to incur additional operating losses and negative cash flows from operations in the foreseeable future as the Company continues its product development programs and starts the commercial launch of The Catamaran System. On April 29, 2022, the Company closed an initial public offering (the “IPO”) of its common stock for proceeds of $13,765, net of issuance costs. Based on the Company’s current level of revenues and expenditures, the Company believes that its existing cash and cash equivalents and short-term investments as of September 30, 2022 will<div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div>not provide sufficient funds to enable it to meet its obligations for a period of at least twelve months from the date of the filing of these consolidated financial statements. The Company plans to raise the necessary additional capital through one or a combination of public or private equity offerings, debt financings, and collaborations or licensing arrangements. The condensed consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty. <div style="font-size: 10pt; font-family: "Times New Roman", Times, serif; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"/></div>

13765000

<div style="margin: 0px 0px 0px 0in; text-align: justify; font-family: "Times New Roman", Times, serif; font-size: 10pt; line-height: 12pt; background: none;;text-indent: 0px;"><div style="font-style:italic;display:inline;">Use of estimates</div></div> <div style="margin: 0px 0px 0px 0in; text-align: justify; font-family: "Times New Roman", Times, serif; font-size: 10pt; line-height: 12pt; background: none;;text-indent: 0px;"> </div> <div style="margin: 0px 0px 0px 0in; text-align: justify; font-family: "Times New Roman", Times, serif; font-size: 10pt; line-height: 12pt; background: none;;text-indent: 0px;">The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect certain reported amounts and disclosures. Accordingly, actual results could differ from those estimates. Significant estimates made by management include, but are not limited to, realization of deferred tax assets, accrued liabilities, obsolescence of inventory, stock-based compensation and the fair value of the Company’s common stock and preferred stock.</div>

<div style="margin: 0px 0px 0px 0in; text-align: justify; font-family: "Times New Roman", Times, serif; font-size: 10pt; line-height: 12pt; background: none;;text-indent: 0px;"><div style="font-style:italic;display:inline;">Income Taxes</div></div> <div style="margin: 0px 0px 0px 0in; text-align: justify; font-family: "Times New Roman", Times, serif; font-size: 10pt; line-height: 12pt; background: none;;text-indent: 0px;"> </div> <div style="margin: 0px 0px 0px 0in; text-align: justify; font-family: "Times New Roman", Times, serif; font-size: 10pt; line-height: 12pt; background: none;;text-indent: 0px;">The Company accounts for income taxes utilizing ASC 740, “Income Taxes”. ASC 740 requires the measurement of deferred tax assets for deductible temporary differences and operating loss carry forwards, and of deferred tax liabilities for taxable temporary differences. Measurement of current and deferred tax liabilities and assets is based on provisions of enacted tax law. The effects of future changes in tax laws or rates are not included in the measurement. The Company recognizes the amount of taxes payable or refundable for the current year and recognizes deferred tax liabilities and assets for the expected future tax consequences of events and transactions that have been recognized in the Company’s financial statements or tax returns. The Company currently has substantial net operating loss carry forwards. The Company has recorded a 100% valuation allowance against net deferred tax assets due to uncertainty of their ultimate realization. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized.</div>

1 <div style="margin: 0px 0px 0px 0in; text-align: justify; font-family: "Times New Roman", Times, serif; font-size: 10pt; line-height: 12pt; background: none;;text-indent: 0px;"><div style="font-style:italic;display:inline;">Impact of COVID-19</div></div> <div style="margin: 0px 0px 0px 0in; text-align: justify; font-family: "Times New Roman", Times, serif; font-size: 10pt; line-height: 12pt; background: none;;text-indent: 0px;"> </div> <div style="margin: 0px 0px 0px 0in; text-align: justify; font-family: "Times New Roman", Times, serif; font-size: 10pt; line-height: 12pt; background: none;;text-indent: 0px;">In March 2020, the World Health Organization declared the coronavirus (“COVID-19”) outbreak to be a pandemic. During the years ended December 31, 2021 and 2020 and the nine months ended September 30, 2022, the Company’s financial results were not significantly affected by the COVID-19 outbreak. The Company has considered all information available as of the date of issuance of these consolidated financial statements and the Company is not aware of any specific events or circumstances that would require an update to its estimates or judgments, or a revision to the carrying value of its assets or liabilities. These estimates may change as new events occur and additional information becomes available. The extent to which the COVID-19 outbreak affects the Company’s future financial results and operations will depend on future developments which are highly uncertain and cannot be predicted, including new information which may emerge concerning the severity of the outbreak, and current or future domestic and international actions to contain and treat it.</div>

<div style="margin: 0px 0px 0px 0in; text-align: justify; font-family: "Times New Roman", Times, serif; font-size: 10pt; line-height: 12pt; background: none;;text-indent: 0px;"><div style="font-style:italic;display:inline;">Net loss per share</div></div> <div style="margin: 0px 0px 0px 0in; text-align: justify; font-family: "Times New Roman", Times, serif; font-size: 10pt; line-height: 12pt; background: none;;text-indent: 0px;"> </div> <div style="margin: 0px 0px 0px 0in; text-align: justify; font-family: "Times New Roman", Times, serif; font-size: 10pt; line-height: 12pt; background: none;;text-indent: 0px;">Basic net loss per share is based upon the weighted-average number of common shares outstanding. Diluted net loss per share is based on the assumption that all potential common stock equivalents (convertible preferred stock, stock options, and warrants) are converted or exercised. The calculation of diluted net loss per share excludes potential common stock equivalents if the effect is anti-dilutive. The Company’s weighted-average common shares outstanding for basic and diluted are the same because the effect of the potential common stock equivalents is anti-dilutive.</div> <div style="margin: 0px 0in; text-align: justify; break-after: avoid; font-family: "Times New Roman", serif; font-size: 10pt;;text-indent: 0px;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, serif; line-height: 12pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The Company had the following dilutive common stock equivalents as of September 30, 2022 and 2021 which were excluded from the calculation because their effect was anti-dilutive.</div></div> <div style="margin: 0px 0in; text-align: justify; break-after: avoid; font-family: "Times New Roman", serif; font-size: 10pt;;text-indent: 0px;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, serif; white-space: pre-wrap; line-height: 12pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;;white-space:pre-wrap;"> </div></div> <table cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;;margin-right : auto;;margin-left : 0;margin-right : auto;"> <tr> <td style="width: 74%; padding: 0px 0in 0.5pt; font-family: "Times New Roman", Times, serif; font-size: 10pt; vertical-align: bottom; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="padding: 0in 0in 0.5pt; font-family: "Times New Roman", Times, serif; font-size: 10pt; vertical-align: bottom; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td colspan="2" style="border-top: none; border-image: initial; border-bottom: 1pt solid windowtext; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; vertical-align: bottom; width: 11%; line-height: 10pt;"> <div style="text-align: center; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; white-space: nowrap; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; font-size: 10pt; line-height: 10pt;;font-weight:bold;display:inline;"><div style="font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">September 30, <br/> 2022</div></div></div></div> </td> <td style="padding: 0in 0in 0.5pt; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; vertical-align: bottom; line-height: 10pt;"> <div style="text-align: center; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; white-space: nowrap; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"><div style="line-height: 10pt; font-size: 10pt;;font-weight:bold;display:inline;width:100%;"> </div></div></div></div> </td> <td style="padding: 0in 0in 0.5pt; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; vertical-align: bottom; line-height: 10pt;"> <div style="text-align: center; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; white-space: nowrap; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"><div style="line-height: 10pt; font-size: 10pt;;font-weight:bold;display:inline;width:100%;"> </div></div></div></div> </td> <td colspan="2" style="border-top: none; border-image: initial; border-bottom: 1pt solid windowtext; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; vertical-align: bottom; width: 11%; line-height: 10pt;"> <div style="text-align: center; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; white-space: nowrap; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; font-size: 10pt; line-height: 10pt;;font-weight:bold;display:inline;"><div style="font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">September 30, <br/> 2021</div></div></div></div> </td> <td style="padding: 0in 0in 0.5pt; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; vertical-align: bottom; line-height: 10pt;"> <div style="text-align: center; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; white-space: nowrap; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"><div style="line-height: 10pt; font-size: 10pt;;font-weight:bold;display:inline;width:100%;"> </div></div></div></div> </td> </tr> <tr> <td style="width: 74%; padding: 0px 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255); vertical-align: bottom; line-height: 10pt;"> <div style="margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Outstanding restricted stock units</div></div></div> </td> <td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255); vertical-align: bottom; line-height: 10pt;"> <div style="margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> </td> <td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255); border-bottom: none; border-top: 0px solid windowtext; text-align: left; vertical-align: bottom; line-height: 10pt;"> <div style="margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; text-indent: 0in; text-align: left; white-space: nowrap; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> </td> <td style="border-bottom: none; border-image: initial; width: 10%; border-top: 0px solid windowtext; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); text-align: right; vertical-align: bottom; line-height: 10pt;"> <div style="margin: 0px 0in; text-align: right; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; white-space: nowrap; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">1,318,530</div></div></div> </td> <td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); text-align: left; vertical-align: bottom; line-height: 10pt;"> <div style="margin: 0px 0px 0px 0in; text-align: left; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; white-space: nowrap; text-indent: 0in; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div></div> </td> <td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; line-height: 10pt;"> <div style="margin: 0px 0px 0px 0in; text-align: right; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; white-space: nowrap; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div></div> </td> <td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); border-bottom: none; border-top: 0px solid windowtext; text-align: left; vertical-align: bottom; line-height: 10pt;"> <div style="margin: 0px 0px 0px 0in; text-align: left; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; white-space: nowrap; text-indent: 0in; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div></div> </td> <td style="border-bottom: none; border-image: initial; width: 10%; border-top: 0px solid windowtext; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; line-height: 10pt;"> <div style="text-align: right; margin: 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; white-space: nowrap; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">—</div></div></div> </td> <td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); text-align: left; vertical-align: bottom; line-height: 10pt;"> <div style="text-align: left; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; white-space: nowrap; text-indent: 0in; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div></div> </td> </tr> <tr> <td style="width: 74%; padding: 0px 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgba(255, 255, 255, 0); vertical-align: bottom; line-height: 10pt;"> <div style="margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Outstanding stock options</div></div></div> </td> <td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgba(255, 255, 255, 0); vertical-align: bottom; line-height: 10pt;"> <div style="margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> </td> <td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgba(255, 255, 255, 0); text-align: left; vertical-align: bottom; line-height: 10pt;"> <div style="margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; text-indent: 0in; text-align: left; white-space: nowrap; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> </td> <td style="width: 10%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); text-align: right; vertical-align: bottom; line-height: 10pt;"> <div style="margin: 0px 0in; text-align: right; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; white-space: nowrap; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">841,344</div></div></div> </td> <td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); text-align: left; vertical-align: bottom; line-height: 10pt;"> <div style="margin: 0px 0px 0px 0in; text-align: left; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; white-space: nowrap; text-indent: 0in; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div></div> </td> <td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); vertical-align: bottom; line-height: 10pt;"> <div style="margin: 0px 0px 0px 0in; text-align: right; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; white-space: nowrap; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div></div> </td> <td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); text-align: left; vertical-align: bottom; line-height: 10pt;"> <div style="margin: 0px 0px 0px 0in; text-align: left; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; white-space: nowrap; text-indent: 0in; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div></div> </td> <td style="width: 10%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); text-align: right; vertical-align: bottom; line-height: 10pt;"> <div style="text-align: right; margin: 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; white-space: nowrap; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">705,394</div></div></div> </td> <td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); text-align: left; vertical-align: bottom; line-height: 10pt;"> <div style="text-align: left; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; white-space: nowrap; text-indent: 0in; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div></div> </td> </tr> <tr> <td style="width: 74%; padding: 0px 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255); vertical-align: bottom; line-height: 10pt;"> <div style="margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Outstanding warrants</div></div></div> </td> <td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255); vertical-align: bottom; line-height: 10pt;"> <div style="margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> </td> <td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255); text-align: left; vertical-align: bottom; line-height: 10pt;"> <div style="margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; text-indent: 0in; text-align: left; white-space: nowrap; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> </td> <td style="width: 10%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); text-align: right; vertical-align: bottom; line-height: 10pt;"> <div style="margin: 0px 0in; text-align: right; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; white-space: nowrap; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">121,000</div></div></div> </td> <td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); text-align: left; vertical-align: bottom; line-height: 10pt;"> <div style="margin: 0px 0px 0px 0in; text-align: left; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; white-space: nowrap; text-indent: 0in; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div></div> </td> <td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; line-height: 10pt;"> <div style="margin: 0px 0px 0px 0in; text-align: right; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; white-space: nowrap; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div></div> </td> <td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); text-align: left; vertical-align: bottom; line-height: 10pt;"> <div style="margin: 0px 0px 0px 0in; text-align: left; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; white-space: nowrap; text-indent: 0in; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div></div> </td> <td style="width: 10%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); text-align: right; vertical-align: bottom; line-height: 10pt;"> <div style="text-align: right; margin: 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; white-space: nowrap; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">25,000</div></div></div> </td> <td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); text-align: left; vertical-align: bottom; line-height: 10pt;"> <div style="text-align: left; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; white-space: nowrap; text-indent: 0in; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div></div> </td> </tr> <tr> <td style="width: 74%; padding: 0px 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgba(255, 255, 255, 0); vertical-align: bottom; line-height: 10pt;"> <div style="margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Common shares convertible from notes payable</div></div></div> </td> <td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgba(255, 255, 255, 0); vertical-align: bottom; line-height: 10pt;"> <div style="margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> </td> <td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgba(255, 255, 255, 0); text-align: left; vertical-align: bottom; line-height: 10pt;"> <div style="margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; text-indent: 0in; text-align: left; white-space: nowrap; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> </td> <td style="width: 10%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); vertical-align: bottom; line-height: 10pt;"> <div style="margin: 0px 0in; text-align: right; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; white-space: nowrap; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">—</div></div></div> </td> <td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); text-align: left; vertical-align: bottom; line-height: 10pt;"> <div style="margin: 0px 0px 0px 0in; text-align: left; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; white-space: nowrap; text-indent: 0in; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div></div> </td> <td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); vertical-align: bottom; line-height: 10pt;"> <div style="margin: 0px 0px 0px 0in; text-align: right; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; white-space: nowrap; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div></div> </td> <td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); text-align: left; vertical-align: bottom; line-height: 10pt;"> <div style="margin: 0px 0px 0px 0in; text-align: left; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; white-space: nowrap; text-indent: 0in; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div></div> </td> <td style="width: 10%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); text-align: right; vertical-align: bottom; line-height: 10pt;"> <div style="text-align: right; margin: 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; white-space: nowrap; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">2,079,510</div></div></div> </td> <td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); text-align: left; vertical-align: bottom; line-height: 10pt;"> <div style="text-align: left; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; white-space: nowrap; text-indent: 0in; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div></div> </td> </tr> <tr> <td style="width: 74%; padding: 0px 0in 0.5pt; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255); vertical-align: bottom; line-height: 10pt;"> <div style="margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Common shares convertible from preferred stock</div></div></div> </td> <td style="width: 1%; padding: 0in 0in 0.5pt; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255); vertical-align: bottom; line-height: 10pt;"> <div style="margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> </td> <td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255); border-bottom: 1pt solid windowtext; border-top: none; text-align: left; vertical-align: bottom; line-height: 10pt;"> <div style="margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; text-indent: 0in; text-align: left; white-space: nowrap; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> </td> <td style="border-top: none; border-image: initial; border-bottom: 1pt solid windowtext; width: 10%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; line-height: 10pt;"> <div style="margin: 0px 0in; text-align: right; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; white-space: nowrap; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">—</div></div></div> </td> <td style="width: 1%; padding: 0in 0in 0.5pt; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); text-align: left; vertical-align: bottom; line-height: 10pt;"> <div style="margin: 0px 0px 0px 0in; text-align: left; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; white-space: nowrap; text-indent: 0in; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div></div> </td> <td style="width: 1%; padding: 0in 0in 0.5pt; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; line-height: 10pt;"> <div style="margin: 0px 0px 0px 0in; text-align: right; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; white-space: nowrap; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div></div> </td> <td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); border-bottom: 1pt solid windowtext; border-top: none; text-align: left; vertical-align: bottom; line-height: 10pt;"> <div style="margin: 0px 0px 0px 0in; text-align: left; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; white-space: nowrap; text-indent: 0in; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div></div> </td> <td style="border-top: none; border-image: initial; border-bottom: 1pt solid windowtext; width: 10%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); text-align: right; vertical-align: bottom; line-height: 10pt;"> <div style="text-align: right; margin: 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; white-space: nowrap; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">245,611</div></div></div> </td> <td style="width: 1%; padding: 0in 0in 0.5pt; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); text-align: left; vertical-align: bottom; line-height: 10pt;"> <div style="text-align: left; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; white-space: nowrap; text-indent: 0in; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div></div> </td> </tr> <tr> <td style="width: 74%; padding: 0px 0in 1.25pt 10pt; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgba(255, 255, 255, 0); vertical-align: bottom; line-height: 10pt;"> <div style="margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div></div> </td> <td style="width: 1%; padding: 0in 0in 1.25pt; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgba(255, 255, 255, 0); vertical-align: bottom; line-height: 10pt;"> <div style="margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> </td> <td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgba(255, 255, 255, 0); border-bottom: 2.5pt double black; border-top: 0px none; text-align: left; vertical-align: bottom; line-height: 10pt;"> <div style="margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; text-indent: 0in; text-align: left; white-space: nowrap; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> </td> <td style="border-bottom: 2.5pt double black; width: 10%; border-top: 0px none; border-image: initial; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); text-align: right; vertical-align: bottom; line-height: 10pt;"> <div style="margin: 0px 0in; text-align: right; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; white-space: nowrap; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">2,280,874</div></div></div> </td> <td style="width: 1%; padding: 0in 0in 1.25pt; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); text-align: left; vertical-align: bottom; line-height: 10pt;"> <div style="margin: 0px 0px 0px 0in; text-align: left; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; white-space: nowrap; text-indent: 0in; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div></div> </td> <td style="width: 1%; padding: 0in 0in 1.25pt; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); vertical-align: bottom; line-height: 10pt;"> <div style="margin: 0px 0px 0px 0in; text-align: right; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; white-space: nowrap; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div></div> </td> <td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); border-bottom: 2.5pt double black; border-top: 0px none; text-align: left; vertical-align: bottom; line-height: 10pt;"> <div style="margin: 0px 0px 0px 0in; text-align: left; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; white-space: nowrap; text-indent: 0in; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div></div> </td> <td style="border-bottom: 2.5pt double black; width: 10%; border-top: 0px none; border-image: initial; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); text-align: right; vertical-align: bottom; line-height: 10pt;"> <div style="text-align: right; margin: 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; white-space: nowrap; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">3,055,515</div></div></div> </td> <td style="width: 1%; padding: 0in 0in 1.25pt; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); text-align: left; vertical-align: bottom; line-height: 10pt;"> <div style="text-align: left; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; white-space: nowrap; text-indent: 0in; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"/> <div style="clear: both; max-height: 0px; text-indent: 0px;"/> <div style="margin: 0px 0in; text-align: justify; break-after: avoid; font-family: "Times New Roman", serif; font-size: 10pt;;text-indent: 0px;"> </div>

<div style="margin: 0px 0in; text-align: justify; break-after: avoid; font-family: "Times New Roman", serif; font-size: 10pt;;text-indent: 0px;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, serif; line-height: 12pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The Company had the following dilutive common stock equivalents as of September 30, 2022 and 2021 which were excluded from the calculation because their effect was anti-dilutive.</div></div> <div style="margin: 0px 0in; text-align: justify; break-after: avoid; font-family: "Times New Roman", serif; font-size: 10pt;;text-indent: 0px;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, serif; white-space: pre-wrap; line-height: 12pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;;white-space:pre-wrap;"> </div></div> <table cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;;margin-right : auto;;margin-left : 0;margin-right : auto;"> <tr> <td style="width: 74%; padding: 0px 0in 0.5pt; font-family: "Times New Roman", Times, serif; font-size: 10pt; vertical-align: bottom; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="padding: 0in 0in 0.5pt; font-family: "Times New Roman", Times, serif; font-size: 10pt; vertical-align: bottom; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td colspan="2" style="border-top: none; border-image: initial; border-bottom: 1pt solid windowtext; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; vertical-align: bottom; width: 11%; line-height: 10pt;"> <div style="text-align: center; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; white-space: nowrap; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; font-size: 10pt; line-height: 10pt;;font-weight:bold;display:inline;"><div style="font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">September 30, <br/> 2022</div></div></div></div> </td> <td style="padding: 0in 0in 0.5pt; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; vertical-align: bottom; line-height: 10pt;"> <div style="text-align: center; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; white-space: nowrap; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"><div style="line-height: 10pt; font-size: 10pt;;font-weight:bold;display:inline;width:100%;"> </div></div></div></div> </td> <td style="padding: 0in 0in 0.5pt; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; vertical-align: bottom; line-height: 10pt;"> <div style="text-align: center; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; white-space: nowrap; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"><div style="line-height: 10pt; font-size: 10pt;;font-weight:bold;display:inline;width:100%;"> </div></div></div></div> </td> <td colspan="2" style="border-top: none; border-image: initial; border-bottom: 1pt solid windowtext; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; vertical-align: bottom; width: 11%; line-height: 10pt;"> <div style="text-align: center; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; white-space: nowrap; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; font-size: 10pt; line-height: 10pt;;font-weight:bold;display:inline;"><div style="font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">September 30, <br/> 2021</div></div></div></div> </td> <td style="padding: 0in 0in 0.5pt; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; vertical-align: bottom; line-height: 10pt;"> <div style="text-align: center; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; white-space: nowrap; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"><div style="line-height: 10pt; font-size: 10pt;;font-weight:bold;display:inline;width:100%;"> </div></div></div></div> </td> </tr> <tr> <td style="width: 74%; padding: 0px 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255); vertical-align: bottom; line-height: 10pt;"> <div style="margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Outstanding restricted stock units</div></div></div> </td> <td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255); vertical-align: bottom; line-height: 10pt;"> <div style="margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> </td> <td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255); border-bottom: none; border-top: 0px solid windowtext; text-align: left; vertical-align: bottom; line-height: 10pt;"> <div style="margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; text-indent: 0in; text-align: left; white-space: nowrap; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> </td> <td style="border-bottom: none; border-image: initial; width: 10%; border-top: 0px solid windowtext; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); text-align: right; vertical-align: bottom; line-height: 10pt;"> <div style="margin: 0px 0in; text-align: right; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; white-space: nowrap; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">1,318,530</div></div></div> </td> <td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); text-align: left; vertical-align: bottom; line-height: 10pt;"> <div style="margin: 0px 0px 0px 0in; text-align: left; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; white-space: nowrap; text-indent: 0in; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div></div> </td> <td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; line-height: 10pt;"> <div style="margin: 0px 0px 0px 0in; text-align: right; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; white-space: nowrap; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div></div> </td> <td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); border-bottom: none; border-top: 0px solid windowtext; text-align: left; vertical-align: bottom; line-height: 10pt;"> <div style="margin: 0px 0px 0px 0in; text-align: left; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; white-space: nowrap; text-indent: 0in; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div></div> </td> <td style="border-bottom: none; border-image: initial; width: 10%; border-top: 0px solid windowtext; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; line-height: 10pt;"> <div style="text-align: right; margin: 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; white-space: nowrap; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">—</div></div></div> </td> <td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); text-align: left; vertical-align: bottom; line-height: 10pt;"> <div style="text-align: left; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; white-space: nowrap; text-indent: 0in; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div></div> </td> </tr> <tr> <td style="width: 74%; padding: 0px 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgba(255, 255, 255, 0); vertical-align: bottom; line-height: 10pt;"> <div style="margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Outstanding stock options</div></div></div> </td> <td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgba(255, 255, 255, 0); vertical-align: bottom; line-height: 10pt;"> <div style="margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> </td> <td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgba(255, 255, 255, 0); text-align: left; vertical-align: bottom; line-height: 10pt;"> <div style="margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; text-indent: 0in; text-align: left; white-space: nowrap; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> </td> <td style="width: 10%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); text-align: right; vertical-align: bottom; line-height: 10pt;"> <div style="margin: 0px 0in; text-align: right; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; white-space: nowrap; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">841,344</div></div></div> </td> <td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); text-align: left; vertical-align: bottom; line-height: 10pt;"> <div style="margin: 0px 0px 0px 0in; text-align: left; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; white-space: nowrap; text-indent: 0in; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div></div> </td> <td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); vertical-align: bottom; line-height: 10pt;"> <div style="margin: 0px 0px 0px 0in; text-align: right; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; white-space: nowrap; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div></div> </td> <td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); text-align: left; vertical-align: bottom; line-height: 10pt;"> <div style="margin: 0px 0px 0px 0in; text-align: left; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; white-space: nowrap; text-indent: 0in; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div></div> </td> <td style="width: 10%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); text-align: right; vertical-align: bottom; line-height: 10pt;"> <div style="text-align: right; margin: 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; white-space: nowrap; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">705,394</div></div></div> </td> <td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); text-align: left; vertical-align: bottom; line-height: 10pt;"> <div style="text-align: left; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; white-space: nowrap; text-indent: 0in; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div></div> </td> </tr> <tr> <td style="width: 74%; padding: 0px 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255); vertical-align: bottom; line-height: 10pt;"> <div style="margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Outstanding warrants</div></div></div> </td> <td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255); vertical-align: bottom; line-height: 10pt;"> <div style="margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> </td> <td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255); text-align: left; vertical-align: bottom; line-height: 10pt;"> <div style="margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; text-indent: 0in; text-align: left; white-space: nowrap; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> </td> <td style="width: 10%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); text-align: right; vertical-align: bottom; line-height: 10pt;"> <div style="margin: 0px 0in; text-align: right; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; white-space: nowrap; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">121,000</div></div></div> </td> <td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); text-align: left; vertical-align: bottom; line-height: 10pt;"> <div style="margin: 0px 0px 0px 0in; text-align: left; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; white-space: nowrap; text-indent: 0in; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div></div> </td> <td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; line-height: 10pt;"> <div style="margin: 0px 0px 0px 0in; text-align: right; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; white-space: nowrap; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div></div> </td> <td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); text-align: left; vertical-align: bottom; line-height: 10pt;"> <div style="margin: 0px 0px 0px 0in; text-align: left; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; white-space: nowrap; text-indent: 0in; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div></div> </td> <td style="width: 10%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); text-align: right; vertical-align: bottom; line-height: 10pt;"> <div style="text-align: right; margin: 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; white-space: nowrap; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">25,000</div></div></div> </td> <td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); text-align: left; vertical-align: bottom; line-height: 10pt;"> <div style="text-align: left; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; white-space: nowrap; text-indent: 0in; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div></div> </td> </tr> <tr> <td style="width: 74%; padding: 0px 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgba(255, 255, 255, 0); vertical-align: bottom; line-height: 10pt;"> <div style="margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Common shares convertible from notes payable</div></div></div> </td> <td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgba(255, 255, 255, 0); vertical-align: bottom; line-height: 10pt;"> <div style="margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> </td> <td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgba(255, 255, 255, 0); text-align: left; vertical-align: bottom; line-height: 10pt;"> <div style="margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; text-indent: 0in; text-align: left; white-space: nowrap; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> </td> <td style="width: 10%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); vertical-align: bottom; line-height: 10pt;"> <div style="margin: 0px 0in; text-align: right; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; white-space: nowrap; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">—</div></div></div> </td> <td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); text-align: left; vertical-align: bottom; line-height: 10pt;"> <div style="margin: 0px 0px 0px 0in; text-align: left; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; white-space: nowrap; text-indent: 0in; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div></div> </td> <td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); vertical-align: bottom; line-height: 10pt;"> <div style="margin: 0px 0px 0px 0in; text-align: right; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; white-space: nowrap; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div></div> </td> <td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); text-align: left; vertical-align: bottom; line-height: 10pt;"> <div style="margin: 0px 0px 0px 0in; text-align: left; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; white-space: nowrap; text-indent: 0in; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div></div> </td> <td style="width: 10%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); text-align: right; vertical-align: bottom; line-height: 10pt;"> <div style="text-align: right; margin: 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; white-space: nowrap; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">2,079,510</div></div></div> </td> <td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); text-align: left; vertical-align: bottom; line-height: 10pt;"> <div style="text-align: left; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; white-space: nowrap; text-indent: 0in; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div></div> </td> </tr> <tr> <td style="width: 74%; padding: 0px 0in 0.5pt; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255); vertical-align: bottom; line-height: 10pt;"> <div style="margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Common shares convertible from preferred stock</div></div></div> </td> <td style="width: 1%; padding: 0in 0in 0.5pt; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255); vertical-align: bottom; line-height: 10pt;"> <div style="margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> </td> <td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255); border-bottom: 1pt solid windowtext; border-top: none; text-align: left; vertical-align: bottom; line-height: 10pt;"> <div style="margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; text-indent: 0in; text-align: left; white-space: nowrap; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> </td> <td style="border-top: none; border-image: initial; border-bottom: 1pt solid windowtext; width: 10%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; line-height: 10pt;"> <div style="margin: 0px 0in; text-align: right; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; white-space: nowrap; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">—</div></div></div> </td> <td style="width: 1%; padding: 0in 0in 0.5pt; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); text-align: left; vertical-align: bottom; line-height: 10pt;"> <div style="margin: 0px 0px 0px 0in; text-align: left; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; white-space: nowrap; text-indent: 0in; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div></div> </td> <td style="width: 1%; padding: 0in 0in 0.5pt; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; line-height: 10pt;"> <div style="margin: 0px 0px 0px 0in; text-align: right; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; white-space: nowrap; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div></div> </td> <td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); border-bottom: 1pt solid windowtext; border-top: none; text-align: left; vertical-align: bottom; line-height: 10pt;"> <div style="margin: 0px 0px 0px 0in; text-align: left; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; white-space: nowrap; text-indent: 0in; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div></div> </td> <td style="border-top: none; border-image: initial; border-bottom: 1pt solid windowtext; width: 10%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); text-align: right; vertical-align: bottom; line-height: 10pt;"> <div style="text-align: right; margin: 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; white-space: nowrap; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">245,611</div></div></div> </td> <td style="width: 1%; padding: 0in 0in 0.5pt; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); text-align: left; vertical-align: bottom; line-height: 10pt;"> <div style="text-align: left; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; white-space: nowrap; text-indent: 0in; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div></div> </td> </tr> <tr> <td style="width: 74%; padding: 0px 0in 1.25pt 10pt; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgba(255, 255, 255, 0); vertical-align: bottom; line-height: 10pt;"> <div style="margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div></div> </td> <td style="width: 1%; padding: 0in 0in 1.25pt; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgba(255, 255, 255, 0); vertical-align: bottom; line-height: 10pt;"> <div style="margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> </td> <td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgba(255, 255, 255, 0); border-bottom: 2.5pt double black; border-top: 0px none; text-align: left; vertical-align: bottom; line-height: 10pt;"> <div style="margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; text-indent: 0in; text-align: left; white-space: nowrap; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> </td> <td style="border-bottom: 2.5pt double black; width: 10%; border-top: 0px none; border-image: initial; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); text-align: right; vertical-align: bottom; line-height: 10pt;"> <div style="margin: 0px 0in; text-align: right; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; white-space: nowrap; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">2,280,874</div></div></div> </td> <td style="width: 1%; padding: 0in 0in 1.25pt; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); text-align: left; vertical-align: bottom; line-height: 10pt;"> <div style="margin: 0px 0px 0px 0in; text-align: left; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; white-space: nowrap; text-indent: 0in; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div></div> </td> <td style="width: 1%; padding: 0in 0in 1.25pt; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); vertical-align: bottom; line-height: 10pt;"> <div style="margin: 0px 0px 0px 0in; text-align: right; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; white-space: nowrap; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div></div> </td> <td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); border-bottom: 2.5pt double black; border-top: 0px none; text-align: left; vertical-align: bottom; line-height: 10pt;"> <div style="margin: 0px 0px 0px 0in; text-align: left; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; white-space: nowrap; text-indent: 0in; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div></div> </td> <td style="border-bottom: 2.5pt double black; width: 10%; border-top: 0px none; border-image: initial; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); text-align: right; vertical-align: bottom; line-height: 10pt;"> <div style="text-align: right; margin: 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; white-space: nowrap; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">3,055,515</div></div></div> </td> <td style="width: 1%; padding: 0in 0in 1.25pt; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); text-align: left; vertical-align: bottom; line-height: 10pt;"> <div style="text-align: left; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; white-space: nowrap; text-indent: 0in; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"/> <div style="clear: both; max-height: 0px; text-indent: 0px;"/> <div style="margin: 0px 0in; text-align: justify; break-after: avoid; font-family: "Times New Roman", serif; font-size: 10pt;;text-indent: 0px;"> </div>

1318530

841344

705394

121000

25000

2079510

245611

2280874

3055515

<div style="margin: 0px 0in; text-align: justify; break-after: avoid; font-family: "Times New Roman", serif; font-size: 10pt;;text-indent: 0px;"><div style="font-style:italic;display:inline;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, serif; line-height: 12pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Recent Accounting Pronouncements</div></div></div> <div style="margin: 0px 0in; text-align: justify; break-after: avoid; font-family: "Times New Roman", serif; font-size: 10pt;;text-indent: 0px;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, serif; white-space: pre-wrap; line-height: 12pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;;white-space:pre-wrap;"> </div></div> <div style="margin: 0px 0px 0px 0in; text-align: justify; font-family: "Times New Roman", Times, serif; font-size: 10pt; line-height: 12pt; background: none;;text-indent: 0px;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, serif; line-height: 12pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">There have been no accounting pronouncements or changes in accounting pronouncements in the nine months ended September 30, 2022 that are significant or potentially significant to the Company.</div></div>

<div style="margin: 0px 0in; break-after: avoid; font-family: "Times New Roman", serif;;text-indent: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, serif; line-height: 12pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">3.</div></div><div style="font-size: 10pt; font-family: "Times New Roman", Times, serif; line-height: 12pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> <div style="font-weight:bold;display:inline;">Investments</div></div></div> <div style="margin: 0px 0in; break-after: avoid; font-family: "Times New Roman", serif; font-size: 10pt;;text-indent: 0px;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, serif; white-space: pre-wrap; line-height: 12pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;;white-space:pre-wrap;"> </div></div> <div style="margin: 0px 0in; text-align: justify; break-after: avoid; font-family: "Times New Roman", serif; font-size: 10pt;;text-indent: 0px;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, serif; line-height: 12pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The following table sets forth by level, within the fair value hierarchy, the Company’s investments at fair value as of September 30, 2022 and December 31, 2021:</div></div> <div style="margin: 0px 0in; text-align: justify; break-after: avoid; font-family: "Times New Roman", serif; font-size: 10pt;;text-indent: 0px;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, serif; white-space: pre-wrap; line-height: 12pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;;white-space:pre-wrap;"> </div></div> <table cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;;margin-right : auto;;margin-left : 0;margin-right : auto;"> <tr> <td style="width: 87%; padding: 0px 0in 0.5pt; font-family: "Times New Roman", Times, serif; font-size: 10pt; vertical-align: bottom; line-height: 10pt;"> <div style="text-align: center; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "Times New Roman", Times, "serif"; white-space: pre-wrap; line-height: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; font-size: 10pt;;display:inline;;white-space:pre-wrap;"><div style="line-height: 10pt; font-size: 10pt;;font-weight:bold;display:inline;width:100%;"> </div></div></div></div> </td> <td style="padding: 0in 0in 0.5pt; font-family: "Times New Roman", Times, serif; font-size: 10pt; vertical-align: bottom; line-height: 10pt;"> <div style="text-align: center; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="line-height: 10pt; font-size: 10pt;;font-weight:bold;display:inline;width:100%;"> </div></div></div> </td> <td colspan="2" style="border-top: none; border-image: initial; border-bottom: 1pt solid black; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; vertical-align: bottom; width: 11%; line-height: 10pt;"> <div style="text-align: center; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; white-space: nowrap; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; font-size: 10pt; line-height: 10pt;;font-weight:bold;display:inline;">Level 2</div></div></div> </td> <td style="padding: 0in 0in 0.5pt; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; vertical-align: bottom; line-height: 10pt;"> <div style="text-align: center; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; white-space: nowrap; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="line-height: 10pt; font-size: 10pt;;font-weight:bold;display:inline;width:100%;"> </div></div></div> </td> </tr> <tr> <td style="width: 87%; padding: 0px 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255); vertical-align: bottom; line-height: 10pt;"> <div style="margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Corporate debt securities:</div></div></div> </td> <td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255); vertical-align: bottom; line-height: 10pt;"> <div style="margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> </td> <td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255); text-align: left; vertical-align: bottom; line-height: 10pt;"> <div style="margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; text-indent: 0in; text-align: left; white-space: nowrap; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> </td> <td style="width: 10%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); text-align: right; vertical-align: bottom; line-height: 10pt;"> <div style="text-align: right; margin: 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; white-space: nowrap; line-height: 10pt;"> </div> </td> <td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); text-align: left; vertical-align: bottom; line-height: 10pt;"> <div style="text-align: left; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; white-space: nowrap; text-indent: 0in; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "Times New Roman", Times, "serif"; white-space: nowrap; line-height: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; font-size: 10pt;;display:inline;;white-space:pre-wrap;"> </div></div></div> </td> </tr> <tr> <td style="width: 87%; padding: 0px 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgba(255, 255, 255, 0); vertical-align: bottom; line-height: 10pt;"> <div style="margin: 0px 0px 0px 0.2in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">September 30, 2022</div></div></div> </td> <td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgba(255, 255, 255, 0); vertical-align: bottom; line-height: 10pt;"> <div style="margin: 0px 0px 0px 0.2in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> </td> <td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgba(255, 255, 255, 0); text-align: left; vertical-align: bottom; line-height: 10pt;"> <div style="text-align: left; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; white-space: nowrap; text-indent: 0in; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">$</div></div></div> </td> <td style="width: 10%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); text-align: right; vertical-align: bottom; line-height: 10pt;"> <div style="text-align: right; margin: 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; white-space: nowrap; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">9,381</div></div></div> </td> <td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); text-align: left; vertical-align: bottom; line-height: 10pt;"> <div style="text-align: left; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; white-space: nowrap; text-indent: 0in; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div></div> </td> </tr> <tr> <td style="width: 87%; padding: 0px 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255); vertical-align: bottom; line-height: 10pt;"> <div style="margin: 0px 0px 0px 0.2in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">December 31, 2021</div></div></div> </td> <td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255); vertical-align: bottom; line-height: 10pt;"> <div style="margin: 0px 0px 0px 0.2in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> </td> <td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255); text-align: left; vertical-align: bottom; line-height: 10pt;"> <div style="text-align: left; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; white-space: nowrap; text-indent: 0in; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">$</div></div></div> </td> <td style="width: 10%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); text-align: right; vertical-align: bottom; line-height: 10pt;"> <div style="text-align: right; margin: 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; white-space: nowrap; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">4,404</div></div></div> </td> <td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); text-align: left; vertical-align: bottom; line-height: 10pt;"> <div style="text-align: left; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; white-space: nowrap; text-indent: 0in; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"/> <div style="clear: both; max-height: 0px; text-indent: 0px;"/> <div style="margin: 0px 0in; text-align: justify; break-after: avoid; font-family: "Times New Roman", serif; font-size: 10pt;;text-indent: 0px;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, serif; white-space: pre-wrap; line-height: 12pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;;white-space:pre-wrap;"> </div></div> <div style="margin: 0px 0in; text-align: justify; break-after: avoid; font-family: "Times New Roman", serif; font-size: 10pt;;text-indent: 0px;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, serif; line-height: 12pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Cost and fair value of available-for-sale investments as of September 30, 2022 and December 31, 2021 are as follows:</div></div> <div style="margin: 0px 0in; text-align: justify; break-after: avoid; font-family: "Times New Roman", serif; font-size: 10pt;;text-indent: 0px;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, serif; white-space: pre-wrap; line-height: 12pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;;white-space:pre-wrap;"> </div></div> <table cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;;margin-right : auto;;margin-left : 0;margin-right : auto;"> <tr> <td style="width: 48%; padding: 0px 0in 0.375pt; font-family: "Times New Roman", Times, serif; font-size: 10pt; vertical-align: bottom; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="padding: 0in 0in 0.375pt; font-family: "Times New Roman", Times, serif; font-size: 10pt; vertical-align: bottom; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td colspan="2" style="padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; vertical-align: bottom; width: 11%; line-height: 10pt; border-bottom: 0.75pt solid black;"> <div style="text-align: center; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; white-space: nowrap; font-size: 10pt; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; font-size: 10pt; line-height: 10pt;;font-weight:bold;display:inline;"><div style="color: rgb(0, 0, 0); font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background: none; letter-spacing: 0px; top: 0px; white-space: nowrap; font-size: 10pt;;display:inline;">Amortized<br/> ‎Cost</div></div></div></div> </td> <td style="padding: 0in 0in 0.375pt; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; vertical-align: bottom; line-height: 10pt;"> <div style="text-align: center; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; white-space: nowrap; font-size: 10pt; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: rgb(0, 0, 0); font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background: none; letter-spacing: 0px; top: 0px; white-space: nowrap; font-size: 10pt;;display:inline;"><div style="line-height: 10pt; font-size: 10pt;;font-weight:bold;display:inline;width:100%;"> </div></div></div></div> </td> <td style="padding: 0in 0in 0.375pt; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; vertical-align: bottom; line-height: 10pt;"> <div style="text-align: center; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; white-space: nowrap; font-size: 10pt; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: rgb(0, 0, 0); font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background: none; letter-spacing: 0px; top: 0px; white-space: nowrap; font-size: 10pt;;display:inline;"><div style="line-height: 10pt; font-size: 10pt;;font-weight:bold;display:inline;width:100%;"> </div></div></div></div> </td> <td colspan="2" style="padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; vertical-align: bottom; width: 11%; line-height: 10pt; border-bottom: 0.75pt solid black;"> <div style="text-align: center; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; white-space: nowrap; font-size: 10pt; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; font-size: 10pt; line-height: 10pt;;font-weight:bold;display:inline;"><div style="color: rgb(0, 0, 0); font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background: none; letter-spacing: 0px; top: 0px; white-space: nowrap; font-size: 10pt;;display:inline;">Gross<br/> ‎Unrealized<br/> ‎Gains</div></div></div></div> </td> <td style="padding: 0in 0in 0.375pt; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; vertical-align: bottom; line-height: 10pt;"> <div style="text-align: center; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; white-space: nowrap; font-size: 10pt; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: rgb(0, 0, 0); font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background: none; letter-spacing: 0px; top: 0px; white-space: nowrap; font-size: 10pt;;display:inline;"><div style="line-height: 10pt; font-size: 10pt;;font-weight:bold;display:inline;width:100%;"> </div></div></div></div> </td> <td style="padding: 0in 0in 0.375pt; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; vertical-align: bottom; line-height: 10pt;"> <div style="text-align: center; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; white-space: nowrap; font-size: 10pt; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: rgb(0, 0, 0); font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background: none; letter-spacing: 0px; top: 0px; white-space: nowrap; font-size: 10pt;;display:inline;"><div style="line-height: 10pt; font-size: 10pt;;font-weight:bold;display:inline;width:100%;"> </div></div></div></div> </td> <td colspan="2" style="padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; vertical-align: bottom; width: 11%; line-height: 10pt; border-bottom: 0.75pt solid black;"> <div style="text-align: center; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; white-space: nowrap; font-size: 10pt; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; font-size: 10pt; line-height: 10pt;;font-weight:bold;display:inline;"><div style="color: rgb(0, 0, 0); font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background: none; letter-spacing: 0px; top: 0px; white-space: nowrap; font-size: 10pt;;display:inline;">Gross<br/> Unrealized Losses</div></div></div></div> </td> <td style="padding: 0in 0in 0.375pt; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; vertical-align: bottom; line-height: 10pt;"> <div style="text-align: center; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; white-space: nowrap; font-size: 10pt; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: rgb(0, 0, 0); font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background: none; letter-spacing: 0px; top: 0px; white-space: nowrap; font-size: 10pt;;display:inline;"><div style="line-height: 10pt; font-size: 10pt;;font-weight:bold;display:inline;width:100%;"> </div></div></div></div> </td> <td style="padding: 0in 0in 0.375pt; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; vertical-align: bottom; line-height: 10pt;"> <div style="text-align: center; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; white-space: nowrap; font-size: 10pt; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: rgb(0, 0, 0); font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background: none; letter-spacing: 0px; top: 0px; white-space: nowrap; font-size: 10pt;;display:inline;"><div style="line-height: 10pt; font-size: 10pt;;font-weight:bold;display:inline;width:100%;"> </div></div></div></div> </td> <td colspan="2" style="padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; vertical-align: bottom; width: 11%; line-height: 10pt; border-bottom: 0.75pt solid black;"> <div style="text-align: center; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; white-space: nowrap; font-size: 10pt; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; font-size: 10pt; line-height: 10pt;;font-weight:bold;display:inline;"><div style="color: rgb(0, 0, 0); font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background: none; letter-spacing: 0px; top: 0px; white-space: nowrap; font-size: 10pt;;display:inline;">Fair<br/> ‎Value</div></div></div></div> </td> <td style="padding: 0in 0in 0.375pt; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; vertical-align: bottom; line-height: 10pt;"> <div style="text-align: center; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; white-space: nowrap; font-size: 10pt; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: rgb(0, 0, 0); font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background: none; letter-spacing: 0px; top: 0px; white-space: nowrap; font-size: 10pt;;display:inline;"><div style="line-height: 10pt; font-size: 10pt;;font-weight:bold;display:inline;width:100%;"> </div></div></div></div> </td> </tr> <tr> <td style="width: 48%; padding: 0px 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255); vertical-align: bottom; line-height: 10pt;"> <div style="text-align: justify; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: rgb(0, 0, 0); font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; letter-spacing: 0px; top: 0px; font-size: 10pt;;display:inline;">Corporate debt securities:</div></div></div> </td> <td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255); vertical-align: bottom; line-height: 10pt;"> <div style="text-align: justify; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: rgb(0, 0, 0); font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; letter-spacing: 0px; top: 0px; font-size: 10pt;;display:inline;"> </div></div></div> </td> <td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255); text-align: left; vertical-align: bottom; line-height: 10pt;"> <div style="text-align: left; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; text-indent: 0in; white-space: nowrap; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: rgb(0, 0, 0); font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; letter-spacing: 0px; top: 0px; font-size: 10pt;;display:inline;"> </div></div></div> </td> <td style="width: 10%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); text-align: right; vertical-align: bottom; line-height: 10pt;"> <div style="text-align: right; margin: 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; white-space: nowrap; line-height: 10pt;"> </div> </td> <td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); text-align: left; vertical-align: bottom; line-height: 10pt;"> <div style="text-align: left; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; white-space: nowrap; text-indent: 0in; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "Times New Roman", Times, "serif"; white-space: nowrap; line-height: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; font-size: 10pt;;display:inline;;white-space:pre-wrap;"> </div></div></div> </td> <td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; line-height: 10pt;"> <div style="text-align: right; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; white-space: nowrap; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "Times New Roman", Times, "serif"; white-space: nowrap; line-height: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; font-size: 10pt;;display:inline;;white-space:pre-wrap;"> </div></div></div> </td> <td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); text-align: left; vertical-align: bottom; line-height: 10pt;"> <div style="text-align: left; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; white-space: nowrap; text-indent: 0in; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "Times New Roman", Times, "serif"; white-space: nowrap; line-height: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; font-size: 10pt;;display:inline;;white-space:pre-wrap;"> </div></div></div> </td> <td style="width: 10%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); text-align: right; vertical-align: bottom; line-height: 10pt;"> <div style="text-align: right; margin: 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; white-space: nowrap; line-height: 10pt;"> </div> </td> <td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); text-align: left; vertical-align: bottom; line-height: 10pt;"> <div style="text-align: left; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; white-space: nowrap; text-indent: 0in; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "Times New Roman", Times, "serif"; white-space: nowrap; line-height: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; font-size: 10pt;;display:inline;;white-space:pre-wrap;"> </div></div></div> </td> <td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; line-height: 10pt;"> <div style="text-align: right; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; white-space: nowrap; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "Times New Roman", Times, "serif"; white-space: nowrap; line-height: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; font-size: 10pt;;display:inline;;white-space:pre-wrap;"> </div></div></div> </td> <td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); text-align: left; vertical-align: bottom; line-height: 10pt;"> <div style="text-align: left; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; white-space: nowrap; text-indent: 0in; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "Times New Roman", Times, "serif"; white-space: nowrap; line-height: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; font-size: 10pt;;display:inline;;white-space:pre-wrap;"> </div></div></div> </td> <td style="width: 10%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); text-align: right; vertical-align: bottom; line-height: 10pt;"> <div style="text-align: right; margin: 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; white-space: nowrap; line-height: 10pt;"> </div> </td> <td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); text-align: left; vertical-align: bottom; line-height: 10pt;"> <div style="text-align: left; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; white-space: nowrap; text-indent: 0in; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "Times New Roman", Times, "serif"; white-space: nowrap; line-height: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; font-size: 10pt;;display:inline;;white-space:pre-wrap;"> </div></div></div> </td> <td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; line-height: 10pt;"> <div style="text-align: right; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; white-space: nowrap; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "Times New Roman", Times, "serif"; white-space: nowrap; line-height: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; font-size: 10pt;;display:inline;;white-space:pre-wrap;"> </div></div></div> </td> <td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); text-align: left; vertical-align: bottom; line-height: 10pt;"> <div style="text-align: left; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; white-space: nowrap; text-indent: 0in; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "Times New Roman", Times, "serif"; white-space: nowrap; line-height: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; font-size: 10pt;;display:inline;;white-space:pre-wrap;"> </div></div></div> </td> <td style="width: 10%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); text-align: right; vertical-align: bottom; line-height: 10pt;"> <div style="text-align: right; margin: 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; white-space: nowrap; line-height: 10pt;"> </div> </td> <td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); text-align: left; vertical-align: bottom; line-height: 10pt;"> <div style="text-align: left; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; white-space: nowrap; text-indent: 0in; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "Times New Roman", Times, "serif"; white-space: nowrap; line-height: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; font-size: 10pt;;display:inline;;white-space:pre-wrap;"> </div></div></div> </td> </tr> <tr> <td style="width: 48%; padding: 0px 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgba(255, 255, 255, 0); vertical-align: bottom; line-height: 10pt;"> <div style="text-align: justify; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: rgb(0, 0, 0); font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; letter-spacing: 0px; top: 0px; font-size: 10pt;;display:inline;">September 30, 2022</div></div></div> </td> <td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgba(255, 255, 255, 0); vertical-align: bottom; line-height: 10pt;"> <div style="text-align: justify; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: rgb(0, 0, 0); font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; letter-spacing: 0px; top: 0px; font-size: 10pt;;display:inline;"> </div></div></div> </td> <td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgba(255, 255, 255, 0); text-align: left; vertical-align: bottom; line-height: 10pt;"> <div style="text-align: left; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; white-space: nowrap; text-indent: 0in; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: rgb(0, 0, 0); font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">$</div></div></div> </td> <td style="width: 10%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); text-align: right; vertical-align: bottom; line-height: 10pt;"> <div style="text-align: right; margin: 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; white-space: nowrap; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: rgb(0, 0, 0); font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">9,418</div></div></div> </td> <td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); text-align: left; vertical-align: bottom; line-height: 10pt;"> <div style="text-align: left; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; white-space: nowrap; text-indent: 0in; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: rgb(0, 0, 0); font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div></div> </td> <td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); vertical-align: bottom; line-height: 10pt;"> <div style="text-align: right; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; white-space: nowrap; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: rgb(0, 0, 0); font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div></div> </td> <td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); text-align: left; vertical-align: bottom; line-height: 10pt;"> <div style="text-align: left; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; white-space: nowrap; text-indent: 0in; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: rgb(0, 0, 0); font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">$</div></div></div> </td> <td style="width: 10%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); vertical-align: bottom; line-height: 10pt;"> <div style="text-align: right; margin: 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; white-space: nowrap; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: rgb(0, 0, 0); font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">—</div></div></div> </td> <td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); text-align: left; vertical-align: bottom; line-height: 10pt;"> <div style="text-align: left; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; white-space: nowrap; text-indent: 0in; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: rgb(0, 0, 0); font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div></div> </td> <td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); vertical-align: bottom; line-height: 10pt;"> <div style="text-align: right; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; white-space: nowrap; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: rgb(0, 0, 0); font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div></div> </td> <td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); text-align: left; vertical-align: bottom; line-height: 10pt;"> <div style="text-align: left; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; white-space: nowrap; text-indent: 0in; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: rgb(0, 0, 0); font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">$</div></div></div> </td> <td style="width: 10%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); text-align: right; vertical-align: bottom; line-height: 10pt;"> <div style="text-align: right; margin: 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; white-space: nowrap; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: rgb(0, 0, 0); font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">(37</div></div></div> </td> <td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); text-align: left; vertical-align: bottom; line-height: 10pt;"> <div style="text-align: left; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; white-space: nowrap; text-indent: 0in; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: rgb(0, 0, 0); font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">)</div></div></div> </td> <td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); vertical-align: bottom; line-height: 10pt;"> <div style="text-align: right; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; white-space: nowrap; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: rgb(0, 0, 0); font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div></div> </td> <td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); text-align: left; vertical-align: bottom; line-height: 10pt;"> <div style="text-align: left; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; white-space: nowrap; text-indent: 0in; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: rgb(0, 0, 0); font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">$</div></div></div> </td> <td style="width: 10%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); text-align: right; vertical-align: bottom; line-height: 10pt;"> <div style="text-align: right; margin: 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; white-space: nowrap; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: rgb(0, 0, 0); font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">9,381</div></div></div> </td> <td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); text-align: left; vertical-align: bottom; line-height: 10pt;"> <div style="text-align: left; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; white-space: nowrap; text-indent: 0in; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: rgb(0, 0, 0); font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div></div> </td> </tr> <tr> <td style="width: 48%; padding: 0px 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255); vertical-align: bottom; line-height: 10pt;"> <div style="text-align: justify; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: rgb(0, 0, 0); font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; letter-spacing: 0px; top: 0px; font-size: 10pt;;display:inline;">December 31, 2021</div></div></div> </td> <td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255); vertical-align: bottom; line-height: 10pt;"> <div style="text-align: justify; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: rgb(0, 0, 0); font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; letter-spacing: 0px; top: 0px; font-size: 10pt;;display:inline;"> </div></div></div> </td> <td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255); text-align: left; vertical-align: bottom; line-height: 10pt;"> <div style="text-align: left; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; white-space: nowrap; text-indent: 0in; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: rgb(0, 0, 0); font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">$</div></div></div> </td> <td style="width: 10%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); text-align: right; vertical-align: bottom; line-height: 10pt;"> <div style="text-align: right; margin: 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; white-space: nowrap; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: rgb(0, 0, 0); font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">4,404</div></div></div> </td> <td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); text-align: left; vertical-align: bottom; line-height: 10pt;"> <div style="text-align: left; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; white-space: nowrap; text-indent: 0in; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: rgb(0, 0, 0); font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div></div> </td> <td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; line-height: 10pt;"> <div style="text-align: right; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; white-space: nowrap; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: rgb(0, 0, 0); font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div></div> </td> <td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); text-align: left; vertical-align: bottom; line-height: 10pt;"> <div style="text-align: left; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; white-space: nowrap; text-indent: 0in; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: rgb(0, 0, 0); font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">$</div></div></div> </td> <td style="width: 10%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; line-height: 10pt;"> <div style="text-align: right; margin: 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; white-space: nowrap; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: rgb(0, 0, 0); font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">—</div></div></div> </td> <td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); text-align: left; vertical-align: bottom; line-height: 10pt;"> <div style="text-align: left; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; white-space: nowrap; text-indent: 0in; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: rgb(0, 0, 0); font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div></div> </td> <td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; line-height: 10pt;"> <div style="text-align: right; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; white-space: nowrap; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: rgb(0, 0, 0); font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div></div> </td> <td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); text-align: left; vertical-align: bottom; line-height: 10pt;"> <div style="text-align: left; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; white-space: nowrap; text-indent: 0in; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: rgb(0, 0, 0); font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">$</div></div></div> </td> <td style="width: 10%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; line-height: 10pt;"> <div style="text-align: right; margin: 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; white-space: nowrap; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: rgb(0, 0, 0); font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">—</div></div></div> </td> <td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); text-align: left; vertical-align: bottom; line-height: 10pt;"> <div style="text-align: left; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; white-space: nowrap; text-indent: 0in; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: rgb(0, 0, 0); font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div></div> </td> <td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; line-height: 10pt;"> <div style="text-align: right; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; white-space: nowrap; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: rgb(0, 0, 0); font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div></div> </td> <td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); text-align: left; vertical-align: bottom; line-height: 10pt;"> <div style="text-align: left; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; white-space: nowrap; text-indent: 0in; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: rgb(0, 0, 0); font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">$</div></div></div> </td> <td style="width: 10%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); text-align: right; vertical-align: bottom; line-height: 10pt;"> <div style="text-align: right; margin: 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; white-space: nowrap; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: rgb(0, 0, 0); font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">4,404</div></div></div> </td> <td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); text-align: left; vertical-align: bottom; line-height: 10pt;"> <div style="text-align: left; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; white-space: nowrap; text-indent: 0in; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: rgb(0, 0, 0); font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div></div> </td> </tr> </table> <div style="margin: 0px 0px 0px 0in; text-align: justify; font-family: "Times New Roman", Times, serif; font-size: 10pt; line-height: 12pt; background: none;;text-indent: 0px;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, serif; white-space: pre-wrap; line-height: 12pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;;white-space:pre-wrap;"> </div></div> <div style="margin: 0px 0px 0px 0in; text-align: justify; font-family: "Times New Roman", Times, serif; font-size: 10pt; line-height: 12pt; background: none;;text-indent: 0px;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, serif; line-height: 12pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">All of the investments with gross unrealized losses have been in a continuous loss position for less than 12 months.</div></div> <div style="margin: 0px 0px 0px 0in; text-align: justify; font-family: "Times New Roman", Times, serif; font-size: 10pt; line-height: 12pt; background: none;;text-indent: 0px;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, serif; white-space: pre-wrap; line-height: 12pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;;white-space:pre-wrap;"> </div></div> <div style="margin: 0px 0px 0px 0in; text-align: justify; font-family: "Times New Roman", Times, serif; font-size: 10pt; line-height: 12pt; background: none;;text-indent: 0px;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, serif; line-height: 12pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">During the three and nine months ended September 30, 2022 and 2021, the Company did not recognize any significant other-than-temporary impairment losses because the Company does not intend to sell the investments before recovery of their amortized cost bases.</div></div> <div style="margin: 0px 0px 0px 0in; text-align: justify; font-family: "Times New Roman", Times, serif; font-size: 10pt; line-height: 12pt; background: none;;text-indent: 0px;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, serif; white-space: pre-wrap; line-height: 12pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;;white-space:pre-wrap;"> </div></div> <div style="margin: 0px 0px 0px 0in; text-align: justify; font-family: "Times New Roman", Times, serif; font-size: 10pt; line-height: 12pt; background: none;;text-indent: 0px;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, serif; line-height: 12pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">During the three and nine months ended September 30, 2022, there were net gains of approximately $72 and $108, respectively, included in the Company’s net loss. During the three and nine months ended September 30, 2021, there were no such gains included in the Company’s net loss. Accrued interest as of September 30, 2022 and December 31, 2021 was approximately $6 and $18, respectively, and is included in prepaid expenses in the Company’s consolidated balance sheet.</div></div>

9381000

4404000

<div style="margin: 0px 0in; text-align: justify; break-after: avoid; font-family: "Times New Roman", serif; font-size: 10pt;;text-indent: 0px;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, serif; line-height: 12pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Cost and fair value of available-for-sale investments as of September 30, 2022 and December 31, 2021 are as follows:</div></div> <div style="margin: 0px 0in; text-align: justify; break-after: avoid; font-family: "Times New Roman", serif; font-size: 10pt;;text-indent: 0px;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, serif; white-space: pre-wrap; line-height: 12pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;;white-space:pre-wrap;"> </div></div> <table cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;;margin-right : auto;;margin-left : 0;margin-right : auto;"> <tr> <td style="width: 48%; padding: 0px 0in 0.375pt; font-family: "Times New Roman", Times, serif; font-size: 10pt; vertical-align: bottom; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="padding: 0in 0in 0.375pt; font-family: "Times New Roman", Times, serif; font-size: 10pt; vertical-align: bottom; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td colspan="2" style="padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; vertical-align: bottom; width: 11%; line-height: 10pt; border-bottom: 0.75pt solid black;"> <div style="text-align: center; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; white-space: nowrap; font-size: 10pt; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; font-size: 10pt; line-height: 10pt;;font-weight:bold;display:inline;"><div style="color: rgb(0, 0, 0); font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background: none; letter-spacing: 0px; top: 0px; white-space: nowrap; font-size: 10pt;;display:inline;">Amortized<br/> ‎Cost</div></div></div></div> </td> <td style="padding: 0in 0in 0.375pt; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; vertical-align: bottom; line-height: 10pt;"> <div style="text-align: center; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; white-space: nowrap; font-size: 10pt; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: rgb(0, 0, 0); font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background: none; letter-spacing: 0px; top: 0px; white-space: nowrap; font-size: 10pt;;display:inline;"><div style="line-height: 10pt; font-size: 10pt;;font-weight:bold;display:inline;width:100%;"> </div></div></div></div> </td> <td style="padding: 0in 0in 0.375pt; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; vertical-align: bottom; line-height: 10pt;"> <div style="text-align: center; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; white-space: nowrap; font-size: 10pt; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: rgb(0, 0, 0); font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background: none; letter-spacing: 0px; top: 0px; white-space: nowrap; font-size: 10pt;;display:inline;"><div style="line-height: 10pt; font-size: 10pt;;font-weight:bold;display:inline;width:100%;"> </div></div></div></div> </td> <td colspan="2" style="padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; vertical-align: bottom; width: 11%; line-height: 10pt; border-bottom: 0.75pt solid black;"> <div style="text-align: center; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; white-space: nowrap; font-size: 10pt; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; font-size: 10pt; line-height: 10pt;;font-weight:bold;display:inline;"><div style="color: rgb(0, 0, 0); font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background: none; letter-spacing: 0px; top: 0px; white-space: nowrap; font-size: 10pt;;display:inline;">Gross<br/> ‎Unrealized<br/> ‎Gains</div></div></div></div> </td> <td style="padding: 0in 0in 0.375pt; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; vertical-align: bottom; line-height: 10pt;"> <div style="text-align: center; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; white-space: nowrap; font-size: 10pt; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: rgb(0, 0, 0); font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background: none; letter-spacing: 0px; top: 0px; white-space: nowrap; font-size: 10pt;;display:inline;"><div style="line-height: 10pt; font-size: 10pt;;font-weight:bold;display:inline;width:100%;"> </div></div></div></div> </td> <td style="padding: 0in 0in 0.375pt; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; vertical-align: bottom; line-height: 10pt;"> <div style="text-align: center; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; white-space: nowrap; font-size: 10pt; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: rgb(0, 0, 0); font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background: none; letter-spacing: 0px; top: 0px; white-space: nowrap; font-size: 10pt;;display:inline;"><div style="line-height: 10pt; font-size: 10pt;;font-weight:bold;display:inline;width:100%;"> </div></div></div></div> </td> <td colspan="2" style="padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; vertical-align: bottom; width: 11%; line-height: 10pt; border-bottom: 0.75pt solid black;"> <div style="text-align: center; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; white-space: nowrap; font-size: 10pt; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; font-size: 10pt; line-height: 10pt;;font-weight:bold;display:inline;"><div style="color: rgb(0, 0, 0); font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background: none; letter-spacing: 0px; top: 0px; white-space: nowrap; font-size: 10pt;;display:inline;">Gross<br/> Unrealized Losses</div></div></div></div> </td> <td style="padding: 0in 0in 0.375pt; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; vertical-align: bottom; line-height: 10pt;"> <div style="text-align: center; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; white-space: nowrap; font-size: 10pt; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: rgb(0, 0, 0); font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background: none; letter-spacing: 0px; top: 0px; white-space: nowrap; font-size: 10pt;;display:inline;"><div style="line-height: 10pt; font-size: 10pt;;font-weight:bold;display:inline;width:100%;"> </div></div></div></div> </td> <td style="padding: 0in 0in 0.375pt; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; vertical-align: bottom; line-height: 10pt;"> <div style="text-align: center; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; white-space: nowrap; font-size: 10pt; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: rgb(0, 0, 0); font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background: none; letter-spacing: 0px; top: 0px; white-space: nowrap; font-size: 10pt;;display:inline;"><div style="line-height: 10pt; font-size: 10pt;;font-weight:bold;display:inline;width:100%;"> </div></div></div></div> </td> <td colspan="2" style="padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; vertical-align: bottom; width: 11%; line-height: 10pt; border-bottom: 0.75pt solid black;"> <div style="text-align: center; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; white-space: nowrap; font-size: 10pt; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; font-size: 10pt; line-height: 10pt;;font-weight:bold;display:inline;"><div style="color: rgb(0, 0, 0); font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background: none; letter-spacing: 0px; top: 0px; white-space: nowrap; font-size: 10pt;;display:inline;">Fair<br/> ‎Value</div></div></div></div> </td> <td style="padding: 0in 0in 0.375pt; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; vertical-align: bottom; line-height: 10pt;"> <div style="text-align: center; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; white-space: nowrap; font-size: 10pt; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: rgb(0, 0, 0); font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background: none; letter-spacing: 0px; top: 0px; white-space: nowrap; font-size: 10pt;;display:inline;"><div style="line-height: 10pt; font-size: 10pt;;font-weight:bold;display:inline;width:100%;"> </div></div></div></div> </td> </tr> <tr> <td style="width: 48%; padding: 0px 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255); vertical-align: bottom; line-height: 10pt;"> <div style="text-align: justify; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: rgb(0, 0, 0); font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; letter-spacing: 0px; top: 0px; font-size: 10pt;;display:inline;">Corporate debt securities:</div></div></div> </td> <td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255); vertical-align: bottom; line-height: 10pt;"> <div style="text-align: justify; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: rgb(0, 0, 0); font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; letter-spacing: 0px; top: 0px; font-size: 10pt;;display:inline;"> </div></div></div> </td> <td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255); text-align: left; vertical-align: bottom; line-height: 10pt;"> <div style="text-align: left; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; text-indent: 0in; white-space: nowrap; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: rgb(0, 0, 0); font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; letter-spacing: 0px; top: 0px; font-size: 10pt;;display:inline;"> </div></div></div> </td> <td style="width: 10%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); text-align: right; vertical-align: bottom; line-height: 10pt;"> <div style="text-align: right; margin: 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; white-space: nowrap; line-height: 10pt;"> </div> </td> <td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); text-align: left; vertical-align: bottom; line-height: 10pt;"> <div style="text-align: left; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; white-space: nowrap; text-indent: 0in; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "Times New Roman", Times, "serif"; white-space: nowrap; line-height: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; font-size: 10pt;;display:inline;;white-space:pre-wrap;"> </div></div></div> </td> <td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; line-height: 10pt;"> <div style="text-align: right; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; white-space: nowrap; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "Times New Roman", Times, "serif"; white-space: nowrap; line-height: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; font-size: 10pt;;display:inline;;white-space:pre-wrap;"> </div></div></div> </td> <td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); text-align: left; vertical-align: bottom; line-height: 10pt;"> <div style="text-align: left; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; white-space: nowrap; text-indent: 0in; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "Times New Roman", Times, "serif"; white-space: nowrap; line-height: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; font-size: 10pt;;display:inline;;white-space:pre-wrap;"> </div></div></div> </td> <td style="width: 10%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); text-align: right; vertical-align: bottom; line-height: 10pt;"> <div style="text-align: right; margin: 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; white-space: nowrap; line-height: 10pt;"> </div> </td> <td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); text-align: left; vertical-align: bottom; line-height: 10pt;"> <div style="text-align: left; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; white-space: nowrap; text-indent: 0in; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "Times New Roman", Times, "serif"; white-space: nowrap; line-height: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; font-size: 10pt;;display:inline;;white-space:pre-wrap;"> </div></div></div> </td> <td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; line-height: 10pt;"> <div style="text-align: right; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; white-space: nowrap; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "Times New Roman", Times, "serif"; white-space: nowrap; line-height: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; font-size: 10pt;;display:inline;;white-space:pre-wrap;"> </div></div></div> </td> <td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); text-align: left; vertical-align: bottom; line-height: 10pt;"> <div style="text-align: left; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; white-space: nowrap; text-indent: 0in; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "Times New Roman", Times, "serif"; white-space: nowrap; line-height: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; font-size: 10pt;;display:inline;;white-space:pre-wrap;"> </div></div></div> </td> <td style="width: 10%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); text-align: right; vertical-align: bottom; line-height: 10pt;"> <div style="text-align: right; margin: 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; white-space: nowrap; line-height: 10pt;"> </div> </td> <td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); text-align: left; vertical-align: bottom; line-height: 10pt;"> <div style="text-align: left; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; white-space: nowrap; text-indent: 0in; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "Times New Roman", Times, "serif"; white-space: nowrap; line-height: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; font-size: 10pt;;display:inline;;white-space:pre-wrap;"> </div></div></div> </td> <td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; line-height: 10pt;"> <div style="text-align: right; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; white-space: nowrap; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "Times New Roman", Times, "serif"; white-space: nowrap; line-height: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; font-size: 10pt;;display:inline;;white-space:pre-wrap;"> </div></div></div> </td> <td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); text-align: left; vertical-align: bottom; line-height: 10pt;"> <div style="text-align: left; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; white-space: nowrap; text-indent: 0in; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "Times New Roman", Times, "serif"; white-space: nowrap; line-height: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; font-size: 10pt;;display:inline;;white-space:pre-wrap;"> </div></div></div> </td> <td style="width: 10%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); text-align: right; vertical-align: bottom; line-height: 10pt;"> <div style="text-align: right; margin: 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; white-space: nowrap; line-height: 10pt;"> </div> </td> <td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); text-align: left; vertical-align: bottom; line-height: 10pt;"> <div style="text-align: left; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; white-space: nowrap; text-indent: 0in; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "Times New Roman", Times, "serif"; white-space: nowrap; line-height: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; font-size: 10pt;;display:inline;;white-space:pre-wrap;"> </div></div></div> </td> </tr> <tr> <td style="width: 48%; padding: 0px 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgba(255, 255, 255, 0); vertical-align: bottom; line-height: 10pt;"> <div style="text-align: justify; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: rgb(0, 0, 0); font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; letter-spacing: 0px; top: 0px; font-size: 10pt;;display:inline;">September 30, 2022</div></div></div> </td> <td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgba(255, 255, 255, 0); vertical-align: bottom; line-height: 10pt;"> <div style="text-align: justify; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: rgb(0, 0, 0); font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; letter-spacing: 0px; top: 0px; font-size: 10pt;;display:inline;"> </div></div></div> </td> <td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgba(255, 255, 255, 0); text-align: left; vertical-align: bottom; line-height: 10pt;"> <div style="text-align: left; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; white-space: nowrap; text-indent: 0in; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: rgb(0, 0, 0); font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">$</div></div></div> </td> <td style="width: 10%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); text-align: right; vertical-align: bottom; line-height: 10pt;"> <div style="text-align: right; margin: 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; white-space: nowrap; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: rgb(0, 0, 0); font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">9,418</div></div></div> </td> <td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); text-align: left; vertical-align: bottom; line-height: 10pt;"> <div style="text-align: left; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; white-space: nowrap; text-indent: 0in; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: rgb(0, 0, 0); font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div></div> </td> <td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); vertical-align: bottom; line-height: 10pt;"> <div style="text-align: right; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; white-space: nowrap; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: rgb(0, 0, 0); font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div></div> </td> <td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); text-align: left; vertical-align: bottom; line-height: 10pt;"> <div style="text-align: left; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; white-space: nowrap; text-indent: 0in; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: rgb(0, 0, 0); font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">$</div></div></div> </td> <td style="width: 10%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); vertical-align: bottom; line-height: 10pt;"> <div style="text-align: right; margin: 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; white-space: nowrap; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: rgb(0, 0, 0); font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">—</div></div></div> </td> <td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); text-align: left; vertical-align: bottom; line-height: 10pt;"> <div style="text-align: left; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; white-space: nowrap; text-indent: 0in; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: rgb(0, 0, 0); font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div></div> </td> <td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); vertical-align: bottom; line-height: 10pt;"> <div style="text-align: right; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; white-space: nowrap; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: rgb(0, 0, 0); font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div></div> </td> <td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); text-align: left; vertical-align: bottom; line-height: 10pt;"> <div style="text-align: left; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; white-space: nowrap; text-indent: 0in; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: rgb(0, 0, 0); font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">$</div></div></div> </td> <td style="width: 10%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); text-align: right; vertical-align: bottom; line-height: 10pt;"> <div style="text-align: right; margin: 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; white-space: nowrap; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: rgb(0, 0, 0); font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">(37</div></div></div> </td> <td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); text-align: left; vertical-align: bottom; line-height: 10pt;"> <div style="text-align: left; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; white-space: nowrap; text-indent: 0in; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: rgb(0, 0, 0); font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">)</div></div></div> </td> <td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); vertical-align: bottom; line-height: 10pt;"> <div style="text-align: right; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; white-space: nowrap; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: rgb(0, 0, 0); font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div></div> </td> <td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); text-align: left; vertical-align: bottom; line-height: 10pt;"> <div style="text-align: left; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; white-space: nowrap; text-indent: 0in; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: rgb(0, 0, 0); font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">$</div></div></div> </td> <td style="width: 10%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); text-align: right; vertical-align: bottom; line-height: 10pt;"> <div style="text-align: right; margin: 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; white-space: nowrap; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: rgb(0, 0, 0); font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">9,381</div></div></div> </td> <td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); text-align: left; vertical-align: bottom; line-height: 10pt;"> <div style="text-align: left; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; white-space: nowrap; text-indent: 0in; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: rgb(0, 0, 0); font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div></div> </td> </tr> <tr> <td style="width: 48%; padding: 0px 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255); vertical-align: bottom; line-height: 10pt;"> <div style="text-align: justify; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: rgb(0, 0, 0); font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; letter-spacing: 0px; top: 0px; font-size: 10pt;;display:inline;">December 31, 2021</div></div></div> </td> <td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255); vertical-align: bottom; line-height: 10pt;"> <div style="text-align: justify; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: rgb(0, 0, 0); font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; letter-spacing: 0px; top: 0px; font-size: 10pt;;display:inline;"> </div></div></div> </td> <td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255); text-align: left; vertical-align: bottom; line-height: 10pt;"> <div style="text-align: left; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; white-space: nowrap; text-indent: 0in; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: rgb(0, 0, 0); font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">$</div></div></div> </td> <td style="width: 10%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); text-align: right; vertical-align: bottom; line-height: 10pt;"> <div style="text-align: right; margin: 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; white-space: nowrap; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: rgb(0, 0, 0); font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">4,404</div></div></div> </td> <td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); text-align: left; vertical-align: bottom; line-height: 10pt;"> <div style="text-align: left; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; white-space: nowrap; text-indent: 0in; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: rgb(0, 0, 0); font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div></div> </td> <td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; line-height: 10pt;"> <div style="text-align: right; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; white-space: nowrap; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: rgb(0, 0, 0); font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div></div> </td> <td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); text-align: left; vertical-align: bottom; line-height: 10pt;"> <div style="text-align: left; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; white-space: nowrap; text-indent: 0in; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: rgb(0, 0, 0); font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">$</div></div></div> </td> <td style="width: 10%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; line-height: 10pt;"> <div style="text-align: right; margin: 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; white-space: nowrap; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: rgb(0, 0, 0); font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">—</div></div></div> </td> <td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); text-align: left; vertical-align: bottom; line-height: 10pt;"> <div style="text-align: left; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; white-space: nowrap; text-indent: 0in; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: rgb(0, 0, 0); font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div></div> </td> <td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; line-height: 10pt;"> <div style="text-align: right; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; white-space: nowrap; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: rgb(0, 0, 0); font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div></div> </td> <td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); text-align: left; vertical-align: bottom; line-height: 10pt;"> <div style="text-align: left; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; white-space: nowrap; text-indent: 0in; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: rgb(0, 0, 0); font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">$</div></div></div> </td> <td style="width: 10%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; line-height: 10pt;"> <div style="text-align: right; margin: 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; white-space: nowrap; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: rgb(0, 0, 0); font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">—</div></div></div> </td> <td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); text-align: left; vertical-align: bottom; line-height: 10pt;"> <div style="text-align: left; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; white-space: nowrap; text-indent: 0in; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: rgb(0, 0, 0); font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div></div> </td> <td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; line-height: 10pt;"> <div style="text-align: right; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; white-space: nowrap; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: rgb(0, 0, 0); font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div></div> </td> <td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); text-align: left; vertical-align: bottom; line-height: 10pt;"> <div style="text-align: left; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; white-space: nowrap; text-indent: 0in; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: rgb(0, 0, 0); font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">$</div></div></div> </td> <td style="width: 10%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); text-align: right; vertical-align: bottom; line-height: 10pt;"> <div style="text-align: right; margin: 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; white-space: nowrap; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: rgb(0, 0, 0); font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">4,404</div></div></div> </td> <td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); text-align: left; vertical-align: bottom; line-height: 10pt;"> <div style="text-align: left; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; white-space: nowrap; text-indent: 0in; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: rgb(0, 0, 0); font-family: "Times New Roman", Times, "serif"; line-height: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div></div> </td> </tr> </table>

9418000

37000

9381000

4404000

72000

108000

6000 18000

<div style="margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, serif; background: none;;text-indent: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, serif; line-height: 12pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">4.</div></div><div style="font-size: 10pt; font-family: "Times New Roman", Times, serif; line-height: 12pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> <div style="font-weight:bold;display:inline;">Fixed Assets</div></div></div> <div style="margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; line-height: 12pt; background: none;;text-indent: 0px;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, serif; white-space: pre-wrap; line-height: 12pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;;white-space:pre-wrap;"> </div></div> <div style="margin: 0px 0px 0px 0in; text-align: justify; font-family: "Times New Roman", Times, serif; font-size: 10pt; line-height: 12pt; background: none;;text-indent: 0px;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, serif; line-height: 12pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Fixed assets, net, consisted of the following:</div></div> <div style="margin: 0px 0px 0px 0in; text-align: justify; font-family: "Times New Roman", Times, serif; font-size: 10pt; line-height: 12pt; background: none;;text-indent: 0px;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, serif; white-space: pre-wrap; line-height: 12pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;;white-space:pre-wrap;"> </div></div> <table cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;;margin-right : auto;;margin-left : 0;margin-right : auto;"> <tr> <td style="width: 74%; padding: 0px 0in 0.375pt; font-family: "Times New Roman", Times, serif; font-size: 10pt; vertical-align: bottom;"> <div style="text-align: center; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; white-space: pre-wrap; line-height: 12pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;;white-space:pre-wrap;"><div style="font-weight:bold;display:inline;width:100%;"> </div></div></div> </td> <td style="padding: 0in 0in 0.375pt; font-family: "Times New Roman", Times, serif; font-size: 10pt; vertical-align: bottom;"> <div style="text-align: center; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; white-space: pre-wrap; line-height: 12pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;;white-space:pre-wrap;"><div style="font-weight:bold;display:inline;width:100%;"> </div></div></div> </td> <td colspan="6" style="padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; vertical-align: bottom; width: 11.58%; border-bottom: 0.75pt solid black;"> <div style="margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap;"><div style="white-space: nowrap; font-size: 10pt;;font-weight:bold;display:inline;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">September 30, 2022</div></div></div> </td> <td style="padding: 0in 0in 0.375pt; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; vertical-align: bottom;"> <div style="margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; text-align: center; white-space: nowrap;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"><div style="font-weight:bold;display:inline;width:100%;"> </div></div></div> </td> <td style="padding: 0in 0in 0.375pt; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; vertical-align: bottom;"> <div style="margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; text-align: center; white-space: nowrap;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"><div style="font-weight:bold;display:inline;width:100%;"> </div></div></div> </td> <td colspan="2" style="padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; vertical-align: bottom; width: 11%; border-bottom: 0.75pt solid black;"> <div style="text-align: center; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap;"><div style="white-space: nowrap; font-size: 10pt;;font-weight:bold;display:inline;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">December 31,2021</div></div></div> </td> <td style="padding: 0in 0in 0.375pt; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; vertical-align: bottom;"> <div style="text-align: center; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"><div style="font-weight:bold;display:inline;width:100%;"> </div></div></div> </td> </tr> <tr> <td style="width: 74%; padding: 0px 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255); vertical-align: bottom;"> <div style="text-align: justify; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Catamaran Tray Sets</div></div> </td> <td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255); vertical-align: bottom;"> <div style="text-align: justify; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255); text-align: left; vertical-align: bottom;"> <div style="text-align: left; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap; text-indent: 0in;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">$</div></div> </td> <td colspan="5" style="width: 10%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); text-align: right; vertical-align: bottom;"> <div style="text-align: right; margin: 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">270</div></div> </td> <td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); text-align: left; vertical-align: bottom;"> <div style="text-align: left; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap; text-indent: 0in;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div> </td> <td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom;"> <div style="text-align: right; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div> </td> <td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); text-align: left; vertical-align: bottom;"> <div style="text-align: left; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap; text-indent: 0in;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">$</div></div> </td> <td style="width: 10%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); text-align: right; vertical-align: bottom;"> <div style="text-align: right; margin: 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">77</div></div> </td> <td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); text-align: left; vertical-align: bottom;"> <div style="text-align: left; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap; text-indent: 0in;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div> </td> </tr> <tr> <td style="width: 74%; padding: 0px 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgba(255, 255, 255, 0); vertical-align: bottom;"> <div style="text-align: justify; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">IT Equipment</div></div> </td> <td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgba(255, 255, 255, 0); vertical-align: bottom;"> <div style="text-align: justify; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgba(255, 255, 255, 0); text-align: left; vertical-align: bottom;"> <div style="text-align: left; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; text-indent: 0in; white-space: nowrap;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td colspan="5" style="width: 10%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); text-align: right; vertical-align: bottom;"> <div style="text-align: right; margin: 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">56</div></div> </td> <td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); text-align: left; vertical-align: bottom;"> <div style="text-align: left; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap; text-indent: 0in;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div> </td> <td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); vertical-align: bottom;"> <div style="text-align: right; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div> </td> <td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); text-align: left; vertical-align: bottom;"> <div style="text-align: left; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap; text-indent: 0in;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div> </td> <td style="width: 10%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); text-align: right; vertical-align: bottom;"> <div style="text-align: right; margin: 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">17</div></div> </td> <td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); text-align: left; vertical-align: bottom;"> <div style="text-align: left; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap; text-indent: 0in;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div> </td> </tr> <tr> <td style="width: 74%; padding: 0px 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255); vertical-align: bottom;"> <div style="text-align: justify; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Lab Equipment</div></div> </td> <td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255); vertical-align: bottom;"> <div style="text-align: justify; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255); text-align: left; vertical-align: bottom;"> <div style="text-align: left; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; text-indent: 0in; white-space: nowrap;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td colspan="5" style="width: 10%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); text-align: right; vertical-align: bottom;"> <div style="text-align: right; margin: 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">14</div></div> </td> <td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); text-align: left; vertical-align: bottom;"> <div style="text-align: left; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap; text-indent: 0in;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div> </td> <td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom;"> <div style="text-align: right; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div> </td> <td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); text-align: left; vertical-align: bottom;"> <div style="text-align: left; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap; text-indent: 0in;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div> </td> <td style="width: 10%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom;"> <div style="text-align: right; margin: 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">—</div></div> </td> <td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); text-align: left; vertical-align: bottom;"> <div style="text-align: left; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap; text-indent: 0in;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div> </td> </tr> <tr> <td style="width: 74%; padding: 0px 0in 0.5px; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgba(255, 255, 255, 0); vertical-align: bottom;"> <div style="text-align: justify; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Office Furniture</div></div> </td> <td style="width: 1%; padding: 0in 0in 0.5px; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgba(255, 255, 255, 0); vertical-align: bottom;"> <div style="text-align: justify; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgba(255, 255, 255, 0); border-bottom: 1px solid windowtext; text-align: left; vertical-align: bottom;"> <div style="text-align: left; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; text-indent: 0in; white-space: nowrap;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td colspan="5" style="width: 10%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; border-bottom: 1px solid windowtext; background-color: rgba(255, 255, 255, 0); text-align: right; vertical-align: bottom;"> <div style="text-align: right; margin: 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">9</div></div> </td> <td style="width: 1%; padding: 0in 0in 0.5px; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); text-align: left; vertical-align: bottom;"> <div style="text-align: left; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap; text-indent: 0in;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div> </td> <td style="width: 1%; padding: 0in 0in 0.5px; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); vertical-align: bottom;"> <div style="text-align: right; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div> </td> <td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); border-bottom: 1px solid windowtext; text-align: left; vertical-align: bottom;"> <div style="text-align: left; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap; text-indent: 0in;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div> </td> <td style="width: 10%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; border-bottom: 1px solid windowtext; background-color: rgba(255, 255, 255, 0); text-align: right; vertical-align: bottom;"> <div style="text-align: right; margin: 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">9</div></div> </td> <td style="width: 1%; padding: 0in 0in 0.5px; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); text-align: left; vertical-align: bottom;"> <div style="text-align: left; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap; text-indent: 0in;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div> </td> </tr> <tr> <td style="width: 74%; padding: 0px 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255); vertical-align: bottom;"> <div style="margin: 0px 0px 0px 9pt; text-align: justify; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Fixed assets, gross</div></div> </td> <td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255); vertical-align: bottom;"> <div style="margin: 0px 0px 0px 9pt; text-align: justify; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255); text-align: left; vertical-align: bottom;"> <div style="margin: 0px 0px 0px 0in; text-align: left; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; text-indent: 0in; white-space: nowrap;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td colspan="5" style="width: 10%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); text-align: right; vertical-align: bottom;"> <div style="text-align: right; margin: 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">349</div></div> </td> <td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); text-align: left; vertical-align: bottom;"> <div style="text-align: left; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap; text-indent: 0in;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div> </td> <td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom;"> <div style="text-align: right; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div> </td> <td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); text-align: left; vertical-align: bottom;"> <div style="text-align: left; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap; text-indent: 0in;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div> </td> <td style="width: 10%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); text-align: right; vertical-align: bottom;"> <div style="text-align: right; margin: 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">103</div></div> </td> <td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); text-align: left; vertical-align: bottom;"> <div style="text-align: left; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap; text-indent: 0in;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div> </td> </tr> <tr> <td style="width: 74%; padding: 0px 0in 0.5px; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgba(255, 255, 255, 0); vertical-align: bottom;"> <div style="text-align: justify; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Less: accumulated depreciation</div></div> </td> <td style="width: 1%; padding: 0in 0in 0.5px; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgba(255, 255, 255, 0); vertical-align: bottom;"> <div style="text-align: justify; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgba(255, 255, 255, 0); border-bottom: 1px solid windowtext; text-align: left; vertical-align: bottom;"> <div style="text-align: left; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; text-indent: 0in; white-space: nowrap;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td colspan="5" style="width: 10%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; border-bottom: 1px solid windowtext; background-color: rgba(255, 255, 255, 0); text-align: right; vertical-align: bottom;"> <div style="text-align: right; margin: 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">(55</div></div> </td> <td style="width: 1%; padding: 0in 0in 0.5px; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); text-align: left; vertical-align: bottom;"> <div style="text-align: left; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap; text-indent: 0in;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">)</div></div> </td> <td style="width: 1%; padding: 0in 0in 0.5px; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); vertical-align: bottom;"> <div style="text-align: right; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div> </td> <td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); border-bottom: 1px solid windowtext; text-align: left; vertical-align: bottom;"> <div style="text-align: left; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap; text-indent: 0in;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div> </td> <td style="width: 10%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; border-bottom: 1px solid windowtext; background-color: rgba(255, 255, 255, 0); text-align: right; vertical-align: bottom;"> <div style="text-align: right; margin: 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">(2</div></div> </td> <td style="width: 1%; padding: 0in 0in 0.5px; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); text-align: left; vertical-align: bottom;"> <div style="text-align: left; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap; text-indent: 0in;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">)</div></div> </td> </tr> <tr> <td style="width: 74%; padding: 0px 0in 1.125pt; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255); vertical-align: bottom;"> <div style="text-align: justify; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Fixed assets, net</div></div> </td> <td style="width: 1%; padding: 0in 0in 1.125pt; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255); vertical-align: bottom;"> <div style="text-align: justify; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255); text-align: left; vertical-align: bottom; border-bottom: 2.25pt double black;"> <div style="text-align: left; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap; text-indent: 0in;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">$</div></div> </td> <td colspan="5" style="width: 10%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); text-align: right; vertical-align: bottom; border-bottom: 2.25pt double black;"> <div style="text-align: right; margin: 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">294</div></div> </td> <td style="width: 1%; padding: 0in 0in 1.125pt; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); text-align: left; vertical-align: bottom;"> <div style="text-align: left; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap; text-indent: 0in;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div> </td> <td style="width: 1%; padding: 0in 0in 1.125pt; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom;"> <div style="text-align: right; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div> </td> <td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); text-align: left; vertical-align: bottom; border-bottom: 2.25pt double black;"> <div style="text-align: left; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap; text-indent: 0in;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">$</div></div> </td> <td style="width: 10%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); text-align: right; vertical-align: bottom; border-bottom: 2.25pt double black;"> <div style="text-align: right; margin: 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">101</div></div> </td> <td style="width: 1%; padding: 0in 0in 1.125pt; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); text-align: left; vertical-align: bottom;"> <div style="text-align: left; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap; text-indent: 0in;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div> </td> </tr> </table> <div style="margin: 0px 0px 0px 0in; text-align: justify; font-family: "Times New Roman", Times, serif; font-size: 10pt; line-height: 12pt; background: none;;text-indent: 0px;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, serif; white-space: pre-wrap; line-height: 12pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;;white-space:pre-wrap;"> </div></div> <div style="margin: 0px 0px 0px 0in; text-align: justify; font-family: "Times New Roman", Times, serif; font-size: 10pt; line-height: 12pt; background: none;;text-indent: 0px;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, serif; line-height: 12pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Depreciation expense was approximately $24 and $1 for the three months ended September 30, 2022 and 2021, respectively. Depreciation expense was approximately $53 and $1 for the nine months ended September 30, 2022 and 2021, respectively.</div></div>

<div style="margin: 0px 0px 0px 0in; text-align: justify; font-family: "Times New Roman", Times, serif; font-size: 10pt; line-height: 12pt; background: none;;text-indent: 0px;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, serif; line-height: 12pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Fixed assets, net, consisted of the following:</div></div> <div style="margin: 0px 0px 0px 0in; text-align: justify; font-family: "Times New Roman", Times, serif; font-size: 10pt; line-height: 12pt; background: none;;text-indent: 0px;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, serif; white-space: pre-wrap; line-height: 12pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;;white-space:pre-wrap;"> </div></div> <table cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;;margin-right : auto;;margin-left : 0;margin-right : auto;"> <tr> <td style="width: 74%; padding: 0px 0in 0.375pt; font-family: "Times New Roman", Times, serif; font-size: 10pt; vertical-align: bottom;"> <div style="text-align: center; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; white-space: pre-wrap; line-height: 12pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;;white-space:pre-wrap;"><div style="font-weight:bold;display:inline;width:100%;"> </div></div></div> </td> <td style="padding: 0in 0in 0.375pt; font-family: "Times New Roman", Times, serif; font-size: 10pt; vertical-align: bottom;"> <div style="text-align: center; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; white-space: pre-wrap; line-height: 12pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;;white-space:pre-wrap;"><div style="font-weight:bold;display:inline;width:100%;"> </div></div></div> </td> <td colspan="6" style="padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; vertical-align: bottom; width: 11.58%; border-bottom: 0.75pt solid black;"> <div style="margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap;"><div style="white-space: nowrap; font-size: 10pt;;font-weight:bold;display:inline;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">September 30, 2022</div></div></div> </td> <td style="padding: 0in 0in 0.375pt; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; vertical-align: bottom;"> <div style="margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; text-align: center; white-space: nowrap;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"><div style="font-weight:bold;display:inline;width:100%;"> </div></div></div> </td> <td style="padding: 0in 0in 0.375pt; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; vertical-align: bottom;"> <div style="margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; text-align: center; white-space: nowrap;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"><div style="font-weight:bold;display:inline;width:100%;"> </div></div></div> </td> <td colspan="2" style="padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; vertical-align: bottom; width: 11%; border-bottom: 0.75pt solid black;"> <div style="text-align: center; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap;"><div style="white-space: nowrap; font-size: 10pt;;font-weight:bold;display:inline;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">December 31,2021</div></div></div> </td> <td style="padding: 0in 0in 0.375pt; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; vertical-align: bottom;"> <div style="text-align: center; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"><div style="font-weight:bold;display:inline;width:100%;"> </div></div></div> </td> </tr> <tr> <td style="width: 74%; padding: 0px 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255); vertical-align: bottom;"> <div style="text-align: justify; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Catamaran Tray Sets</div></div> </td> <td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255); vertical-align: bottom;"> <div style="text-align: justify; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255); text-align: left; vertical-align: bottom;"> <div style="text-align: left; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap; text-indent: 0in;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">$</div></div> </td> <td colspan="5" style="width: 10%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); text-align: right; vertical-align: bottom;"> <div style="text-align: right; margin: 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">270</div></div> </td> <td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); text-align: left; vertical-align: bottom;"> <div style="text-align: left; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap; text-indent: 0in;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div> </td> <td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom;"> <div style="text-align: right; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div> </td> <td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); text-align: left; vertical-align: bottom;"> <div style="text-align: left; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap; text-indent: 0in;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">$</div></div> </td> <td style="width: 10%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); text-align: right; vertical-align: bottom;"> <div style="text-align: right; margin: 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">77</div></div> </td> <td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); text-align: left; vertical-align: bottom;"> <div style="text-align: left; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap; text-indent: 0in;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div> </td> </tr> <tr> <td style="width: 74%; padding: 0px 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgba(255, 255, 255, 0); vertical-align: bottom;"> <div style="text-align: justify; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">IT Equipment</div></div> </td> <td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgba(255, 255, 255, 0); vertical-align: bottom;"> <div style="text-align: justify; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgba(255, 255, 255, 0); text-align: left; vertical-align: bottom;"> <div style="text-align: left; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; text-indent: 0in; white-space: nowrap;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td colspan="5" style="width: 10%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); text-align: right; vertical-align: bottom;"> <div style="text-align: right; margin: 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">56</div></div> </td> <td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); text-align: left; vertical-align: bottom;"> <div style="text-align: left; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap; text-indent: 0in;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div> </td> <td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); vertical-align: bottom;"> <div style="text-align: right; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div> </td> <td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); text-align: left; vertical-align: bottom;"> <div style="text-align: left; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap; text-indent: 0in;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div> </td> <td style="width: 10%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); text-align: right; vertical-align: bottom;"> <div style="text-align: right; margin: 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">17</div></div> </td> <td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); text-align: left; vertical-align: bottom;"> <div style="text-align: left; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap; text-indent: 0in;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div> </td> </tr> <tr> <td style="width: 74%; padding: 0px 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255); vertical-align: bottom;"> <div style="text-align: justify; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Lab Equipment</div></div> </td> <td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255); vertical-align: bottom;"> <div style="text-align: justify; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255); text-align: left; vertical-align: bottom;"> <div style="text-align: left; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; text-indent: 0in; white-space: nowrap;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td colspan="5" style="width: 10%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); text-align: right; vertical-align: bottom;"> <div style="text-align: right; margin: 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">14</div></div> </td> <td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); text-align: left; vertical-align: bottom;"> <div style="text-align: left; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap; text-indent: 0in;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div> </td> <td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom;"> <div style="text-align: right; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div> </td> <td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); text-align: left; vertical-align: bottom;"> <div style="text-align: left; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap; text-indent: 0in;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div> </td> <td style="width: 10%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom;"> <div style="text-align: right; margin: 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">—</div></div> </td> <td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); text-align: left; vertical-align: bottom;"> <div style="text-align: left; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap; text-indent: 0in;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div> </td> </tr> <tr> <td style="width: 74%; padding: 0px 0in 0.5px; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgba(255, 255, 255, 0); vertical-align: bottom;"> <div style="text-align: justify; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Office Furniture</div></div> </td> <td style="width: 1%; padding: 0in 0in 0.5px; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgba(255, 255, 255, 0); vertical-align: bottom;"> <div style="text-align: justify; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgba(255, 255, 255, 0); border-bottom: 1px solid windowtext; text-align: left; vertical-align: bottom;"> <div style="text-align: left; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; text-indent: 0in; white-space: nowrap;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td colspan="5" style="width: 10%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; border-bottom: 1px solid windowtext; background-color: rgba(255, 255, 255, 0); text-align: right; vertical-align: bottom;"> <div style="text-align: right; margin: 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">9</div></div> </td> <td style="width: 1%; padding: 0in 0in 0.5px; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); text-align: left; vertical-align: bottom;"> <div style="text-align: left; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap; text-indent: 0in;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div> </td> <td style="width: 1%; padding: 0in 0in 0.5px; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); vertical-align: bottom;"> <div style="text-align: right; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div> </td> <td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); border-bottom: 1px solid windowtext; text-align: left; vertical-align: bottom;"> <div style="text-align: left; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap; text-indent: 0in;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div> </td> <td style="width: 10%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; border-bottom: 1px solid windowtext; background-color: rgba(255, 255, 255, 0); text-align: right; vertical-align: bottom;"> <div style="text-align: right; margin: 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">9</div></div> </td> <td style="width: 1%; padding: 0in 0in 0.5px; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); text-align: left; vertical-align: bottom;"> <div style="text-align: left; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap; text-indent: 0in;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div> </td> </tr> <tr> <td style="width: 74%; padding: 0px 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255); vertical-align: bottom;"> <div style="margin: 0px 0px 0px 9pt; text-align: justify; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Fixed assets, gross</div></div> </td> <td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255); vertical-align: bottom;"> <div style="margin: 0px 0px 0px 9pt; text-align: justify; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255); text-align: left; vertical-align: bottom;"> <div style="margin: 0px 0px 0px 0in; text-align: left; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; text-indent: 0in; white-space: nowrap;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td colspan="5" style="width: 10%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); text-align: right; vertical-align: bottom;"> <div style="text-align: right; margin: 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">349</div></div> </td> <td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); text-align: left; vertical-align: bottom;"> <div style="text-align: left; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap; text-indent: 0in;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div> </td> <td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom;"> <div style="text-align: right; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div> </td> <td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); text-align: left; vertical-align: bottom;"> <div style="text-align: left; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap; text-indent: 0in;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div> </td> <td style="width: 10%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); text-align: right; vertical-align: bottom;"> <div style="text-align: right; margin: 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">103</div></div> </td> <td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); text-align: left; vertical-align: bottom;"> <div style="text-align: left; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap; text-indent: 0in;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div> </td> </tr> <tr> <td style="width: 74%; padding: 0px 0in 0.5px; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgba(255, 255, 255, 0); vertical-align: bottom;"> <div style="text-align: justify; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Less: accumulated depreciation</div></div> </td> <td style="width: 1%; padding: 0in 0in 0.5px; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgba(255, 255, 255, 0); vertical-align: bottom;"> <div style="text-align: justify; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgba(255, 255, 255, 0); border-bottom: 1px solid windowtext; text-align: left; vertical-align: bottom;"> <div style="text-align: left; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; text-indent: 0in; white-space: nowrap;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td colspan="5" style="width: 10%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; border-bottom: 1px solid windowtext; background-color: rgba(255, 255, 255, 0); text-align: right; vertical-align: bottom;"> <div style="text-align: right; margin: 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">(55</div></div> </td> <td style="width: 1%; padding: 0in 0in 0.5px; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); text-align: left; vertical-align: bottom;"> <div style="text-align: left; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap; text-indent: 0in;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">)</div></div> </td> <td style="width: 1%; padding: 0in 0in 0.5px; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); vertical-align: bottom;"> <div style="text-align: right; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div> </td> <td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); border-bottom: 1px solid windowtext; text-align: left; vertical-align: bottom;"> <div style="text-align: left; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap; text-indent: 0in;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div> </td> <td style="width: 10%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; border-bottom: 1px solid windowtext; background-color: rgba(255, 255, 255, 0); text-align: right; vertical-align: bottom;"> <div style="text-align: right; margin: 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">(2</div></div> </td> <td style="width: 1%; padding: 0in 0in 0.5px; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); text-align: left; vertical-align: bottom;"> <div style="text-align: left; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap; text-indent: 0in;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">)</div></div> </td> </tr> <tr> <td style="width: 74%; padding: 0px 0in 1.125pt; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255); vertical-align: bottom;"> <div style="text-align: justify; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Fixed assets, net</div></div> </td> <td style="width: 1%; padding: 0in 0in 1.125pt; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255); vertical-align: bottom;"> <div style="text-align: justify; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255); text-align: left; vertical-align: bottom; border-bottom: 2.25pt double black;"> <div style="text-align: left; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap; text-indent: 0in;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">$</div></div> </td> <td colspan="5" style="width: 10%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); text-align: right; vertical-align: bottom; border-bottom: 2.25pt double black;"> <div style="text-align: right; margin: 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">294</div></div> </td> <td style="width: 1%; padding: 0in 0in 1.125pt; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); text-align: left; vertical-align: bottom;"> <div style="text-align: left; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap; text-indent: 0in;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div> </td> <td style="width: 1%; padding: 0in 0in 1.125pt; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom;"> <div style="text-align: right; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div> </td> <td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); text-align: left; vertical-align: bottom; border-bottom: 2.25pt double black;"> <div style="text-align: left; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap; text-indent: 0in;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">$</div></div> </td> <td style="width: 10%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); text-align: right; vertical-align: bottom; border-bottom: 2.25pt double black;"> <div style="text-align: right; margin: 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">101</div></div> </td> <td style="width: 1%; padding: 0in 0in 1.125pt; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); text-align: left; vertical-align: bottom;"> <div style="text-align: left; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap; text-indent: 0in;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div> </td> </tr> </table>

270000

77000

56000

17000

14000

9000

349000

103000

55000

2000

294000

101000

24000

1000

53000

1000

339000

846000

49000

14000

215000

228000

603000

1088000

53000

0.08

500000 0.90

68000

0.08

1000000 0.90

2021-06-12

68000

2022-05-07

0.08

5000000 0.80

1.9565

5000000 0 14000

118000

0.08

500000 0.90

2019-01-01

118000

2022-04-30

0.08

5000000 0.80

1.9565

5000000 0 56000

70000

0.08

500000 0.80

2022-10-12

70000

2022-04-30

0.08

5000000 0.70

1.9565

5000000 0 12000

50000

0.08

500000 0.80

2022-10-21

50000

2022-05-03

0.08

5000000 0.70

1.9565

5000000 0 9000

200000

0.08

2000000 0.80

2022-11-16

200000

2022-05-03

0.08

5000000 0.70 0.70 0 18000

131000

0.03

2021-07-27

0.05

40000

170000

0.08

5000000 0.70 0.70 0 11000

12177000

620000

50000

0.08

5000000 0.70 22500000

71000

0 527000

3955415

107000

0.08

114000

<div style="margin: 0px 0in; break-after: avoid; font-family: "Times New Roman", serif; font-size: 10pt;;text-indent: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, serif; line-height: 12pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">7. Leases</div></div></div> <div style="margin: 0px 0in; break-after: avoid; font-family: "Times New Roman", serif; font-size: 10pt;;text-indent: 0px;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, serif; white-space: pre-wrap; line-height: 12pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;;white-space:pre-wrap;"> </div></div> <div style="margin: 0px 0px 0px 0in; text-align: justify; font-family: "Times New Roman", Times, serif; font-size: 10pt; line-height: 12pt; background: none;;text-indent: 0px;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, serif; line-height: 12pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">In June 2021, the Company entered into a facility lease agreement for its company headquarters in Los Gatos, California. This non-cancelable operating lease expires in June 2026. The Company includes options that are reasonably certain to be exercised as part of the determination of lease terms. The Company may negotiate termination clauses in anticipation of any changes in market conditions, but generally these termination options are not exercised. Residual value guarantees are generally not included within operating leases. In addition to base rent payments, leases may require the Company to pay directly for taxes and other non-lease components, such as insurance, maintenance, and other operating expenses, which may be dependent on usage or vary month-to-month. Non-lease components were considered and determined not to be material. The Company determined if an arrangement is a lease at inception of the contract in accordance with guidance detailed in the new standard and performed the lease classification test as of the lease commencement date. ROU assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent the obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at the lease’s commencement date based on the present value of lease payments over the lease term. When a lease did not provide an implicit rate, the Company used its estimated incremental borrowing rate based on the information available at the commencement date in determining the present value of future payments.</div></div> <div style="margin: 0px 0px 0px 0in; text-align: justify; font-family: "Times New Roman", Times, serif; font-size: 10pt; line-height: 12pt; background: none;;text-indent: 0px;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, serif; white-space: pre-wrap; line-height: 12pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;;white-space:pre-wrap;"> </div></div><div style="margin: 0px 0px 0px 0in; text-align: justify; font-family: "Times New Roman", Times, serif; font-size: 10pt; line-height: 12pt; background: none;;text-indent: 0px;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, serif; line-height: 12pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Operating lease costs for the facility lease were $73 and $73 for the three months ended September 30, 2022 and 2021, respectively, and $219 and $85 for the nine months ended September 30, 2022 and 2021, respectively. Lease costs are included in general and administrative expenses in the consolidated statements of operations and comprehensive loss.</div></div> <div style="margin: 0px 0px 0px 0in; text-align: justify; font-family: "Times New Roman", Times, serif; font-size: 10pt; line-height: 12pt; background: none;;text-indent: 0px;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, serif; white-space: pre-wrap; line-height: 12pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;;white-space:pre-wrap;"> </div></div> <div style="margin: 0px 0in; text-align: justify; break-after: avoid; font-family: "Times New Roman", serif; font-size: 10pt;;text-indent: 0px;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, serif; line-height: 12pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Supplemental balance sheet information related to leases was as follows:</div></div> <div style="margin: 0px 0in; text-align: justify; break-after: avoid; font-family: "Times New Roman", serif; font-size: 10pt;;text-indent: 0px;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, serif; white-space: pre-wrap; line-height: 12pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;;white-space:pre-wrap;"> </div></div> <table cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;;margin-right : auto;;margin-left : 0;margin-right : auto;"><tr><td style="width: 74%; padding: 0px 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; vertical-align: bottom;"><div style="text-align: center; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt;"><div style="font-size: 10pt;;font-weight:bold;display:inline;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div></td><td style="padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; vertical-align: bottom;"><div style="text-align: center; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;width:100%;"> </div></div></div></td><td colspan="2" style="padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; vertical-align: bottom; width: 11%;"><div style="text-align: center; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap;"><div style="white-space: nowrap; font-size: 10pt;;font-weight:bold;display:inline;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">September 30,</div></div></div></td><td style="padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; vertical-align: bottom;"><div style="text-align: center; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"><div style="font-weight:bold;display:inline;width:100%;"> </div></div></div></td><td style="padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; vertical-align: bottom;"><div style="text-align: center; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"><div style="font-weight:bold;display:inline;width:100%;"> </div></div></div></td><td colspan="2" style="padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; vertical-align: bottom; width: 11%;"><div style="text-align: center; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap;"><div style="white-space: nowrap; font-size: 10pt;;font-weight:bold;display:inline;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">December 31,</div></div></div></td><td style="padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; vertical-align: bottom;"><div style="text-align: center; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"><div style="font-weight:bold;display:inline;width:100%;"> </div></div></div></td></tr><tr><td style="width: 74%; padding: 0px 0in 0.5pt; font-family: "Times New Roman", Times, serif; font-size: 10pt; vertical-align: bottom;"><div style="text-align: center; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt;"><div style="font-size: 10pt;;font-weight:bold;display:inline;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div></td><td style="padding: 0in 0in 0.5pt; font-family: "Times New Roman", Times, serif; font-size: 10pt; vertical-align: bottom;"><div style="text-align: center; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;width:100%;"> </div></div></div></td><td colspan="2" style="border-top: none; border-image: initial; border-bottom: 1pt solid black; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; vertical-align: bottom; width: 11%;"><div style="text-align: center; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap;"><div style="white-space: nowrap; font-size: 10pt;;font-weight:bold;display:inline;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">2022</div></div></div></td><td style="padding: 0in 0in 0.5pt; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; vertical-align: bottom;"><div style="text-align: center; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"><div style="font-weight:bold;display:inline;width:100%;"> </div></div></div></td><td style="padding: 0in 0in 0.5pt; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; vertical-align: bottom;"><div style="text-align: center; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"><div style="font-weight:bold;display:inline;width:100%;"> </div></div></div></td><td colspan="2" style="border-top: none; border-image: initial; border-bottom: 1pt solid black; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; vertical-align: bottom; width: 11%;"><div style="text-align: center; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap;"><div style="white-space: nowrap; font-size: 10pt;;font-weight:bold;display:inline;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">2021</div></div></div></td><td style="padding: 0in 0in 0.5pt; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; vertical-align: bottom;"><div style="text-align: center; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"><div style="font-weight:bold;display:inline;width:100%;"> </div></div></div></td></tr><tr><td style="width: 74%; padding: 0px 0in 1.25pt; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255); vertical-align: bottom;"><div style="margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Operating lease right-of-use assets</div></div></td><td style="width: 1%; padding: 0in 0in 1.25pt; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255); vertical-align: bottom;"><div style="margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255); border-bottom: 2.5pt double black; border-top: 0px none; text-align: left; vertical-align: bottom;"><div style="text-align: left; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap; text-indent: 0in;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">$</div></div></td><td style="border-bottom: 2.5pt double black; width: 10%; border-top: 0px none; border-image: initial; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); text-align: right; vertical-align: bottom;"><div style="text-align: right; margin: 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">927</div></div></td><td style="width: 1%; padding: 0in 0in 1.25pt; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); text-align: left; vertical-align: bottom;"><div style="text-align: left; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap; text-indent: 0in;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div></td><td style="width: 1%; padding: 0in 0in 1.25pt; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom;"><div style="text-align: right; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div></td><td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); border-bottom: 2.5pt double black; border-top: 0px none; text-align: left; vertical-align: bottom;"><div style="text-align: left; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap; text-indent: 0in;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">$</div></div></td><td style="border-bottom: 2.5pt double black; width: 10%; border-top: 0px none; border-image: initial; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); text-align: right; vertical-align: bottom;"><div style="text-align: right; margin: 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">1,084</div></div></td><td style="width: 1%; padding: 0in 0in 1.25pt; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); text-align: left; vertical-align: bottom;"><div style="text-align: left; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap; text-indent: 0in;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div></td></tr><tr><td style="width: 74%; padding: 0px 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgba(255, 255, 255, 0); vertical-align: bottom;"><div style="text-align: right; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; white-space: pre-wrap; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;;white-space:pre-wrap;"> </div></div></td><td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgba(255, 255, 255, 0); vertical-align: bottom;"><div style="text-align: right; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; white-space: pre-wrap; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;;white-space:pre-wrap;"> </div></div></td><td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgba(255, 255, 255, 0); text-align: left; vertical-align: bottom;"><div style="text-align: left; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; text-indent: 0in; white-space: nowrap;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; white-space: pre-wrap; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;;white-space:pre-wrap;"> </div></div></td><td style="width: 10%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); text-align: right; vertical-align: bottom;"><div style="text-align: right; margin: 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap;"> </div></td><td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); text-align: left; vertical-align: bottom;"><div style="text-align: left; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap; text-indent: 0in;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; white-space: nowrap; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;;white-space:pre-wrap;"> </div></div></td><td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); vertical-align: bottom;"><div style="text-align: right; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; white-space: nowrap; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;;white-space:pre-wrap;"> </div></div></td><td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); text-align: left; vertical-align: bottom;"><div style="text-align: left; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap; text-indent: 0in;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; white-space: nowrap; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;;white-space:pre-wrap;"> </div></div></td><td style="width: 10%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); text-align: right; vertical-align: bottom;"><div style="text-align: right; margin: 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap;"> </div></td><td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); text-align: left; vertical-align: bottom;"><div style="text-align: left; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap; text-indent: 0in;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; white-space: nowrap; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;;white-space:pre-wrap;"> </div></div></td></tr><tr><td style="width: 74%; padding: 0px 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255); vertical-align: bottom;"><div style="margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Operating lease liability, current</div></div></td><td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255); vertical-align: bottom;"><div style="margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255); text-align: left; vertical-align: bottom;"><div style="text-align: left; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap; text-indent: 0in;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">$</div></div></td><td style="width: 10%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); text-align: right; vertical-align: bottom;"><div style="text-align: right; margin: 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">(241</div></div></td><td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); text-align: left; vertical-align: bottom;"><div style="text-align: left; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap; text-indent: 0in;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">)</div></div></td><td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom;"><div style="text-align: right; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div></td><td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); text-align: left; vertical-align: bottom;"><div style="text-align: left; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap; text-indent: 0in;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">$</div></div></td><td style="width: 10%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); text-align: right; vertical-align: bottom;"><div style="text-align: right; margin: 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">(202</div></div></td><td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); text-align: left; vertical-align: bottom;"><div style="text-align: left; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap; text-indent: 0in;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">)</div></div></td></tr><tr><td style="width: 74%; padding: 0px 0in 0.5pt; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgba(255, 255, 255, 0); vertical-align: bottom;"><div style="margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Operating lease liability, noncurrent</div></div></td><td style="width: 1%; padding: 0in 0in 0.5pt; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgba(255, 255, 255, 0); vertical-align: bottom;"><div style="margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgba(255, 255, 255, 0); border-bottom: 1pt solid black; border-top: 0in none; text-align: left; vertical-align: bottom;"><div style="margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; text-indent: 0in; text-align: left; white-space: nowrap;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="border-top: 0in none; border-image: initial; border-bottom: 1pt solid black; width: 10%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); text-align: right; vertical-align: bottom;"><div style="text-align: right; margin: 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">(724</div></div></td><td style="width: 1%; padding: 0in 0in 0.5pt; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); text-align: left; vertical-align: bottom;"><div style="text-align: left; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap; text-indent: 0in;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">)</div></div></td><td style="width: 1%; padding: 0in 0in 0.5pt; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); vertical-align: bottom;"><div style="text-align: right; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div></td><td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); border-bottom: 1pt solid black; border-top: 0in none; text-align: left; vertical-align: bottom;"><div style="text-align: left; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap; text-indent: 0in;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div></td><td style="border-top: 0in none; border-image: initial; border-bottom: 1pt solid black; width: 10%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); text-align: right; vertical-align: bottom;"><div style="text-align: right; margin: 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">(911</div></div></td><td style="width: 1%; padding: 0in 0in 0.5pt; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); text-align: left; vertical-align: bottom;"><div style="text-align: left; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap; text-indent: 0in;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">)</div></div></td></tr><tr><td style="width: 74%; padding: 0px 0in 1.25pt; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255); vertical-align: bottom;"><div style="margin: 0px 0px 0px 0.2in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Total operating lease liabilities</div></div></td><td style="width: 1%; padding: 0in 0in 1.25pt; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255); vertical-align: bottom;"><div style="margin: 0px 0px 0px 0.2in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255); border-bottom: 2.5pt double black; border-top: 0in none; text-align: left; vertical-align: bottom;"><div style="text-align: left; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap; text-indent: 0in;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">$</div></div></td><td style="border-bottom: 2.5pt double black; width: 10%; border-top: 0in none; border-image: initial; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); text-align: right; vertical-align: bottom;"><div style="text-align: right; margin: 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">(965</div></div></td><td style="width: 1%; padding: 0in 0in 1.25pt; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); text-align: left; vertical-align: bottom;"><div style="text-align: left; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap; text-indent: 0in;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">)</div></div></td><td style="width: 1%; padding: 0in 0in 1.25pt; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom;"><div style="text-align: right; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div></td><td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); border-bottom: 2.5pt double black; border-top: 0in none; text-align: left; vertical-align: bottom;"><div style="text-align: left; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap; text-indent: 0in;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">$</div></div></td><td style="border-bottom: 2.5pt double black; width: 10%; border-top: 0in none; border-image: initial; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); text-align: right; vertical-align: bottom;"><div style="text-align: right; margin: 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">(1,113</div></div></td><td style="width: 1%; padding: 0in 0in 1.25pt; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); text-align: left; vertical-align: bottom;"><div style="text-align: left; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap; text-indent: 0in;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">)</div></div></td></tr></table> <div style="clear: both; max-height: 0px;"/> <div style="clear: both; max-height: 0px; text-indent: 0px;"/> <div style="margin: 0px 0in; text-align: justify; break-after: avoid; font-family: "Times New Roman", serif; font-size: 10pt;;text-indent: 0px;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, serif; white-space: pre-wrap; line-height: 12pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;;white-space:pre-wrap;"> </div></div> <div style="margin: 0px 0in; text-align: justify; break-after: avoid; font-family: "Times New Roman", serif; font-size: 10pt;;text-indent: 0px;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, serif; line-height: 12pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Future maturities of operating lease liabilities as of September 30, 2022 were as follows:</div></div> <div style="margin: 0px 0in; text-align: justify; break-after: avoid; font-family: "Times New Roman", serif; font-size: 10pt;;text-indent: 0px;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, serif; white-space: pre-wrap; line-height: 12pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;;white-space:pre-wrap;"> </div></div> <table cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;;margin-right : auto;;margin-left : 0;margin-right : auto;"><tr><td style="width: 87%; padding: 0px 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255); vertical-align: bottom;"><div style="margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">2022</div></div></td><td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255); vertical-align: bottom;"><div style="margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255); text-align: left; vertical-align: bottom;"><div style="text-align: left; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap; text-indent: 0in;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">$</div></div></td><td style="width: 10%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); text-align: right; vertical-align: bottom;"><div style="text-align: right; margin: 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">73</div></div></td><td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); text-align: left; vertical-align: bottom;"><div style="text-align: left; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap; text-indent: 0in;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div></td></tr><tr><td style="width: 87%; padding: 0px 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgba(255, 255, 255, 0); vertical-align: bottom;"><div style="margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">2023</div></div></td><td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgba(255, 255, 255, 0); vertical-align: bottom;"><div style="margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgba(255, 255, 255, 0); text-align: left; vertical-align: bottom;"><div style="margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; text-indent: 0in; text-align: left; white-space: nowrap;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="width: 10%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); text-align: right; vertical-align: bottom;"><div style="text-align: right; margin: 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">293</div></div></td><td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); text-align: left; vertical-align: bottom;"><div style="text-align: left; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap; text-indent: 0in;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div></td></tr><tr><td style="width: 87%; padding: 0px 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255); vertical-align: bottom;"><div style="margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">2024</div></div></td><td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255); vertical-align: bottom;"><div style="margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255); text-align: left; vertical-align: bottom;"><div style="margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; text-indent: 0in; text-align: left; white-space: nowrap;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="width: 10%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); text-align: right; vertical-align: bottom;"><div style="text-align: right; margin: 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">301</div></div></td><td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); text-align: left; vertical-align: bottom;"><div style="text-align: left; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap; text-indent: 0in;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div></td></tr><tr><td style="width: 87%; padding: 0px 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgba(255, 255, 255, 0); vertical-align: bottom;"><div style="margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">2025</div></div></td><td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgba(255, 255, 255, 0); vertical-align: bottom;"><div style="margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgba(255, 255, 255, 0); text-align: left; vertical-align: bottom;"><div style="margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; text-indent: 0in; text-align: left; white-space: nowrap;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="width: 10%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); text-align: right; vertical-align: bottom;"><div style="text-align: right; margin: 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">310</div></div></td><td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); text-align: left; vertical-align: bottom;"><div style="text-align: left; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap; text-indent: 0in;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div></td></tr><tr><td style="width: 87%; padding: 0px 0in 0.5pt; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255); vertical-align: bottom;"><div style="margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">2026</div></div></td><td style="width: 1%; padding: 0in 0in 0.5pt; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255); vertical-align: bottom;"><div style="margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255); border-bottom: 1pt solid black; border-top: none; text-align: left; vertical-align: bottom;"><div style="margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; text-indent: 0in; text-align: left; white-space: nowrap;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="border-top: none; border-image: initial; border-bottom: 1pt solid black; width: 10%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); text-align: right; vertical-align: bottom;"><div style="text-align: right; margin: 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">144</div></div></td><td style="width: 1%; padding: 0in 0in 0.5pt; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); text-align: left; vertical-align: bottom;"><div style="text-align: left; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap; text-indent: 0in;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div></td></tr><tr><td style="width: 87%; padding: 0px 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgba(255, 255, 255, 0); vertical-align: bottom;"><div style="margin: 0px 0px 0px 0.2in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Total lease payments</div></div></td><td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgba(255, 255, 255, 0); vertical-align: bottom;"><div style="margin: 0px 0px 0px 0.2in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgba(255, 255, 255, 0); text-align: left; vertical-align: bottom;"><div style="margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; text-indent: 0in; text-align: left; white-space: nowrap;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="width: 10%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); text-align: right; vertical-align: bottom;"><div style="text-align: right; margin: 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">1,121</div></div></td><td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); text-align: left; vertical-align: bottom;"><div style="text-align: left; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap; text-indent: 0in;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div></td></tr><tr><td style="width: 87%; padding: 0px 0in 0.5pt; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255); vertical-align: bottom;"><div style="margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Less: imputed interest</div></div></td><td style="width: 1%; padding: 0in 0in 0.5pt; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255); vertical-align: bottom;"><div style="margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255); border-bottom: 1pt solid black; border-top: none; text-align: left; vertical-align: bottom;"><div style="margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; text-indent: 0in; text-align: left; white-space: nowrap;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="border-top: none; border-image: initial; border-bottom: 1pt solid black; width: 10%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); text-align: right; vertical-align: bottom;"><div style="text-align: right; margin: 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">(156</div></div></td><td style="width: 1%; padding: 0in 0in 0.5pt; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); text-align: left; vertical-align: bottom;"><div style="text-align: left; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap; text-indent: 0in;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">)</div></div></td></tr><tr><td style="width: 87%; padding: 0px 0in 1.25pt; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgba(255, 255, 255, 0); vertical-align: bottom;"><div style="margin: 0px 0px 0px 0.2in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Present value of operating lease liabilities</div></div></td><td style="width: 1%; padding: 0in 0in 1.25pt; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgba(255, 255, 255, 0); vertical-align: bottom;"><div style="margin: 0px 0px 0px 0.2in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgba(255, 255, 255, 0); border-bottom: 2.5pt double windowtext; border-top: 0in none; text-align: left; vertical-align: bottom;"><div style="text-align: left; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap; text-indent: 0in;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">$</div></div></td><td style="border-bottom: 2.5pt double windowtext; width: 10%; border-top: 0in none; border-image: initial; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); text-align: right; vertical-align: bottom;"><div style="text-align: right; margin: 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">965</div></div></td><td style="width: 1%; padding: 0in 0in 1.25pt; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); text-align: left; vertical-align: bottom;"><div style="text-align: left; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap; text-indent: 0in;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div></td></tr></table> <div style="clear: both; max-height: 0px;"/> <div style="clear: both; max-height: 0px; text-indent: 0px;"/> <div style="margin: 0px 0px 0px 0in; text-align: justify; font-family: "Times New Roman", Times, serif; font-size: 10pt; line-height: 12pt; background: none;;text-indent: 0px;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, serif; white-space: pre-wrap; line-height: 12pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;;white-space:pre-wrap;"> </div></div> <div style="margin: 0px 0px 0px 0in; text-align: justify; font-family: "Times New Roman", Times, serif; font-size: 10pt; line-height: 12pt; background: none;;text-indent: 0px;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, serif; line-height: 12pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Other information:</div></div> <div style="margin: 0px 0px 0px 0in; text-align: justify; font-family: "Times New Roman", Times, serif; font-size: 10pt; line-height: 12pt; background: none;;text-indent: 0px;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, serif; white-space: pre-wrap; line-height: 12pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;;white-space:pre-wrap;"> </div></div> <table cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"><tr><td style="width: 87%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; line-height: 12pt; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; line-height: 12pt;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, serif; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Cash paid for operating leases for the nine months ended September 30, 2022</div></div></td><td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; line-height: 12pt; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; line-height: 12pt;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, serif; white-space: pre-wrap; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;;white-space:pre-wrap;"> </div></div></td><td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; line-height: 12pt; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; line-height: 12pt;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, serif; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="width: 10%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; line-height: 12pt; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="text-align: right; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; line-height: 12pt;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, serif; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">212</div></div></td><td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; line-height: 12pt; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; line-height: 12pt;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, serif; white-space: pre-wrap; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;;white-space:pre-wrap;"> </div></div></td></tr><tr><td style="width: 87%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; line-height: 12pt; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"><div style="margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; line-height: 12pt;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, serif; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Cash paid for operating leases for the nine months ended September 30, 2021</div></div></td><td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; line-height: 12pt; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"><div style="margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; line-height: 12pt;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, serif; white-space: pre-wrap; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;;white-space:pre-wrap;"> </div></div></td><td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; line-height: 12pt; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"><div style="margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; line-height: 12pt;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, serif; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="width: 10%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; line-height: 12pt; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"><div style="text-align: right; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; line-height: 12pt;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, serif; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">58</div></div></td><td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; line-height: 12pt; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"><div style="margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; line-height: 12pt;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, serif; white-space: pre-wrap; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;;white-space:pre-wrap;"> </div></div></td></tr><tr><td style="width: 87%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; line-height: 12pt; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; line-height: 12pt;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, serif; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Remaining lease term - operating leases (in years)</div></div></td><td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; line-height: 12pt; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; line-height: 12pt;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, serif; white-space: pre-wrap; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;;white-space:pre-wrap;"> </div></div></td><td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; line-height: 12pt; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; line-height: 12pt;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, serif; white-space: pre-wrap; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;;white-space:pre-wrap;"> </div></div></td><td style="width: 10%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; line-height: 12pt; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="text-align: right; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; line-height: 12pt;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, serif; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">3.75</div></div></td><td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; line-height: 12pt; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; line-height: 12pt;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, serif; white-space: pre-wrap; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;;white-space:pre-wrap;"> </div></div></td></tr><tr><td style="width: 87%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; line-height: 12pt; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"><div style="margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; line-height: 12pt;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, serif; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Average discount rate - operating leases</div></div></td><td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; line-height: 12pt; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"><div style="margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; line-height: 12pt;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, serif; white-space: pre-wrap; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;;white-space:pre-wrap;"> </div></div></td><td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; line-height: 12pt; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"><div style="margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; line-height: 12pt;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, serif; white-space: pre-wrap; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;;white-space:pre-wrap;"> </div></div></td><td style="width: 10%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; line-height: 12pt; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"><div style="text-align: right; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; line-height: 12pt;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, serif; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">8.0</div></div></td><td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; line-height: 12pt; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"><div style="margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; line-height: 12pt;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, serif; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">%</div></div></td></tr></table>

2026-06

73000

219000

85000

927000

1084000

241000

202000

724000

911000

965000

1113000

73000

293000

301000

310000

144000

1121000

156000

965000

212000

58000

P3Y9M

0.08

<div style="margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; line-height: 12pt; background: none;;text-indent: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, serif; line-height: 12pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">8. Stockholders’ Equity</div></div></div> <div style="margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; line-height: 12pt; background: none;;text-indent: 0px;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, serif; white-space: pre-wrap; line-height: 12pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;;white-space:pre-wrap;"> </div></div> <div style="margin: 0px 0px 0px 0in; text-align: justify; font-family: "Times New Roman", Times, serif; font-size: 10pt; line-height: 12pt; background: none;;text-indent: 0px;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, serif; line-height: 12pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The Amended and Restated Certificate of Incorporation dated February 18, 2014 authorized the issuance of 3,937,550 shares of common stock and 2,099,525 shares of preferred stock, with a par value of $0.001 per share. <div style="display:inline;">In</div> April 2021 the Company increased the number of authorized shares to 7,000,000 shares of common stock and 2,460,802 shares of preferred stock, and increased the number of authorized shares of Series A Convertible Preferred Stock (“Series A Preferred Stock”) to 1,798,905. <div style="display:inline;">In</div> October 2021 the Company increased the number of authorized shares to 10,487,904 shares of common stock and 3,297,061 shares of preferred stock. <div style="display:inline;">In</div> February 2022, the Company increased the number of authorized shares to 130,000,000 shares of common stock and 20,000,000 shares of preferred stock.</div></div> <div style="margin: 0px 0px 0px 0in; text-align: justify; font-family: "Times New Roman", Times, serif; font-size: 10pt; line-height: 12pt; background: none;;text-indent: 0px;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, serif; white-space: pre-wrap; line-height: 12pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;;white-space:pre-wrap;"> </div></div> <div style="margin: 0px 0in; text-align: justify; break-after: avoid; font-family: "Times New Roman", serif; font-size: 10pt;;text-indent: 0px;"><div style="font-style:italic;display:inline;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, serif; line-height: 12pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Reverse Stock Split</div></div></div> <div style="margin: 0px 0in; text-align: justify; break-after: avoid; font-family: "Times New Roman", serif; font-size: 10pt;;text-indent: 0px;"> </div> <div style="margin: 0px 0px 0px 0in; text-align: justify; font-family: "Times New Roman", Times, serif; font-size: 10pt; line-height: 12pt; background: none;;text-indent: 0px;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, serif; line-height: 12pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">On April 6, 2022, the Company effected a 1:2 reverse stock split (the “Reverse Stock Split”) by filing an amendment to the Company’s Amended and Restated Certificate Incorporation, as amended, with the Delaware Secretary of State. The Reverse Stock Split combined every two shares of our common stock issued and outstanding immediately prior to effecting the Reverse Stock Split into one share of common stock. Similarly, shares of Series A and Series B Preferred Stock became convertible into common stock at a conversion rate of one-to-0.5, subject to adjustments for stock dividends, splits, combinations, and similar events. No fractional shares were issued in connection with the Reverse Stock Split. All historical and per share amounts reflected throughout this document have been adjusted to reflect the Reverse Stock Split. The authorized number of shares and the par value per share of the Company’s common stock were not affected by the Reverse Stock Split.</div></div><div style="margin: 0px 0px 0px 0in; text-align: justify; font-family: "Times New Roman", Times, serif; font-size: 10pt; line-height: 12pt; background: none;;text-indent: 0px;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, serif; white-space: pre-wrap; line-height: 12pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;;white-space:pre-wrap;"> </div></div><div style="margin: 0px 0in; text-align: justify; break-after: avoid; font-family: "Times New Roman", serif; font-size: 10pt;;text-indent: 0px;"><div style="font-style:italic;display:inline;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, serif; line-height: 12pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Initial Public Offering</div></div></div><div style="margin: 0px 0in; text-align: justify; break-after: avoid; font-family: "Times New Roman", serif; font-size: 10pt;;text-indent: 0px;"> </div><div style="margin: 0px 0in; text-align: justify; break-after: avoid; font-family: "Times New Roman", serif; font-size: 10pt;;text-indent: 0px;"/><div style="margin: 0px 0in; text-align: justify; break-after: avoid; font-family: "Times New Roman", serif; font-size: 10pt;;text-indent: 0px;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, serif; line-height: 12pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">On April 26, 2022, the Company’s Registration Statement relating to the IPO was declared effective by the SEC. The IPO consisted of 3,200,000 shares of common stock, par value $0.001 per share at a public offering price of $5.00 per share. Pursuant to the Underwriting Agreement dated April 26, 2022, between the Company, The Benchmark Company, LLC (“Benchmark”) and Valuable Capital Limited (together with Benchmark, the “Underwriters”), the Company granted the Underwriters warrants to purchase a total of 96,000 shares of the Company’s common stock at an exercise price of $5.00 per share. The warrants expire on the fifth anniversary of the commencement of sales under the IPO. On April 27, 2022, the shares of the Company’s common stock began trading on the Nasdaq Capital Market LLC under the symbol “TNON.”</div></div><div style="margin: 0px 0in; text-align: justify; break-after: avoid; font-family: "Times New Roman", serif; font-size: 10pt;;text-indent: 0px;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, serif; white-space: pre-wrap; line-height: 12pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;;white-space:pre-wrap;"> </div></div><div style="margin: 0px 0px 0px 0in; text-align: justify; font-family: "Times New Roman", Times, serif; font-size: 10pt; line-height: 12pt; background: none;;text-indent: 0px;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, serif; line-height: 12pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">On April 29, 2022, the IPO closed, and the Company received approximately $13.8 million in net proceeds from the IPO after deducting the underwriting discount and commission and other estimated IPO expenses payable by the Company. As a result of the completion of the IPO and as required under the terms of the convertible notes payable described in Note 6, the Company converted the entirety of the related outstanding principal and accrued interest to 3,955,415 shares of the Company’s common stock at the conversion price detailed in Note 6 and issued the common stock to the noteholders, fully satisfying the Company’s obligations.</div></div><div style="margin: 0px 0px 0px 0in; text-align: justify; font-family: "Times New Roman", Times, serif; font-size: 10pt; line-height: 12pt; background: none;;text-indent: 0px;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, serif; white-space: pre-wrap; line-height: 12pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;;white-space:pre-wrap;"> </div></div><div style="margin: 0px 0px 0px 0in; text-align: justify; font-family: "Times New Roman", Times, serif; font-size: 10pt; line-height: 12pt; background: none;;text-indent: 0px;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, serif; line-height: 12pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">On April 29, 2022, as result of the completion of the IPO, the Company converted all shares of Series A and Series B Preferred Stock to 2,693,342 shares of the Company’s common stock at the conversion rate detailed below and issued the common stock to the preferred stockholders, fully satisfying the Company’s obligations. This includes 1,172,346 shares issued to TTAG’s minority shareholder in accordance with the anti-dilution protection provisions of the Exchange Agreement.</div></div><div style="margin: 0px 0px 0px 0in; text-align: justify; font-family: "Times New Roman", Times, serif; font-size: 10pt; line-height: 12pt; background: none;;text-indent: 0px;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, serif; white-space: pre-wrap; line-height: 12pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;;white-space:pre-wrap;"> </div></div><div style="margin: 0px 0px 0px 0in; text-align: justify; font-family: "Times New Roman", Times, serif; font-size: 10pt; line-height: 12pt; background: none;;text-indent: 0px;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, serif; line-height: 12pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Concurrent with the completion of the IPO and in accordance with the Amended and Restated Exclusive Sales Representative Agreement executed in May 2021, the counterparty to the agreement received anti-dilution protections to maintain ownership of 3.0% of the fully diluted equity of the Company through the date of an initial public offering and was issued 312,351 shares of the Company’s common stock to the Representative, fully satisfying the Company’s obligations. Also, as a result of the completion of the IPO, the Company issued 85,739 shares of its common stock to a consultant. The value of these shares issued at the IPO price of $5.00 per share was charged to operating expenses in the Company’s financial statements.</div></div><div style="margin: 0px 0px 0px 0in; text-align: justify; font-family: "Times New Roman", Times, serif; font-size: 10pt; line-height: 12pt; background: none;;text-indent: 0px;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, serif; white-space: pre-wrap; line-height: 12pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;;white-space:pre-wrap;"> </div></div><div style="margin: 0px 0in; text-align: justify; break-after: avoid; font-family: "Times New Roman", serif; font-size: 10pt;;text-indent: 0px;"><div style="font-style:italic;display:inline;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, serif; line-height: 12pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Preferred Stock</div></div></div><div style="margin: 0px 0in; text-align: justify; break-after: avoid; font-family: "Times New Roman", serif; font-size: 10pt;;text-indent: 0px;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, serif; white-space: pre-wrap; line-height: 12pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;;white-space:pre-wrap;"> </div></div><div style="margin: 0px 0px 0px 0in; text-align: justify; font-family: "Times New Roman", Times, serif; font-size: 10pt; line-height: 12pt; background: none;;text-indent: 0px;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, serif; line-height: 12pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">On October 28, 2021, the Company entered into an Agreement (the “Exchange Agreement”) with TTAG’s minority shareholder. Pursuant to the Exchange Agreement, TTAG’s minority shareholder agreed to exchange 574,033 shares of Series A Convertible Preferred Stock issued by TTAG, representing its entire ownership interest in TTAG, for the Company’s Series A Preferred Stock, representing a 24% ownership interest in the Company’s fully-diluted capital, which includes the pro forma conversion of all outstanding convertible preferred stock and promissory notes, options, and warrants. Pursuant to the terms of the Exchange Agreement, the Company issued TTAG’s minority shareholder 2,550,763 shares of Series A Preferred Stock. These shares were subject to anti-dilution protection to maintain TTAG’s minority shareholder’s 24% ownership interest in the Company, excluding any shares issued by the Company in an IPO or a qualified offering of at least $5,000 at a per share price of at least $3.3737. Upon conversion of the Company’s convertible notes payable as described in Note 6, the Company issued 1,172,346 shares of its common stock to TTAG’s minority shareholder.</div></div><div style="margin: 0px 0px 0px 0in; text-align: justify; font-family: "Times New Roman", Times, serif; font-size: 10pt; line-height: 12pt; background: none;;text-indent: 0px;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, serif; white-space: pre-wrap; line-height: 12pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;;white-space:pre-wrap;"> </div></div><div style="margin: 0px 0px 0px 0in; text-align: justify; font-family: "Times New Roman", Times, serif; font-size: 10pt; line-height: 12pt; background: none;;text-indent: 0px;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, serif; line-height: 12pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">In accordance with ASC 810-10-45-23, the Company did not recognize any gain or loss in the consolidated statements of operations and comprehensive loss in conjunction with the Exchange Agreement. The carrying value of the non-controlling interest in TTAG was reduced to zero, and the value of the Company’s investment in TTAG increased accordingly. The shares of Series A Preferred Stock issued were recorded at fair value. The difference between the increase in the Company’s investment and the fair value of the Series A Preferred Stock issued was recorded as a decrease in Additional Paid in Capital (“APIC”). The resulting negative APIC was then reclassified to accumulated deficit.</div></div><div style="margin: 0px 0px 0px 0in; text-align: justify; font-family: "Times New Roman", Times, serif; font-size: 10pt; line-height: 12pt; background: none;;text-indent: 0px;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, serif; white-space: pre-wrap; line-height: 12pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;;white-space:pre-wrap;"> </div></div><div style="margin: 0px 0px 0px 0in; text-align: justify; font-family: "Times New Roman", Times, serif; font-size: 10pt; line-height: 12pt; background: none;;text-indent: 0px;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, serif; line-height: 12pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">In a series of closings from 2012 through 2015, the Company issued an aggregate of 491,222 shares of Series B Convertible Preferred Stock (“Series B Preferred Stock”) at $2.795 per share for proceeds of $1,272, net of stock issuance costs.</div></div><div style="margin: 0px 0px 0px 0in; text-align: justify; font-family: "Times New Roman", Times, serif; font-size: 10pt; line-height: 12pt; background: none;;text-indent: 0px;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, serif; white-space: pre-wrap; line-height: 12pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;;white-space:pre-wrap;"> </div></div><div style="margin: 0px 0px 0px 0in; text-align: justify; font-family: "Times New Roman", Times, serif; font-size: 10pt; line-height: 12pt; background: none;;text-indent: 0px;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, serif; line-height: 12pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The Company classified the convertible preferred stock outside of total stockholders’ deficit because, in the event of certain deemed liquidation events that are not solely within the control of the Company, the shares would become redeemable at the option of the holders. The Company did not adjust the carrying values of the convertible preferred stock to the deemed liquidation values of such shares since a liquidation event was not probable of occurring.</div></div><div style="margin: 0px 0px 0px 0in; text-align: justify; font-family: "Times New Roman", Times, serif; font-size: 10pt; line-height: 12pt; background: none;;text-indent: 0px;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, serif; white-space: pre-wrap; line-height: 12pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;;white-space:pre-wrap;"> </div></div><div style="margin: 0px 0in; break-after: avoid; font-family: "Times New Roman", serif; font-size: 10pt;;text-indent: 0px;"><div style="font-style:italic;display:inline;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, serif; line-height: 12pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Conversion</div></div></div><div style="margin: 0px 0in; break-after: avoid; font-family: "Times New Roman", serif; font-size: 10pt;;text-indent: 0px;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, serif; white-space: pre-wrap; line-height: 12pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;;white-space:pre-wrap;"> </div></div><div style="margin: 0px 0px 0px 0in; text-align: justify; font-family: "Times New Roman", Times, serif; font-size: 10pt; line-height: 12pt; background: none;;text-indent: 0px;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, serif; line-height: 12pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">At the option of the holder, shares of Series A and Series B Preferred Stock were convertible into common stock at a conversion rate of one-to-0.5, subject to adjustments for stock dividends, splits, combinations, and similar events. Automatic conversion will occur in the event of a firmly underwritten public offering of common stock of the Company at a price of at least $4.00 per share, subject to appropriate adjustments for stock dividends, splits, combinations, and similar events, and with total gross proceeds to the Company of at least $15,000, before deduction of underwriters’ commissions and expenses. As noted above, the Series A and Series B Preferred Stock were converted to common stock at the time of the Company’s IPO.</div></div><div style="margin: 0px 0px 0px 0in; text-align: justify; font-family: "Times New Roman", Times, serif; font-size: 10pt; line-height: 12pt; background: none;;text-indent: 0px;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, serif; white-space: pre-wrap; line-height: 12pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;;white-space:pre-wrap;"> </div></div><div style="margin: 0px 0in; text-align: justify; break-after: avoid; font-family: "Times New Roman", serif; font-size: 10pt;;text-indent: 0px;"><div style="font-style:italic;display:inline;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, serif; line-height: 12pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Redemption</div></div></div><div style="margin: 0px 0in; text-align: justify; break-after: avoid; font-family: "Times New Roman", serif; font-size: 10pt;;text-indent: 0px;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, serif; white-space: pre-wrap; line-height: 12pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;;white-space:pre-wrap;"> </div></div><div style="margin: 0px 0px 0px 0in; text-align: justify; font-family: "Times New Roman", Times, serif; font-size: 10pt; line-height: 12pt; background: none;;text-indent: 0px;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, serif; line-height: 12pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The shares of the Series A and Series B Preferred Stock were redeemable only upon acquisition or liquidation of the Company.</div></div><div style="margin: 0px 0px 0px 0in; text-align: justify; font-family: "Times New Roman", Times, serif; font-size: 10pt; line-height: 12pt; background: none;;text-indent: 0px;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, serif; white-space: pre-wrap; line-height: 12pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;;white-space:pre-wrap;"> </div></div><div style="margin: 0px 0in; text-align: justify; break-after: avoid; font-family: "Times New Roman", serif; font-size: 10pt;;text-indent: 0px;"><div style="font-style:italic;display:inline;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, serif; line-height: 12pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Liquidation preference</div></div></div><div style="margin: 0px 0in; text-align: justify; break-after: avoid; font-family: "Times New Roman", serif; font-size: 10pt;;text-indent: 0px;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, serif; white-space: pre-wrap; line-height: 12pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;;white-space:pre-wrap;"> </div></div><div style="margin: 0px 0px 0px 0in; text-align: justify; font-family: "Times New Roman", Times, serif; font-size: 10pt; line-height: 12pt; background: none;;text-indent: 0px;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, serif; line-height: 12pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">With respect to any distributions in connection with a liquidation, dissolution or winding up of the Company, or in connection with the sale of voting control of all or substantially all of the assets of the Company, by way of merger, acquisition, consolidation or similar transaction, prior to any distribution to common stockholders, the holders of Series A and Series B Preferred Stock were entitled to receive $1.526 and $4.981 per share, respectively, plus any declared but unpaid dividends, adjusted to reflect any dividends previously paid. If, upon the occurrence of such event, the assets and funds distributed among the holders of Series A and Series B Preferred Stock shall be insufficient to permit the payment to such holders of the full liquidation preference amounts, the entire assets and funds of the Company legally available shall be distributed ratably among the preferred stockholders in proportion to the preferential amount to which each holder is entitled.</div></div><div style="margin: 0px 0px 0px 0in; text-align: justify; font-family: "Times New Roman", Times, serif; font-size: 10pt; line-height: 12pt; background: none;;text-indent: 0px;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, serif; white-space: pre-wrap; line-height: 12pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;;white-space:pre-wrap;"> </div></div><div style="margin: 0px 0px 0px 0in; text-align: justify; font-family: "Times New Roman", Times, serif; font-size: 10pt; line-height: 12pt; background: none;;text-indent: 0px;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, serif; line-height: 12pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">After payment of the liquidation preferences, the holders of common stock are entitled to receive the remaining assets of the Company available for distribution to its stockholders pro rata based on the number of shares of common stock held by each holder.</div></div><div style="margin: 0px 0px 0px 0in; text-align: justify; font-family: "Times New Roman", Times, serif; font-size: 10pt; line-height: 12pt; background: none;;text-indent: 0px;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, serif; white-space: pre-wrap; line-height: 12pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;;white-space:pre-wrap;"> </div></div><div style="margin: 0px 0in; text-align: justify; break-after: avoid; font-family: "Times New Roman", serif; font-size: 10pt;;text-indent: 0px;"><div style="font-style:italic;display:inline;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, serif; line-height: 12pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Voting rights</div></div></div><div style="margin: 0px 0in; text-align: justify; break-after: avoid; font-family: "Times New Roman", serif; font-size: 10pt;;text-indent: 0px;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, serif; white-space: pre-wrap; line-height: 12pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;;white-space:pre-wrap;"> </div></div><div style="margin: 0px 0px 0px 0in; text-align: justify; font-family: "Times New Roman", Times, serif; font-size: 10pt; line-height: 12pt; background: none;;text-indent: 0px;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, serif; line-height: 12pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The holders of vested shares of common stock shall be entitled to vote on any matter submitted to a vote of the stockholders and each such holder shall be entitled to one vote per share of common stock held. The holders of Series A and Series B Preferred Stock were entitled to vote together with the common stock as a single class on any matter submitted to a vote of the stockholders. Holders of Series A and Series B Preferred Stock were entitled to the number of votes equal to the number of common stock issuable upon conversion of their respective Series A and Series B Preferred Stock at the time such shares are voted. The holders of a majority of the preferred stock had additional voting rights as specified in the Company’s Amended and Restated Certificate of Incorporation, as amended.</div></div><div style="margin: 0px 0px 0px 0in; text-align: justify; font-family: "Times New Roman", Times, serif; font-size: 10pt; line-height: 12pt; background: none;;text-indent: 0px;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, serif; white-space: pre-wrap; line-height: 12pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;;white-space:pre-wrap;"> </div></div><div style="margin: 0px 0in; text-align: justify; break-after: avoid; font-family: "Times New Roman", serif; font-size: 10pt;;text-indent: 0px;"><div style="font-style:italic;display:inline;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, serif; line-height: 12pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Equity awards</div></div></div><div style="margin: 0px 0in; text-align: justify; break-after: avoid; font-family: "Times New Roman", serif; font-size: 10pt;;text-indent: 0px;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, serif; white-space: pre-wrap; line-height: 12pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;;white-space:pre-wrap;"> </div></div><div style="margin: 0px 0px 0px 0in; text-align: justify; font-family: "Times New Roman", Times, serif; font-size: 10pt; line-height: 12pt; background: none;;text-indent: 0px;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, serif; line-height: 12pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">In 2012, the Board of Directors of the Company (the “Board”) approved the Tenon Medical, Inc. 2012 Equity Incentive Plan (the “2012 Plan”). The 2012 Plan provides for the issuance of common stock options, appreciation rights, and other awards to employees, directors, and consultants. Options issued under the 2012 Plan generally vest over a period of <span style="-sec-ix-hidden:hidden59107509">two</span> to four years and have a 10-year expiration date. In April 2021, the Board increased the number of shares of common stock reserved for issuance under the 2012 Plan to 662,516. In July 2021, the Board increased the number of shares of common stock reserved for issuance under the 2012 Plan to 737,516. In August 2021, the Board increased the number of shares of common stock reserved for issuance under the 2012 Plan from 737,516 shares to 799,266 shares and approved the form of a 2022 Equity Incentive Plan.</div></div><div style="margin: 0px 0px 0px 0in; text-align: justify; font-family: "Times New Roman", Times, serif; font-size: 10pt; line-height: 12pt; background: none;;text-indent: 0px;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, serif; white-space: pre-wrap; line-height: 12pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;;white-space:pre-wrap;"> </div></div><div style="margin: 0px 0px 0px 0in; text-align: justify; font-family: "Times New Roman", Times, serif; font-size: 10pt; line-height: 12pt; background: none;;text-indent: 0px;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, serif; line-height: 12pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">On January 10, 2022 and February 2, 2022, the Board and stockholders, respectively, of the Company approved the Tenon Medical, Inc. 2022 Equity Incentive Plan (the “2022 Plan”), which was effective on April 25, 2022. The number of shares of common stock that may be subject to awards and sold under the 2022 Plan is equal to 1,600,000. Automatic annual increases in number of shares available for issuance under the 2022 Plan is equal to the least of (a) 1,100,000 shares, (b) 4% of the total number of shares of all classes of common stock outstanding on the last day of the immediately preceding fiscal year, or (c) such number determined by the 2022 Plan administrator no later than the last day of the immediately preceding fiscal year. Annual increases will continue until the tenth anniversary of the earlier of the Board or stockholder approval of the 2022 Plan, which is January 10, 2032. Upon the effective date of the 2022 Plan, the Board terminated the 2012 Plan such that no new equity awards will be issued by the 2012 Plan.</div></div><div style="margin: 0px 0px 0px 0in; text-align: justify; font-family: "Times New Roman", Times, serif; font-size: 10pt; line-height: 12pt; background: none;;text-indent: 0px;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, serif; white-space: pre-wrap; line-height: 12pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;;white-space:pre-wrap;"> </div></div><div style="margin: 0px 0px 0px 0in; text-align: justify; font-family: "Times New Roman", Times, serif; font-size: 10pt; line-height: 12pt; background: none;;text-indent: 0px;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, serif; line-height: 12pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The Company adopted the fair value recognition provisions in accordance with authoritative guidance related to equity-based payments. Compensation expense in 2022 and 2021 includes the portion of awards vested in the periods for all equity-based awards granted, based on the grant date fair value estimated using a Black-Scholes option valuation model, consistent with authoritative guidance.</div></div><div style="margin: 0px 0px 0px 0in; text-align: justify; font-family: "Times New Roman", Times, serif; font-size: 10pt; line-height: 12pt; background: none;;text-indent: 0px;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, serif; white-space: pre-wrap; line-height: 12pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;;white-space:pre-wrap;"> </div></div> <div style="margin: 0px 0in; text-align: justify; break-after: avoid; font-family: "Times New Roman", serif; font-size: 10pt;;text-indent: 0px;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, serif; line-height: 12pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">A summary of the Company’s share option and restricted stock unit activity under its plans is as follows:</div></div> <div style="margin: 0px 0in; text-align: justify; break-after: avoid; font-family: "Times New Roman", serif; font-size: 10pt;;text-indent: 0px;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, serif; white-space: pre-wrap; line-height: 12pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;;white-space:pre-wrap;"> </div></div> <table cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;;margin-right : auto;;margin-left : 0;margin-right : auto;"><tr><td style="width: 48%; padding: 0px 0in 0.5pt; font-family: "Times New Roman", Times, serif; font-size: 10pt; vertical-align: bottom;"><div style="margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; text-align: center;"><div style="font-size: 10pt;;font-weight:bold;display:inline;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div></td><td style="padding: 0in 0in 0.5pt; font-family: "Times New Roman", Times, serif; font-size: 10pt; vertical-align: bottom;"><div style="margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; text-align: center;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;width:100%;"> </div></div></div></td><td colspan="2" style="border-top: none; border-image: initial; border-bottom: 1pt solid black; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; vertical-align: bottom; width: 11%;"><div style="text-align: center; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap;"><div style="white-space: nowrap; font-size: 10pt;;font-weight:bold;display:inline;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">Number of<br/> Shares Subject<br/> to Outstanding<br/> Stock Options</div></div></div></td><td style="padding: 0in 0in 0.5pt; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; vertical-align: bottom;"><div style="text-align: center; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"><div style="font-weight:bold;display:inline;width:100%;"> </div></div></div></td><td style="padding: 0in 0in 0.5pt; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; vertical-align: bottom;"><div style="text-align: center; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"><div style="font-weight:bold;display:inline;width:100%;"> </div></div></div></td><td colspan="2" style="border-top: none; border-image: initial; border-bottom: 1pt solid black; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; vertical-align: bottom; width: 11%;"><div style="text-align: center; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap;"><div style="white-space: nowrap; font-size: 10pt;;font-weight:bold;display:inline;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">Weighted <br/> Average <br/> Exercise <br/> Price Per <br/> Share</div></div></div></td><td style="padding: 0in 0in 0.5pt; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; vertical-align: bottom;"><div style="text-align: center; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"><div style="font-weight:bold;display:inline;width:100%;"> </div></div></div></td><td style="padding: 0in 0in 0.5pt; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; vertical-align: bottom;"><div style="text-align: center; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"><div style="font-weight:bold;display:inline;width:100%;"> </div></div></div></td><td colspan="2" style="border-top: none; border-image: initial; border-bottom: 1pt solid windowtext; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; vertical-align: bottom; width: 11%;"><div style="text-align: center; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap;"><div style="white-space: nowrap; font-size: 10pt;;font-weight:bold;display:inline;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">Number of<br/> Outstanding<br/> Restricted Stock<br/> Units</div></div></div></td><td style="padding: 0in 0in 0.5pt; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; vertical-align: bottom;"><div style="text-align: center; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"><div style="font-weight:bold;display:inline;width:100%;"> </div></div></div></td><td style="padding: 0in 0in 0.5pt; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; vertical-align: bottom;"><div style="text-align: center; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"><div style="font-weight:bold;display:inline;width:100%;"> </div></div></div></td><td colspan="2" style="border-top: none; border-image: initial; border-bottom: 1pt solid windowtext; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; vertical-align: bottom; width: 11%;"><div style="text-align: center; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap;"><div style="white-space: nowrap; font-size: 10pt;;font-weight:bold;display:inline;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">Weighted-average Grant<br/> Date Fair<br/> Value per<br/> Share</div></div></div></td><td style="padding: 0in 0in 0.5pt; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; vertical-align: bottom;"><div style="text-align: center; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"><div style="font-weight:bold;display:inline;width:100%;"> </div></div></div></td></tr><tr><td style="width: 48%; padding: 0px 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255); vertical-align: bottom;"><div style="margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Outstanding at December 31, 2021</div></div></td><td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255); vertical-align: bottom;"><div style="margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255); text-align: left; vertical-align: bottom;"><div style="margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; text-indent: 0in; text-align: left; white-space: nowrap;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="width: 10%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); text-align: right; vertical-align: bottom;"><div style="text-align: right; margin: 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">727,394</div></div></td><td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); text-align: left; vertical-align: bottom;"><div style="text-align: left; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap; text-indent: 0in;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div></td><td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom;"><div style="text-align: right; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div></td><td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); text-align: left; vertical-align: bottom;"><div style="text-align: left; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap; text-indent: 0in;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">$</div></div></td><td style="width: 10%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); text-align: right; vertical-align: bottom;"><div style="text-align: right; margin: 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">5.32</div></div></td><td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); text-align: left; vertical-align: bottom;"><div style="text-align: left; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap; text-indent: 0in;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div></td><td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom;"><div style="text-align: right; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div></td><td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); border-bottom: none; border-top: 0px none; text-align: left; vertical-align: bottom;"><div style="text-align: left; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap; text-indent: 0in;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div></td><td style="border-top: 0px none; border-bottom: none; border-image: initial; width: 10%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom;"><div style="text-align: right; margin: 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">—</div></div></td><td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); text-align: left; vertical-align: bottom;"><div style="text-align: left; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap; text-indent: 0in;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div></td><td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom;"><div style="text-align: right; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div></td><td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); border-bottom: none; border-top: 0px solid windowtext; text-align: left; vertical-align: bottom;"><div style="text-align: left; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap; text-indent: 0in;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">$</div></div></td><td style="border-bottom: none; border-image: initial; width: 10%; border-top: 0px solid windowtext; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom;"><div style="text-align: right; margin: 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">—</div></div></td><td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); text-align: left; vertical-align: bottom;"><div style="text-align: left; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap; text-indent: 0in;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div></td></tr><tr><td style="width: 48%; padding: 0px 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgba(255, 255, 255, 0); vertical-align: bottom;"><div style="margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Granted</div></div></td><td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgba(255, 255, 255, 0); vertical-align: bottom;"><div style="margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgba(255, 255, 255, 0); text-align: left; vertical-align: bottom;"><div style="margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; text-indent: 0in; text-align: left; white-space: nowrap;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="width: 10%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); text-align: right; vertical-align: bottom;"><div style="text-align: right; margin: 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">113,950</div></div></td><td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); text-align: left; vertical-align: bottom;"><div style="text-align: left; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap; text-indent: 0in;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div></td><td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); vertical-align: bottom;"><div style="text-align: right; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div></td><td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); text-align: left; vertical-align: bottom;"><div style="text-align: left; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap; text-indent: 0in;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">$</div></div></td><td style="width: 10%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); text-align: right; vertical-align: bottom;"><div style="text-align: right; margin: 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">2.47</div></div></td><td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); text-align: left; vertical-align: bottom;"><div style="text-align: left; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap; text-indent: 0in;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div></td><td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); vertical-align: bottom;"><div style="text-align: right; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div></td><td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); text-align: left; vertical-align: bottom;"><div style="text-align: left; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap; text-indent: 0in;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div></td><td style="width: 10%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); text-align: right; vertical-align: bottom;"><div style="text-align: right; margin: 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">1,318,530</div></div></td><td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); text-align: left; vertical-align: bottom;"><div style="text-align: left; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap; text-indent: 0in;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div></td><td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); vertical-align: bottom;"><div style="text-align: right; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div></td><td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); text-align: left; vertical-align: bottom;"><div style="text-align: left; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap; text-indent: 0in;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">$</div></div></td><td style="width: 10%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); text-align: right; vertical-align: bottom;"><div style="text-align: right; margin: 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">7.93</div></div></td><td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); text-align: left; vertical-align: bottom;"><div style="text-align: left; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap; text-indent: 0in;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div></td></tr><tr><td style="width: 48%; padding: 0px 0in 0.5pt; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255); vertical-align: bottom;"><div style="margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Forfeited</div></div></td><td style="width: 1%; padding: 0in 0in 0.5pt; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255); vertical-align: bottom;"><div style="margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255); border-bottom: 1pt solid black; border-top: none; text-align: left; vertical-align: bottom;"><div style="margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; text-indent: 0in; text-align: left; white-space: nowrap;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="border-top: none; border-image: initial; border-bottom: 1pt solid black; width: 10%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom;"><div style="text-align: right; margin: 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">— </div></div></td><td style="width: 1%; padding: 0in 0in 0.5pt; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); text-align: left; vertical-align: bottom;"><div style="text-align: left; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap; text-indent: 0in;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div></td><td style="width: 1%; padding: 0in 0in 0.5pt; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom;"><div style="text-align: right; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div></td><td style="width: 1%; padding: 0in 0in 0.5pt; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); text-align: left; vertical-align: bottom;"><div style="text-align: left; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap; text-indent: 0in;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">$</div></div></td><td style="width: 10%; padding: 0in 0in 0.5pt; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom;"><div style="text-align: right; margin: 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">—</div></div></td><td style="width: 1%; padding: 0in 0in 0.5pt; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); text-align: left; vertical-align: bottom;"><div style="text-align: left; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap; text-indent: 0in;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div></td><td style="width: 1%; padding: 0in 0in 0.5pt; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom;"><div style="text-align: right; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div></td><td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); border-bottom: 1pt solid windowtext; border-top: none; text-align: left; vertical-align: bottom;"><div style="text-align: left; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap; text-indent: 0in;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div></td><td style="border-top: none; border-image: initial; border-bottom: 1pt solid windowtext; width: 10%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom;"><div style="text-align: right; margin: 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">—</div></div></td><td style="width: 1%; padding: 0in 0in 0.5pt; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); text-align: left; vertical-align: bottom;"><div style="text-align: left; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap; text-indent: 0in;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div></td><td style="width: 1%; padding: 0in 0in 0.5pt; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom;"><div style="text-align: right; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div></td><td style="width: 1%; padding: 0in 0in 0.5pt; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); text-align: left; vertical-align: bottom;"><div style="text-align: left; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap; text-indent: 0in;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">$</div></div></td><td style="width: 10%; padding: 0in 0in 0.5pt; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom;"><div style="text-align: right; margin: 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">—</div></div></td><td style="width: 1%; padding: 0in 0in 0.5pt; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); text-align: left; vertical-align: bottom;"><div style="text-align: left; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap; text-indent: 0in;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div></td></tr><tr><td style="width: 48%; padding: 0px 0in 1.25pt; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgba(255, 255, 255, 0); vertical-align: bottom;"><div style="margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Outstanding at September 30, 2022</div></div></td><td style="width: 1%; padding: 0in 0in 1.25pt; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgba(255, 255, 255, 0); vertical-align: bottom;"><div style="margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgba(255, 255, 255, 0); border-bottom: 1pt solid black; border-top: 0px none; text-align: left; vertical-align: bottom;"><div style="margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; text-indent: 0in; text-align: left; white-space: nowrap;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="border-top: 0px none; border-image: initial; border-bottom: 1pt solid black; width: 10%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); text-align: right; vertical-align: bottom;"><div style="text-align: right; margin: 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">841,344</div></div></td><td style="width: 1%; padding: 0in 0in 0.5pt; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); text-align: left; vertical-align: bottom;"><div style="text-align: left; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap; text-indent: 0in;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div></td><td style="width: 1%; padding: 0in 0in 1.25pt; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); vertical-align: bottom;"><div style="text-align: right; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div></td><td style="width: 1%; padding: 0in 0in 1.25pt; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); text-align: left; vertical-align: bottom;"><div style="text-align: left; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap; text-indent: 0in;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">$</div></div></td><td style="width: 10%; padding: 0in 0in 1.25pt; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); text-align: right; vertical-align: bottom;"><div style="text-align: right; margin: 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">4.93</div></div></td><td style="width: 1%; padding: 0in 0in 1.25pt; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); text-align: left; vertical-align: bottom;"><div style="text-align: left; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap; text-indent: 0in;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div></td><td style="width: 1%; padding: 0in 0in 1.25pt; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); vertical-align: bottom;"><div style="text-align: right; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div></td><td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); border-bottom: 2.5pt double windowtext; border-top: 0px none; text-align: left; vertical-align: bottom;"><div style="text-align: left; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap; text-indent: 0in;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div></td><td style="border-bottom: 2.5pt double windowtext; width: 10%; border-top: 0px none; border-image: initial; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); text-align: right; vertical-align: bottom;"><div style="text-align: right; margin: 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">1,318,530</div></div></td><td style="width: 1%; padding: 0in 0in 1.25pt; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); text-align: left; vertical-align: bottom;"><div style="text-align: left; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap; text-indent: 0in;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div></td><td style="width: 1%; padding: 0in 0in 1.25pt; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); vertical-align: bottom;"><div style="text-align: right; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div></td><td style="width: 1%; padding: 0in 0in 1.25pt; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); text-align: left; vertical-align: bottom;"><div style="text-align: left; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap; text-indent: 0in;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">$</div></div></td><td style="width: 10%; padding: 0in 0in 1.25pt; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); text-align: right; vertical-align: bottom;"><div style="text-align: right; margin: 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">7.93</div></div></td><td style="width: 1%; padding: 0in 0in 1.25pt; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); text-align: left; vertical-align: bottom;"><div style="text-align: left; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap; text-indent: 0in;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div></td></tr></table> <div style="margin: 0px 0in; text-align: justify; break-after: avoid; font-family: "Times New Roman", serif; font-size: 10pt;;text-indent: 0px;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, serif; white-space: pre-wrap; line-height: 12pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;;white-space:pre-wrap;"> </div></div> <div style="margin: 0px 0in; text-align: justify; break-after: avoid; font-family: "Times New Roman", serif; font-size: 10pt;;text-indent: 0px;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, serif; line-height: 12pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The following table sets forth stock-based compensation expense recognized for the three and nine months ended September 30, 2022 and 2021:</div></div> <div style="margin: 0px 0in; text-align: justify; break-after: avoid; font-family: "Times New Roman", serif; font-size: 10pt;;text-indent: 0px;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, serif; white-space: pre-wrap; line-height: 12pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;;white-space:pre-wrap;"> </div></div> <table cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;;margin-right : auto;;margin-left : 0;margin-right : auto;"><tr><td style="width: 48%; padding: 0px 0in 0.5pt; font-family: "Times New Roman", Times, serif; font-size: 10pt; vertical-align: bottom;"><div style="margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; text-align: center;"><div style="font-size: 10pt;;font-weight:bold;display:inline;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div></td><td style="padding: 0in 0in 0.5pt; font-family: "Times New Roman", Times, serif; font-size: 10pt; vertical-align: bottom;"><div style="margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; text-align: center;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;width:100%;"> </div></div></div></td><td colspan="6" style="border-top: none; border-image: initial; border-bottom: 1pt solid black; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; vertical-align: bottom; width: 11%;"><div style="text-align: center; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap;"><div style="white-space: nowrap; font-size: 10pt;;font-weight:bold;display:inline;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">Three months ended<br/> September 30,</div></div></div></td><td style="padding: 0in 0in 0.5pt; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; vertical-align: bottom;"><div style="text-align: center; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"><div style="font-weight:bold;display:inline;width:100%;"> </div></div></div></td><td style="padding: 0in 0in 0.5pt; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; vertical-align: bottom;"><div style="text-align: center; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"><div style="font-weight:bold;display:inline;width:100%;"> </div></div></div></td><td colspan="6" style="border-top: none; border-image: initial; border-bottom: 1pt solid windowtext; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; vertical-align: bottom; width: 11%;"><div style="text-align: center; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap;"><div style="white-space: nowrap; font-size: 10pt;;font-weight:bold;display:inline;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">Nine months ended<br/> September 30,</div></div></div></td><td style="padding: 0in 0in 0.5pt; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; vertical-align: bottom;"><div style="text-align: center; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"><div style="font-weight:bold;display:inline;width:100%;"> </div></div></div></td></tr><tr><td style="width: 48%; padding: 0px 0in 0.5pt; font-family: "Times New Roman", Times, serif; font-size: 0px; vertical-align: bottom;"> </td><td style="padding: 0in 0in 0.5pt; font-family: "Times New Roman", Times, serif; font-size: 0px; vertical-align: bottom;"> </td><td colspan="2" style="border-top: 0px none; border-image: initial; border-bottom: 1pt solid black; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; vertical-align: bottom; width: 11%;"><div style="text-align: center; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap;"><div style="white-space: nowrap; font-size: 10pt;;font-weight:bold;display:inline;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">2022</div></div></div></td><td style="padding: 0in 0in 0.5pt; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; vertical-align: bottom;"><div style="text-align: center; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"><div style="font-weight:bold;display:inline;width:100%;"> </div></div></div></td><td style="padding: 0in 0in 0.5pt; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; vertical-align: bottom;"><div style="text-align: center; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"><div style="font-weight:bold;display:inline;width:100%;"> </div></div></div></td><td colspan="2" style="border-top: 0px none; border-image: initial; border-bottom: 1pt solid black; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; vertical-align: bottom; width: 11%;"><div style="text-align: center; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap;"><div style="white-space: nowrap; font-size: 10pt;;font-weight:bold;display:inline;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">2021</div></div></div></td><td style="padding: 0in 0in 0.5pt; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; vertical-align: bottom;"><div style="text-align: center; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"><div style="font-weight:bold;display:inline;width:100%;"> </div></div></div></td><td style="padding: 0in 0in 0.5pt; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; vertical-align: bottom;"><div style="text-align: center; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"><div style="font-weight:bold;display:inline;width:100%;"> </div></div></div></td><td colspan="2" style="border-top: 0px none; border-image: initial; border-bottom: 1pt solid windowtext; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; vertical-align: bottom; width: 11%;"><div style="text-align: center; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap;"><div style="white-space: nowrap; font-size: 10pt;;font-weight:bold;display:inline;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">2022</div></div></div></td><td style="padding: 0in 0in 0.5pt; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; vertical-align: bottom;"><div style="text-align: center; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"><div style="font-weight:bold;display:inline;width:100%;"> </div></div></div></td><td style="padding: 0in 0in 0.5pt; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; vertical-align: bottom;"><div style="text-align: center; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"><div style="font-weight:bold;display:inline;width:100%;"> </div></div></div></td><td colspan="2" style="border-bottom: 1pt solid windowtext; border-top: 0px solid windowtext; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; vertical-align: bottom; width: 11%;"><div style="text-align: center; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap;"><div style="white-space: nowrap; font-size: 10pt;;font-weight:bold;display:inline;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">2021</div></div></div></td><td style="padding: 0in 0in 0.5pt; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; vertical-align: bottom;"><div style="text-align: center; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"><div style="font-weight:bold;display:inline;width:100%;"> </div></div></div></td></tr><tr><td style="border-bottom: none; border-image: initial; width: 48%; border-top: 1pt solid windowtext; padding: 0px 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255); vertical-align: bottom;"><div style="margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Research and development</div></div></td><td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255); vertical-align: bottom;"><div style="margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255); border-bottom: none; border-top: 0px solid windowtext; text-align: left; vertical-align: bottom;"><div style="text-align: left; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap; text-indent: 0in;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">$</div></div></td><td style="border-bottom: none; border-image: initial; width: 10%; border-top: 0px solid windowtext; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); text-align: right; vertical-align: bottom;"><div style="text-align: right; margin: 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">374</div></div></td><td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); text-align: left; vertical-align: bottom;"><div style="text-align: left; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap; text-indent: 0in;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div></td><td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom;"><div style="text-align: right; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div></td><td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); border-bottom: none; border-top: 0px solid windowtext; text-align: left; vertical-align: bottom;"><div style="text-align: left; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap; text-indent: 0in;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">$</div></div></td><td style="border-bottom: none; border-image: initial; width: 10%; border-top: 0px solid windowtext; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); text-align: right; vertical-align: bottom;"><div style="text-align: right; margin: 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">23</div></div></td><td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); text-align: left; vertical-align: bottom;"><div style="text-align: left; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap; text-indent: 0in;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div></td><td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom;"><div style="text-align: right; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div></td><td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); border-bottom: none; border-top: 0px solid windowtext; text-align: left; vertical-align: bottom;"><div style="text-align: left; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap; text-indent: 0in;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">$</div></div></td><td style="border-bottom: none; border-image: initial; width: 10%; border-top: 0px solid windowtext; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); text-align: right; vertical-align: bottom;"><div style="text-align: right; margin: 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">581</div></div></td><td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); text-align: left; vertical-align: bottom;"><div style="text-align: left; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap; text-indent: 0in;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div></td><td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom;"><div style="text-align: right; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div></td><td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); border-bottom: none; border-top: 0px solid windowtext; text-align: left; vertical-align: bottom;"><div style="text-align: left; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap; text-indent: 0in;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">$</div></div></td><td style="border-bottom: none; border-image: initial; width: 10%; border-top: 0px solid windowtext; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); text-align: right; vertical-align: bottom;"><div style="text-align: right; margin: 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">36</div></div></td><td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); text-align: left; vertical-align: bottom;"><div style="text-align: left; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap; text-indent: 0in;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div></td></tr><tr><td style="width: 48%; padding: 0px 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgba(255, 255, 255, 0); vertical-align: bottom;"><div style="margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Sales and marketing</div></div></td><td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgba(255, 255, 255, 0); vertical-align: bottom;"><div style="margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgba(255, 255, 255, 0); text-align: left; vertical-align: bottom;"><div style="margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; text-indent: 0in; text-align: left; white-space: nowrap;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="width: 10%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); text-align: right; vertical-align: bottom;"><div style="text-align: right; margin: 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">37</div></div></td><td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); text-align: left; vertical-align: bottom;"><div style="text-align: left; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap; text-indent: 0in;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div></td><td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); vertical-align: bottom;"><div style="text-align: right; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div></td><td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); text-align: left; vertical-align: bottom;"><div style="text-align: left; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap; text-indent: 0in;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div></td><td style="width: 10%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); text-align: right; vertical-align: bottom;"><div style="text-align: right; margin: 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">10</div></div></td><td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); text-align: left; vertical-align: bottom;"><div style="text-align: left; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap; text-indent: 0in;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div></td><td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); vertical-align: bottom;"><div style="text-align: right; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div></td><td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); text-align: left; vertical-align: bottom;"><div style="text-align: left; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap; text-indent: 0in;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div></td><td style="width: 10%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); text-align: right; vertical-align: bottom;"><div style="text-align: right; margin: 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">61</div></div></td><td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); text-align: left; vertical-align: bottom;"><div style="text-align: left; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap; text-indent: 0in;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div></td><td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); vertical-align: bottom;"><div style="text-align: right; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div></td><td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); text-align: left; vertical-align: bottom;"><div style="text-align: left; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap; text-indent: 0in;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div></td><td style="width: 10%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); text-align: right; vertical-align: bottom;"><div style="text-align: right; margin: 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">18</div></div></td><td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); text-align: left; vertical-align: bottom;"><div style="text-align: left; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap; text-indent: 0in;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div></td></tr><tr><td style="width: 48%; padding: 0px 0in 0.5pt; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255); vertical-align: bottom;"><div style="margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">General, and administrative</div></div></td><td style="width: 1%; padding: 0in 0in 0.5pt; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255); vertical-align: bottom;"><div style="margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255); border-bottom: 1pt solid black; border-top: none; text-align: left; vertical-align: bottom;"><div style="margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; text-indent: 0in; text-align: left; white-space: nowrap;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="border-top: none; border-image: initial; border-bottom: 1pt solid black; width: 10%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); text-align: right; vertical-align: bottom;"><div style="text-align: right; margin: 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">623</div></div></td><td style="width: 1%; padding: 0in 0in 0.5pt; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); text-align: left; vertical-align: bottom;"><div style="text-align: left; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap; text-indent: 0in;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div></td><td style="width: 1%; padding: 0in 0in 0.5pt; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom;"><div style="text-align: right; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div></td><td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); border-bottom: 1pt solid black; border-top: none; text-align: left; vertical-align: bottom;"><div style="text-align: left; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap; text-indent: 0in;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div></td><td style="border-top: none; border-image: initial; border-bottom: 1pt solid black; width: 10%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); text-align: right; vertical-align: bottom;"><div style="text-align: right; margin: 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">110</div></div></td><td style="width: 1%; padding: 0in 0in 0.5pt; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); text-align: left; vertical-align: bottom;"><div style="text-align: left; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap; text-indent: 0in;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div></td><td style="width: 1%; padding: 0in 0in 0.5pt; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom;"><div style="text-align: right; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div></td><td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); border-bottom: 1pt solid windowtext; border-top: none; text-align: left; vertical-align: bottom;"><div style="text-align: left; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap; text-indent: 0in;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div></td><td style="border-top: none; border-image: initial; border-bottom: 1pt solid windowtext; width: 10%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); text-align: right; vertical-align: bottom;"><div style="text-align: right; margin: 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">1,113</div></div></td><td style="width: 1%; padding: 0in 0in 0.5pt; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); text-align: left; vertical-align: bottom;"><div style="text-align: left; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap; text-indent: 0in;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div></td><td style="width: 1%; padding: 0in 0in 0.5pt; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom;"><div style="text-align: right; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div></td><td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); border-bottom: 1pt solid windowtext; border-top: none; text-align: left; vertical-align: bottom;"><div style="text-align: left; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap; text-indent: 0in;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div></td><td style="border-top: none; border-image: initial; border-bottom: 1pt solid windowtext; width: 10%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); text-align: right; vertical-align: bottom;"><div style="text-align: right; margin: 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">154</div></div></td><td style="width: 1%; padding: 0in 0in 0.5pt; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); text-align: left; vertical-align: bottom;"><div style="text-align: left; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap; text-indent: 0in;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div></td></tr><tr><td style="width: 48%; padding: 0px 0in 1.25pt 10pt; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgba(255, 255, 255, 0); vertical-align: bottom;"><div style="margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Total stock-based compensation expense</div></div></td><td style="width: 1%; padding: 0in 0in 1.25pt; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgba(255, 255, 255, 0); vertical-align: bottom;"><div style="margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgba(255, 255, 255, 0); border-bottom: 2.5pt double black; border-top: 0px none; text-align: left; vertical-align: bottom;"><div style="text-align: left; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap; text-indent: 0in;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">$</div></div></td><td style="border-bottom: 2.5pt double black; width: 10%; border-top: 0px none; border-image: initial; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); text-align: right; vertical-align: bottom;"><div style="text-align: right; margin: 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">1,034</div></div></td><td style="width: 1%; padding: 0in 0in 1.25pt; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); text-align: left; vertical-align: bottom;"><div style="text-align: left; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap; text-indent: 0in;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div></td><td style="width: 1%; padding: 0in 0in 1.25pt; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); vertical-align: bottom;"><div style="text-align: right; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div></td><td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); border-bottom: 2.5pt double black; border-top: 0px none; text-align: left; vertical-align: bottom;"><div style="text-align: left; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap; text-indent: 0in;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">$</div></div></td><td style="border-bottom: 2.5pt double black; width: 10%; border-top: 0px none; border-image: initial; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); text-align: right; vertical-align: bottom;"><div style="text-align: right; margin: 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">143</div></div></td><td style="width: 1%; padding: 0in 0in 1.25pt; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); text-align: left; vertical-align: bottom;"><div style="text-align: left; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap; text-indent: 0in;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div></td><td style="width: 1%; padding: 0in 0in 1.25pt; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); vertical-align: bottom;"><div style="text-align: right; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div></td><td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); border-bottom: 2.5pt double windowtext; border-top: 0px none; text-align: left; vertical-align: bottom;"><div style="text-align: left; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap; text-indent: 0in;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">$</div></div></td><td style="border-bottom: 2.5pt double windowtext; width: 10%; border-top: 0px none; border-image: initial; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); text-align: right; vertical-align: bottom;"><div style="text-align: right; margin: 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">1,755</div></div></td><td style="width: 1%; padding: 0in 0in 1.25pt; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); text-align: left; vertical-align: bottom;"><div style="text-align: left; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap; text-indent: 0in;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div></td><td style="width: 1%; padding: 0in 0in 1.25pt; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); vertical-align: bottom;"><div style="text-align: right; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div></td><td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); border-bottom: 2.5pt double windowtext; border-top: 0px none; text-align: left; vertical-align: bottom;"><div style="text-align: left; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap; text-indent: 0in;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">$</div></div></td><td style="border-bottom: 2.5pt double windowtext; width: 10%; border-top: 0px none; border-image: initial; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); text-align: right; vertical-align: bottom;"><div style="text-align: right; margin: 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">208</div></div></td><td style="width: 1%; padding: 0in 0in 1.25pt; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); text-align: left; vertical-align: bottom;"><div style="text-align: left; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap; text-indent: 0in;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div></td></tr></table> <div style="clear: both; max-height: 0px;"/> <div style="clear: both; max-height: 0px; text-indent: 0px;"/> <div style="margin: 0px 0px 0px 0in; text-align: justify; font-family: "Times New Roman", Times, serif; font-size: 10pt; line-height: 12pt; background: none;;text-indent: 0px;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, serif; white-space: pre-wrap; line-height: 12pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;;white-space:pre-wrap;"> </div></div> <div style="margin: 0px 0px 0px 0in; text-align: justify; font-family: "Times New Roman", Times, serif; font-size: 10pt; line-height: 12pt; background: none;;text-indent: 0px;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, serif; line-height: 12pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">At September 30, 2022, there were 167,520 shares available for issuance under the 2022 Plan.</div></div> <div style="margin: 0px 0px 0px 0in; text-align: justify; font-family: "Times New Roman", Times, serif; font-size: 10pt; line-height: 12pt; background: none;;text-indent: 0px;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, serif; white-space: pre-wrap; line-height: 12pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;;white-space:pre-wrap;"> </div></div> <div style="margin: 0px 0in; text-align: justify; break-after: avoid; font-family: "Times New Roman", serif; font-size: 10pt;;text-indent: 0px;"><div style="font-style:italic;display:inline;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, serif; line-height: 12pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Warrants</div></div></div> <div style="margin: 0px 0in; text-align: justify; break-after: avoid; font-family: "Times New Roman", serif; font-size: 10pt;;text-indent: 0px;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, serif; white-space: pre-wrap; line-height: 12pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;;white-space:pre-wrap;"> </div></div> <div style="margin: 0px 0px 0px 0in; text-align: justify; font-family: "Times New Roman", Times, serif; font-size: 10pt; line-height: 12pt; background: none;;text-indent: 0px;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, serif; line-height: 12pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">During 2020, the Company issued warrants to purchase 25,000 shares of common stock to a consultant. The warrants, which are equity-classified, are immediately exercisable at an exercise price of $5.20 per share. The fair value of the warrants on the grant date was $2.30 per warrant, which was calculated based on the following weighted-average assumptions, using a Black-Scholes option valuation model: expected term of 5.00 years; expected volatility of 51.88%; dividend yield of 0%, and risk-free interest rate of 0.30%. The Company recorded deferred offering costs of approximately $58 associated with these warrants during 2020<div style="letter-spacing: 0px; top: 0px;;display:inline;"> which was recorded in additional paid-in capital in 2022<div style="display:inline;">.</div></div></div> </div> <div style="margin: 0px 0px 0px 0in; text-align: justify; font-family: "Times New Roman", Times, serif; font-size: 10pt; line-height: 12pt; background: none;;text-indent: 0px;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, serif; white-space: pre-wrap; line-height: 12pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;;white-space:pre-wrap;"> </div></div> <div style="margin: 0px 0px 0px 0in; text-align: justify; font-family: "Times New Roman", Times, serif; font-size: 10pt; line-height: 12pt; background: none;;text-indent: 0px;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, serif; line-height: 12pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">In April 2022, as noted above, the Company granted the Underwriters warrants to purchase a total of 96,000 shares of the Company’s common stock. The warrants are immediately exercisable at an exercise price of $5.00 per share and expire on the fifth anniversary of the commencement of sales under the IPO. The fair value of the warrants on the grant date was $2.75 per warrant, which was calculated based on the following weighted-average assumptions, using a Black-Scholes option valuation model: expected term of 5.00 years; expected volatility of 62.55%; dividend yield of 0%, and risk-free interest rate of 2.92%. The Company recorded the fair value of these warrants of approximately $264 as an issuance cost to additional paid-in capital in 2022. As the IPO issuance costs were also recorded to additional paid-in capital, the net impact was $0.</div><br/></div>

3937550

2099525

0.001

7000000

2460802

1798905

10487904

3297061

130000000

20000000

3200000

0.001

96000

13800000

3955415

2693342

1172346

0.03

312351

85739

574033

0.24

2550763

0.24

5000000 3.3737

1172346

491222

2.795

1272000

0.5

4 15000000

1.526

4.981

one vote

P4Y

P10Y

662516

737516

799266

1600000

1100000 0.04

<div style="margin: 0px 0in; text-align: justify; break-after: avoid; font-family: "Times New Roman", serif; font-size: 10pt;;text-indent: 0px;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, serif; line-height: 12pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">A summary of the Company’s share option and restricted stock unit activity under its plans is as follows:</div></div> <div style="margin: 0px 0in; text-align: justify; break-after: avoid; font-family: "Times New Roman", serif; font-size: 10pt;;text-indent: 0px;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, serif; white-space: pre-wrap; line-height: 12pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;;white-space:pre-wrap;"> </div></div> <table cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;;margin-right : auto;;margin-left : 0;margin-right : auto;"><tr><td style="width: 48%; padding: 0px 0in 0.5pt; font-family: "Times New Roman", Times, serif; font-size: 10pt; vertical-align: bottom;"><div style="margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; text-align: center;"><div style="font-size: 10pt;;font-weight:bold;display:inline;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div></td><td style="padding: 0in 0in 0.5pt; font-family: "Times New Roman", Times, serif; font-size: 10pt; vertical-align: bottom;"><div style="margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; text-align: center;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;width:100%;"> </div></div></div></td><td colspan="2" style="border-top: none; border-image: initial; border-bottom: 1pt solid black; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; vertical-align: bottom; width: 11%;"><div style="text-align: center; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap;"><div style="white-space: nowrap; font-size: 10pt;;font-weight:bold;display:inline;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">Number of<br/> Shares Subject<br/> to Outstanding<br/> Stock Options</div></div></div></td><td style="padding: 0in 0in 0.5pt; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; vertical-align: bottom;"><div style="text-align: center; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"><div style="font-weight:bold;display:inline;width:100%;"> </div></div></div></td><td style="padding: 0in 0in 0.5pt; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; vertical-align: bottom;"><div style="text-align: center; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"><div style="font-weight:bold;display:inline;width:100%;"> </div></div></div></td><td colspan="2" style="border-top: none; border-image: initial; border-bottom: 1pt solid black; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; vertical-align: bottom; width: 11%;"><div style="text-align: center; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap;"><div style="white-space: nowrap; font-size: 10pt;;font-weight:bold;display:inline;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">Weighted <br/> Average <br/> Exercise <br/> Price Per <br/> Share</div></div></div></td><td style="padding: 0in 0in 0.5pt; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; vertical-align: bottom;"><div style="text-align: center; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"><div style="font-weight:bold;display:inline;width:100%;"> </div></div></div></td><td style="padding: 0in 0in 0.5pt; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; vertical-align: bottom;"><div style="text-align: center; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"><div style="font-weight:bold;display:inline;width:100%;"> </div></div></div></td><td colspan="2" style="border-top: none; border-image: initial; border-bottom: 1pt solid windowtext; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; vertical-align: bottom; width: 11%;"><div style="text-align: center; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap;"><div style="white-space: nowrap; font-size: 10pt;;font-weight:bold;display:inline;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">Number of<br/> Outstanding<br/> Restricted Stock<br/> Units</div></div></div></td><td style="padding: 0in 0in 0.5pt; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; vertical-align: bottom;"><div style="text-align: center; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"><div style="font-weight:bold;display:inline;width:100%;"> </div></div></div></td><td style="padding: 0in 0in 0.5pt; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; vertical-align: bottom;"><div style="text-align: center; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"><div style="font-weight:bold;display:inline;width:100%;"> </div></div></div></td><td colspan="2" style="border-top: none; border-image: initial; border-bottom: 1pt solid windowtext; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; vertical-align: bottom; width: 11%;"><div style="text-align: center; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap;"><div style="white-space: nowrap; font-size: 10pt;;font-weight:bold;display:inline;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">Weighted-average Grant<br/> Date Fair<br/> Value per<br/> Share</div></div></div></td><td style="padding: 0in 0in 0.5pt; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; vertical-align: bottom;"><div style="text-align: center; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"><div style="font-weight:bold;display:inline;width:100%;"> </div></div></div></td></tr><tr><td style="width: 48%; padding: 0px 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255); vertical-align: bottom;"><div style="margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Outstanding at December 31, 2021</div></div></td><td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255); vertical-align: bottom;"><div style="margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255); text-align: left; vertical-align: bottom;"><div style="margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; text-indent: 0in; text-align: left; white-space: nowrap;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="width: 10%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); text-align: right; vertical-align: bottom;"><div style="text-align: right; margin: 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">727,394</div></div></td><td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); text-align: left; vertical-align: bottom;"><div style="text-align: left; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap; text-indent: 0in;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div></td><td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom;"><div style="text-align: right; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div></td><td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); text-align: left; vertical-align: bottom;"><div style="text-align: left; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap; text-indent: 0in;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">$</div></div></td><td style="width: 10%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); text-align: right; vertical-align: bottom;"><div style="text-align: right; margin: 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">5.32</div></div></td><td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); text-align: left; vertical-align: bottom;"><div style="text-align: left; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap; text-indent: 0in;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div></td><td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom;"><div style="text-align: right; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div></td><td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); border-bottom: none; border-top: 0px none; text-align: left; vertical-align: bottom;"><div style="text-align: left; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap; text-indent: 0in;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div></td><td style="border-top: 0px none; border-bottom: none; border-image: initial; width: 10%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom;"><div style="text-align: right; margin: 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">—</div></div></td><td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); text-align: left; vertical-align: bottom;"><div style="text-align: left; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap; text-indent: 0in;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div></td><td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom;"><div style="text-align: right; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div></td><td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); border-bottom: none; border-top: 0px solid windowtext; text-align: left; vertical-align: bottom;"><div style="text-align: left; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap; text-indent: 0in;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">$</div></div></td><td style="border-bottom: none; border-image: initial; width: 10%; border-top: 0px solid windowtext; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom;"><div style="text-align: right; margin: 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">—</div></div></td><td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); text-align: left; vertical-align: bottom;"><div style="text-align: left; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap; text-indent: 0in;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div></td></tr><tr><td style="width: 48%; padding: 0px 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgba(255, 255, 255, 0); vertical-align: bottom;"><div style="margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Granted</div></div></td><td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgba(255, 255, 255, 0); vertical-align: bottom;"><div style="margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgba(255, 255, 255, 0); text-align: left; vertical-align: bottom;"><div style="margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; text-indent: 0in; text-align: left; white-space: nowrap;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="width: 10%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); text-align: right; vertical-align: bottom;"><div style="text-align: right; margin: 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">113,950</div></div></td><td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); text-align: left; vertical-align: bottom;"><div style="text-align: left; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap; text-indent: 0in;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div></td><td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); vertical-align: bottom;"><div style="text-align: right; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div></td><td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); text-align: left; vertical-align: bottom;"><div style="text-align: left; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap; text-indent: 0in;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">$</div></div></td><td style="width: 10%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); text-align: right; vertical-align: bottom;"><div style="text-align: right; margin: 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">2.47</div></div></td><td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); text-align: left; vertical-align: bottom;"><div style="text-align: left; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap; text-indent: 0in;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div></td><td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); vertical-align: bottom;"><div style="text-align: right; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div></td><td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); text-align: left; vertical-align: bottom;"><div style="text-align: left; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap; text-indent: 0in;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div></td><td style="width: 10%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); text-align: right; vertical-align: bottom;"><div style="text-align: right; margin: 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">1,318,530</div></div></td><td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); text-align: left; vertical-align: bottom;"><div style="text-align: left; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap; text-indent: 0in;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div></td><td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); vertical-align: bottom;"><div style="text-align: right; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div></td><td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); text-align: left; vertical-align: bottom;"><div style="text-align: left; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap; text-indent: 0in;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">$</div></div></td><td style="width: 10%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); text-align: right; vertical-align: bottom;"><div style="text-align: right; margin: 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">7.93</div></div></td><td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); text-align: left; vertical-align: bottom;"><div style="text-align: left; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap; text-indent: 0in;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div></td></tr><tr><td style="width: 48%; padding: 0px 0in 0.5pt; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255); vertical-align: bottom;"><div style="margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Forfeited</div></div></td><td style="width: 1%; padding: 0in 0in 0.5pt; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255); vertical-align: bottom;"><div style="margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255); border-bottom: 1pt solid black; border-top: none; text-align: left; vertical-align: bottom;"><div style="margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; text-indent: 0in; text-align: left; white-space: nowrap;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="border-top: none; border-image: initial; border-bottom: 1pt solid black; width: 10%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom;"><div style="text-align: right; margin: 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">— </div></div></td><td style="width: 1%; padding: 0in 0in 0.5pt; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); text-align: left; vertical-align: bottom;"><div style="text-align: left; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap; text-indent: 0in;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div></td><td style="width: 1%; padding: 0in 0in 0.5pt; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom;"><div style="text-align: right; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div></td><td style="width: 1%; padding: 0in 0in 0.5pt; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); text-align: left; vertical-align: bottom;"><div style="text-align: left; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap; text-indent: 0in;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">$</div></div></td><td style="width: 10%; padding: 0in 0in 0.5pt; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom;"><div style="text-align: right; margin: 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">—</div></div></td><td style="width: 1%; padding: 0in 0in 0.5pt; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); text-align: left; vertical-align: bottom;"><div style="text-align: left; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap; text-indent: 0in;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div></td><td style="width: 1%; padding: 0in 0in 0.5pt; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom;"><div style="text-align: right; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div></td><td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); border-bottom: 1pt solid windowtext; border-top: none; text-align: left; vertical-align: bottom;"><div style="text-align: left; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap; text-indent: 0in;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div></td><td style="border-top: none; border-image: initial; border-bottom: 1pt solid windowtext; width: 10%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom;"><div style="text-align: right; margin: 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">—</div></div></td><td style="width: 1%; padding: 0in 0in 0.5pt; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); text-align: left; vertical-align: bottom;"><div style="text-align: left; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap; text-indent: 0in;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div></td><td style="width: 1%; padding: 0in 0in 0.5pt; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom;"><div style="text-align: right; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div></td><td style="width: 1%; padding: 0in 0in 0.5pt; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); text-align: left; vertical-align: bottom;"><div style="text-align: left; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap; text-indent: 0in;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">$</div></div></td><td style="width: 10%; padding: 0in 0in 0.5pt; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom;"><div style="text-align: right; margin: 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">—</div></div></td><td style="width: 1%; padding: 0in 0in 0.5pt; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); text-align: left; vertical-align: bottom;"><div style="text-align: left; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap; text-indent: 0in;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div></td></tr><tr><td style="width: 48%; padding: 0px 0in 1.25pt; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgba(255, 255, 255, 0); vertical-align: bottom;"><div style="margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Outstanding at September 30, 2022</div></div></td><td style="width: 1%; padding: 0in 0in 1.25pt; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgba(255, 255, 255, 0); vertical-align: bottom;"><div style="margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgba(255, 255, 255, 0); border-bottom: 1pt solid black; border-top: 0px none; text-align: left; vertical-align: bottom;"><div style="margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; text-indent: 0in; text-align: left; white-space: nowrap;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="border-top: 0px none; border-image: initial; border-bottom: 1pt solid black; width: 10%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); text-align: right; vertical-align: bottom;"><div style="text-align: right; margin: 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">841,344</div></div></td><td style="width: 1%; padding: 0in 0in 0.5pt; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); text-align: left; vertical-align: bottom;"><div style="text-align: left; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap; text-indent: 0in;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div></td><td style="width: 1%; padding: 0in 0in 1.25pt; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); vertical-align: bottom;"><div style="text-align: right; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div></td><td style="width: 1%; padding: 0in 0in 1.25pt; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); text-align: left; vertical-align: bottom;"><div style="text-align: left; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap; text-indent: 0in;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">$</div></div></td><td style="width: 10%; padding: 0in 0in 1.25pt; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); text-align: right; vertical-align: bottom;"><div style="text-align: right; margin: 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">4.93</div></div></td><td style="width: 1%; padding: 0in 0in 1.25pt; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); text-align: left; vertical-align: bottom;"><div style="text-align: left; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap; text-indent: 0in;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div></td><td style="width: 1%; padding: 0in 0in 1.25pt; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); vertical-align: bottom;"><div style="text-align: right; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div></td><td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); border-bottom: 2.5pt double windowtext; border-top: 0px none; text-align: left; vertical-align: bottom;"><div style="text-align: left; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap; text-indent: 0in;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div></td><td style="border-bottom: 2.5pt double windowtext; width: 10%; border-top: 0px none; border-image: initial; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); text-align: right; vertical-align: bottom;"><div style="text-align: right; margin: 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">1,318,530</div></div></td><td style="width: 1%; padding: 0in 0in 1.25pt; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); text-align: left; vertical-align: bottom;"><div style="text-align: left; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap; text-indent: 0in;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div></td><td style="width: 1%; padding: 0in 0in 1.25pt; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); vertical-align: bottom;"><div style="text-align: right; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div></td><td style="width: 1%; padding: 0in 0in 1.25pt; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); text-align: left; vertical-align: bottom;"><div style="text-align: left; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap; text-indent: 0in;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">$</div></div></td><td style="width: 10%; padding: 0in 0in 1.25pt; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); text-align: right; vertical-align: bottom;"><div style="text-align: right; margin: 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">7.93</div></div></td><td style="width: 1%; padding: 0in 0in 1.25pt; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); text-align: left; vertical-align: bottom;"><div style="text-align: left; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap; text-indent: 0in;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div></td></tr></table>

727394

5.32

113950

2.47

1318530

7.93

841344

4.93

1318530

7.93

<div style="margin: 0px 0in; text-align: justify; break-after: avoid; font-family: "Times New Roman", serif; font-size: 10pt;;text-indent: 0px;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, serif; line-height: 12pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The following table sets forth stock-based compensation expense recognized for the three and nine months ended September 30, 2022 and 2021:</div></div> <div style="margin: 0px 0in; text-align: justify; break-after: avoid; font-family: "Times New Roman", serif; font-size: 10pt;;text-indent: 0px;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, serif; white-space: pre-wrap; line-height: 12pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;;white-space:pre-wrap;"> </div></div> <table cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;;margin-right : auto;;margin-left : 0;margin-right : auto;"><tr><td style="width: 48%; padding: 0px 0in 0.5pt; font-family: "Times New Roman", Times, serif; font-size: 10pt; vertical-align: bottom;"><div style="margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; text-align: center;"><div style="font-size: 10pt;;font-weight:bold;display:inline;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div></td><td style="padding: 0in 0in 0.5pt; font-family: "Times New Roman", Times, serif; font-size: 10pt; vertical-align: bottom;"><div style="margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; text-align: center;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;width:100%;"> </div></div></div></td><td colspan="6" style="border-top: none; border-image: initial; border-bottom: 1pt solid black; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; vertical-align: bottom; width: 11%;"><div style="text-align: center; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap;"><div style="white-space: nowrap; font-size: 10pt;;font-weight:bold;display:inline;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">Three months ended<br/> September 30,</div></div></div></td><td style="padding: 0in 0in 0.5pt; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; vertical-align: bottom;"><div style="text-align: center; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"><div style="font-weight:bold;display:inline;width:100%;"> </div></div></div></td><td style="padding: 0in 0in 0.5pt; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; vertical-align: bottom;"><div style="text-align: center; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"><div style="font-weight:bold;display:inline;width:100%;"> </div></div></div></td><td colspan="6" style="border-top: none; border-image: initial; border-bottom: 1pt solid windowtext; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; vertical-align: bottom; width: 11%;"><div style="text-align: center; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap;"><div style="white-space: nowrap; font-size: 10pt;;font-weight:bold;display:inline;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">Nine months ended<br/> September 30,</div></div></div></td><td style="padding: 0in 0in 0.5pt; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; vertical-align: bottom;"><div style="text-align: center; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"><div style="font-weight:bold;display:inline;width:100%;"> </div></div></div></td></tr><tr><td style="width: 48%; padding: 0px 0in 0.5pt; font-family: "Times New Roman", Times, serif; font-size: 0px; vertical-align: bottom;"> </td><td style="padding: 0in 0in 0.5pt; font-family: "Times New Roman", Times, serif; font-size: 0px; vertical-align: bottom;"> </td><td colspan="2" style="border-top: 0px none; border-image: initial; border-bottom: 1pt solid black; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; vertical-align: bottom; width: 11%;"><div style="text-align: center; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap;"><div style="white-space: nowrap; font-size: 10pt;;font-weight:bold;display:inline;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">2022</div></div></div></td><td style="padding: 0in 0in 0.5pt; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; vertical-align: bottom;"><div style="text-align: center; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"><div style="font-weight:bold;display:inline;width:100%;"> </div></div></div></td><td style="padding: 0in 0in 0.5pt; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; vertical-align: bottom;"><div style="text-align: center; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"><div style="font-weight:bold;display:inline;width:100%;"> </div></div></div></td><td colspan="2" style="border-top: 0px none; border-image: initial; border-bottom: 1pt solid black; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; vertical-align: bottom; width: 11%;"><div style="text-align: center; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap;"><div style="white-space: nowrap; font-size: 10pt;;font-weight:bold;display:inline;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">2021</div></div></div></td><td style="padding: 0in 0in 0.5pt; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; vertical-align: bottom;"><div style="text-align: center; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"><div style="font-weight:bold;display:inline;width:100%;"> </div></div></div></td><td style="padding: 0in 0in 0.5pt; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; vertical-align: bottom;"><div style="text-align: center; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"><div style="font-weight:bold;display:inline;width:100%;"> </div></div></div></td><td colspan="2" style="border-top: 0px none; border-image: initial; border-bottom: 1pt solid windowtext; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; vertical-align: bottom; width: 11%;"><div style="text-align: center; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap;"><div style="white-space: nowrap; font-size: 10pt;;font-weight:bold;display:inline;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">2022</div></div></div></td><td style="padding: 0in 0in 0.5pt; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; vertical-align: bottom;"><div style="text-align: center; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"><div style="font-weight:bold;display:inline;width:100%;"> </div></div></div></td><td style="padding: 0in 0in 0.5pt; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; vertical-align: bottom;"><div style="text-align: center; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"><div style="font-weight:bold;display:inline;width:100%;"> </div></div></div></td><td colspan="2" style="border-bottom: 1pt solid windowtext; border-top: 0px solid windowtext; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; vertical-align: bottom; width: 11%;"><div style="text-align: center; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap;"><div style="white-space: nowrap; font-size: 10pt;;font-weight:bold;display:inline;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">2021</div></div></div></td><td style="padding: 0in 0in 0.5pt; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; vertical-align: bottom;"><div style="text-align: center; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"><div style="font-weight:bold;display:inline;width:100%;"> </div></div></div></td></tr><tr><td style="border-bottom: none; border-image: initial; width: 48%; border-top: 1pt solid windowtext; padding: 0px 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255); vertical-align: bottom;"><div style="margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Research and development</div></div></td><td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255); vertical-align: bottom;"><div style="margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255); border-bottom: none; border-top: 0px solid windowtext; text-align: left; vertical-align: bottom;"><div style="text-align: left; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap; text-indent: 0in;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">$</div></div></td><td style="border-bottom: none; border-image: initial; width: 10%; border-top: 0px solid windowtext; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); text-align: right; vertical-align: bottom;"><div style="text-align: right; margin: 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">374</div></div></td><td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); text-align: left; vertical-align: bottom;"><div style="text-align: left; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap; text-indent: 0in;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div></td><td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom;"><div style="text-align: right; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div></td><td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); border-bottom: none; border-top: 0px solid windowtext; text-align: left; vertical-align: bottom;"><div style="text-align: left; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap; text-indent: 0in;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">$</div></div></td><td style="border-bottom: none; border-image: initial; width: 10%; border-top: 0px solid windowtext; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); text-align: right; vertical-align: bottom;"><div style="text-align: right; margin: 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">23</div></div></td><td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); text-align: left; vertical-align: bottom;"><div style="text-align: left; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap; text-indent: 0in;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div></td><td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom;"><div style="text-align: right; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div></td><td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); border-bottom: none; border-top: 0px solid windowtext; text-align: left; vertical-align: bottom;"><div style="text-align: left; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap; text-indent: 0in;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">$</div></div></td><td style="border-bottom: none; border-image: initial; width: 10%; border-top: 0px solid windowtext; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); text-align: right; vertical-align: bottom;"><div style="text-align: right; margin: 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">581</div></div></td><td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); text-align: left; vertical-align: bottom;"><div style="text-align: left; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap; text-indent: 0in;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div></td><td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom;"><div style="text-align: right; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div></td><td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); border-bottom: none; border-top: 0px solid windowtext; text-align: left; vertical-align: bottom;"><div style="text-align: left; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap; text-indent: 0in;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">$</div></div></td><td style="border-bottom: none; border-image: initial; width: 10%; border-top: 0px solid windowtext; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); text-align: right; vertical-align: bottom;"><div style="text-align: right; margin: 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">36</div></div></td><td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); text-align: left; vertical-align: bottom;"><div style="text-align: left; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap; text-indent: 0in;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div></td></tr><tr><td style="width: 48%; padding: 0px 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgba(255, 255, 255, 0); vertical-align: bottom;"><div style="margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Sales and marketing</div></div></td><td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgba(255, 255, 255, 0); vertical-align: bottom;"><div style="margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgba(255, 255, 255, 0); text-align: left; vertical-align: bottom;"><div style="margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; text-indent: 0in; text-align: left; white-space: nowrap;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="width: 10%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); text-align: right; vertical-align: bottom;"><div style="text-align: right; margin: 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">37</div></div></td><td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); text-align: left; vertical-align: bottom;"><div style="text-align: left; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap; text-indent: 0in;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div></td><td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); vertical-align: bottom;"><div style="text-align: right; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div></td><td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); text-align: left; vertical-align: bottom;"><div style="text-align: left; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap; text-indent: 0in;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div></td><td style="width: 10%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); text-align: right; vertical-align: bottom;"><div style="text-align: right; margin: 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">10</div></div></td><td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); text-align: left; vertical-align: bottom;"><div style="text-align: left; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap; text-indent: 0in;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div></td><td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); vertical-align: bottom;"><div style="text-align: right; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div></td><td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); text-align: left; vertical-align: bottom;"><div style="text-align: left; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap; text-indent: 0in;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div></td><td style="width: 10%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); text-align: right; vertical-align: bottom;"><div style="text-align: right; margin: 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">61</div></div></td><td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); text-align: left; vertical-align: bottom;"><div style="text-align: left; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap; text-indent: 0in;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div></td><td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); vertical-align: bottom;"><div style="text-align: right; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div></td><td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); text-align: left; vertical-align: bottom;"><div style="text-align: left; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap; text-indent: 0in;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div></td><td style="width: 10%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); text-align: right; vertical-align: bottom;"><div style="text-align: right; margin: 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">18</div></div></td><td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); text-align: left; vertical-align: bottom;"><div style="text-align: left; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap; text-indent: 0in;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div></td></tr><tr><td style="width: 48%; padding: 0px 0in 0.5pt; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255); vertical-align: bottom;"><div style="margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">General, and administrative</div></div></td><td style="width: 1%; padding: 0in 0in 0.5pt; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255); vertical-align: bottom;"><div style="margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255); border-bottom: 1pt solid black; border-top: none; text-align: left; vertical-align: bottom;"><div style="margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; text-indent: 0in; text-align: left; white-space: nowrap;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="border-top: none; border-image: initial; border-bottom: 1pt solid black; width: 10%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); text-align: right; vertical-align: bottom;"><div style="text-align: right; margin: 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">623</div></div></td><td style="width: 1%; padding: 0in 0in 0.5pt; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); text-align: left; vertical-align: bottom;"><div style="text-align: left; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap; text-indent: 0in;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div></td><td style="width: 1%; padding: 0in 0in 0.5pt; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom;"><div style="text-align: right; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div></td><td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); border-bottom: 1pt solid black; border-top: none; text-align: left; vertical-align: bottom;"><div style="text-align: left; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap; text-indent: 0in;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div></td><td style="border-top: none; border-image: initial; border-bottom: 1pt solid black; width: 10%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); text-align: right; vertical-align: bottom;"><div style="text-align: right; margin: 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">110</div></div></td><td style="width: 1%; padding: 0in 0in 0.5pt; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); text-align: left; vertical-align: bottom;"><div style="text-align: left; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap; text-indent: 0in;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div></td><td style="width: 1%; padding: 0in 0in 0.5pt; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom;"><div style="text-align: right; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div></td><td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); border-bottom: 1pt solid windowtext; border-top: none; text-align: left; vertical-align: bottom;"><div style="text-align: left; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap; text-indent: 0in;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div></td><td style="border-top: none; border-image: initial; border-bottom: 1pt solid windowtext; width: 10%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); text-align: right; vertical-align: bottom;"><div style="text-align: right; margin: 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">1,113</div></div></td><td style="width: 1%; padding: 0in 0in 0.5pt; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); text-align: left; vertical-align: bottom;"><div style="text-align: left; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap; text-indent: 0in;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div></td><td style="width: 1%; padding: 0in 0in 0.5pt; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom;"><div style="text-align: right; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div></td><td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); border-bottom: 1pt solid windowtext; border-top: none; text-align: left; vertical-align: bottom;"><div style="text-align: left; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap; text-indent: 0in;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div></td><td style="border-top: none; border-image: initial; border-bottom: 1pt solid windowtext; width: 10%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); text-align: right; vertical-align: bottom;"><div style="text-align: right; margin: 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">154</div></div></td><td style="width: 1%; padding: 0in 0in 0.5pt; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgb(204, 238, 255); text-align: left; vertical-align: bottom;"><div style="text-align: left; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap; text-indent: 0in;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div></td></tr><tr><td style="width: 48%; padding: 0px 0in 1.25pt 10pt; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgba(255, 255, 255, 0); vertical-align: bottom;"><div style="margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Total stock-based compensation expense</div></div></td><td style="width: 1%; padding: 0in 0in 1.25pt; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgba(255, 255, 255, 0); vertical-align: bottom;"><div style="margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgba(255, 255, 255, 0); border-bottom: 2.5pt double black; border-top: 0px none; text-align: left; vertical-align: bottom;"><div style="text-align: left; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap; text-indent: 0in;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">$</div></div></td><td style="border-bottom: 2.5pt double black; width: 10%; border-top: 0px none; border-image: initial; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); text-align: right; vertical-align: bottom;"><div style="text-align: right; margin: 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">1,034</div></div></td><td style="width: 1%; padding: 0in 0in 1.25pt; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); text-align: left; vertical-align: bottom;"><div style="text-align: left; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap; text-indent: 0in;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div></td><td style="width: 1%; padding: 0in 0in 1.25pt; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); vertical-align: bottom;"><div style="text-align: right; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div></td><td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); border-bottom: 2.5pt double black; border-top: 0px none; text-align: left; vertical-align: bottom;"><div style="text-align: left; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap; text-indent: 0in;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">$</div></div></td><td style="border-bottom: 2.5pt double black; width: 10%; border-top: 0px none; border-image: initial; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); text-align: right; vertical-align: bottom;"><div style="text-align: right; margin: 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">143</div></div></td><td style="width: 1%; padding: 0in 0in 1.25pt; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); text-align: left; vertical-align: bottom;"><div style="text-align: left; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap; text-indent: 0in;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div></td><td style="width: 1%; padding: 0in 0in 1.25pt; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); vertical-align: bottom;"><div style="text-align: right; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div></td><td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); border-bottom: 2.5pt double windowtext; border-top: 0px none; text-align: left; vertical-align: bottom;"><div style="text-align: left; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap; text-indent: 0in;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">$</div></div></td><td style="border-bottom: 2.5pt double windowtext; width: 10%; border-top: 0px none; border-image: initial; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); text-align: right; vertical-align: bottom;"><div style="text-align: right; margin: 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">1,755</div></div></td><td style="width: 1%; padding: 0in 0in 1.25pt; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); text-align: left; vertical-align: bottom;"><div style="text-align: left; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap; text-indent: 0in;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div></td><td style="width: 1%; padding: 0in 0in 1.25pt; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); vertical-align: bottom;"><div style="text-align: right; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div></td><td style="width: 1%; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); border-bottom: 2.5pt double windowtext; border-top: 0px none; text-align: left; vertical-align: bottom;"><div style="text-align: left; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap; text-indent: 0in;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">$</div></div></td><td style="border-bottom: 2.5pt double windowtext; width: 10%; border-top: 0px none; border-image: initial; padding: 0in; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); text-align: right; vertical-align: bottom;"><div style="text-align: right; margin: 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">208</div></div></td><td style="width: 1%; padding: 0in 0in 1.25pt; font-family: "Times New Roman", Times, serif; font-size: 10pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); text-align: left; vertical-align: bottom;"><div style="text-align: left; margin: 0px 0px 0px 0in; font-family: "Times New Roman", Times, "serif"; font-size: 10pt; line-height: 12pt; white-space: nowrap; text-indent: 0in;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, "serif"; line-height: 12pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div></td></tr></table> <div style="clear: both; max-height: 0px;"/> <div style="clear: both; max-height: 0px; text-indent: 0px;"/> <div style="margin: 0px 0px 0px 0in; text-align: justify; font-family: "Times New Roman", Times, serif; font-size: 10pt; line-height: 12pt; background: none;;text-indent: 0px;"><div style="font-size: 10pt; font-family: "Times New Roman", Times, serif; white-space: pre-wrap; line-height: 12pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;;white-space:pre-wrap;"> </div></div>

374000

23000

581000

36000

37000

10000

61000

18000

623000

110000

1113000

154000

1034000

143000

1755000

208000

25000

5.2

2.3

51.88

0.3

58000

96000

2.75

62.55

2.92

264000

P5Y P5Y 500000

53757

880000

0.03

44447

333000

312351

6000000

50000

3000000

1200000

8000

21000

107000

114000

600000

300000

5000000 25000

300000

3000000

5000000

8000

574000

25000

600000

620000

114000

818000

1000000 85000 0.20 0.10 3600000 3600000

4600000

October 6, 2022, until October 05, 2023 P1Y 700000 62500

EXCEL 56 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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how.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 58 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 59 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.2.2 html 248 273 1 false 78 0 false 6 false false R1.htm 1001 - Document - Cover Page Sheet http://www.tenonmed.com/role/CoverPage Cover Page Cover 1 false false R2.htm 1002 - Statement - Condensed Consolidated Balance Sheets Sheet http://www.tenonmed.com/role/CondensedConsolidatedBalanceSheets Condensed Consolidated Balance Sheets Statements 2 false false R3.htm 1003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) Sheet http://www.tenonmed.com/role/CondensedConsolidatedBalanceSheetsParenthetical Condensed Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 1004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss Sheet http://www.tenonmed.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss Condensed Consolidated Statements of Operations and Comprehensive Loss Statements 4 false false R5.htm 1005 - Statement - Condensed Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) Sheet http://www.tenonmed.com/role/CondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit Condensed Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) Statements 5 false false R6.htm 1006 - Statement - Condensed Consolidated Statements of Cash Flows Sheet http://www.tenonmed.com/role/CondensedConsolidatedStatementsOfCashFlows Condensed Consolidated Statements of Cash Flows Statements 6 false false R7.htm 1007 - Disclosure - Organization and Business Sheet http://www.tenonmed.com/role/OrganizationAndBusiness Organization and Business Notes 7 false false R8.htm 1008 - Disclosure - Summary of Significant Accounting Principles Sheet http://www.tenonmed.com/role/SummaryOfSignificantAccountingPrinciples Summary of Significant Accounting Principles Notes 8 false false R9.htm 1009 - Disclosure - Investments Sheet http://www.tenonmed.com/role/Investments Investments Notes 9 false false R10.htm 1010 - Disclosure - Fixed Assets Sheet http://www.tenonmed.com/role/FixedAssets Fixed Assets Notes 10 false false R11.htm 1011 - Disclosure - Accrued Expenses Sheet http://www.tenonmed.com/role/AccruedExpenses Accrued Expenses Notes 11 false false R12.htm 1012 - Disclosure - Debt Sheet http://www.tenonmed.com/role/Debt Debt Notes 12 false false R13.htm 1013 - Disclosure - Leases Sheet http://www.tenonmed.com/role/Leases Leases Notes 13 false false R14.htm 1014 - Disclosure - Stockholders' Equity Sheet http://www.tenonmed.com/role/StockholdersEquity Stockholders' Equity Notes 14 false false R15.htm 1015 - Disclosure - Commitments and Contingencies Sheet http://www.tenonmed.com/role/CommitmentsAndContingencies Commitments and Contingencies Notes 15 false false R16.htm 1016 - Disclosure - Concentrations of Risk Sheet http://www.tenonmed.com/role/ConcentrationsOfRisk Concentrations of Risk Notes 16 false false R17.htm 1017 - Disclosure - Related Party Transactions Sheet http://www.tenonmed.com/role/RelatedPartyTransactions Related Party Transactions Notes 17 false false R18.htm 1018 - Disclosure - Subsequent Events Sheet http://www.tenonmed.com/role/SubsequentEvents Subsequent Events Notes 18 false false R19.htm 1019 - Disclosure - Summary of Significant Accounting Principles (Policies) Sheet http://www.tenonmed.com/role/SummaryOfSignificantAccountingPrinciplesPolicies Summary of Significant Accounting Principles (Policies) Policies http://www.tenonmed.com/role/SummaryOfSignificantAccountingPrinciples 19 false false R20.htm 1020 - Disclosure - Summary of Significant Accounting Principles (Tables) Sheet http://www.tenonmed.com/role/SummaryOfSignificantAccountingPrinciplesTables Summary of Significant Accounting Principles (Tables) Tables http://www.tenonmed.com/role/SummaryOfSignificantAccountingPrinciples 20 false false R21.htm 1021 - Disclosure - Investments (Tables) Sheet http://www.tenonmed.com/role/InvestmentsTables Investments (Tables) Tables http://www.tenonmed.com/role/Investments 21 false false R22.htm 1022 - Disclosure - Fixed Assets (Tables) Sheet http://www.tenonmed.com/role/FixedAssetsTables Fixed Assets (Tables) Tables http://www.tenonmed.com/role/FixedAssets 22 false false R23.htm 1023 - Disclosure - Accrued Expenses (Tables) Sheet http://www.tenonmed.com/role/AccruedExpensesTables Accrued Expenses (Tables) Tables http://www.tenonmed.com/role/AccruedExpenses 23 false false R24.htm 1024 - Disclosure - Leases (Tables) Sheet http://www.tenonmed.com/role/LeasesTables Leases (Tables) Tables http://www.tenonmed.com/role/Leases 24 false false R25.htm 1025 - Disclosure - Stockholders' Equity (Tables) Sheet http://www.tenonmed.com/role/StockholdersEquityTables Stockholders' Equity (Tables) Tables http://www.tenonmed.com/role/StockholdersEquity 25 false false R26.htm 1026 - Disclosure - Summary of Significant Accounting Principles - Schedule of Securities Excluded Due To Anti Dilutive Effect (Detail) Sheet http://www.tenonmed.com/role/SummaryOfSignificantAccountingPrinciplesScheduleOfSecuritiesExcludedDueToAntiDilutiveEffectDetail Summary of Significant Accounting Principles - Schedule of Securities Excluded Due To Anti Dilutive Effect (Detail) Details 26 false false R27.htm 1027 - Disclosure - Summary of Significant Accounting Principles - Additional Information (Detail) Sheet http://www.tenonmed.com/role/SummaryOfSignificantAccountingPrinciplesAdditionalInformationDetail Summary of Significant Accounting Principles - Additional Information (Detail) Details 27 false false R28.htm 1028 - Disclosure - Investments - Schedule of Investments At Fair Value in Fair Value Hierarchy Level (Detail) Sheet http://www.tenonmed.com/role/InvestmentsScheduleOfInvestmentsAtFairValueInFairValueHierarchyLevelDetail Investments - Schedule of Investments At Fair Value in Fair Value Hierarchy Level (Detail) Details 28 false false R29.htm 1029 - Disclosure - Investments - Schedule of Cost And Fair Value of Available For Sale Investments (Detail) Sheet http://www.tenonmed.com/role/InvestmentsScheduleOfCostAndFairValueOfAvailableForSaleInvestmentsDetail Investments - Schedule of Cost And Fair Value of Available For Sale Investments (Detail) Details 29 false false R30.htm 1030 - Disclosure - Investments - Additional Information (Detail) Sheet http://www.tenonmed.com/role/InvestmentsAdditionalInformationDetail Investments - Additional Information (Detail) Details 30 false false R31.htm 1031 - Disclosure - Fixed Assets - Summary of Fixed Assets and Equipment Net (Detail) Sheet http://www.tenonmed.com/role/FixedAssetsSummaryOfFixedAssetsAndEquipmentNetDetail Fixed Assets - Summary of Fixed Assets and Equipment Net (Detail) Details 31 false false R32.htm 1032 - Disclosure - Fixed Assets - Additional Information (Detail) Sheet http://www.tenonmed.com/role/FixedAssetsAdditionalInformationDetail Fixed Assets - Additional Information (Detail) Details 32 false false R33.htm 1033 - Disclosure - Accrued Expenses - Schedule of Accrued Expenses (Detail) Sheet http://www.tenonmed.com/role/AccruedExpensesScheduleOfAccruedExpensesDetail Accrued Expenses - Schedule of Accrued Expenses (Detail) Details 33 false false R34.htm 1034 - Disclosure - Debt - Additional Information (Detail) Sheet http://www.tenonmed.com/role/DebtAdditionalInformationDetail Debt - Additional Information (Detail) Details 34 false false R35.htm 1035 - Disclosure - Leases - Summary of Supplemental Balance Sheet Information Related to Leases (Detail) Sheet http://www.tenonmed.com/role/LeasesSummaryOfSupplementalBalanceSheetInformationRelatedToLeasesDetail Leases - Summary of Supplemental Balance Sheet Information Related to Leases (Detail) Details 35 false false R36.htm 1036 - Disclosure - Leases - Summary of Future Maturities of Operating Lease Liabilities (Detail) Sheet http://www.tenonmed.com/role/LeasesSummaryOfFutureMaturitiesOfOperatingLeaseLiabilitiesDetail Leases - Summary of Future Maturities of Operating Lease Liabilities (Detail) Details 36 false false R37.htm 1037 - Disclosure - Leases - Additional Information (Detail) Sheet http://www.tenonmed.com/role/LeasesAdditionalInformationDetail Leases - Additional Information (Detail) Details 37 false false R38.htm 1038 - Disclosure - Stockholders' Equity - Additional Information (Detail) Sheet http://www.tenonmed.com/role/StockholdersEquityAdditionalInformationDetail Stockholders' Equity - Additional Information (Detail) Details 38 false false R39.htm 1039 - Disclosure - Stockholders' Equity - Summary of Share Based Compensation Arrangements By Share Based Payment Award (Detail) Sheet http://www.tenonmed.com/role/StockholdersEquitySummaryOfShareBasedCompensationArrangementsByShareBasedPaymentAwardDetail Stockholders' Equity - Summary of Share Based Compensation Arrangements By Share Based Payment Award (Detail) Details 39 false false R40.htm 1040 - Disclosure - Stockholders' Equity - Summary of Employee Service Share Based Compensation Allocation of Recognized Period Costs (Detail) Sheet http://www.tenonmed.com/role/StockholdersEquitySummaryOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsDetail Stockholders' Equity - Summary of Employee Service Share Based Compensation Allocation of Recognized Period Costs (Detail) Details 40 false false R41.htm 1041 - Disclosure - Commitments and Contingencies - Additional Information (Detail) Sheet http://www.tenonmed.com/role/CommitmentsAndContingenciesAdditionalInformationDetail Commitments and Contingencies - Additional Information (Detail) Details 41 false false R42.htm 1042 - Disclosure - Concentrations of Risk - Additional Information (Detail) Sheet http://www.tenonmed.com/role/ConcentrationsOfRiskAdditionalInformationDetail Concentrations of Risk - Additional Information (Detail) Details 42 false false R43.htm 1043 - Disclosure - Related Party Transactions - Additional Information (Detail) Sheet http://www.tenonmed.com/role/RelatedPartyTransactionsAdditionalInformationDetail Related Party Transactions - Additional Information (Detail) Details 43 false false R44.htm 1044 - Disclosure - Subsequent Events - Additional Information (Detail) Sheet http://www.tenonmed.com/role/SubsequentEventsAdditionalInformationDetail Subsequent Events - Additional Information (Detail) Details 44 false false All Reports Book All Reports [ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 1 fact(s) appearing in ix:hidden were eligible for transformation: us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 - tnon-20220930.htm 4 tnon-20220930.htm cm177_ex31-1.htm cm177_ex31-2.htm cm177_ex32-1.htm cm177_ex32-2.htm tnon-20220930.xsd tnon-20220930_cal.xml tnon-20220930_def.xml tnon-20220930_lab.xml tnon-20220930_pre.xml http://fasb.org/us-gaap/2022 http://xbrl.sec.gov/dei/2022 true true JSON 62 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "tnon-20220930.htm": { "axisCustom": 3, "axisStandard": 27, "contextCount": 248, "dts": { "calculationLink": { "local": [ "tnon-20220930_cal.xml" ] }, "definitionLink": { "local": [ "tnon-20220930_def.xml" ] }, "inline": { "local": [ "tnon-20220930.htm" ] }, "labelLink": { "local": [ "tnon-20220930_lab.xml" ] }, "presentationLink": { "local": [ "tnon-20220930_pre.xml" ] }, "schema": { "local": [ "tnon-20220930.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/srt/2022q3/srt-sup-2022q3.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022q3/us-gaap-sup-2022q3.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/currency/2022/currency-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd", "https://xbrl.sec.gov/exch/2022/exch-2022.xsd", "https://xbrl.sec.gov/naics/2022/naics-2022.xsd", "https://xbrl.sec.gov/sic/2022/sic-2022.xsd", "https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd" ] } }, "elementCount": 468, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2022": 1, "http://xbrl.sec.gov/dei/2022": 5, "total": 6 }, "keyCustom": 50, "keyStandard": 223, "memberCustom": 43, "memberStandard": 30, "nsprefix": "tnon", "nsuri": "http://www.tenonmed.com/20220930", "report": { "R1": { "firstAnchor": { "ancestors": [ "div", "div", "div", "div", "body", "html" ], "baseRef": "tnon-20220930.htm", "contextRef": "P01_01_2022To09_30_2022", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "1001 - Document - Cover Page", "role": "http://www.tenonmed.com/role/CoverPage", "shortName": "Cover Page", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "div", "body", "html" ], "baseRef": "tnon-20220930.htm", "contextRef": "P01_01_2022To09_30_2022", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "tnon-20220930.htm", "contextRef": "P01_01_2022To09_30_2022", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1010 - Disclosure - Fixed Assets", "role": "http://www.tenonmed.com/role/FixedAssets", "shortName": "Fixed Assets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "tnon-20220930.htm", "contextRef": "P01_01_2022To09_30_2022", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "tnon-20220930.htm", "contextRef": "P01_01_2022To09_30_2022", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1011 - Disclosure - Accrued Expenses", "role": "http://www.tenonmed.com/role/AccruedExpenses", "shortName": "Accrued Expenses", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "tnon-20220930.htm", "contextRef": "P01_01_2022To09_30_2022", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "tnon-20220930.htm", "contextRef": "P01_01_2022To09_30_2022", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1012 - Disclosure - Debt", "role": "http://www.tenonmed.com/role/Debt", "shortName": "Debt", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "tnon-20220930.htm", "contextRef": "P01_01_2022To09_30_2022", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "tnon-20220930.htm", "contextRef": "P01_01_2022To09_30_2022", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1013 - Disclosure - Leases", "role": "http://www.tenonmed.com/role/Leases", "shortName": "Leases", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "tnon-20220930.htm", "contextRef": "P01_01_2022To09_30_2022", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "tnon-20220930.htm", "contextRef": "P01_01_2022To09_30_2022", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1014 - Disclosure - Stockholders' Equity", "role": "http://www.tenonmed.com/role/StockholdersEquity", "shortName": "Stockholders' Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "tnon-20220930.htm", "contextRef": "P01_01_2022To09_30_2022", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "tnon-20220930.htm", "contextRef": "P01_01_2022To09_30_2022", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1015 - Disclosure - Commitments and Contingencies", "role": "http://www.tenonmed.com/role/CommitmentsAndContingencies", "shortName": "Commitments and Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "tnon-20220930.htm", "contextRef": "P01_01_2022To09_30_2022", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "tnon-20220930.htm", "contextRef": "P01_01_2022To09_30_2022", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConcentrationRiskDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1016 - Disclosure - Concentrations of Risk", "role": "http://www.tenonmed.com/role/ConcentrationsOfRisk", "shortName": "Concentrations of Risk", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "tnon-20220930.htm", "contextRef": "P01_01_2022To09_30_2022", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConcentrationRiskDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "tnon-20220930.htm", "contextRef": "P01_01_2022To09_30_2022", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1017 - Disclosure - Related Party Transactions", "role": "http://www.tenonmed.com/role/RelatedPartyTransactions", "shortName": "Related Party Transactions", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "tnon-20220930.htm", "contextRef": "P01_01_2022To09_30_2022", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "tnon-20220930.htm", "contextRef": "P01_01_2022To09_30_2022", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1018 - Disclosure - Subsequent Events", "role": "http://www.tenonmed.com/role/SubsequentEvents", "shortName": "Subsequent Events", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "tnon-20220930.htm", "contextRef": "P01_01_2022To09_30_2022", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "baseRef": "tnon-20220930.htm", "contextRef": "P01_01_2022To09_30_2022", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1019 - Disclosure - Summary of Significant Accounting Principles (Policies)", "role": "http://www.tenonmed.com/role/SummaryOfSignificantAccountingPrinciplesPolicies", "shortName": "Summary of Significant Accounting Principles (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "baseRef": "tnon-20220930.htm", "contextRef": "P01_01_2022To09_30_2022", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "tnon-20220930.htm", "contextRef": "PAsOn09_30_2022", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1002 - Statement - Condensed Consolidated Balance Sheets", "role": "http://www.tenonmed.com/role/CondensedConsolidatedBalanceSheets", "shortName": "Condensed Consolidated Balance Sheets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "tnon-20220930.htm", "contextRef": "PAsOn09_30_2022", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "tnon-20220930.htm", "contextRef": "P01_01_2022To09_30_2022", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1020 - Disclosure - Summary of Significant Accounting Principles (Tables)", "role": "http://www.tenonmed.com/role/SummaryOfSignificantAccountingPrinciplesTables", "shortName": "Summary of Significant Accounting Principles (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "tnon-20220930.htm", "contextRef": "P01_01_2022To09_30_2022", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "us-gaap:InvestmentTextBlock", "div", "body", "html" ], "baseRef": "tnon-20220930.htm", "contextRef": "P01_01_2022To09_30_2022", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1021 - Disclosure - Investments (Tables)", "role": "http://www.tenonmed.com/role/InvestmentsTables", "shortName": "Investments (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:InvestmentTextBlock", "div", "body", "html" ], "baseRef": "tnon-20220930.htm", "contextRef": "P01_01_2022To09_30_2022", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "body", "html" ], "baseRef": "tnon-20220930.htm", "contextRef": "P01_01_2022To09_30_2022", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1022 - Disclosure - Fixed Assets (Tables)", "role": "http://www.tenonmed.com/role/FixedAssetsTables", "shortName": "Fixed Assets (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "body", "html" ], "baseRef": "tnon-20220930.htm", "contextRef": "P01_01_2022To09_30_2022", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "div", "body", "html" ], "baseRef": "tnon-20220930.htm", "contextRef": "P01_01_2022To09_30_2022", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1023 - Disclosure - Accrued Expenses (Tables)", "role": "http://www.tenonmed.com/role/AccruedExpensesTables", "shortName": "Accrued Expenses (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "div", "body", "html" ], "baseRef": "tnon-20220930.htm", "contextRef": "P01_01_2022To09_30_2022", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "tnon-20220930.htm", "contextRef": "P01_01_2022To09_30_2022", "decimals": null, "first": true, "lang": "en-US", "name": "tnon:SupplementalBalanceSheetDisclosureRelatedToLeasesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1024 - Disclosure - Leases (Tables)", "role": "http://www.tenonmed.com/role/LeasesTables", "shortName": "Leases (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "tnon-20220930.htm", "contextRef": "P01_01_2022To09_30_2022", "decimals": null, "first": true, "lang": "en-US", "name": "tnon:SupplementalBalanceSheetDisclosureRelatedToLeasesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "tnon-20220930.htm", "contextRef": "P01_01_2022To09_30_2022", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1025 - Disclosure - Stockholders' Equity (Tables)", "role": "http://www.tenonmed.com/role/StockholdersEquityTables", "shortName": "Stockholders' Equity (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "tnon-20220930.htm", "contextRef": "P01_01_2022To09_30_2022", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "div", "div", "div", "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "tnon-20220930.htm", "contextRef": "P01_01_2022To09_30_2022", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "Unit_shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1026 - Disclosure - Summary of Significant Accounting Principles - Schedule of Securities Excluded Due To Anti Dilutive Effect (Detail)", "role": "http://www.tenonmed.com/role/SummaryOfSignificantAccountingPrinciplesScheduleOfSecuritiesExcludedDueToAntiDilutiveEffectDetail", "shortName": "Summary of Significant Accounting Principles - Schedule of Securities Excluded Due To Anti Dilutive Effect (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "tnon-20220930.htm", "contextRef": "P01_01_2022To09_30_2022", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "Unit_shares", "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "div", "us-gaap:IncomeTaxPolicyTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "tnon-20220930.htm", "contextRef": "P01_01_2022To09_30_2022", "decimals": "2", "first": true, "lang": null, "name": "tnon:PercentageOfValuationAllowanceInDeferredTaxAssets", "reportCount": 1, "unique": true, "unitRef": "Unit_pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1027 - Disclosure - Summary of Significant Accounting Principles - Additional Information (Detail)", "role": "http://www.tenonmed.com/role/SummaryOfSignificantAccountingPrinciplesAdditionalInformationDetail", "shortName": "Summary of Significant Accounting Principles - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:IncomeTaxPolicyTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "tnon-20220930.htm", "contextRef": "P01_01_2022To09_30_2022", "decimals": "2", "first": true, "lang": null, "name": "tnon:PercentageOfValuationAllowanceInDeferredTaxAssets", "reportCount": 1, "unique": true, "unitRef": "Unit_pure", "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "div", "div", "div", "td", "tr", "table", "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "us-gaap:InvestmentTextBlock", "div", "body", "html" ], "baseRef": "tnon-20220930.htm", "contextRef": "PAsOn09_30_2022_CorporateDebtSecuritiesMemberusgaapFinancialInstrumentAxis_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:InvestmentsFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1028 - Disclosure - Investments - Schedule of Investments At Fair Value in Fair Value Hierarchy Level (Detail)", "role": "http://www.tenonmed.com/role/InvestmentsScheduleOfInvestmentsAtFairValueInFairValueHierarchyLevelDetail", "shortName": "Investments - Schedule of Investments At Fair Value in Fair Value Hierarchy Level (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "td", "tr", "table", "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "us-gaap:InvestmentTextBlock", "div", "body", "html" ], "baseRef": "tnon-20220930.htm", "contextRef": "PAsOn09_30_2022_CorporateDebtSecuritiesMemberusgaapFinancialInstrumentAxis_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:InvestmentsFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "div", "div", "div", "td", "tr", "table", "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "us-gaap:InvestmentTextBlock", "div", "body", "html" ], "baseRef": "tnon-20220930.htm", "contextRef": "PAsOn09_30_2022_CorporateDebtSecuritiesMemberusgaapFinancialInstrumentAxis", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1029 - Disclosure - Investments - Schedule of Cost And Fair Value of Available For Sale Investments (Detail)", "role": "http://www.tenonmed.com/role/InvestmentsScheduleOfCostAndFairValueOfAvailableForSaleInvestmentsDetail", "shortName": "Investments - Schedule of Cost And Fair Value of Available For Sale Investments (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "td", "tr", "table", "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "us-gaap:InvestmentTextBlock", "div", "body", "html" ], "baseRef": "tnon-20220930.htm", "contextRef": "PAsOn09_30_2022_CorporateDebtSecuritiesMemberusgaapFinancialInstrumentAxis", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "tnon-20220930.htm", "contextRef": "PAsOn09_30_2022", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DebtInstrumentUnamortizedDiscountCurrent", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)", "role": "http://www.tenonmed.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "tnon-20220930.htm", "contextRef": "PAsOn09_30_2022", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DebtInstrumentUnamortizedDiscountCurrent", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "tnon-20220930.htm", "contextRef": "P07_01_2022To09_30_2022", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OtherThanTemporaryImpairmentLossesInvestmentsPortionInOtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAvailableforsaleSecurities", "reportCount": 1, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1030 - Disclosure - Investments - Additional Information (Detail)", "role": "http://www.tenonmed.com/role/InvestmentsAdditionalInformationDetail", "shortName": "Investments - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "div", "us-gaap:InvestmentTextBlock", "div", "body", "html" ], "baseRef": "tnon-20220930.htm", "contextRef": "PAsOn12_31_2021_PrepaidExpensesAndOtherCurrentAssetsMemberusgaapBalanceSheetLocationAxis", "decimals": "-3", "lang": null, "name": "tnon:AccruedInterest", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "div", "div", "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "body", "html" ], "baseRef": "tnon-20220930.htm", "contextRef": "PAsOn09_30_2022", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1031 - Disclosure - Fixed Assets - Summary of Fixed Assets and Equipment Net (Detail)", "role": "http://www.tenonmed.com/role/FixedAssetsSummaryOfFixedAssetsAndEquipmentNetDetail", "shortName": "Fixed Assets - Summary of Fixed Assets and Equipment Net (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "div", "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "body", "html" ], "baseRef": "tnon-20220930.htm", "contextRef": "PAsOn09_30_2022", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "div", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "tnon-20220930.htm", "contextRef": "P07_01_2022To09_30_2022", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:Depreciation", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1032 - Disclosure - Fixed Assets - Additional Information (Detail)", "role": "http://www.tenonmed.com/role/FixedAssetsAdditionalInformationDetail", "shortName": "Fixed Assets - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "tnon-20220930.htm", "contextRef": "P07_01_2022To09_30_2022", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:Depreciation", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "div", "div", "td", "tr", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "div", "body", "html" ], "baseRef": "tnon-20220930.htm", "contextRef": "PAsOn09_30_2022", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:EmployeeRelatedLiabilitiesCurrentAndNoncurrent", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1033 - Disclosure - Accrued Expenses - Schedule of Accrued Expenses (Detail)", "role": "http://www.tenonmed.com/role/AccruedExpensesScheduleOfAccruedExpensesDetail", "shortName": "Accrued Expenses - Schedule of Accrued Expenses (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "div", "td", "tr", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "div", "body", "html" ], "baseRef": "tnon-20220930.htm", "contextRef": "PAsOn09_30_2022", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:EmployeeRelatedLiabilitiesCurrentAndNoncurrent", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "div", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "tnon-20220930.htm", "contextRef": "P04_29_2022To04_29_2022_IPOMemberusgaapSubsidiarySaleOfStockAxis", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities", "reportCount": 1, "unique": true, "unitRef": "Unit_shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1034 - Disclosure - Debt - Additional Information (Detail)", "role": "http://www.tenonmed.com/role/DebtAdditionalInformationDetail", "shortName": "Debt - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "tnon-20220930.htm", "contextRef": "P04_29_2022To04_29_2022_IPOMemberusgaapSubsidiarySaleOfStockAxis", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities", "reportCount": 1, "unique": true, "unitRef": "Unit_shares", "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "tnon-20220930.htm", "contextRef": "PAsOn09_30_2022", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseRightOfUseAsset", "reportCount": 1, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1035 - Disclosure - Leases - Summary of Supplemental Balance Sheet Information Related to Leases (Detail)", "role": "http://www.tenonmed.com/role/LeasesSummaryOfSupplementalBalanceSheetInformationRelatedToLeasesDetail", "shortName": "Leases - Summary of Supplemental Balance Sheet Information Related to Leases (Detail)", "subGroupType": "details", "uniqueAnchor": null }, "R36": { "firstAnchor": { "ancestors": [ "div", "div", "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "tnon-20220930.htm", "contextRef": "PAsOn09_30_2022", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1036 - Disclosure - Leases - Summary of Future Maturities of Operating Lease Liabilities (Detail)", "role": "http://www.tenonmed.com/role/LeasesSummaryOfFutureMaturitiesOfOperatingLeaseLiabilitiesDetail", "shortName": "Leases - Summary of Future Maturities of Operating Lease Liabilities (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "div", "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "tnon-20220930.htm", "contextRef": "PAsOn09_30_2022", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "div", "div", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "body", "html" ], "baseRef": "tnon-20220930.htm", "contextRef": "P06_01_2021To06_30_2021", "decimals": null, "first": true, "lang": "en-US", "name": "tnon:LesseeOperatingLeaseExpirationMonthAndYear", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1037 - Disclosure - Leases - Additional Information (Detail)", "role": "http://www.tenonmed.com/role/LeasesAdditionalInformationDetail", "shortName": "Leases - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "div", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "body", "html" ], "baseRef": "tnon-20220930.htm", "contextRef": "P06_01_2021To06_30_2021", "decimals": null, "first": true, "lang": "en-US", "name": "tnon:LesseeOperatingLeaseExpirationMonthAndYear", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "div", "div", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html" ], "baseRef": "tnon-20220930.htm", "contextRef": "PAsOn10_31_2021", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockSharesAuthorized", "reportCount": 1, "unique": true, "unitRef": "Unit_shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1038 - Disclosure - Stockholders' Equity - Additional Information (Detail)", "role": "http://www.tenonmed.com/role/StockholdersEquityAdditionalInformationDetail", "shortName": "Stockholders' Equity - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "div", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html" ], "baseRef": "tnon-20220930.htm", "contextRef": "PAsOn10_31_2021", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockSharesAuthorized", "reportCount": 1, "unique": true, "unitRef": "Unit_shares", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "div", "div", "td", "tr", "table", "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "ix:continuation", "body", "html" ], "baseRef": "tnon-20220930.htm", "contextRef": "PAsOn12_31_2021", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares", "reportCount": 1, "unique": true, "unitRef": "Unit_shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1039 - Disclosure - Stockholders' Equity - Summary of Share Based Compensation Arrangements By Share Based Payment Award (Detail)", "role": "http://www.tenonmed.com/role/StockholdersEquitySummaryOfShareBasedCompensationArrangementsByShareBasedPaymentAwardDetail", "shortName": "Stockholders' Equity - Summary of Share Based Compensation Arrangements By Share Based Payment Award (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "div", "td", "tr", "table", "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "ix:continuation", "body", "html" ], "baseRef": "tnon-20220930.htm", "contextRef": "PAsOn12_31_2021", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares", "reportCount": 1, "unique": true, "unitRef": "Unit_shares", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "tnon-20220930.htm", "contextRef": "P07_01_2022To09_30_2022", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss", "role": "http://www.tenonmed.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss", "shortName": "Condensed Consolidated Statements of Operations and Comprehensive Loss", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "tnon-20220930.htm", "contextRef": "P07_01_2022To09_30_2022", "decimals": "-3", "lang": null, "name": "us-gaap:CostOfRevenue", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "tnon-20220930.htm", "contextRef": "P07_01_2022To09_30_2022", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1040 - Disclosure - Stockholders' Equity - Summary of Employee Service Share Based Compensation Allocation of Recognized Period Costs (Detail)", "role": "http://www.tenonmed.com/role/StockholdersEquitySummaryOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsDetail", "shortName": "Stockholders' Equity - Summary of Employee Service Share Based Compensation Allocation of Recognized Period Costs (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "div", "td", "tr", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "tnon-20220930.htm", "contextRef": "P07_01_2022To09_30_2022_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis", "decimals": "-3", "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "tnon-20220930.htm", "contextRef": "P07_01_2022To09_30_2022", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:SellingAndMarketingExpense", "reportCount": 1, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1041 - Disclosure - Commitments and Contingencies - Additional Information (Detail)", "role": "http://www.tenonmed.com/role/CommitmentsAndContingenciesAdditionalInformationDetail", "shortName": "Commitments and Contingencies - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "div", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "tnon-20220930.htm", "contextRef": "P07_21_2022To07_21_2022_KeyMedicalMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis", "decimals": "-3", "lang": null, "name": "us-gaap:LitigationSettlementAmountAwardedToOtherParty", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "div", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "tnon-20220930.htm", "contextRef": "PAsOn09_30_2022_CHFsrtCurrencyAxis_NetAssetsGeographicAreaMemberusgaapConcentrationRiskByBenchmarkAxis", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AssetsNet", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1042 - Disclosure - Concentrations of Risk - Additional Information (Detail)", "role": "http://www.tenonmed.com/role/ConcentrationsOfRiskAdditionalInformationDetail", "shortName": "Concentrations of Risk - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "tnon-20220930.htm", "contextRef": "PAsOn09_30_2022_CHFsrtCurrencyAxis_NetAssetsGeographicAreaMemberusgaapConcentrationRiskByBenchmarkAxis", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AssetsNet", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "tnon-20220930.htm", "contextRef": "P07_01_2022To09_30_2022", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1043 - Disclosure - Related Party Transactions - Additional Information (Detail)", "role": "http://www.tenonmed.com/role/RelatedPartyTransactionsAdditionalInformationDetail", "shortName": "Related Party Transactions - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "div", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "div", "body", "html" ], "baseRef": "tnon-20220930.htm", "contextRef": "PAsOn12_31_2021_IpSaleAndPurchaseAgreementMemberusgaapRelatedPartyTransactionAxis_UnsecuredPromissoryNoteMemberusgaapDebtInstrumentAxis", "decimals": "-3", "lang": null, "name": "us-gaap:DebtInstrumentFaceAmount", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "tnon-20220930.htm", "contextRef": "P07_01_2022To09_30_2022", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:SellingAndMarketingExpense", "reportCount": 1, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1044 - Disclosure - Subsequent Events - Additional Information (Detail)", "role": "http://www.tenonmed.com/role/SubsequentEventsAdditionalInformationDetail", "shortName": "Subsequent Events - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "div", "us-gaap:SubsequentEventsTextBlock", "div", "body", "html" ], "baseRef": "tnon-20220930.htm", "contextRef": "P10_06_2022To10_06_2022_RepresentativeMembersrtCounterpartyNameAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis_TerminationAgreementMemberTNONAgreementAxis", "decimals": "-3", "lang": null, "name": "tnon:PaymentToRepresentativeAsPerAgreement", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "tnon-20220930.htm", "contextRef": "PAsOn12_31_2020_SeriesAConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1005 - Statement - Condensed Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit)", "role": "http://www.tenonmed.com/role/CondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit", "shortName": "Condensed Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "tnon-20220930.htm", "contextRef": "PAsOn12_31_2020_SeriesAConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "tnon-20220930.htm", "contextRef": "P01_01_2022To09_30_2022", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1006 - Statement - Condensed Consolidated Statements of Cash Flows", "role": "http://www.tenonmed.com/role/CondensedConsolidatedStatementsOfCashFlows", "shortName": "Condensed Consolidated Statements of Cash Flows", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "tnon-20220930.htm", "contextRef": "P01_01_2022To09_30_2022", "decimals": "-3", "lang": null, "name": "us-gaap:UnrealizedGainLossOnInvestments", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "tnon-20220930.htm", "contextRef": "P01_01_2022To09_30_2022", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1007 - Disclosure - Organization and Business", "role": "http://www.tenonmed.com/role/OrganizationAndBusiness", "shortName": "Organization and Business", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "tnon-20220930.htm", "contextRef": "P01_01_2022To09_30_2022", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "tnon-20220930.htm", "contextRef": "P01_01_2022To09_30_2022", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1008 - Disclosure - Summary of Significant Accounting Principles", "role": "http://www.tenonmed.com/role/SummaryOfSignificantAccountingPrinciples", "shortName": "Summary of Significant Accounting Principles", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "tnon-20220930.htm", "contextRef": "P01_01_2022To09_30_2022", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "tnon-20220930.htm", "contextRef": "P01_01_2022To09_30_2022", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InvestmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1009 - Disclosure - Investments", "role": "http://www.tenonmed.com/role/Investments", "shortName": "Investments", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "tnon-20220930.htm", "contextRef": "P01_01_2022To09_30_2022", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InvestmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 78, "tag": { "currency_AllCurrenciesDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "All Currencies [Domain]" } } }, "localname": "AllCurrenciesDomain", "nsuri": "http://xbrl.sec.gov/currency/2022", "presentation": [ "http://www.tenonmed.com/role/ConcentrationsOfRiskAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "currency_CHF": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Switzerland, Francs", "terseLabel": "Switzerland, Francs [Member]" } } }, "localname": "CHF", "nsuri": "http://xbrl.sec.gov/currency/2022", "presentation": [ "http://www.tenonmed.com/role/ConcentrationsOfRiskAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.tenonmed.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.tenonmed.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.tenonmed.com/role/CoverPage" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.tenonmed.com/role/CoverPage" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.tenonmed.com/role/CoverPage" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.tenonmed.com/role/CoverPage" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r543" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.tenonmed.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r544" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.tenonmed.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.tenonmed.com/role/CoverPage" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.tenonmed.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.tenonmed.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.tenonmed.com/role/CoverPage" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.tenonmed.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r541" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.tenonmed.com/role/CoverPage" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.tenonmed.com/role/CoverPage" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.tenonmed.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.", "label": "Entity [Domain]" } } }, "localname": "EntityDomain", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.tenonmed.com/role/StockholdersEquityAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r541" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.tenonmed.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r553" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Entity Ex Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.tenonmed.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.tenonmed.com/role/CoverPage" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r541" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.tenonmed.com/role/CoverPage" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.tenonmed.com/role/CoverPage" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r552" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.tenonmed.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r541" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.tenonmed.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r541" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.tenonmed.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r541" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.tenonmed.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r541" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.tenonmed.com/role/CoverPage" ], "xbrltype": "employerIdItemType" }, "dei_LegalEntityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The set of legal entities associated with a report.", "label": "Legal Entity [Axis]" } } }, "localname": "LegalEntityAxis", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.tenonmed.com/role/StockholdersEquityAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.tenonmed.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r540" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.tenonmed.com/role/CoverPage" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r542" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.tenonmed.com/role/CoverPage" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.tenonmed.com/role/CoverPage" ], "xbrltype": "tradingSymbolItemType" }, "srt_ChiefExecutiveOfficerMember": { "auth_ref": [ "r172" ], "lang": { "en-us": { "role": { "label": "Chief Executive Officer [Member]" } } }, "localname": "ChiefExecutiveOfficerMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.tenonmed.com/role/DebtAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "srt_CounterpartyNameAxis": { "auth_ref": [ "r46", "r48", "r105", "r106", "r245", "r281" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Axis]" } } }, "localname": "CounterpartyNameAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.tenonmed.com/role/CommitmentsAndContingenciesAdditionalInformationDetail", "http://www.tenonmed.com/role/StockholdersEquityAdditionalInformationDetail", "http://www.tenonmed.com/role/SubsequentEventsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "srt_CurrencyAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Currency [Axis]" } } }, "localname": "CurrencyAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.tenonmed.com/role/ConcentrationsOfRiskAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "srt_EquityMethodInvesteeNameDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Investment, Name [Domain]" } } }, "localname": "EquityMethodInvesteeNameDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.tenonmed.com/role/CommitmentsAndContingenciesAdditionalInformationDetail", "http://www.tenonmed.com/role/StockholdersEquityAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "srt_MaximumMember": { "auth_ref": [ "r220", "r222", "r223", "r224", "r244", "r280", "r309", "r310", "r437", "r438", "r439", "r440", "r441", "r442", "r461", "r513", "r514", "r537", "r538" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]", "terseLabel": "Maximum [Member]" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.tenonmed.com/role/StockholdersEquityAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r220", "r222", "r223", "r224", "r244", "r280", "r309", "r310", "r437", "r438", "r439", "r440", "r441", "r442", "r461", "r513", "r514", "r537", "r538" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]", "terseLabel": "Minimum [Member]" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.tenonmed.com/role/StockholdersEquityAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r213", "r220", "r222", "r223", "r224", "r244", "r280", "r299", "r309", "r310", "r335", "r336", "r337", "r437", "r438", "r439", "r440", "r441", "r442", "r461", "r513", "r514", "r537", "r538" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.tenonmed.com/role/StockholdersEquityAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r213", "r220", "r222", "r223", "r224", "r244", "r280", "r299", "r309", "r310", "r335", "r336", "r337", "r437", "r438", "r439", "r440", "r441", "r442", "r461", "r513", "r514", "r537", "r538" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.tenonmed.com/role/StockholdersEquityAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "auth_ref": [ "r47", "r48", "r105", "r106", "r245", "r281" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Domain]" } } }, "localname": "RepurchaseAgreementCounterpartyNameDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.tenonmed.com/role/CommitmentsAndContingenciesAdditionalInformationDetail", "http://www.tenonmed.com/role/StockholdersEquityAdditionalInformationDetail", "http://www.tenonmed.com/role/SubsequentEventsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "srt_RestatementAxis": { "auth_ref": [ "r1", "r109", "r110", "r111", "r112", "r113", "r114", "r115", "r116", "r117", "r119", "r120", "r121", "r122", "r123", "r124", "r137", "r193", "r194", "r354", "r375", "r376", "r377", "r378", "r403", "r414", "r415", "r515", "r516", "r517", "r518", "r519", "r520", "r521", "r522", "r523", "r524" ], "lang": { "en-us": { "role": { "label": "Revision of Prior Period [Axis]" } } }, "localname": "RestatementAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.tenonmed.com/role/StockholdersEquityAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "srt_RestatementDomain": { "auth_ref": [ "r1", "r109", "r110", "r111", "r112", "r113", "r114", "r115", "r116", "r117", "r119", "r120", "r121", "r122", "r123", "r124", "r137", "r193", "r194", "r354", "r375", "r376", "r377", "r378", "r403", "r414", "r415", "r515", "r516", "r517", "r518", "r519", "r520", "r521", "r522", "r523", "r524" ], "lang": { "en-us": { "role": { "label": "Revision of Prior Period [Domain]" } } }, "localname": "RestatementDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.tenonmed.com/role/StockholdersEquityAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": { "auth_ref": [ "r188" ], "lang": { "en-us": { "role": { "label": "Investment, Name [Axis]" } } }, "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.tenonmed.com/role/CommitmentsAndContingenciesAdditionalInformationDetail", "http://www.tenonmed.com/role/StockholdersEquityAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualAxis": { "auth_ref": [ "r172", "r421" ], "lang": { "en-us": { "role": { "label": "Title of Individual [Axis]" } } }, "localname": "TitleOfIndividualAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.tenonmed.com/role/StockholdersEquityAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Title of Individual [Domain]" } } }, "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.tenonmed.com/role/StockholdersEquityAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "tnon_AccruedInterest": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accrued interest.", "label": "Accrued Interest", "verboseLabel": "Accrued interest" } } }, "localname": "AccruedInterest", "nsuri": "http://www.tenonmed.com/20220930", "presentation": [ "http://www.tenonmed.com/role/InvestmentsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "tnon_AccruedInterestOnTheDebtArrangements": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accrued interest on the debt arrangements.", "label": "Accrued Interest On The Debt Arrangements", "terseLabel": "Accrued Interest" } } }, "localname": "AccruedInterestOnTheDebtArrangements", "nsuri": "http://www.tenonmed.com/20220930", "presentation": [ "http://www.tenonmed.com/role/DebtAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "tnon_AdditionalCompensationPayablePerQuarter": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Additional compensation payable per quarter.", "label": "Additional Compensation Payable Per Quarter", "terseLabel": "Additional compensation payable per quarter" } } }, "localname": "AdditionalCompensationPayablePerQuarter", "nsuri": "http://www.tenonmed.com/20220930", "presentation": [ "http://www.tenonmed.com/role/SubsequentEventsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "tnon_AdditionalTermOfAgreementByMutualAgreementOfThePartiesInWriting": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Additional term of agreement by mutual agreement of the parties in writing.", "label": "Additional Term Of Agreement By Mutual Agreement Of The Parties In Writing", "terseLabel": "Additional term of agreement by mutual agreement of the parties in writing" } } }, "localname": "AdditionalTermOfAgreementByMutualAgreementOfThePartiesInWriting", "nsuri": "http://www.tenonmed.com/20220930", "presentation": [ "http://www.tenonmed.com/role/SubsequentEventsAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "tnon_AgreementAdditionalExtensionTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Agreement additional extension term.", "label": "Agreement Additional Extension Term", "terseLabel": "Agreement additional extension term" } } }, "localname": "AgreementAdditionalExtensionTerm", "nsuri": "http://www.tenonmed.com/20220930", "presentation": [ "http://www.tenonmed.com/role/CommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "tnon_AgreementAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Agreement.", "label": "Agreement [Axis]" } } }, "localname": "AgreementAxis", "nsuri": "http://www.tenonmed.com/20220930", "presentation": [ "http://www.tenonmed.com/role/CommitmentsAndContingenciesAdditionalInformationDetail", "http://www.tenonmed.com/role/StockholdersEquityAdditionalInformationDetail", "http://www.tenonmed.com/role/SubsequentEventsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "tnon_AgreementDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Agreement.", "label": "Agreement [Domain]" } } }, "localname": "AgreementDomain", "nsuri": "http://www.tenonmed.com/20220930", "presentation": [ "http://www.tenonmed.com/role/CommitmentsAndContingenciesAdditionalInformationDetail", "http://www.tenonmed.com/role/StockholdersEquityAdditionalInformationDetail", "http://www.tenonmed.com/role/SubsequentEventsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "tnon_AgreementTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Agreement term.", "label": "Agreement Term", "terseLabel": "Agreement term" } } }, "localname": "AgreementTerm", "nsuri": "http://www.tenonmed.com/20220930", "presentation": [ "http://www.tenonmed.com/role/CommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "tnon_AmendedAndRestatedExclusiveSalesRepresentativeAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Amended and restated exclusive sales representative agreement.", "label": "Amended and Restated Exclusive Sales Representative Agreement [Member]", "terseLabel": "Amended and Restated Exclusive Sales Representative Agreement [Member]" } } }, "localname": "AmendedAndRestatedExclusiveSalesRepresentativeAgreementMember", "nsuri": "http://www.tenonmed.com/20220930", "presentation": [ "http://www.tenonmed.com/role/CommitmentsAndContingenciesAdditionalInformationDetail", "http://www.tenonmed.com/role/StockholdersEquityAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "tnon_ArbitrationClaimMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Arbitration Claim.", "label": "Arbitration Claim [Member]", "terseLabel": "Arbitration Claim [Member]" } } }, "localname": "ArbitrationClaimMember", "nsuri": "http://www.tenonmed.com/20220930", "presentation": [ "http://www.tenonmed.com/role/CommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "tnon_AsPerAgreementValueAgreedToPayTheRepresentativePerMonth": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "As per agreement value agreed to pay the representative per month.", "label": "As Per Agreement Value Agreed To Pay The Representative Per Month", "terseLabel": "As per agreement value agreed to pay the representative per month" } } }, "localname": "AsPerAgreementValueAgreedToPayTheRepresentativePerMonth", "nsuri": "http://www.tenonmed.com/20220930", "presentation": [ "http://www.tenonmed.com/role/SubsequentEventsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "tnon_AsPerAgreementValueToPayTheRepresentativeInTheEventOfAcquisitionNetOfPreviousAmountPaid": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "As per agreement value to pay the representative in the event of acquisition net of previous amount paid.", "label": "As Per Agreement Value To Pay The Representative In The Event Of Acquisition Net Of Previous Amount Paid", "terseLabel": "As per agreement value to pay the representative in the event of acquisition net of previous amount paid" } } }, "localname": "AsPerAgreementValueToPayTheRepresentativeInTheEventOfAcquisitionNetOfPreviousAmountPaid", "nsuri": "http://www.tenonmed.com/20220930", "presentation": [ "http://www.tenonmed.com/role/SubsequentEventsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "tnon_CatamaranTraySetsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Catamaran Tray Sets", "label": "Catamaran Tray Sets [Member]" } } }, "localname": "CatamaranTraySetsMember", "nsuri": "http://www.tenonmed.com/20220930", "presentation": [ "http://www.tenonmed.com/role/FixedAssetsSummaryOfFixedAssetsAndEquipmentNetDetail" ], "xbrltype": "domainItemType" }, "tnon_ChiefExecutiveOfficerOfTheRepresentativeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Chief executive officer of the representative.", "label": "Chief Executive Officer of the Representative [Member]" } } }, "localname": "ChiefExecutiveOfficerOfTheRepresentativeMember", "nsuri": "http://www.tenonmed.com/20220930", "presentation": [ "http://www.tenonmed.com/role/DebtAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "tnon_ClassOfWarrantsOfRightsGrantDateFairValueOfWarrants": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Class of warrants of rights grant date fair value of warrants .", "label": "Class Of Warrants Of Rights Grant Date Fair Value Of Warrants", "terseLabel": "Class of warrants of rights grant date fair value of warrants" } } }, "localname": "ClassOfWarrantsOfRightsGrantDateFairValueOfWarrants", "nsuri": "http://www.tenonmed.com/20220930", "presentation": [ "http://www.tenonmed.com/role/StockholdersEquityAdditionalInformationDetail" ], "xbrltype": "perShareItemType" }, "tnon_CommonStockIssuedUponConversionOfDebt": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Common stock issued upon conversion of debt.", "label": "Common Stock Issued Upon Conversion Of Debt", "terseLabel": "Common stock issued upon conversion of debt" } } }, "localname": "CommonStockIssuedUponConversionOfDebt", "nsuri": "http://www.tenonmed.com/20220930", "presentation": [ "http://www.tenonmed.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "tnon_CommonStockIssuedUponConversionOfPreferredStock": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Common stock issued upon conversion of preferred stock.", "label": "Common Stock Issued Upon Conversion Of Preferred Stock", "terseLabel": "Common stock issued upon conversion of preferred stock" } } }, "localname": "CommonStockIssuedUponConversionOfPreferredStock", "nsuri": "http://www.tenonmed.com/20220930", "presentation": [ "http://www.tenonmed.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "tnon_CommonStockWarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Common stock warrants.", "label": "Common Stock Warrants [Member]" } } }, "localname": "CommonStockWarrantsMember", "nsuri": "http://www.tenonmed.com/20220930", "presentation": [ "http://www.tenonmed.com/role/StockholdersEquityAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "tnon_ConsultantMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Consultant.", "label": "Consultant [Member]" } } }, "localname": "ConsultantMember", "nsuri": "http://www.tenonmed.com/20220930", "presentation": [ "http://www.tenonmed.com/role/DebtAdditionalInformationDetail", "http://www.tenonmed.com/role/StockholdersEquityAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "tnon_ConsultingAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Consulting agreement.", "label": "Consulting Agreement [Member]", "terseLabel": "Consulting Agreement [Member]" } } }, "localname": "ConsultingAgreementMember", "nsuri": "http://www.tenonmed.com/20220930", "presentation": [ "http://www.tenonmed.com/role/RelatedPartyTransactionsAdditionalInformationDetail", "http://www.tenonmed.com/role/SubsequentEventsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "tnon_ConsultingAgreementMontlyPayments": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Consulting agreement monthly payments.", "label": "Consulting Agreement Montly Payments", "terseLabel": "Consulting agreement monthly payments" } } }, "localname": "ConsultingAgreementMontlyPayments", "nsuri": "http://www.tenonmed.com/20220930", "presentation": [ "http://www.tenonmed.com/role/RelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "tnon_ConsultingAgreementTrancheOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Consulting Agreement Tranche One.", "label": "Consulting Agreement Tranche One [Member]", "terseLabel": "Consulting Agreement Tranche One [Member]" } } }, "localname": "ConsultingAgreementTrancheOneMember", "nsuri": "http://www.tenonmed.com/20220930", "presentation": [ "http://www.tenonmed.com/role/RelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "tnon_ConsultingAgreementTrancheTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Consulting Agreement Tranche Two.", "label": "Consulting Agreement Tranche Two [Member]", "terseLabel": "Consulting Agreement Tranche Two [Member]" } } }, "localname": "ConsultingAgreementTrancheTwoMember", "nsuri": "http://www.tenonmed.com/20220930", "presentation": [ "http://www.tenonmed.com/role/RelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "tnon_ConsultingFeePerYearPayableInMonthlyInstallments": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Consulting fee per year payable in monthly installments.", "label": "Consulting Fee Per Year Payable In Monthly Installments", "terseLabel": "Consulting fee per year payable in monthly installments" } } }, "localname": "ConsultingFeePerYearPayableInMonthlyInstallments", "nsuri": "http://www.tenonmed.com/20220930", "presentation": [ "http://www.tenonmed.com/role/SubsequentEventsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "tnon_ConversionOfConvertibleNotesToCommonStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Conversion of convertible notes to common stock.", "label": "Conversion of Convertible Notes to Common Stock [Member]", "terseLabel": "Conversion of Convertible Notes to Common Stock [Member]" } } }, "localname": "ConversionOfConvertibleNotesToCommonStockMember", "nsuri": "http://www.tenonmed.com/20220930", "presentation": [ "http://www.tenonmed.com/role/StockholdersEquityAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "tnon_ConversionOfSeriesAAndSeriesBPreferredStockToCommonStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Conversion of Series A and Series B Preferred Stock to Common Stock.", "label": "Conversion of Series A and Series B Preferred Stock to Common Stock [Member]", "terseLabel": "Conversion of Series A and Series B Preferred Stock to Common Stock [Member]" } } }, "localname": "ConversionOfSeriesAAndSeriesBPreferredStockToCommonStockMember", "nsuri": "http://www.tenonmed.com/20220930", "presentation": [ "http://www.tenonmed.com/role/StockholdersEquityAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "tnon_ConversionOfTradePayableToLawFirmToNotePayable": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Conversion of trade payable to law firm to note payable.", "label": "Conversion Of Trade Payable To Law Firm To Note Payable", "terseLabel": "Conversion of trade payable to law firm to note payable" } } }, "localname": "ConversionOfTradePayableToLawFirmToNotePayable", "nsuri": "http://www.tenonmed.com/20220930", "presentation": [ "http://www.tenonmed.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "tnon_ConvertibleNotesPayableAndAccruedInterestDueToRelatedPartiesNetOfDebtDiscountCurrent": { "auth_ref": [], "calculation": { "http://www.tenonmed.com/role/CondensedConsolidatedBalanceSheets": { "order": 18.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Convertible notes payable and accrued interest due to related parties net of debt discount current.", "label": "Convertible Notes Payable And Accrued Interest Due To Related Parties Net Of Debt Discount Current", "terseLabel": "Convertible notes payable and accrued interest due to related parties, net of debt discount of $0 and $2 at June 30, 2022 and December 31, 2021, respectively" } } }, "localname": "ConvertibleNotesPayableAndAccruedInterestDueToRelatedPartiesNetOfDebtDiscountCurrent", "nsuri": "http://www.tenonmed.com/20220930", "presentation": [ "http://www.tenonmed.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "tnon_ConvertibleNotesPayableAndAccruedInterestNetOfDebtDiscountCurrent": { "auth_ref": [], "calculation": { "http://www.tenonmed.com/role/CondensedConsolidatedBalanceSheets": { "order": 17.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Convertible notes payable and accrued interest net of debt discount current.", "label": "Convertible Notes Payable And Accrued Interest Net Of Debt Discount Current", "terseLabel": "Convertible notes payable and accrued interest, net of debt discount of $0 and $31 at June 30, 2022 and December 31, 2021, respectively" } } }, "localname": "ConvertibleNotesPayableAndAccruedInterestNetOfDebtDiscountCurrent", "nsuri": "http://www.tenonmed.com/20220930", "presentation": [ "http://www.tenonmed.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "tnon_ConvertiblePromissoryNotesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Convertible Promissory Notes.", "label": "Convertible Promissory Notes [Member]", "terseLabel": "Convertible Promissory Notes [Member]" } } }, "localname": "ConvertiblePromissoryNotesMember", "nsuri": "http://www.tenonmed.com/20220930", "presentation": [ "http://www.tenonmed.com/role/DebtAdditionalInformationDetail", "http://www.tenonmed.com/role/RelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "tnon_ConvertiblePromissoryNotesOneAndTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Convertible promissory notes one and two.", "label": "Convertible Promissory Notes One and Two [Member]" } } }, "localname": "ConvertiblePromissoryNotesOneAndTwoMember", "nsuri": "http://www.tenonmed.com/20220930", "presentation": [ "http://www.tenonmed.com/role/DebtAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "tnon_ConvertiblePromissoryNotesOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Convertible promissory notes one.", "label": "Convertible Promissory Notes One [Member]" } } }, "localname": "ConvertiblePromissoryNotesOneMember", "nsuri": "http://www.tenonmed.com/20220930", "presentation": [ "http://www.tenonmed.com/role/DebtAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "tnon_ConvertiblePromissoryNotesTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Convertible promissory notes two.", "label": "Convertible Promissory Notes Two [Member]" } } }, "localname": "ConvertiblePromissoryNotesTwoMember", "nsuri": "http://www.tenonmed.com/20220930", "presentation": [ "http://www.tenonmed.com/role/DebtAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "tnon_DebtConversionConvertibleAutomaticallyUponTheMinimumAmountOfInitialPublicOfferingOrCapitalStockFinancing": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Debt conversion convertible automatically upon the minimum amount of initial public offering or capital stock financing.", "label": "Debt Conversion Convertible Automatically Upon The Minimum Amount Of Initial Public Offering Or Capital Stock Financing" } } }, "localname": "DebtConversionConvertibleAutomaticallyUponTheMinimumAmountOfInitialPublicOfferingOrCapitalStockFinancing", "nsuri": "http://www.tenonmed.com/20220930", "presentation": [ "http://www.tenonmed.com/role/DebtAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "tnon_DebtConversionConvertiblePricePerShareAtAValuationAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Debt conversion convertible price per share at a valuation amount.", "label": "Debt Conversion Convertible Price Per Share At A Valuation Amount", "terseLabel": "Valuation amount" } } }, "localname": "DebtConversionConvertiblePricePerShareAtAValuationAmount", "nsuri": "http://www.tenonmed.com/20220930", "presentation": [ "http://www.tenonmed.com/role/DebtAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "tnon_DebtDisclosureLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Disclosure.", "label": "Debt Disclosure [Line Items]" } } }, "localname": "DebtDisclosureLineItems", "nsuri": "http://www.tenonmed.com/20220930", "presentation": [ "http://www.tenonmed.com/role/DebtAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "tnon_DebtDisclosureTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt disclosure.", "label": "Debt Disclosure [Table]" } } }, "localname": "DebtDisclosureTable", "nsuri": "http://www.tenonmed.com/20220930", "presentation": [ "http://www.tenonmed.com/role/DebtAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "tnon_DebtDiscountRelatedToRelatedParties": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Debt Discount Related To Related Parties", "label": "Debt Discount Related To Related Parties", "terseLabel": "Debt discount related to related parties" } } }, "localname": "DebtDiscountRelatedToRelatedParties", "nsuri": "http://www.tenonmed.com/20220930", "presentation": [ "http://www.tenonmed.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "monetaryItemType" }, "tnon_DebtInstrumentConversionPriceEqualToPercentageOfIpoPrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt instrument conversion price equal to percentage of IPO price.", "label": "Debt Instrument Conversion Price Equal To Percentage Of IPO Price" } } }, "localname": "DebtInstrumentConversionPriceEqualToPercentageOfIpoPrice", "nsuri": "http://www.tenonmed.com/20220930", "presentation": [ "http://www.tenonmed.com/role/DebtAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "tnon_DeferredCostsAssociatedWithWarrants": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Deferred costs associated with warrants.", "label": "Deferred Costs Associated With Warrants", "terseLabel": "Deferred costs associated with warrants" } } }, "localname": "DeferredCostsAssociatedWithWarrants", "nsuri": "http://www.tenonmed.com/20220930", "presentation": [ "http://www.tenonmed.com/role/StockholdersEquityAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "tnon_EntityMinorityShareholderMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Entity minority shareholder.", "label": "Entity Minority Shareholder [Member]", "terseLabel": "Entity Minority Shareholder [Member]" } } }, "localname": "EntityMinorityShareholderMember", "nsuri": "http://www.tenonmed.com/20220930", "presentation": [ "http://www.tenonmed.com/role/DebtAdditionalInformationDetail", "http://www.tenonmed.com/role/RelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "tnon_EventBasisAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Event Basis.", "label": "Event Basis [Axis]" } } }, "localname": "EventBasisAxis", "nsuri": "http://www.tenonmed.com/20220930", "presentation": [ "http://www.tenonmed.com/role/StockholdersEquityAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "tnon_EventBasisDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Event Basis.", "label": "Event Basis [Domain]" } } }, "localname": "EventBasisDomain", "nsuri": "http://www.tenonmed.com/20220930", "presentation": [ "http://www.tenonmed.com/role/StockholdersEquityAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "tnon_EventTriggeringAutomaticConversionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Event Triggering Automatic Conversion.", "label": "Event Triggering Automatic Conversion [Member]", "terseLabel": "Event Triggering Automatic Conversion [Member]" } } }, "localname": "EventTriggeringAutomaticConversionMember", "nsuri": "http://www.tenonmed.com/20220930", "presentation": [ "http://www.tenonmed.com/role/StockholdersEquityAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "tnon_ExchangeAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Exchange agreement.", "label": "Exchange Agreement [Member]", "terseLabel": "Exchange Agreement [Member]" } } }, "localname": "ExchangeAgreementMember", "nsuri": "http://www.tenonmed.com/20220930", "presentation": [ "http://www.tenonmed.com/role/StockholdersEquityAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "tnon_FormerChiefExecutiveOfficerMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Former chief executive officer.", "label": "Former Chief Executive Officer [Member]", "terseLabel": "Former Chief Executive Officer [Member]" } } }, "localname": "FormerChiefExecutiveOfficerMember", "nsuri": "http://www.tenonmed.com/20220930", "presentation": [ "http://www.tenonmed.com/role/RelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "tnon_GainLossOnAgreement": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Gain loss on agreement.", "label": "Gain Loss On Agreement", "terseLabel": "Gain loss on agreement" } } }, "localname": "GainLossOnAgreement", "nsuri": "http://www.tenonmed.com/20220930", "presentation": [ "http://www.tenonmed.com/role/StockholdersEquityAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "tnon_GoingConcernUncertaintiesAndLiquidityRequirementsPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Going concern uncertainties and liquidity requirements.", "label": "Going Concern Uncertainties And Liquidity Requirements [Policy Text Block]", "verboseLabel": "Going concern uncertainty and liquidity requirements" } } }, "localname": "GoingConcernUncertaintiesAndLiquidityRequirementsPolicyTextBlock", "nsuri": "http://www.tenonmed.com/20220930", "presentation": [ "http://www.tenonmed.com/role/SummaryOfSignificantAccountingPrinciplesPolicies" ], "xbrltype": "textBlockItemType" }, "tnon_ImpactOfCovid19PolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Impact of covid19.", "label": "Impact Of Covid19 [Policy Text Block]", "verboseLabel": "Impact of COVID-19" } } }, "localname": "ImpactOfCovid19PolicyTextBlock", "nsuri": "http://www.tenonmed.com/20220930", "presentation": [ "http://www.tenonmed.com/role/SummaryOfSignificantAccountingPrinciplesPolicies" ], "xbrltype": "textBlockItemType" }, "tnon_InvestorOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Investor One", "label": "Investor One [Member]" } } }, "localname": "InvestorOneMember", "nsuri": "http://www.tenonmed.com/20220930", "presentation": [ "http://www.tenonmed.com/role/DebtAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "tnon_IpSaleAndPurchaseAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "IP Sale and Purchase Agreement.", "label": "IP Sale and Purchase Agreement [Member]", "terseLabel": "IP Sale and Purchase Agreement [Member]" } } }, "localname": "IpSaleAndPurchaseAgreementMember", "nsuri": "http://www.tenonmed.com/20220930", "presentation": [ "http://www.tenonmed.com/role/RelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "tnon_ItEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "IT Equipment Member", "label": "IT Equipment [Member]", "terseLabel": "IT Equipment [Member]" } } }, "localname": "ItEquipmentMember", "nsuri": "http://www.tenonmed.com/20220930", "presentation": [ "http://www.tenonmed.com/role/FixedAssetsSummaryOfFixedAssetsAndEquipmentNetDetail" ], "xbrltype": "domainItemType" }, "tnon_KeyMedicalMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Key medical.", "label": "Key Medical [Member]", "terseLabel": "Key Medical [Member]" } } }, "localname": "KeyMedicalMember", "nsuri": "http://www.tenonmed.com/20220930", "presentation": [ "http://www.tenonmed.com/role/CommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "tnon_KhalidMentakMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Khalid Mentak.", "label": "Khalid Mentak [Member]", "terseLabel": "Khalid Mentak [Member]" } } }, "localname": "KhalidMentakMember", "nsuri": "http://www.tenonmed.com/20220930", "presentation": [ "http://www.tenonmed.com/role/CommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "tnon_LabEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lab Equipment Member", "label": "Lab Equipment [Member]", "terseLabel": "Lab Equipment [Member]" } } }, "localname": "LabEquipmentMember", "nsuri": "http://www.tenonmed.com/20220930", "presentation": [ "http://www.tenonmed.com/role/FixedAssetsSummaryOfFixedAssetsAndEquipmentNetDetail" ], "xbrltype": "domainItemType" }, "tnon_LawFirmMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Law firm.", "label": "Law Firm [Member]" } } }, "localname": "LawFirmMember", "nsuri": "http://www.tenonmed.com/20220930", "presentation": [ "http://www.tenonmed.com/role/DebtAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "tnon_LesseeOperatingLeaseExpirationMonthAndYear": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lessee operating lease expiration month and year.", "label": "Lessee Operating Lease Expiration Month And Year", "terseLabel": "Lessee, Operating lease, Expiration, Month and Year" } } }, "localname": "LesseeOperatingLeaseExpirationMonthAndYear", "nsuri": "http://www.tenonmed.com/20220930", "presentation": [ "http://www.tenonmed.com/role/LeasesAdditionalInformationDetail" ], "xbrltype": "gYearMonthItemType" }, "tnon_MinimumGrossProceedsFromFirmlyUnderwrittenPublicOffering": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Minimum gross proceeds from firmly underwritten public offering.", "label": "Minimum Gross Proceeds From Firmly Underwritten Public Offering", "terseLabel": "Minimum gross proceeds from firmly underwritten public offering" } } }, "localname": "MinimumGrossProceedsFromFirmlyUnderwrittenPublicOffering", "nsuri": "http://www.tenonmed.com/20220930", "presentation": [ "http://www.tenonmed.com/role/StockholdersEquityAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "tnon_MinimumPricePerShareAtWhichSharesAreIssuedUnderFirmlyUnderwrittenPublicOffering": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Minimum price per share at which shares are issued under firmly underwritten public offering.", "label": "Minimum Price Per Share At Which Shares Are Issued Under Firmly Underwritten Public Offering", "terseLabel": "Minimum price per share at which shares are issued under firmly underwritten public offering" } } }, "localname": "MinimumPricePerShareAtWhichSharesAreIssuedUnderFirmlyUnderwrittenPublicOffering", "nsuri": "http://www.tenonmed.com/20220930", "presentation": [ "http://www.tenonmed.com/role/StockholdersEquityAdditionalInformationDetail" ], "xbrltype": "perShareItemType" }, "tnon_MinimumRepresentativeBonusPayable": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Minimum representative bonus payable.", "label": "Minimum Representative Bonus Payable", "terseLabel": "Minimum representative bonus payable" } } }, "localname": "MinimumRepresentativeBonusPayable", "nsuri": "http://www.tenonmed.com/20220930", "presentation": [ "http://www.tenonmed.com/role/CommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "tnon_MinimumThresholdAmountOfCapitalStockFinancingRequiredForConversionOfConvertibleInstrument": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Minimum threshold amount of capital stock financing required for conversion of convertible instrument.", "label": "Minimum Threshold Amount Of Capital Stock Financing Required For Conversion Of Convertible Instrument" } } }, "localname": "MinimumThresholdAmountOfCapitalStockFinancingRequiredForConversionOfConvertibleInstrument", "nsuri": "http://www.tenonmed.com/20220930", "presentation": [ "http://www.tenonmed.com/role/DebtAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "tnon_MinimumThresholdAmountOfPreferrredStockFinancingRequiredForConversionOfConvertibleDebt": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Minimum threshold amount of preferred stock financing required for conversion of convertible debt.", "label": "Minimum Threshold Amount Of Preferrred Stock Financing Required For Conversion Of Convertible Debt", "terseLabel": "Minimum Threshold Amount Of Preferred Stock Financing Required For Conversion Of Convertible Debt" } } }, "localname": "MinimumThresholdAmountOfPreferrredStockFinancingRequiredForConversionOfConvertibleDebt", "nsuri": "http://www.tenonmed.com/20220930", "presentation": [ "http://www.tenonmed.com/role/DebtAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "tnon_MinimumThresholdAmountOfSharesIssuedInAnInitialPublicOfferingOrAQualifiedOfferingThatWereExcluded": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Minimum threshold amount of shares issued in an initial public offering or a qualified offering that were excluded.", "label": "Minimum Threshold Amount Of Shares Issued In An Initial Public Offering Or A Qualified Offering That Were Excluded", "terseLabel": "Minimum threshold amount of shares issued in an initial public offering or a qualified offering that were excluded" } } }, "localname": "MinimumThresholdAmountOfSharesIssuedInAnInitialPublicOfferingOrAQualifiedOfferingThatWereExcluded", "nsuri": "http://www.tenonmed.com/20220930", "presentation": [ "http://www.tenonmed.com/role/StockholdersEquityAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "tnon_MinimumThresholdFinancing": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Minimum threshold financing.", "label": "Minimum Threshold Financing", "terseLabel": "Minimum threshold financing" } } }, "localname": "MinimumThresholdFinancing", "nsuri": "http://www.tenonmed.com/20220930", "presentation": [ "http://www.tenonmed.com/role/RelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "tnon_MinimumThresholdPricePerShareOfSharesIssuedInAnInitialPublicOfferingOrAQualifiedOfferingThatWereExcluded": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Minimum threshold price per share of shares issued in an initial public offering or a qualified offering that were excluded.", "label": "Minimum Threshold Price Per Share Of Shares Issued In An Initial Public Offering Or A Qualified Offering That Were Excluded", "terseLabel": "Minimum threshold price per share of shares issued in an initial public offering or a qualified offering that were excluded" } } }, "localname": "MinimumThresholdPricePerShareOfSharesIssuedInAnInitialPublicOfferingOrAQualifiedOfferingThatWereExcluded", "nsuri": "http://www.tenonmed.com/20220930", "presentation": [ "http://www.tenonmed.com/role/StockholdersEquityAdditionalInformationDetail" ], "xbrltype": "perShareItemType" }, "tnon_OfficersDirectorsAndTheirFamilyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Officers, directors, and their family.", "label": "Officers, Directors, and their Family [Member]" } } }, "localname": "OfficersDirectorsAndTheirFamilyMember", "nsuri": "http://www.tenonmed.com/20220930", "presentation": [ "http://www.tenonmed.com/role/DebtAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "tnon_OrganizationAndBusinessDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Organization and business disclosure.", "label": "Organization And Business Disclosure [Abstract]" } } }, "localname": "OrganizationAndBusinessDisclosureAbstract", "nsuri": "http://www.tenonmed.com/20220930", "xbrltype": "stringItemType" }, "tnon_OtherMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Other.", "label": "Other [Member]", "terseLabel": "Other [Member]" } } }, "localname": "OtherMember", "nsuri": "http://www.tenonmed.com/20220930", "presentation": [ "http://www.tenonmed.com/role/CommitmentsAndContingenciesAdditionalInformationDetail", "http://www.tenonmed.com/role/StockholdersEquityAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "tnon_PaymentOfRepresentativeBonus": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Payment of representative bonus.", "label": "Payment of Representative Bonus", "terseLabel": "Payment of representative bonus" } } }, "localname": "PaymentOfRepresentativeBonus", "nsuri": "http://www.tenonmed.com/20220930", "presentation": [ "http://www.tenonmed.com/role/CommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "tnon_PaymentToRepresentativeAsPerAgreement": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Payment to representative as per agreement.", "label": "Payment To Representative As Per Agreement", "terseLabel": "Payment to representative as per agreement" } } }, "localname": "PaymentToRepresentativeAsPerAgreement", "nsuri": "http://www.tenonmed.com/20220930", "presentation": [ "http://www.tenonmed.com/role/SubsequentEventsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "tnon_PaymentsForDeferredOfferingCosts": { "auth_ref": [], "calculation": { "http://www.tenonmed.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Payments for deferred offering costs.", "label": "Payments For Deferred Offering Costs", "negatedLabel": "Deferred offering costs" } } }, "localname": "PaymentsForDeferredOfferingCosts", "nsuri": "http://www.tenonmed.com/20220930", "presentation": [ "http://www.tenonmed.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "tnon_PercentageOfCommissionToNetSalesAgreedToPayTheRepresentativeUntilAggregateAmountPaid": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of commission to net sales agreed to pay the representative until aggregate amount paid.", "label": "Percentage Of Commission To Net Sales Agreed To Pay The Representative Until Aggregate Amount Paid", "terseLabel": "Percentage of commission to net sales agreed to pay the representative until aggregate amount paid" } } }, "localname": "PercentageOfCommissionToNetSalesAgreedToPayTheRepresentativeUntilAggregateAmountPaid", "nsuri": "http://www.tenonmed.com/20220930", "presentation": [ "http://www.tenonmed.com/role/SubsequentEventsAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "tnon_PercentageOfDebtConversionPriceEqualToPricePerSharePaidByTheOtherCashPurchasersInTheFutureFinancing": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of debt conversion price equal to price per share paid by the other cash purchasers in the future financing.", "label": "Percentage Of Debt Conversion Price Equal To Price Per Share Paid By The Other Cash Purchasers In The Future Financing", "terseLabel": "Percentage Of Debt Conversion Price Equal To Price Per Share Paid By The Other Cash Purchasers In The Future Financing" } } }, "localname": "PercentageOfDebtConversionPriceEqualToPricePerSharePaidByTheOtherCashPurchasersInTheFutureFinancing", "nsuri": "http://www.tenonmed.com/20220930", "presentation": [ "http://www.tenonmed.com/role/DebtAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "tnon_PercentageOfIncreaseInInterestRateIfPrincipalAndInterestNotBeenPaidByMaturityDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of increase in interest rate if principal and interest not been paid by maturity date.", "label": "Percentage Of Increase IN Interest Rate If Principal And Interest Not Been Paid By Maturity Date" } } }, "localname": "PercentageOfIncreaseInInterestRateIfPrincipalAndInterestNotBeenPaidByMaturityDate", "nsuri": "http://www.tenonmed.com/20220930", "presentation": [ "http://www.tenonmed.com/role/DebtAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "tnon_PercentageOfNetSalesOfTheProductSoldAgreedToPayTheReprensentative": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of net sales of the product sold agreed to pay the representative.", "label": "Percentage Of Net Sales Of The Product Sold Agreed To Pay The Reprensentative", "terseLabel": "Percentage of net sales of the product sold agreed to pay the representative" } } }, "localname": "PercentageOfNetSalesOfTheProductSoldAgreedToPayTheReprensentative", "nsuri": "http://www.tenonmed.com/20220930", "presentation": [ "http://www.tenonmed.com/role/SubsequentEventsAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "tnon_PercentageOfValuationAllowanceInDeferredTaxAssets": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of valuation allowance in deferred tax assets.", "label": "Percentage Of Valuation Allowance In Deferred Tax Assets", "verboseLabel": "Percentage of valuation allowance in deferred tax assets" } } }, "localname": "PercentageOfValuationAllowanceInDeferredTaxAssets", "nsuri": "http://www.tenonmed.com/20220930", "presentation": [ "http://www.tenonmed.com/role/SummaryOfSignificantAccountingPrinciplesAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "tnon_PromissoryNotesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Promissory notes.", "label": "Promissory Notes [Member]" } } }, "localname": "PromissoryNotesMember", "nsuri": "http://www.tenonmed.com/20220930", "presentation": [ "http://www.tenonmed.com/role/DebtAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "tnon_RepresentativeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Representative.", "label": "Representative [Member]", "terseLabel": "Representative [Member]" } } }, "localname": "RepresentativeMember", "nsuri": "http://www.tenonmed.com/20220930", "presentation": [ "http://www.tenonmed.com/role/CommitmentsAndContingenciesAdditionalInformationDetail", "http://www.tenonmed.com/role/StockholdersEquityAdditionalInformationDetail", "http://www.tenonmed.com/role/SubsequentEventsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "tnon_RightOfUseAssetsObtainedInExchangeForLeaseLiability": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Right-of-use assets obtained in exchange for lease liability.", "label": "Right of use Assets Obtained In Exchange For Lease Liability", "terseLabel": "Right-of-use assets obtained in exchange for lease liability" } } }, "localname": "RightOfUseAssetsObtainedInExchangeForLeaseLiability", "nsuri": "http://www.tenonmed.com/20220930", "presentation": [ "http://www.tenonmed.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "tnon_SalesRepresentativeAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sales Representative Agreement.", "label": "Sales Representative Agreement [Member]", "terseLabel": "Sales Representative Agreement [Member]" } } }, "localname": "SalesRepresentativeAgreementMember", "nsuri": "http://www.tenonmed.com/20220930", "presentation": [ "http://www.tenonmed.com/role/CommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "tnon_SeriesAConvertiblePreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Series A Convertible Preferred Stock [Member]", "label": "Series A Convertible Preferred Stock [Member]", "terseLabel": "Series A Convertible Preferred Stock [Member]" } } }, "localname": "SeriesAConvertiblePreferredStockMember", "nsuri": "http://www.tenonmed.com/20220930", "presentation": [ "http://www.tenonmed.com/role/CondensedConsolidatedBalanceSheets", "http://www.tenonmed.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://www.tenonmed.com/role/CondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit", "http://www.tenonmed.com/role/StockholdersEquityAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "tnon_SeriesASeriesBConvertiblePreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Series A Series B Convertible Preferred Stock.", "label": "Series A Series B Convertible Preferred Stock [Member]", "terseLabel": "Series A Series B Convertible Preferred Stock [Member]" } } }, "localname": "SeriesASeriesBConvertiblePreferredStockMember", "nsuri": "http://www.tenonmed.com/20220930", "presentation": [ "http://www.tenonmed.com/role/StockholdersEquityAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "tnon_SeriesBConvertiblePreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Series B Convertible Preferred Stock [Member]", "label": "Series B Convertible Preferred Stock [Member]", "terseLabel": "Series B Convertible Preferred Stock [Member]" } } }, "localname": "SeriesBConvertiblePreferredStockMember", "nsuri": "http://www.tenonmed.com/20220930", "presentation": [ "http://www.tenonmed.com/role/CondensedConsolidatedBalanceSheets", "http://www.tenonmed.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://www.tenonmed.com/role/CondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit", "http://www.tenonmed.com/role/StockholdersEquityAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "tnon_ShareBasedCompensationArrangementByShareBasedPaymentAwardCumulativeAnnualIncreasePercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share based compensation arrangement by share based payment award cumulative annual increase percentage.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Cumulative Annual Increase Percentage", "terseLabel": "Share based compensation arrangement by share based payment award cumulative annual increase percentage" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardCumulativeAnnualIncreasePercentage", "nsuri": "http://www.tenonmed.com/20220930", "presentation": [ "http://www.tenonmed.com/role/StockholdersEquityAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "tnon_ShareBasedCompensationArrangementByShareBasedPaymentAwardCumulativeAnnualIncreaseShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share based compensation arrangement by share based payment award cumulative annual increase shares.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Cumulative Annual Increase Shares", "terseLabel": "Share based compensation arrangement by share based payment award cumulative annual increase shares" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardCumulativeAnnualIncreaseShares", "nsuri": "http://www.tenonmed.com/20220930", "presentation": [ "http://www.tenonmed.com/role/StockholdersEquityAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "tnon_SharesCategoryAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Shares Category.", "label": "Shares Category [Axis]" } } }, "localname": "SharesCategoryAxis", "nsuri": "http://www.tenonmed.com/20220930", "presentation": [ "http://www.tenonmed.com/role/StockholdersEquityAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "tnon_SharesCategoryDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Shares Category.", "label": "Shares Category [Domain]" } } }, "localname": "SharesCategoryDomain", "nsuri": "http://www.tenonmed.com/20220930", "presentation": [ "http://www.tenonmed.com/role/StockholdersEquityAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "tnon_SharesConvertedByTtagSMinorityShareholderForCompanySharesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Shares Converted By TTAG s Minority Shareholder For Company Shares.", "label": "Shares Converted By TTAG s Minority Shareholder For Company Shares [Member]", "terseLabel": "Shares Converted By TTAG s Minority Shareholder For Company Shares [Member]" } } }, "localname": "SharesConvertedByTtagSMinorityShareholderForCompanySharesMember", "nsuri": "http://www.tenonmed.com/20220930", "presentation": [ "http://www.tenonmed.com/role/StockholdersEquityAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "tnon_SharesSubjectToAntiDilutionProtectionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Shares Subject To Anti Dilution Protection.", "label": "Shares Subject To Anti Dilution Protection [Member]", "terseLabel": "Shares Subject To Anti Dilution Protection [Member]" } } }, "localname": "SharesSubjectToAntiDilutionProtectionMember", "nsuri": "http://www.tenonmed.com/20220930", "presentation": [ "http://www.tenonmed.com/role/StockholdersEquityAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "tnon_SupplementalBalanceSheetDisclosureRelatedToLeasesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Supplemental balance sheet disclosure related to leases.", "label": "Supplemental Balance Sheet Disclosure Related To Leases [Table Text Block]", "terseLabel": "Summary of Supplemental Balance Sheet Information Related To Leases" } } }, "localname": "SupplementalBalanceSheetDisclosureRelatedToLeasesTableTextBlock", "nsuri": "http://www.tenonmed.com/20220930", "presentation": [ "http://www.tenonmed.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "tnon_TemporaryEquityConversionOfStockAmountConverted1": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Temporary Equity Conversion Of Stock Amount Converted1", "label": "Temporary Equity Conversion Of Stock Amount Converted1", "verboseLabel": "Common stock issued upon conversion of debt" } } }, "localname": "TemporaryEquityConversionOfStockAmountConverted1", "nsuri": "http://www.tenonmed.com/20220930", "presentation": [ "http://www.tenonmed.com/role/CondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "tnon_TemporaryEquityConversionOfStockSharesConverted1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Temporary Equity Conversion Of Stock Shares Converted1.", "label": "Temporary Equity Conversion Of Stock Shares Converted1", "verboseLabel": "Common stock issued upon conversion of debt, Share" } } }, "localname": "TemporaryEquityConversionOfStockSharesConverted1", "nsuri": "http://www.tenonmed.com/20220930", "presentation": [ "http://www.tenonmed.com/role/CondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "tnon_TemporaryEquityOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Temporary equity, outstanding.", "label": "Temporary Equity, Outstanding", "periodEndLabel": "Ending Balance (in shares)", "periodStartLabel": "Beginning Balance (in shares)" } } }, "localname": "TemporaryEquityOutstanding", "nsuri": "http://www.tenonmed.com/20220930", "presentation": [ "http://www.tenonmed.com/role/CondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "tnon_TermOfAgreement": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Term of agreement.", "label": "Term Of Agreement", "terseLabel": "Term of agreement" } } }, "localname": "TermOfAgreement", "nsuri": "http://www.tenonmed.com/20220930", "presentation": [ "http://www.tenonmed.com/role/SubsequentEventsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "tnon_TerminationAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Termination agreement.", "label": "Termination Agreement [Member]" } } }, "localname": "TerminationAgreementMember", "nsuri": "http://www.tenonmed.com/20220930", "presentation": [ "http://www.tenonmed.com/role/SubsequentEventsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "tnon_TriggeringEventAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Triggering Event.", "label": "Triggering Event [Axis]" } } }, "localname": "TriggeringEventAxis", "nsuri": "http://www.tenonmed.com/20220930", "presentation": [ "http://www.tenonmed.com/role/StockholdersEquityAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "tnon_TriggeringEventDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Triggering Event.", "label": "Triggering Event [Domain]" } } }, "localname": "TriggeringEventDomain", "nsuri": "http://www.tenonmed.com/20220930", "presentation": [ "http://www.tenonmed.com/role/StockholdersEquityAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "tnon_TtagMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "TTAG.", "label": "TTAG [Member]", "terseLabel": "TTAG [Member]" } } }, "localname": "TtagMember", "nsuri": "http://www.tenonmed.com/20220930", "presentation": [ "http://www.tenonmed.com/role/StockholdersEquityAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "tnon_TwoThousandAndTwelvePlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two Thousand And Twelve Plan.", "label": "Two Thousand And Twelve Plan [Member]", "terseLabel": "Two Thousand And Twelve Plan [Member]" } } }, "localname": "TwoThousandAndTwelvePlanMember", "nsuri": "http://www.tenonmed.com/20220930", "presentation": [ "http://www.tenonmed.com/role/StockholdersEquityAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "tnon_TwoThousandAndTwentyTwoEquityIncentivePlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two thousand and twenty two equity incentive plan.", "label": "Two Thousand and Twenty Two Equity Incentive Plan [Member]" } } }, "localname": "TwoThousandAndTwentyTwoEquityIncentivePlanMember", "nsuri": "http://www.tenonmed.com/20220930", "presentation": [ "http://www.tenonmed.com/role/StockholdersEquityAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "tnon_UnderwritingAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Underwriting agreement.", "label": "Underwriting Agreement [Member]", "terseLabel": "Underwriting Agreement [Member]" } } }, "localname": "UnderwritingAgreementMember", "nsuri": "http://www.tenonmed.com/20220930", "presentation": [ "http://www.tenonmed.com/role/StockholdersEquityAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "tnon_UnsecuredPromissoryNoteMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Unsecured Promissory Note.", "label": "Unsecured Promissory Note [Member]", "terseLabel": "Unsecured Promissory Note [Member]" } } }, "localname": "UnsecuredPromissoryNoteMember", "nsuri": "http://www.tenonmed.com/20220930", "presentation": [ "http://www.tenonmed.com/role/RelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "tnon_ValueOfCommissionAgreedToPayAsPerAgreement": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of commission agreed to pay as per agreement.", "label": "Value Of Commission Agreed To Pay As Per Agreement", "terseLabel": "Value of commission agreed to pay as per agreement" } } }, "localname": "ValueOfCommissionAgreedToPayAsPerAgreement", "nsuri": "http://www.tenonmed.com/20220930", "presentation": [ "http://www.tenonmed.com/role/SubsequentEventsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "tnon_VendorMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Vendor.", "label": "Vendor [Member]" } } }, "localname": "VendorMember", "nsuri": "http://www.tenonmed.com/20220930", "presentation": [ "http://www.tenonmed.com/role/DebtAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": { "auth_ref": [ "r33" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.", "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]", "verboseLabel": "Accrued Expenses" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/AccruedExpenses" ], "xbrltype": "textBlockItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r32", "r427" ], "calculation": { "http://www.tenonmed.com/role/CondensedConsolidatedBalanceSheets": { "order": 14.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable, Current", "terseLabel": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r173", "r174" ], "calculation": { "http://www.tenonmed.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "terseLabel": "Accounts receivable" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrent": { "auth_ref": [ "r35" ], "calculation": { "http://www.tenonmed.com/role/CondensedConsolidatedBalanceSheets": { "order": 15.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Liabilities, Current", "terseLabel": "Accrued expenses" } } }, "localname": "AccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrentAndNoncurrent": { "auth_ref": [ "r486", "r506" ], "calculation": { "http://www.tenonmed.com/role/AccruedExpensesScheduleOfAccruedExpensesDetail": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities.", "label": "Accrued Liabilities", "totalLabel": "Total accrued expenses" } } }, "localname": "AccruedLiabilitiesCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/AccruedExpensesScheduleOfAccruedExpensesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedSalesCommissionCurrentAndNoncurrent": { "auth_ref": [ "r16", "r18", "r479", "r499" ], "calculation": { "http://www.tenonmed.com/role/AccruedExpensesScheduleOfAccruedExpensesDetail": { "order": 2.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrentAndNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for sales commissions.", "label": "Accrued Sales Commission", "verboseLabel": "Accrued commissions" } } }, "localname": "AccruedSalesCommissionCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/AccruedExpensesScheduleOfAccruedExpensesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r12", "r209" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "negatedLabel": "Less: accumulated depreciation" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/FixedAssetsSummaryOfFixedAssetsAndEquipmentNetDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r24", "r50", "r51", "r52", "r500", "r520", "r524" ], "calculation": { "http://www.tenonmed.com/role/CondensedConsolidatedBalanceSheets": { "order": 23.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Accumulated other comprehensive income (loss)" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r49", "r52", "r60", "r61", "r62", "r109", "r110", "r111", "r365", "r415", "r515", "r516" ], "lang": { "en-us": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "AOCI Attributable to Parent [Member]", "terseLabel": "Accumulated Other Comprehensive Income [Member]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/CondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r22", "r427" ], "calculation": { "http://www.tenonmed.com/role/CondensedConsolidatedBalanceSheets": { "order": 21.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.", "label": "Additional Paid in Capital", "terseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r109", "r110", "r111", "r342", "r343", "r344", "r376" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]", "terseLabel": "Additional Paid-in Capital [Member]" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/CondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts": { "auth_ref": [ "r294", "r296" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.", "label": "Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs", "terseLabel": "Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/StockholdersEquityAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r340" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Share-based Payment Arrangement, Expense", "terseLabel": "Stock-based compensation expense" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/CondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit", "http://www.tenonmed.com/role/StockholdersEquitySummaryOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r135" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/SummaryOfSignificantAccountingPrinciplesScheduleOfSecuritiesExcludedDueToAntiDilutiveEffectDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "auth_ref": [ "r135" ], "lang": { "en-us": { "role": { "documentation": "Information by type of antidilutive security.", "label": "Antidilutive Securities [Axis]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/SummaryOfSignificantAccountingPrinciplesScheduleOfSecuritiesExcludedDueToAntiDilutiveEffectDetail" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/SummaryOfSignificantAccountingPrinciplesScheduleOfSecuritiesExcludedDueToAntiDilutiveEffectDetail" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "auth_ref": [ "r135" ], "lang": { "en-us": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.", "label": "Antidilutive Securities, Name [Domain]" } } }, "localname": "AntidilutiveSecuritiesNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/SummaryOfSignificantAccountingPrinciplesScheduleOfSecuritiesExcludedDueToAntiDilutiveEffectDetail" ], "xbrltype": "domainItemType" }, "us-gaap_Assets": { "auth_ref": [ "r14", "r103", "r158", "r161", "r167", "r189", "r228", "r229", "r230", "r232", "r233", "r234", "r235", "r236", "r237", "r239", "r240", "r359", "r366", "r389", "r425", "r427", "r477", "r498" ], "calculation": { "http://www.tenonmed.com/role/CondensedConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "TOTAL ASSETS" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "Assets" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r7", "r31", "r103", "r189", "r228", "r229", "r230", "r232", "r233", "r234", "r235", "r236", "r237", "r239", "r240", "r359", "r366", "r389", "r425", "r427" ], "calculation": { "http://www.tenonmed.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current assets" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsNet": { "auth_ref": [ "r3", "r527", "r529", "r530", "r531" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of net assets (liabilities).", "label": "Net Assets", "terseLabel": "Net assets" } } }, "localname": "AssetsNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/ConcentrationsOfRiskAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": { "auth_ref": [ "r177", "r200" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale, Amortized Cost", "verboseLabel": "Amortized Cost" } } }, "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/InvestmentsScheduleOfCostAndFairValueOfAvailableForSaleInvestmentsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain": { "auth_ref": [ "r178" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of unrealized gain on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-Sale, Unrealized Gain", "terseLabel": "Unrealized \u200eGains" } } }, "localname": "AvailableForSaleDebtSecuritiesGrossUnrealizedGain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/InvestmentsScheduleOfCostAndFairValueOfAvailableForSaleInvestmentsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss": { "auth_ref": [ "r179" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale, Unrealized Loss", "negatedLabel": "Unrealized Losses" } } }, "localname": "AvailableForSaleDebtSecuritiesGrossUnrealizedLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/InvestmentsScheduleOfCostAndFairValueOfAvailableForSaleInvestmentsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r338" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/StockholdersEquityAdditionalInformationDetail", "http://www.tenonmed.com/role/StockholdersEquitySummaryOfShareBasedCompensationArrangementsByShareBasedPaymentAwardDetail" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by location on balance sheet (statement of financial position).", "label": "Balance Sheet Location [Axis]" } } }, "localname": "BalanceSheetLocationAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/InvestmentsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationDomain": { "auth_ref": [ "r371", "r372" ], "lang": { "en-us": { "role": { "documentation": "Location in the balance sheet (statement of financial position).", "label": "Balance Sheet Location [Domain]" } } }, "localname": "BalanceSheetLocationDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/InvestmentsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Accounting, Policy [Policy Text Block]", "terseLabel": "Basis of presentation" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/SummaryOfSignificantAccountingPrinciplesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r4", "r10", "r92" ], "calculation": { "http://www.tenonmed.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "terseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r86", "r92", "r97" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "periodEndLabel": "Cash and Cash Equivalents at End of Period", "periodStartLabel": "Cash and Cash Equivalents at Beginning of Period" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r86", "r390" ], "calculation": { "http://www.tenonmed.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Net Increase in Cash and Cash Equivalents" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [ "r19", "r20", "r21", "r100", "r103", "r128", "r129", "r130", "r132", "r134", "r140", "r141", "r142", "r189", "r228", "r233", "r234", "r235", "r239", "r240", "r277", "r278", "r283", "r287", "r294", "r389", "r545" ], "lang": { "en-us": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.", "label": "Class of Stock [Domain]" } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/CondensedConsolidatedBalanceSheets", "http://www.tenonmed.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://www.tenonmed.com/role/CondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit", "http://www.tenonmed.com/role/LeasesAdditionalInformationDetail", "http://www.tenonmed.com/role/StockholdersEquityAdditionalInformationDetail", "http://www.tenonmed.com/role/StockholdersEquitySummaryOfShareBasedCompensationArrangementsByShareBasedPaymentAwardDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfWarrantOrRightAxis": { "auth_ref": [ "r297", "r311" ], "lang": { "en-us": { "role": { "documentation": "Information by type of warrant or right issued.", "label": "Class of Warrant or Right [Axis]" } } }, "localname": "ClassOfWarrantOrRightAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/StockholdersEquityAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfWarrantOrRightDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months.", "label": "Class of Warrant or Right [Domain]" } } }, "localname": "ClassOfWarrantOrRightDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/StockholdersEquityAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "auth_ref": [ "r295" ], "lang": { "en-us": { "role": { "documentation": "Exercise price per share or per unit of warrants or rights outstanding.", "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights", "terseLabel": "Class of warrants or rights exercise price" } } }, "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/StockholdersEquityAdditionalInformationDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": { "auth_ref": [ "r295" ], "lang": { "en-us": { "role": { "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.", "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights", "terseLabel": "Class of warrant or right, number of common stock called by warrants or rights" } } }, "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/StockholdersEquityAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r40", "r487", "r505" ], "calculation": { "http://www.tenonmed.com/role/CondensedConsolidatedBalanceSheets": { "order": 24.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and Contingencies", "terseLabel": "Commitments and contingencies (Notes 6 and 9)" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r215", "r216", "r217", "r225", "r533" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "Commitments and Contingencies" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/CommitmentsAndContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": { "auth_ref": [ "r42" ], "lang": { "en-us": { "role": { "documentation": "Aggregate number of common shares reserved for future issuance.", "label": "Common Stock, Capital Shares Reserved for Future Issuance" } } }, "localname": "CommonStockCapitalSharesReservedForFutureIssuance", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/StockholdersEquityAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r109", "r110", "r376" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common Stock [Member]" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/CondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit", "http://www.tenonmed.com/role/StockholdersEquityAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r21" ], "lang": { "en-us": { "role": { "definitionGuidance": "Common stock, Par or stated value per share", "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock par or stated value per share" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://www.tenonmed.com/role/StockholdersEquityAdditionalInformationDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r21" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "terseLabel": "Common stock shares authorized", "verboseLabel": "Common stock, Shares authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://www.tenonmed.com/role/StockholdersEquityAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r21" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "terseLabel": "Common stock shares issued" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r21", "r294" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "terseLabel": "Common stock shares outstanding" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesSubscribedButUnissued": { "auth_ref": [ "r21" ], "lang": { "en-us": { "role": { "documentation": "Amount of common stock allocated to investors to buy shares of a new issue of common stock before they are offered to the public. When stock is sold on a subscription basis, the issuer does not initially receive the total proceeds. In general, the issuer does not issue the shares to the investor until it receives the entire proceeds.", "label": "Common Stock, Shares Subscribed but Unissued", "terseLabel": "Common stock shares subscribed but unissued" } } }, "localname": "CommonStockSharesSubscribedButUnissued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/StockholdersEquityAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r21", "r427" ], "calculation": { "http://www.tenonmed.com/role/CondensedConsolidatedBalanceSheets": { "order": 20.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "terseLabel": "Common stock, $0.001 par value; 130,000,000 and 10,487,904 shares authorized at September 30, 2022 and December 31, 2021, respectively; 11,236,801 and 989,954 shares issued and outstanding at September 30, 2022 and December 31, 2021, respectively" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommonStockVotingRights": { "auth_ref": [ "r295" ], "lang": { "en-us": { "role": { "documentation": "Description of voting rights of common stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights.", "label": "Common Stock, Voting Rights", "terseLabel": "Common stock, Voting rights" } } }, "localname": "CommonStockVotingRights", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/StockholdersEquityAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r55", "r57", "r58", "r67", "r491", "r511" ], "calculation": { "http://www.tenonmed.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "Total comprehensive loss attributable to Tenon Medical, Inc." } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest": { "auth_ref": [ "r55", "r57", "r66", "r357", "r358", "r369", "r490", "r510" ], "calculation": { "http://www.tenonmed.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest", "terseLabel": "Comprehensive loss attributable to non-controlling interest" } } }, "localname": "ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": { "auth_ref": [ "r55", "r57", "r65", "r356", "r369", "r489", "r509" ], "calculation": { "http://www.tenonmed.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest", "totalLabel": "Total Comprehensive Loss" } } }, "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "auth_ref": [ "r148", "r149", "r171", "r386", "r387", "r532" ], "lang": { "en-us": { "role": { "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.", "label": "Concentration Risk Benchmark [Domain]" } } }, "localname": "ConcentrationRiskBenchmarkDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/ConcentrationsOfRiskAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "auth_ref": [ "r148", "r149", "r171", "r386", "r387", "r526", "r532" ], "lang": { "en-us": { "role": { "documentation": "Information by benchmark of concentration risk.", "label": "Concentration Risk Benchmark [Axis]" } } }, "localname": "ConcentrationRiskByBenchmarkAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/ConcentrationsOfRiskAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskDisclosureTextBlock": { "auth_ref": [ "r154" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date.", "label": "Concentration Risk Disclosure [Text Block]", "terseLabel": "Concentrations of Risk" } } }, "localname": "ConcentrationRiskDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/ConcentrationsOfRisk" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConcentrationRiskLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Concentration Risk [Line Items]" } } }, "localname": "ConcentrationRiskLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/ConcentrationsOfRiskAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskTable": { "auth_ref": [ "r147", "r148", "r149", "r150", "r386", "r388", "r532" ], "lang": { "en-us": { "role": { "documentation": "Describes the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.", "label": "Concentration Risk [Table]" } } }, "localname": "ConcentrationRiskTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/ConcentrationsOfRiskAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ConversionOfStockByUniqueDescriptionAxis": { "auth_ref": [ "r94", "r95", "r96" ], "lang": { "en-us": { "role": { "documentation": "Information by description of stock conversions.", "label": "Stock Conversion Description [Axis]" } } }, "localname": "ConversionOfStockByUniqueDescriptionAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/StockholdersEquityAdditionalInformationDetail", "http://www.tenonmed.com/role/SubsequentEventsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ConversionOfStockNameDomain": { "auth_ref": [ "r94", "r95", "r96" ], "lang": { "en-us": { "role": { "documentation": "The unique name of a noncash or part noncash stock conversion.", "label": "Conversion of Stock, Name [Domain]" } } }, "localname": "ConversionOfStockNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/StockholdersEquityAdditionalInformationDetail", "http://www.tenonmed.com/role/SubsequentEventsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ConversionOfStockSharesConverted1": { "auth_ref": [ "r94", "r95", "r96" ], "lang": { "en-us": { "role": { "documentation": "The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Conversion of Stock, Shares Converted", "terseLabel": "Conversion of stock, Shares converted" } } }, "localname": "ConversionOfStockSharesConverted1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/StockholdersEquityAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ConversionOfStockSharesIssued1": { "auth_ref": [ "r94", "r95", "r96" ], "lang": { "en-us": { "role": { "documentation": "The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Conversion of Stock, Shares Issued", "verboseLabel": "Conversion of stock, Shares issued" } } }, "localname": "ConversionOfStockSharesIssued1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/StockholdersEquityAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ConvertibleNotesPayableMember": { "auth_ref": [ "r15", "r478", "r495", "r528" ], "lang": { "en-us": { "role": { "documentation": "Written promise to pay a note which can be exchanged for a specified quantity of securities (typically common stock), at the option of the issuer or the holder.", "label": "Convertible Notes Payable [Member]", "terseLabel": "Convertible Notes Payable [Member]", "verboseLabel": "Common shares convertible from notes payable [Member]" } } }, "localname": "ConvertibleNotesPayableMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/CommitmentsAndContingenciesAdditionalInformationDetail", "http://www.tenonmed.com/role/SummaryOfSignificantAccountingPrinciplesScheduleOfSecuritiesExcludedDueToAntiDilutiveEffectDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ConvertiblePreferredStockMember": { "auth_ref": [ "r277", "r278", "r283" ], "lang": { "en-us": { "role": { "documentation": "Preferred stock that may be exchanged into common shares or other types of securities at the owner's option.", "label": "Convertible Preferred Stock [Member]", "terseLabel": "Convertible Preferred Stock [Member]", "verboseLabel": "Common shares convertible from preferred stock [Member]" } } }, "localname": "ConvertiblePreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/StockholdersEquityAdditionalInformationDetail", "http://www.tenonmed.com/role/SummaryOfSignificantAccountingPrinciplesScheduleOfSecuritiesExcludedDueToAntiDilutiveEffectDetail" ], "xbrltype": "domainItemType" }, "us-gaap_CorporateDebtSecuritiesMember": { "auth_ref": [ "r300", "r308", "r525" ], "lang": { "en-us": { "role": { "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.", "label": "Corporate Debt Securities [Member]" } } }, "localname": "CorporateDebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/InvestmentsScheduleOfCostAndFairValueOfAvailableForSaleInvestmentsDetail", "http://www.tenonmed.com/role/InvestmentsScheduleOfInvestmentsAtFairValueInFairValueHierarchyLevelDetail" ], "xbrltype": "domainItemType" }, "us-gaap_CostOfRevenue": { "auth_ref": [ "r71", "r103", "r189", "r228", "r229", "r230", "r233", "r234", "r235", "r236", "r237", "r239", "r240", "r389" ], "calculation": { "http://www.tenonmed.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 14.0, "parentTag": "us-gaap_GrossProfit", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period.", "label": "Cost of Revenue", "terseLabel": "Cost of sales" } } }, "localname": "CostOfRevenue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtConversionByUniqueDescriptionAxis": { "auth_ref": [ "r94", "r96" ], "lang": { "en-us": { "role": { "documentation": "Information by description of debt issuances converted in a noncash or part noncash transaction.", "label": "Debt Conversion Description [Axis]" } } }, "localname": "DebtConversionByUniqueDescriptionAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/StockholdersEquityAdditionalInformationDetail", "http://www.tenonmed.com/role/SubsequentEventsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_DebtConversionConvertedInstrumentSharesIssued1": { "auth_ref": [ "r94", "r96" ], "lang": { "en-us": { "role": { "documentation": "The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or payments in the period.", "label": "Debt Conversion, Converted Instrument, Shares Issued", "terseLabel": "Number of shares issued during the period on conversion of convertible notes" } } }, "localname": "DebtConversionConvertedInstrumentSharesIssued1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/StockholdersEquityAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_DebtConversionNameDomain": { "auth_ref": [ "r94", "r96" ], "lang": { "en-us": { "role": { "documentation": "The name of the original debt issue that has been converted in a noncash (or part noncash) transaction during the accounting period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Debt Conversion, Name [Domain]" } } }, "localname": "DebtConversionNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/StockholdersEquityAdditionalInformationDetail", "http://www.tenonmed.com/role/SubsequentEventsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Debt Disclosure [Abstract]" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_DebtDisclosureTextBlock": { "auth_ref": [ "r99", "r247", "r248", "r249", "r250", "r251", "r252", "r253", "r258", "r265", "r266", "r268", "r275" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.", "label": "Debt Disclosure [Text Block]", "terseLabel": "Debt" } } }, "localname": "DebtDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/Debt" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r15", "r16", "r17", "r102", "r107", "r241", "r242", "r243", "r244", "r245", "r246", "r248", "r254", "r255", "r256", "r257", "r259", "r260", "r261", "r262", "r263", "r264", "r271", "r272", "r273", "r274", "r401", "r478", "r480", "r495" ], "lang": { "en-us": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/CommitmentsAndContingenciesAdditionalInformationDetail", "http://www.tenonmed.com/role/DebtAdditionalInformationDetail", "http://www.tenonmed.com/role/RelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentConvertibleConversionPrice1": { "auth_ref": [ "r243", "r269" ], "lang": { "en-us": { "role": { "documentation": "The price per share of the conversion feature embedded in the debt instrument.", "label": "Debt Instrument, Convertible, Conversion Price", "terseLabel": "Debt instrument conversion price per share" } } }, "localname": "DebtInstrumentConvertibleConversionPrice1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/DebtAdditionalInformationDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_DebtInstrumentFaceAmount": { "auth_ref": [ "r241", "r271", "r272", "r399", "r401", "r402" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Face (par) amount of debt instrument at time of issuance.", "label": "Debt Instrument, Face Amount", "terseLabel": "Debt instrument principal amount" } } }, "localname": "DebtInstrumentFaceAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/CommitmentsAndContingenciesAdditionalInformationDetail", "http://www.tenonmed.com/role/DebtAdditionalInformationDetail", "http://www.tenonmed.com/role/RelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "auth_ref": [ "r37", "r242" ], "lang": { "en-us": { "role": { "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.", "label": "Debt Instrument, Interest Rate, Stated Percentage", "terseLabel": "Interest rate" } } }, "localname": "DebtInstrumentInterestRateStatedPercentage", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/DebtAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentMaturityDate": { "auth_ref": [ "r38", "r244", "r383" ], "lang": { "en-us": { "role": { "documentation": "Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.", "label": "Debt Instrument, Maturity Date", "terseLabel": "Maturity date" } } }, "localname": "DebtInstrumentMaturityDate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/DebtAdditionalInformationDetail" ], "xbrltype": "dateItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r39", "r102", "r107", "r241", "r242", "r243", "r244", "r245", "r246", "r248", "r254", "r255", "r256", "r257", "r259", "r260", "r261", "r262", "r263", "r264", "r271", "r272", "r273", "r274", "r401" ], "lang": { "en-us": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.", "label": "Debt Instrument, Name [Domain]" } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/CommitmentsAndContingenciesAdditionalInformationDetail", "http://www.tenonmed.com/role/DebtAdditionalInformationDetail", "http://www.tenonmed.com/role/RelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentRepurchaseAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "definitionGuidance": "Debt instrument convertible note and accrued interest", "documentation": "Fair value amount of debt instrument that was repurchased.", "label": "Debt Instrument, Repurchase Amount", "terseLabel": "Debt instrument convertible note and accrued interest" } } }, "localname": "DebtInstrumentRepurchaseAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/DebtAdditionalInformationDetail", "http://www.tenonmed.com/role/RelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentUnamortizedDiscountCurrent": { "auth_ref": [ "r398", "r402" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of debt discount to be amortized within one year or within the normal operating cycle, if longer.", "label": "Debt Instrument, Unamortized Discount, Current", "terseLabel": "Debt discount" } } }, "localname": "DebtInstrumentUnamortizedDiscountCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleTable": { "auth_ref": [ "r183" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale [Table]" } } }, "localname": "DebtSecuritiesAvailableForSaleTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/InvestmentsScheduleOfCostAndFairValueOfAvailableForSaleInvestmentsDetail" ], "xbrltype": "stringItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": { "auth_ref": [ "r183" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale [Table Text Block]", "terseLabel": "Schedule of Cost And Fair Value of Available For Sale Investments" } } }, "localname": "DebtSecuritiesAvailableForSaleTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/InvestmentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DeferredCosts": { "auth_ref": [ "r13", "r476", "r497" ], "calculation": { "http://www.tenonmed.com/role/CondensedConsolidatedBalanceSheets": { "order": 10.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred cost, excluding capitalized cost related to contract with customer; classified as noncurrent.", "label": "Deferred Costs, Noncurrent", "terseLabel": "Deferred offering costs" } } }, "localname": "DeferredCosts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredFinanceCostsNet": { "auth_ref": [ "r254", "r400" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.", "label": "Debt Issuance Costs, Net", "terseLabel": "Debt issuance costs" } } }, "localname": "DeferredFinanceCostsNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/DebtAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepositsAssetsNoncurrent": { "auth_ref": [ "r13" ], "calculation": { "http://www.tenonmed.com/role/CondensedConsolidatedBalanceSheets": { "order": 8.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer.", "label": "Deposits Assets, Noncurrent", "terseLabel": "Deposits" } } }, "localname": "DepositsAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_Depreciation": { "auth_ref": [ "r90", "r207" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.", "label": "Depreciation" } } }, "localname": "Depreciation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/FixedAssetsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationDepletionAndAmortization": { "auth_ref": [ "r90", "r157" ], "calculation": { "http://www.tenonmed.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 16.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.", "label": "Depreciation, Depletion and Amortization", "verboseLabel": "Depreciation and amortization" } } }, "localname": "DepreciationDepletionAndAmortization", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock": { "auth_ref": [ "r312", "r341" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of share-based payment arrangement.", "label": "Disclosure of Share-based Compensation Arrangements by Share-based Payment Award [Table Text Block]", "terseLabel": "Summary of Share Based Compensation Arrangements By Share Based Payment Award" } } }, "localname": "DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/StockholdersEquityTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DueToRelatedPartiesCurrentAndNoncurrent": { "auth_ref": [ "r104", "r231", "r233", "r234", "r238", "r239", "r240", "r419", "r485", "r507" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of obligations due all related parties.", "label": "Due to Related Parties", "terseLabel": "Due to Related Parties" } } }, "localname": "DueToRelatedPartiesCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/RelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Abstract]", "terseLabel": "Net Loss Attributable to Tenon Medical, Inc. Per Share of Common Stock" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r68", "r114", "r115", "r117", "r118", "r119", "r126", "r128", "r132", "r133", "r134", "r137", "r138", "r377", "r378", "r492", "r512" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share, Basic", "terseLabel": "Basic" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r68", "r114", "r115", "r117", "r118", "r119", "r128", "r132", "r133", "r134", "r137", "r138", "r377", "r378", "r492", "r512" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Diluted", "terseLabel": "Diluted" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r135", "r136" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "Earnings Per Share, Policy [Policy Text Block]", "verboseLabel": "Net loss per share" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/SummaryOfSignificantAccountingPrinciplesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r390" ], "calculation": { "http://www.tenonmed.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "verboseLabel": "Effect of foreign currency translation on cash flow" } } }, "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent": { "auth_ref": [ "r486", "r506" ], "calculation": { "http://www.tenonmed.com/role/AccruedExpensesScheduleOfAccruedExpensesDetail": { "order": 1.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrentAndNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.", "label": "Employee-related Liabilities", "verboseLabel": "Accrued compensation" } } }, "localname": "EmployeeRelatedLiabilitiesCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/AccruedExpensesScheduleOfAccruedExpensesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]" } } }, "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/StockholdersEquitySummaryOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsDetail" ], "xbrltype": "stringItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "definitionGuidance": "Employee Stock Option [Member]", "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.", "label": "Share-based Payment Arrangement, Option [Member]", "verboseLabel": "Outstanding stock options [Member]" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/StockholdersEquityAdditionalInformationDetail", "http://www.tenonmed.com/role/StockholdersEquitySummaryOfShareBasedCompensationArrangementsByShareBasedPaymentAwardDetail", "http://www.tenonmed.com/role/SummaryOfSignificantAccountingPrinciplesScheduleOfSecuritiesExcludedDueToAntiDilutiveEffectDetail" ], "xbrltype": "domainItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity [Abstract]" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r0", "r60", "r61", "r62", "r109", "r110", "r111", "r113", "r120", "r123", "r139", "r192", "r294", "r296", "r342", "r343", "r344", "r353", "r354", "r376", "r391", "r392", "r393", "r394", "r395", "r396", "r415", "r515", "r516", "r517" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/CondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit", "http://www.tenonmed.com/role/StockholdersEquityAdditionalInformationDetail", "http://www.tenonmed.com/role/SubsequentEventsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_EquityMethodInvestmentOwnershipPercentage": { "auth_ref": [ "r188" ], "lang": { "en-us": { "role": { "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.", "label": "Equity Method Investment, Ownership Percentage", "terseLabel": "Ownership Percentage" } } }, "localname": "EquityMethodInvestmentOwnershipPercentage", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/CommitmentsAndContingenciesAdditionalInformationDetail", "http://www.tenonmed.com/role/StockholdersEquityAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "us-gaap_EquitySecuritiesFvNiCost": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Cost of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI). Excludes equity method investment and investment in equity security without readily determinable fair value.", "label": "Equity Securities, FV-NI, Cost", "verboseLabel": "Fair Value" } } }, "localname": "EquitySecuritiesFvNiCost", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/InvestmentsScheduleOfCostAndFairValueOfAvailableForSaleInvestmentsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/InvestmentsScheduleOfInvestmentsAtFairValueInFairValueHierarchyLevelDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "auth_ref": [ "r379", "r380", "r385" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.", "label": "Fair Value, Recurring and Nonrecurring [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/InvestmentsScheduleOfInvestmentsAtFairValueInFairValueHierarchyLevelDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock": { "auth_ref": [ "r379", "r380", "r381", "r384", "r385" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.", "label": "Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]", "terseLabel": "Schedule of Investments At Fair Value in Fair Value Hierarchy Level" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/InvestmentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r256", "r271", "r272", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r308", "r380", "r434", "r435", "r436" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/InvestmentsScheduleOfInvestmentsAtFairValueInFairValueHierarchyLevelDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r256", "r271", "r272", "r300", "r301", "r306", "r308", "r380", "r435" ], "lang": { "en-us": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value, Inputs, Level 2 [Member]" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/InvestmentsScheduleOfInvestmentsAtFairValueInFairValueHierarchyLevelDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r256", "r271", "r272", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r308", "r434", "r435", "r436" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Hierarchy and NAV [Domain]" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/InvestmentsScheduleOfInvestmentsAtFairValueInFairValueHierarchyLevelDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FinancialInstrumentAxis": { "auth_ref": [ "r181", "r182", "r184", "r185", "r186", "r195", "r196", "r197", "r198", "r199", "r201", "r202", "r203", "r204", "r267", "r292", "r373", "r431", "r432", "r433", "r434", "r435", "r436", "r437", "r438", "r439", "r440", "r441", "r442", "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r457", "r458", "r459", "r460", "r545", "r546", "r547", "r548", "r549", "r550", "r551" ], "lang": { "en-us": { "role": { "documentation": "Information by type of financial instrument.", "label": "Financial Instrument [Axis]" } } }, "localname": "FinancialInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/InvestmentsScheduleOfCostAndFairValueOfAvailableForSaleInvestmentsDetail", "http://www.tenonmed.com/role/InvestmentsScheduleOfInvestmentsAtFairValueInFairValueHierarchyLevelDetail" ], "xbrltype": "stringItemType" }, "us-gaap_GainLossOnInvestments": { "auth_ref": [ "r73", "r90", "r176" ], "calculation": { "http://www.tenonmed.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 8.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of realized and unrealized gain (loss) on investment.", "label": "Gain (Loss) on Investments", "terseLabel": "Gain on investments", "verboseLabel": "Net gain on investments" } } }, "localname": "GainLossOnInvestments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss", "http://www.tenonmed.com/role/InvestmentsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r72" ], "calculation": { "http://www.tenonmed.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 18.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General and Administrative Expense", "terseLabel": "General and administrative" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "auth_ref": [ "r69" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing general and administrative expense.", "label": "General and Administrative Expense [Member]", "terseLabel": "General and Administrative Expense [Member]", "verboseLabel": "General, and administrative" } } }, "localname": "GeneralAndAdministrativeExpenseMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/LeasesAdditionalInformationDetail", "http://www.tenonmed.com/role/StockholdersEquitySummaryOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsDetail" ], "xbrltype": "domainItemType" }, "us-gaap_GrossProfit": { "auth_ref": [ "r70", "r103", "r158", "r160", "r163", "r166", "r168", "r189", "r228", "r229", "r230", "r233", "r234", "r235", "r236", "r237", "r239", "r240", "r389" ], "calculation": { "http://www.tenonmed.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 12.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.", "label": "Gross Profit", "totalLabel": "Gross (Loss) Profit" } } }, "localname": "GrossProfit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_IPOMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "First sale of stock by a private company to the public.", "label": "IPO [Member]", "terseLabel": "IPO [Member]" } } }, "localname": "IPOMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/DebtAdditionalInformationDetail", "http://www.tenonmed.com/role/StockholdersEquityAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r211", "r214" ], "lang": { "en-us": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/LeasesAdditionalInformationDetail", "http://www.tenonmed.com/role/StockholdersEquitySummaryOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsDetail" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [ "r214" ], "lang": { "en-us": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/LeasesAdditionalInformationDetail", "http://www.tenonmed.com/role/StockholdersEquitySummaryOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsDetail" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxPolicyTextBlock": { "auth_ref": [ "r59", "r347", "r348", "r349", "r350", "r351", "r352" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.", "label": "Income Tax, Policy [Policy Text Block]", "terseLabel": "Income Taxes" } } }, "localname": "IncomeTaxPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/SummaryOfSignificantAccountingPrinciplesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxesPaidNet": { "auth_ref": [ "r93" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.", "label": "Income Taxes Paid, Net", "verboseLabel": "Income taxes" } } }, "localname": "IncomeTaxesPaidNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "auth_ref": [ "r89" ], "calculation": { "http://www.tenonmed.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 21.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.", "label": "Increase (Decrease) in Accounts Payable", "terseLabel": "Accounts payable" } } }, "localname": "IncreaseDecreaseInAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "auth_ref": [ "r89" ], "calculation": { "http://www.tenonmed.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 18.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.", "label": "Increase (Decrease) in Accounts Receivable", "negatedLabel": "Accounts receivable" } } }, "localname": "IncreaseDecreaseInAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedLiabilities": { "auth_ref": [ "r89" ], "calculation": { "http://www.tenonmed.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 22.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.", "label": "Increase (Decrease) in Accrued Liabilities", "verboseLabel": "Accrued expenses" } } }, "localname": "IncreaseDecreaseInAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInInventories": { "auth_ref": [ "r89" ], "calculation": { "http://www.tenonmed.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 19.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.", "label": "Increase (Decrease) in Inventories", "negatedLabel": "Inventory" } } }, "localname": "IncreaseDecreaseInInventories", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "Increase (decrease) in cash resulting from changes in:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": { "auth_ref": [ "r89", "r409" ], "calculation": { "http://www.tenonmed.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 23.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in obligation for operating lease.", "label": "Increase (Decrease) in Operating Lease Liability", "verboseLabel": "Operating lease liability" } } }, "localname": "IncreaseDecreaseInOperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "auth_ref": [ "r89" ], "calculation": { "http://www.tenonmed.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 20.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "negatedLabel": "Prepaid expenses and other assets" } } }, "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpenseDebt": { "auth_ref": [ "r75", "r262", "r270", "r273", "r274" ], "calculation": { "http://www.tenonmed.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 9.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt.", "label": "Interest Expense, Debt", "negatedLabel": "Interest expense" } } }, "localname": "InterestExpenseDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaidNet": { "auth_ref": [ "r84", "r87", "r93" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.", "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "verboseLabel": "Interest" } } }, "localname": "InterestPaidNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNet": { "auth_ref": [ "r5", "r28", "r427" ], "calculation": { "http://www.tenonmed.com/role/CondensedConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventory, Net", "terseLabel": "Inventory" } } }, "localname": "InventoryNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentTextBlock": { "auth_ref": [ "r183", "r187", "r190", "r191" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for investment.", "label": "Investment [Text Block]", "terseLabel": "Investments" } } }, "localname": "InvestmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/Investments" ], "xbrltype": "textBlockItemType" }, "us-gaap_InvestmentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Investments [Abstract]" } } }, "localname": "InvestmentsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_InvestmentsFairValueDisclosure": { "auth_ref": [ "r379" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.", "label": "Investments, Fair Value Disclosure" } } }, "localname": "InvestmentsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/InvestmentsScheduleOfInvestmentsAtFairValueInFairValueHierarchyLevelDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestorMember": { "auth_ref": [ "r418", "r419" ], "lang": { "en-us": { "role": { "documentation": "Business entity or individual that puts money, by purchase or expenditure, in something offering potential profitable returns, such as interest income or appreciation in value.", "label": "Investor [Member]" } } }, "localname": "InvestorMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/DebtAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims": { "auth_ref": [ "r90" ], "calculation": { "http://www.tenonmed.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 24.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims.", "label": "Issuance of Stock and Warrants for Services or Claims", "terseLabel": "Common stock issued for services" } } }, "localname": "IssuanceOfStockAndWarrantsForServicesOrClaims", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeasesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Leases [Abstract]" } } }, "localname": "LeasesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_LesseeDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Lessee Disclosure [Abstract]" } } }, "localname": "LesseeDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "auth_ref": [ "r411" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.", "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]", "terseLabel": "Summary of Future Maturities of Operating Lease Liabilities" } } }, "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "auth_ref": [ "r411" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.", "label": "Lessee, Operating Lease, Liability, to be Paid", "totalLabel": "Total lease payments" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/LeasesSummaryOfFutureMaturitiesOfOperatingLeaseLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "auth_ref": [ "r411" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year One", "terseLabel": "2023" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/LeasesSummaryOfFutureMaturitiesOfOperatingLeaseLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [ "r411" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four", "terseLabel": "2026" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/LeasesSummaryOfFutureMaturitiesOfOperatingLeaseLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r411" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three", "terseLabel": "2025" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/LeasesSummaryOfFutureMaturitiesOfOperatingLeaseLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r411" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two", "terseLabel": "2024" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/LeasesSummaryOfFutureMaturitiesOfOperatingLeaseLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": { "auth_ref": [ "r411" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.", "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year", "terseLabel": "2022" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/LeasesSummaryOfFutureMaturitiesOfOperatingLeaseLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r411" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "negatedLabel": "Less: imputed interest" } } }, "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/LeasesSummaryOfFutureMaturitiesOfOperatingLeaseLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseRemainingLeaseTerm": { "auth_ref": [ "r407" ], "lang": { "en-us": { "role": { "documentation": "Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Lessee, Operating Lease, Remaining Lease Term", "terseLabel": "Remaining lease term - operating leases (in years)" } } }, "localname": "LesseeOperatingLeaseRemainingLeaseTerm", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/LeasesSummaryOfFutureMaturitiesOfOperatingLeaseLiabilitiesDetail" ], "xbrltype": "durationItemType" }, "us-gaap_LesseeOperatingLeasesTextBlock": { "auth_ref": [ "r413" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.", "label": "Lessee, Operating Leases [Text Block]", "terseLabel": "Leases" } } }, "localname": "LesseeOperatingLeasesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/Leases" ], "xbrltype": "textBlockItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r34", "r103", "r162", "r189", "r228", "r229", "r230", "r233", "r234", "r235", "r236", "r237", "r239", "r240", "r360", "r366", "r367", "r389", "r425", "r426" ], "calculation": { "http://www.tenonmed.com/role/CondensedConsolidatedBalanceSheets": { "order": 11.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r27", "r103", "r189", "r389", "r427", "r482", "r503" ], "calculation": { "http://www.tenonmed.com/role/CondensedConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "TOTAL LIABILITIES, CONVERTIBLE PREFERRED STOCK, AND STOCKHOLDERS' EQUITY (DEFICIT)" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "LIABILITIES, CONVERTIBLE PREFERRED STOCK, AND STOCKHOLDERS' EQUITY (DEFICIT)" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r8", "r36", "r103", "r189", "r228", "r229", "r230", "r233", "r234", "r235", "r236", "r237", "r239", "r240", "r360", "r366", "r367", "r389", "r425", "r426", "r427" ], "calculation": { "http://www.tenonmed.com/role/CondensedConsolidatedBalanceSheets": { "order": 13.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LitigationSettlementAmountAwardedToOtherParty": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount awarded to other party in judgment or settlement of litigation.", "label": "Litigation Settlement, Amount Awarded to Other Party", "terseLabel": "Litigation Settlement" } } }, "localname": "LitigationSettlementAmountAwardedToOtherParty", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/CommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LossContingenciesByNatureOfContingencyAxis": { "auth_ref": [ "r218", "r219", "r220", "r221", "r222", "r226", "r227" ], "lang": { "en-us": { "role": { "documentation": "Information by type of existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur.", "label": "Loss Contingency Nature [Axis]" } } }, "localname": "LossContingenciesByNatureOfContingencyAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/CommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_LossContingencyDamagesSoughtValue": { "auth_ref": [ "r218", "r219", "r221" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The value (monetary amount) of the award the plaintiff seeks in the legal matter.", "label": "Loss Contingency, Damages Sought, Value", "terseLabel": "Loss Contingency, Damages Sought, Value" } } }, "localname": "LossContingencyDamagesSoughtValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/CommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LossContingencyNatureDomain": { "auth_ref": [ "r218", "r219", "r220", "r221", "r222", "r226", "r227" ], "lang": { "en-us": { "role": { "documentation": "An existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur. Resolution of the uncertainty may confirm the incurrence of a loss or impairment of an asset or the incurrence of a liability.", "label": "Loss Contingency, Nature [Domain]" } } }, "localname": "LossContingencyNatureDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/CommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputExpectedDividendRateMember": { "auth_ref": [ "r382" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using expected dividend rate to be paid to holder of share per year.", "label": "Measurement Input, Expected Dividend Rate [Member]" } } }, "localname": "MeasurementInputExpectedDividendRateMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/StockholdersEquityAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputExpectedTermMember": { "auth_ref": [ "r382" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date.", "label": "Measurement Input, Expected Term [Member]" } } }, "localname": "MeasurementInputExpectedTermMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/StockholdersEquityAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputPriceVolatilityMember": { "auth_ref": [ "r382" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns.", "label": "Measurement Input, Price Volatility [Member]" } } }, "localname": "MeasurementInputPriceVolatilityMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/StockholdersEquityAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputRiskFreeInterestRateMember": { "auth_ref": [ "r382" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss.", "label": "Measurement Input, Risk Free Interest Rate [Member]" } } }, "localname": "MeasurementInputRiskFreeInterestRateMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/StockholdersEquityAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputTypeAxis": { "auth_ref": [ "r382" ], "lang": { "en-us": { "role": { "documentation": "Information by type of measurement input used to determine value of asset and liability.", "label": "Measurement Input Type [Axis]" } } }, "localname": "MeasurementInputTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/StockholdersEquityAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_MeasurementInputTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement input used to determine value of asset and liability.", "label": "Measurement Input Type [Domain]" } } }, "localname": "MeasurementInputTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/StockholdersEquityAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_MinorityInterest": { "auth_ref": [ "r45", "r103", "r189", "r228", "r233", "r234", "r235", "r239", "r240", "r389", "r481", "r502" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).", "label": "Stockholders' Equity Attributable to Noncontrolling Interest", "terseLabel": "Carrying value of the non controlling interest" } } }, "localname": "MinorityInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/StockholdersEquityAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetAssetsGeographicAreaMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of the total assets less the total liabilities of a designated geographic area ( such as a state, country, continent, or market) when it serves as a benchmark in a concentration of risk calculation.", "label": "Net Assets, Geographic Area [Member]", "terseLabel": "Net Assets, Geographic Area [Member]" } } }, "localname": "NetAssetsGeographicAreaMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/ConcentrationsOfRiskAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r86" ], "calculation": { "http://www.tenonmed.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 6.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "Cash Flows from Financing Activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r86" ], "calculation": { "http://www.tenonmed.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash used in investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "verboseLabel": "Cash Flows from Investing Activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r86", "r88", "r91" ], "calculation": { "http://www.tenonmed.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 12.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash used in operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "verboseLabel": "Cash Flows from Operating Activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r2", "r53", "r56", "r62", "r64", "r91", "r103", "r112", "r114", "r115", "r117", "r118", "r122", "r123", "r131", "r158", "r160", "r163", "r166", "r168", "r189", "r228", "r229", "r230", "r233", "r234", "r235", "r236", "r237", "r239", "r240", "r378", "r389", "r488", "r508" ], "calculation": { "http://www.tenonmed.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "totalLabel": "Net Loss Attributable to Tenon Medical, Inc." } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": { "auth_ref": [ "r53", "r56", "r62", "r122", "r123", "r362", "r368" ], "calculation": { "http://www.tenonmed.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 19.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest.", "label": "Net Income (Loss) Attributable to Noncontrolling Interest", "terseLabel": "Loss attributable to non-controlling interest" } } }, "localname": "NetIncomeLossAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "verboseLabel": "Recent Accounting Pronouncements" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/SummaryOfSignificantAccountingPrinciplesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NoncashInvestingAndFinancingItemsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Noncash Investing and Financing Items [Abstract]", "terseLabel": "Non-cash investment and financing activities:" } } }, "localname": "NoncashInvestingAndFinancingItemsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NoncontrollingInterestMember": { "auth_ref": [ "r109", "r110", "r111", "r296", "r355" ], "lang": { "en-us": { "role": { "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.", "label": "Noncontrolling Interest [Member]", "terseLabel": "Noncontrolling Interest [Member]" } } }, "localname": "NoncontrollingInterestMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/CondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit", "http://www.tenonmed.com/role/StockholdersEquityAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_NonoperatingIncomeExpense": { "auth_ref": [ "r74" ], "calculation": { "http://www.tenonmed.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 7.0, "parentTag": "us-gaap_ProfitLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).", "label": "Nonoperating Income (Expense)", "totalLabel": "Total Other Income (Expense), net" } } }, "localname": "NonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Nonoperating Income (Expense) [Abstract]", "terseLabel": "Other Income (Expense)" } } }, "localname": "NonoperatingIncomeExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "stringItemType" }, "us-gaap_OfficeEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tangible personal property used in an office setting. Examples include, but are not limited to, computers, copiers and fax machine.", "label": "Office Equipment [Member]", "terseLabel": "Office Equipment [Member]" } } }, "localname": "OfficeEquipmentMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/FixedAssetsSummaryOfFixedAssetsAndEquipmentNetDetail" ], "xbrltype": "domainItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://www.tenonmed.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 15.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating Expenses", "totalLabel": "Total Operating Expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating Expenses [Abstract]", "terseLabel": "Operating Expenses" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r158", "r160", "r163", "r166", "r168" ], "calculation": { "http://www.tenonmed.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 11.0, "parentTag": "us-gaap_ProfitLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Loss from Operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseCost": { "auth_ref": [ "r408", "r412" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.", "label": "Operating Lease, Cost", "terseLabel": "Operating lease costs" } } }, "localname": "OperatingLeaseCost", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/LeasesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiability": { "auth_ref": [ "r405" ], "calculation": { "http://www.tenonmed.com/role/LeasesSummaryOfSupplementalBalanceSheetInformationRelatedToLeasesDetail": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "label": "Operating Lease, Liability", "negatedTotalLabel": "Total operating lease liabilities", "terseLabel": "Present value of operating lease liabilities" } } }, "localname": "OperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/LeasesSummaryOfFutureMaturitiesOfOperatingLeaseLiabilitiesDetail", "http://www.tenonmed.com/role/LeasesSummaryOfSupplementalBalanceSheetInformationRelatedToLeasesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r405" ], "calculation": { "http://www.tenonmed.com/role/CondensedConsolidatedBalanceSheets": { "order": 16.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 }, "http://www.tenonmed.com/role/LeasesSummaryOfSupplementalBalanceSheetInformationRelatedToLeasesDetail": { "order": 1.0, "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Operating Lease, Liability, Current", "negatedLabel": "Operating lease liability, current", "terseLabel": "Current portion of operating lease liability" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/CondensedConsolidatedBalanceSheets", "http://www.tenonmed.com/role/LeasesSummaryOfSupplementalBalanceSheetInformationRelatedToLeasesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r405" ], "calculation": { "http://www.tenonmed.com/role/CondensedConsolidatedBalanceSheets": { "order": 12.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 }, "http://www.tenonmed.com/role/LeasesSummaryOfSupplementalBalanceSheetInformationRelatedToLeasesDetail": { "order": 2.0, "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating Lease, Liability, Noncurrent", "negatedLabel": "Operating lease liability, noncurrent", "terseLabel": "Operating lease liability, net of current portion" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/CondensedConsolidatedBalanceSheets", "http://www.tenonmed.com/role/LeasesSummaryOfSupplementalBalanceSheetInformationRelatedToLeasesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasePayments": { "auth_ref": [ "r406", "r409" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.", "label": "Operating Lease, Payments", "terseLabel": "Cash paid for operating leases" } } }, "localname": "OperatingLeasePayments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/LeasesSummaryOfFutureMaturitiesOfOperatingLeaseLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r404" ], "calculation": { "http://www.tenonmed.com/role/CondensedConsolidatedBalanceSheets": { "order": 9.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating Lease, Right-of-Use Asset", "terseLabel": "Operating lease right-of-use asset", "verboseLabel": "Operating lease right-of-use assets" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/CondensedConsolidatedBalanceSheets", "http://www.tenonmed.com/role/LeasesSummaryOfSupplementalBalanceSheetInformationRelatedToLeasesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": { "auth_ref": [ "r90" ], "calculation": { "http://www.tenonmed.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 17.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense for right-of-use asset from operating lease.", "label": "Operating Lease, Right-of-Use Asset, Amortization Expense", "verboseLabel": "Amortization of operating right-of-use asset" } } }, "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r410", "r412" ], "lang": { "en-us": { "role": { "documentation": "Weighted average discount rate for operating lease calculated at point in time.", "label": "Operating Lease, Weighted Average Discount Rate, Percent", "terseLabel": "Average discount rate - operating leases" } } }, "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/LeasesSummaryOfFutureMaturitiesOfOperatingLeaseLiabilitiesDetail" ], "xbrltype": "percentItemType" }, "us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock": { "auth_ref": [ "r108", "r125", "r154", "r370" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the general note to the financial statements for the reporting entity which may include, descriptions of the basis of presentation, business description, significant accounting policies, consolidations, reclassifications, new pronouncements not yet adopted and changes in accounting principles.", "label": "Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block]", "verboseLabel": "Organization and Business" } } }, "localname": "OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/OrganizationAndBusiness" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent": { "auth_ref": [ "r486", "r506" ], "calculation": { "http://www.tenonmed.com/role/AccruedExpensesScheduleOfAccruedExpensesDetail": { "order": 3.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrentAndNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses incurred but not yet paid classified as other.", "label": "Other Accrued Liabilities", "verboseLabel": "Other accrued expenses" } } }, "localname": "OtherAccruedLiabilitiesCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/AccruedExpensesScheduleOfAccruedExpensesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherCommitmentsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Other Commitments [Line Items]" } } }, "localname": "OtherCommitmentsLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/CommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_OtherCommitmentsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about obligations resulting from other commitments.", "label": "Other Commitments [Table]" } } }, "localname": "OtherCommitmentsTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/CommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent": { "auth_ref": [ "r356", "r357", "r364" ], "calculation": { "http://www.tenonmed.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 5.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent", "terseLabel": "Foreign currency translation adjustment" } } }, "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": { "auth_ref": [ "r54", "r57", "r356", "r357", "r364" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.", "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent", "terseLabel": "Other comprehensive income" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/CondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingIncomeExpense": { "auth_ref": [ "r76" ], "calculation": { "http://www.tenonmed.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 10.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.", "label": "Other Nonoperating Income (Expense)", "terseLabel": "Other income (expense)" } } }, "localname": "OtherNonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsPortionInOtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAvailableforsaleSecurities": { "auth_ref": [ "r180" ], "calculation": { "http://www.tenonmed.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 4.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of other than temporary impairment (OTTI) on investment in available-for-sale debt security, recognized in other comprehensive loss, attributable to parent entity.", "label": "Other than Temporary Impairment Losses, Investments, Portion in Other Comprehensive Loss, Net of Tax, Portion Attributable to Parent, Available-for-sale Securities", "negatedLabel": "Unrealized loss on investments", "verboseLabel": "Other than temporary impairment losses" } } }, "localname": "OtherThanTemporaryImpairmentLossesInvestmentsPortionInOtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAvailableforsaleSecurities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss", "http://www.tenonmed.com/role/InvestmentsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaidInKindInterest": { "auth_ref": [ "r90" ], "calculation": { "http://www.tenonmed.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 14.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Interest paid other than in cash for example by issuing additional debt securities. As a noncash item, it is added to net income when calculating cash provided by or used in operations using the indirect method.", "label": "Paid-in-Kind Interest", "verboseLabel": "Non-cash interest expense" } } }, "localname": "PaidInKindInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PayablesAndAccrualsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Payables and Accruals [Abstract]" } } }, "localname": "PayablesAndAccrualsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_PaymentsOfDebtIssuanceCosts": { "auth_ref": [ "r83" ], "calculation": { "http://www.tenonmed.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.", "label": "Payments of Debt Issuance Costs", "negatedLabel": "Debt issuance costs" } } }, "localname": "PaymentsOfDebtIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireInvestments": { "auth_ref": [ "r79" ], "calculation": { "http://www.tenonmed.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the purchase of all investments (debt, security, other) during the period.", "label": "Payments to Acquire Investments", "negatedLabel": "Purchases of short-term investments" } } }, "localname": "PaymentsToAcquireInvestments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r78" ], "calculation": { "http://www.tenonmed.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments to Acquire Property, Plant, and Equipment", "negatedLabel": "Purchases of property and equipment" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r338" ], "lang": { "en-us": { "role": { "documentation": "Information by plan name for share-based payment arrangement.", "label": "Plan Name [Axis]" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/StockholdersEquityAdditionalInformationDetail", "http://www.tenonmed.com/role/SubsequentEventsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [ "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r338" ], "lang": { "en-us": { "role": { "documentation": "Plan name for share-based payment arrangement.", "label": "Plan Name [Domain]" } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/StockholdersEquityAdditionalInformationDetail", "http://www.tenonmed.com/role/SubsequentEventsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockConvertibleConversionRatio": { "auth_ref": [ "r279" ], "lang": { "en-us": { "role": { "documentation": "Number of common shares issuable upon conversion for each share of preferred stock to be converted.", "label": "Preferred Stock, Convertible, Conversion Ratio", "terseLabel": "Conversion ratio" } } }, "localname": "PreferredStockConvertibleConversionRatio", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/StockholdersEquityAdditionalInformationDetail" ], "xbrltype": "pureItemType" }, "us-gaap_PrepaidExpenseCurrent": { "auth_ref": [ "r6", "r29", "r205", "r206" ], "calculation": { "http://www.tenonmed.com/role/CondensedConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Prepaid Expense, Current", "terseLabel": "Prepaid expenses" } } }, "localname": "PrepaidExpenseCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing prepaid expenses and other current assets.", "label": "Prepaid Expenses and Other Current Assets [Member]" } } }, "localname": "PrepaidExpensesAndOtherCurrentAssetsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/InvestmentsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ProceedsFromConvertibleDebt": { "auth_ref": [ "r81" ], "calculation": { "http://www.tenonmed.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.", "label": "Proceeds from Convertible Debt", "terseLabel": "Proceeds from issuance of convertible notes payable" } } }, "localname": "ProceedsFromConvertibleDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "auth_ref": [ "r80" ], "calculation": { "http://www.tenonmed.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the additional capital contribution to the entity.", "label": "Proceeds from Issuance of Common Stock", "terseLabel": "Proceeds from issuance of common stock, net of issuance costs" } } }, "localname": "ProceedsFromIssuanceOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/CondensedConsolidatedStatementsOfCashFlows", "http://www.tenonmed.com/role/SummaryOfSignificantAccountingPrinciplesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock": { "auth_ref": [ "r80" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock.", "label": "Proceeds from Issuance of Convertible Preferred Stock", "terseLabel": "Proceeds from issuance of convertible preferred stock" } } }, "localname": "ProceedsFromIssuanceOfConvertiblePreferredStock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/StockholdersEquityAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromRelatedPartyDebt": { "auth_ref": [ "r81" ], "crdr": "debit", "lang": { "en-us": { "role": { "definitionGuidance": "Proceeds from related party debt", "documentation": "The cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates.", "label": "Proceeds from Related Party Debt", "terseLabel": "Proceeds from related party debt" } } }, "localname": "ProceedsFromRelatedPartyDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/DebtAdditionalInformationDetail", "http://www.tenonmed.com/role/RelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments": { "auth_ref": [ "r77" ], "calculation": { "http://www.tenonmed.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the sale, maturity and collection of all investments such as debt, security and so forth during the period.", "label": "Proceeds from Sale, Maturity and Collection of Investments", "terseLabel": "Sales of short-term investments" } } }, "localname": "ProceedsFromSaleMaturityAndCollectionsOfInvestments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProfitLoss": { "auth_ref": [ "r2", "r53", "r56", "r62", "r85", "r103", "r112", "r122", "r123", "r158", "r160", "r163", "r166", "r168", "r189", "r228", "r229", "r230", "r233", "r234", "r235", "r236", "r237", "r239", "r240", "r356", "r361", "r363", "r368", "r369", "r378", "r389", "r493" ], "calculation": { "http://www.tenonmed.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.tenonmed.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 6.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.", "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "terseLabel": "Net loss", "totalLabel": "Net Loss" } } }, "localname": "ProfitLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/CondensedConsolidatedStatementsOfCashFlows", "http://www.tenonmed.com/role/CondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit", "http://www.tenonmed.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Abstract]", "terseLabel": "Fixed Assets [Abstract]" } } }, "localname": "PropertyPlantAndEquipmentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r210" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Long-Lived Tangible Asset [Axis]", "terseLabel": "Long-Lived Tangible Asset [Axis]" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/FixedAssetsSummaryOfFixedAssetsAndEquipmentNetDetail" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "auth_ref": [ "r212", "r534", "r535", "r536" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property, Plant and Equipment Disclosure [Text Block]", "terseLabel": "Fixed Assets" } } }, "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/FixedAssets" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentGross": { "auth_ref": [ "r11", "r208" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Gross", "terseLabel": "Fixed Assets, gross" } } }, "localname": "PropertyPlantAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/FixedAssetsSummaryOfFixedAssetsAndEquipmentNetDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Property, Plant and Equipment [Line Items]", "terseLabel": "Fixed Assets [Line Items]" } } }, "localname": "PropertyPlantAndEquipmentLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/FixedAssetsSummaryOfFixedAssetsAndEquipmentNetDetail" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r210", "r427", "r494", "r504" ], "calculation": { "http://www.tenonmed.com/role/CondensedConsolidatedBalanceSheets": { "order": 7.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Net", "terseLabel": "Fixed assets - net", "totalLabel": "Fixed Assets, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/CondensedConsolidatedBalanceSheets", "http://www.tenonmed.com/role/FixedAssetsSummaryOfFixedAssetsAndEquipmentNetDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "auth_ref": [ "r210" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table Text Block]", "verboseLabel": "Summary of Fixed Assets" } } }, "localname": "PropertyPlantAndEquipmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/FixedAssetsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r208" ], "lang": { "en-us": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.", "label": "Long-Lived Tangible Asset [Domain]", "terseLabel": "Long-Lived Tangible Asset [Domain]" } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/FixedAssetsSummaryOfFixedAssetsAndEquipmentNetDetail" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyDomain": { "auth_ref": [ "r307", "r418", "r419" ], "lang": { "en-us": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Domain]", "terseLabel": "Related Party [Domain]" } } }, "localname": "RelatedPartyDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/CommitmentsAndContingenciesAdditionalInformationDetail", "http://www.tenonmed.com/role/DebtAdditionalInformationDetail", "http://www.tenonmed.com/role/RelatedPartyTransactionsAdditionalInformationDetail", "http://www.tenonmed.com/role/SubsequentEventsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionAmountsOfTransaction": { "auth_ref": [ "r418", "r422" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of transactions with related party during the financial reporting period.", "label": "Related Party Transaction, Amounts of Transaction", "terseLabel": "Related party transaction amounts of payments" } } }, "localname": "RelatedPartyTransactionAmountsOfTransaction", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/RelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyTransactionAxis": { "auth_ref": [ "r307", "r418", "r419", "r422" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party transaction.", "label": "Related Party Transaction [Axis]" } } }, "localname": "RelatedPartyTransactionAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/RelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionDomain": { "auth_ref": [ "r307" ], "lang": { "en-us": { "role": { "documentation": "Transaction between related party.", "label": "Related Party Transaction [Domain]" } } }, "localname": "RelatedPartyTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/RelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty": { "auth_ref": [ "r418" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.", "label": "Related Party Transaction, Expenses from Transactions with Related Party", "terseLabel": "Related party transaction, expenses from transactions with related party" } } }, "localname": "RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/RelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyTransactionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Related Party Transaction [Line Items]" } } }, "localname": "RelatedPartyTransactionLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/RelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Related Party Transactions [Abstract]" } } }, "localname": "RelatedPartyTransactionsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "auth_ref": [ "r307", "r418", "r422", "r464", "r465", "r466", "r467", "r468", "r469", "r470", "r471", "r472", "r473", "r474", "r475" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Axis]", "terseLabel": "Related Party [Axis]" } } }, "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/CommitmentsAndContingenciesAdditionalInformationDetail", "http://www.tenonmed.com/role/DebtAdditionalInformationDetail", "http://www.tenonmed.com/role/RelatedPartyTransactionsAdditionalInformationDetail", "http://www.tenonmed.com/role/SubsequentEventsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "auth_ref": [ "r416", "r417", "r419", "r423", "r424" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Related Party Transactions Disclosure [Text Block]", "terseLabel": "Related Party Transactions" } } }, "localname": "RelatedPartyTransactionsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/RelatedPartyTransactions" ], "xbrltype": "textBlockItemType" }, "us-gaap_RepaymentsOfConvertibleDebt": { "auth_ref": [ "r82" ], "calculation": { "http://www.tenonmed.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow from the repayment of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.", "label": "Repayments of Convertible Debt", "negatedLabel": "Repayment of notes payable" } } }, "localname": "RepaymentsOfConvertibleDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r346", "r462", "r539" ], "calculation": { "http://www.tenonmed.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 16.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and Development Expense", "terseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.", "label": "Research and Development Expense [Member]", "terseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpenseMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/StockholdersEquitySummaryOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsDetail" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedStockMember": { "auth_ref": [ "r135" ], "lang": { "en-us": { "role": { "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.", "label": "Restricted Stock [Member]", "terseLabel": "Outstanding restricted stock units [Member]" } } }, "localname": "RestrictedStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/SummaryOfSignificantAccountingPrinciplesScheduleOfSecuritiesExcludedDueToAntiDilutiveEffectDetail" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedStockUnitsRSUMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.", "label": "Restricted Stock Units (RSUs) [Member]" } } }, "localname": "RestrictedStockUnitsRSUMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/StockholdersEquitySummaryOfShareBasedCompensationArrangementsByShareBasedPaymentAwardDetail" ], "xbrltype": "domainItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r23", "r296", "r427", "r501", "r519", "r524" ], "calculation": { "http://www.tenonmed.com/role/CondensedConsolidatedBalanceSheets": { "order": 22.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "terseLabel": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r0", "r109", "r110", "r111", "r113", "r120", "r123", "r192", "r342", "r343", "r344", "r353", "r354", "r376", "r515", "r517" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "terseLabel": "Accumulated Deficit [Member]" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/CondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_Revenues": { "auth_ref": [ "r63", "r103", "r155", "r156", "r159", "r164", "r165", "r169", "r170", "r171", "r189", "r228", "r229", "r230", "r233", "r234", "r235", "r236", "r237", "r239", "r240", "r389", "r493" ], "calculation": { "http://www.tenonmed.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 13.0, "parentTag": "us-gaap_GrossProfit", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).", "label": "Revenues", "terseLabel": "Revenue", "verboseLabel": "Revenues" } } }, "localname": "Revenues", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss", "http://www.tenonmed.com/role/RelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_RisksAndUncertaintiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Risks and Uncertainties [Abstract]" } } }, "localname": "RisksAndUncertaintiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Cash received on stock transaction after deduction of issuance costs.", "label": "Sale of Stock, Consideration Received on Transaction", "terseLabel": "Net proceeds from the IPO after deducting expenses" } } }, "localname": "SaleOfStockConsiderationReceivedOnTransaction", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/StockholdersEquityAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.", "label": "Sale of Stock [Domain]" } } }, "localname": "SaleOfStockNameOfTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/DebtAdditionalInformationDetail", "http://www.tenonmed.com/role/StockholdersEquityAdditionalInformationDetail", "http://www.tenonmed.com/role/SubsequentEventsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_SaleOfStockPricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.", "label": "Sale of Stock, Price Per Share", "terseLabel": "Sale of stock, price per share" } } }, "localname": "SaleOfStockPricePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/StockholdersEquityAdditionalInformationDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of accrued liabilities.", "label": "Schedule of Accrued Liabilities [Table Text Block]", "verboseLabel": "Schedule of Accrued Expenses" } } }, "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/AccruedExpensesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "auth_ref": [ "r135" ], "lang": { "en-us": { "role": { "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/SummaryOfSignificantAccountingPrinciplesScheduleOfSecuritiesExcludedDueToAntiDilutiveEffectDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "auth_ref": [ "r135" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "verboseLabel": "Schedule of Securities Excluded Due To Anti Dilutive Effect" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/SummaryOfSignificantAccountingPrinciplesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Securities, Available-for-sale [Line Items]" } } }, "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/InvestmentsScheduleOfCostAndFairValueOfAvailableForSaleInvestmentsDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": { "auth_ref": [ "r339", "r345" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.", "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/StockholdersEquitySummaryOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "auth_ref": [ "r339" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.", "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]", "terseLabel": "Summary of Employee Service Share Based Compensation Allocation of Recognized Period Costs" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/StockholdersEquityTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "auth_ref": [ "r210" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table]", "terseLabel": "Fixed Assets [Table]" } } }, "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/FixedAssetsSummaryOfFixedAssetsAndEquipmentNetDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": { "auth_ref": [ "r420", "r422" ], "lang": { "en-us": { "role": { "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Schedule of Related Party Transactions, by Related Party [Table]" } } }, "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/RelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_SellingAndMarketingExpense": { "auth_ref": [], "calculation": { "http://www.tenonmed.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 17.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "definitionGuidance": "Selling and marketing expense", "documentation": "The aggregate total amount of expenses directly related to the marketing or selling of products or services.", "label": "Selling and Marketing Expense", "terseLabel": "Sales and marketing", "verboseLabel": "Sales and marketing expense" } } }, "localname": "SellingAndMarketingExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/CommitmentsAndContingenciesAdditionalInformationDetail", "http://www.tenonmed.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss", "http://www.tenonmed.com/role/SubsequentEventsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_SellingAndMarketingExpenseMember": { "auth_ref": [ "r69" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing selling and marketing expense.", "label": "Selling and Marketing Expense [Member]", "terseLabel": "Sales and marketing" } } }, "localname": "SellingAndMarketingExpenseMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/StockholdersEquitySummaryOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r89" ], "calculation": { "http://www.tenonmed.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 15.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-based Payment Arrangement, Noncash Expense", "verboseLabel": "Stock-based compensation expense" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "auth_ref": [ "r313" ], "lang": { "en-us": { "role": { "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/StockholdersEquityAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "auth_ref": [ "r329" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "terseLabel": "Number of Outstanding Restricted Stock Units Forfeited" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/StockholdersEquitySummaryOfShareBasedCompensationArrangementsByShareBasedPaymentAwardDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "auth_ref": [ "r329" ], "lang": { "en-us": { "role": { "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value", "terseLabel": "Weighted-average Grant Date Fair Value per Share Forfeited" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/StockholdersEquitySummaryOfShareBasedCompensationArrangementsByShareBasedPaymentAwardDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "auth_ref": [ "r327" ], "lang": { "en-us": { "role": { "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period", "terseLabel": "Number of Outstanding Restricted Stock Units Granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/StockholdersEquitySummaryOfShareBasedCompensationArrangementsByShareBasedPaymentAwardDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r327" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Weighted-average Grant Date Fair Value per Share Granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/StockholdersEquitySummaryOfShareBasedCompensationArrangementsByShareBasedPaymentAwardDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "auth_ref": [ "r324", "r325" ], "lang": { "en-us": { "role": { "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "periodEndLabel": "Number of Outstanding Restricted Stock Units (Ending Balance)", "periodStartLabel": "Number of Outstanding Restricted Stock Units (Beginning Balance)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/StockholdersEquitySummaryOfShareBasedCompensationArrangementsByShareBasedPaymentAwardDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "auth_ref": [ "r324", "r325" ], "lang": { "en-us": { "role": { "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "periodEndLabel": "Weighted-average Grant Date Fair Value per Share (Ending Balance)", "periodStartLabel": "Weighted-average Grant Date Fair Value per Share (Beginning Balance)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/StockholdersEquitySummaryOfShareBasedCompensationArrangementsByShareBasedPaymentAwardDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "auth_ref": [ "r341" ], "lang": { "en-us": { "role": { "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant", "verboseLabel": "Share based compensation by share based payment award number of shares available for grant" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/StockholdersEquityAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [ "r320" ], "lang": { "en-us": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross", "terseLabel": "Number of Shares Subject to Outstanding Stock Options Granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/StockholdersEquitySummaryOfShareBasedCompensationArrangementsByShareBasedPaymentAwardDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r316", "r317" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "periodEndLabel": "Weighted Average Exercise Price Per Share Outstanding (Ending Balance)", "periodStartLabel": "Weighted Average Exercise Price Per Share Outstanding (Beginning Balance)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/StockholdersEquitySummaryOfShareBasedCompensationArrangementsByShareBasedPaymentAwardDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r338" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Award Type [Domain]" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/StockholdersEquityAdditionalInformationDetail", "http://www.tenonmed.com/role/StockholdersEquitySummaryOfShareBasedCompensationArrangementsByShareBasedPaymentAwardDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r322" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price", "terseLabel": "Weighted Average Exercise Price Per Share Forfeited" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/StockholdersEquitySummaryOfShareBasedCompensationArrangementsByShareBasedPaymentAwardDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r320" ], "lang": { "en-us": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "terseLabel": "Weighted Average Exercise Price Per Share Granted" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/StockholdersEquitySummaryOfShareBasedCompensationArrangementsByShareBasedPaymentAwardDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": { "auth_ref": [ "r314" ], "lang": { "en-us": { "role": { "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/StockholdersEquityAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of non-vested options outstanding.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares", "periodEndLabel": "Number of Shares Subject to Outstanding Stock Options Outstanding (Ending Balance)", "periodStartLabel": "Number of Shares Subject to Outstanding Stock Options (Beginning Balance)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/StockholdersEquitySummaryOfShareBasedCompensationArrangementsByShareBasedPaymentAwardDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of non-vested options forfeited.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested Options Forfeited, Number of Shares", "terseLabel": "Number of Shares Subject to Outstanding Stock Options Forfeited" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/StockholdersEquitySummaryOfShareBasedCompensationArrangementsByShareBasedPaymentAwardDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_SharesIssuedPricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Per share or per unit amount of equity securities issued.", "label": "Shares Issued, Price Per Share", "terseLabel": "Shares issued, Price per share" } } }, "localname": "SharesIssuedPricePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/StockholdersEquityAdditionalInformationDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "Shares, Outstanding", "periodEndLabel": "Ending Balance (in shares)", "periodStartLabel": "Beginning Balance (in shares)" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/CondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_ShortTermInvestments": { "auth_ref": [ "r30", "r483", "r484", "r496" ], "calculation": { "http://www.tenonmed.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.", "label": "Short-term Investments", "terseLabel": "Short-term investments" } } }, "localname": "ShortTermInvestments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r98", "r108" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "Significant Accounting Policies [Text Block]", "verboseLabel": "Summary of Significant Accounting Principles" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/SummaryOfSignificantAccountingPrinciples" ], "xbrltype": "textBlockItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [ "r19", "r20", "r21", "r100", "r103", "r128", "r129", "r130", "r132", "r134", "r140", "r141", "r142", "r189", "r228", "r233", "r234", "r235", "r239", "r240", "r277", "r278", "r283", "r287", "r294", "r389", "r545" ], "lang": { "en-us": { "role": { "documentation": "Information by the different classes of stock of the entity.", "label": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/CondensedConsolidatedBalanceSheets", "http://www.tenonmed.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://www.tenonmed.com/role/CondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit", "http://www.tenonmed.com/role/LeasesAdditionalInformationDetail", "http://www.tenonmed.com/role/StockholdersEquityAdditionalInformationDetail", "http://www.tenonmed.com/role/StockholdersEquitySummaryOfShareBasedCompensationArrangementsByShareBasedPaymentAwardDetail" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r0", "r44", "r60", "r61", "r62", "r109", "r110", "r111", "r113", "r120", "r123", "r139", "r192", "r294", "r296", "r342", "r343", "r344", "r353", "r354", "r376", "r391", "r392", "r393", "r394", "r395", "r396", "r415", "r515", "r516", "r517" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/CondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit", "http://www.tenonmed.com/role/StockholdersEquityAdditionalInformationDetail", "http://www.tenonmed.com/role/SubsequentEventsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/CondensedConsolidatedBalanceSheets", "http://www.tenonmed.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://www.tenonmed.com/role/CondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit", "http://www.tenonmed.com/role/InvestmentsAdditionalInformationDetail", "http://www.tenonmed.com/role/LeasesAdditionalInformationDetail", "http://www.tenonmed.com/role/StockholdersEquityAdditionalInformationDetail", "http://www.tenonmed.com/role/StockholdersEquitySummaryOfShareBasedCompensationArrangementsByShareBasedPaymentAwardDetail" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Comprehensive Income [Abstract]" } } }, "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r109", "r110", "r111", "r139", "r463" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/CondensedConsolidatedBalanceSheets", "http://www.tenonmed.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://www.tenonmed.com/role/CondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit", "http://www.tenonmed.com/role/InvestmentsAdditionalInformationDetail", "http://www.tenonmed.com/role/LeasesAdditionalInformationDetail", "http://www.tenonmed.com/role/StockholdersEquityAdditionalInformationDetail", "http://www.tenonmed.com/role/StockholdersEquitySummaryOfShareBasedCompensationArrangementsByShareBasedPaymentAwardDetail" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": { "auth_ref": [ "r43", "r259", "r294", "r295", "r296" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.", "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities", "terseLabel": "Common stock issued upon conversion of debt, Share", "verboseLabel": "Stock Issued During Period, Shares, Conversion of Convertible Securities" } } }, "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/CondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit", "http://www.tenonmed.com/role/DebtAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits": { "auth_ref": [ "r20", "r21", "r294", "r295", "r296" ], "lang": { "en-us": { "role": { "documentation": "The number of shares issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit).", "label": "Stock Issued During Period, Shares, Conversion of Units", "terseLabel": "Common stock issued upon conversion, Share" } } }, "localname": "StockIssuedDuringPeriodSharesConversionOfUnits", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/CondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.", "label": "Stock Issued During Period, Shares, Issued for Services", "terseLabel": "Stock issued during period, shares, issued for services to consultant", "verboseLabel": "Common stock issued for services, Share" } } }, "localname": "StockIssuedDuringPeriodSharesIssuedForServices", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/CondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit", "http://www.tenonmed.com/role/StockholdersEquityAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r20", "r21", "r294", "r296" ], "lang": { "en-us": { "role": { "definitionGuidance": "Stock issued during period, Shares, New issues", "documentation": "Number of new stock issued during the period.", "label": "Stock Issued During Period, Shares, New Issues", "terseLabel": "Stock issued during period shares new issues", "verboseLabel": "Issuance of common stock and warrants, net of issuance costs, Share" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/CommitmentsAndContingenciesAdditionalInformationDetail", "http://www.tenonmed.com/role/CondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit", "http://www.tenonmed.com/role/StockholdersEquityAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": { "auth_ref": [ "r44", "r294", "r296" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities.", "label": "Stock Issued During Period, Value, Conversion of Convertible Securities", "terseLabel": "Common stock issued upon conversion of debt" } } }, "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/CondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueConversionOfUnits": { "auth_ref": [ "r44", "r294", "r296" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit).", "label": "Stock Issued During Period, Value, Conversion of Units", "terseLabel": "Common stock issued upon conversion" } } }, "localname": "StockIssuedDuringPeriodValueConversionOfUnits", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/CondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.", "label": "Stock Issued During Period, Value, Issued for Services", "verboseLabel": "Common stock issued for services" } } }, "localname": "StockIssuedDuringPeriodValueIssuedForServices", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/CondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "auth_ref": [ "r20", "r21", "r294", "r296" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.", "label": "Stock Issued During Period, Value, New Issues", "terseLabel": "Stock issued during period value new issues", "verboseLabel": "Issuance of common stock and warrants, net of issuance costs" } } }, "localname": "StockIssuedDuringPeriodValueNewIssues", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/CommitmentsAndContingenciesAdditionalInformationDetail", "http://www.tenonmed.com/role/CondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r21", "r25", "r26", "r103", "r175", "r189", "r389", "r427" ], "calculation": { "http://www.tenonmed.com/role/CondensedConsolidatedBalanceSheets": { "order": 19.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Ending Balance", "periodStartLabel": "Beginning Balance", "totalLabel": "Total stockholders' equity (deficit)" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/CondensedConsolidatedBalanceSheets", "http://www.tenonmed.com/role/CondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Attributable to Parent [Abstract]", "terseLabel": "Stockholders' equity (deficit):" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r101", "r278", "r282", "r283", "r284", "r285", "r286", "r287", "r288", "r289", "r290", "r291", "r293", "r296", "r298", "r374" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "Stockholders' Equity Note Disclosure [Text Block]", "terseLabel": "Stockholders' Equity" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/StockholdersEquity" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsequentEventLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.", "label": "Subsequent Event [Line Items]" } } }, "localname": "SubsequentEventLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/SubsequentEventsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [ "r397", "r429" ], "lang": { "en-us": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event [Member]", "verboseLabel": "Subsequent Event [Member]" } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/SubsequentEventsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTable": { "auth_ref": [ "r397", "r429" ], "lang": { "en-us": { "role": { "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.", "label": "Subsequent Event [Table]" } } }, "localname": "SubsequentEventTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/SubsequentEventsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r397", "r429" ], "lang": { "en-us": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/CommitmentsAndContingenciesAdditionalInformationDetail", "http://www.tenonmed.com/role/StockholdersEquityAdditionalInformationDetail", "http://www.tenonmed.com/role/SubsequentEventsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r397", "r429" ], "lang": { "en-us": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Domain]" } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/CommitmentsAndContingenciesAdditionalInformationDetail", "http://www.tenonmed.com/role/StockholdersEquityAdditionalInformationDetail", "http://www.tenonmed.com/role/SubsequentEventsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]" } } }, "localname": "SubsequentEventsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [ "r428", "r430" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "Subsequent Events [Text Block]", "terseLabel": "Subsequent Events" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/SubsequentEvents" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsidiarySaleOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of sale of the entity's stock.", "label": "Sale of Stock [Axis]" } } }, "localname": "SubsidiarySaleOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/DebtAdditionalInformationDetail", "http://www.tenonmed.com/role/StockholdersEquityAdditionalInformationDetail", "http://www.tenonmed.com/role/SubsequentEventsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental Cash Flow Information [Abstract]", "terseLabel": "Supplemental Disclosures of Cash Flow Information" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_TemporaryEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Temporary Equity [Abstract]", "terseLabel": "Convertible preferred stock" } } }, "localname": "TemporaryEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_TemporaryEquityCarryingAmountAttributableToParent": { "auth_ref": [ "r228", "r233", "r234", "r235", "r239", "r240" ], "calculation": { "http://www.tenonmed.com/role/CondensedConsolidatedBalanceSheets": { "order": 25.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.", "label": "Temporary Equity, Carrying Amount, Attributable to Parent", "terseLabel": "Convertible Preferred Stock" } } }, "localname": "TemporaryEquityCarryingAmountAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests": { "auth_ref": [ "r41", "r103", "r189", "r389" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount, attributable to parent and noncontrolling interests, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.", "label": "Temporary Equity, Carrying Amount, Including Portion Attributable to Noncontrolling Interests", "periodEndLabel": "Ending Balance", "periodStartLabel": "Beginning Balance" } } }, "localname": "TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/CondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_TemporaryEquityLiquidationPreferencePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The per share liquidation preference (or restrictions) of stock classified as temporary equity that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.", "label": "Temporary Equity, Liquidation Preference Per Share", "terseLabel": "Temporary equity, Liquidation preference per share" } } }, "localname": "TemporaryEquityLiquidationPreferencePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/StockholdersEquityAdditionalInformationDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_TemporaryEquityParOrStatedValuePerShare": { "auth_ref": [ "r9", "r276" ], "lang": { "en-us": { "role": { "documentation": "Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable.", "label": "Temporary Equity, Par or Stated Value Per Share", "terseLabel": "Temporary equity par or stated value per share" } } }, "localname": "TemporaryEquityParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_TemporaryEquitySharesAuthorized": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.", "label": "Temporary Equity, Shares Authorized", "terseLabel": "Temporary equity shares authorized", "verboseLabel": "Temporary equity, Shares authorized" } } }, "localname": "TemporaryEquitySharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://www.tenonmed.com/role/StockholdersEquityAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_TemporaryEquitySharesIssued": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.", "label": "Temporary Equity, Shares Issued", "terseLabel": "Temporary equity shares issued" } } }, "localname": "TemporaryEquitySharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_TemporaryEquitySharesOutstanding": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.", "label": "Temporary Equity, Shares Outstanding", "terseLabel": "Temporary equity shares outstanding" } } }, "localname": "TemporaryEquitySharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "auth_ref": [ "r181", "r182", "r184", "r185", "r186", "r267", "r292", "r373", "r431", "r432", "r433", "r434", "r435", "r436", "r437", "r438", "r439", "r440", "r441", "r442", "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r457", "r458", "r459", "r460", "r545", "r546", "r547", "r548", "r549", "r550", "r551" ], "lang": { "en-us": { "role": { "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.", "label": "Financial Instruments [Domain]" } } }, "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/InvestmentsScheduleOfCostAndFairValueOfAvailableForSaleInvestmentsDetail", "http://www.tenonmed.com/role/InvestmentsScheduleOfInvestmentsAtFairValueInFairValueHierarchyLevelDetail" ], "xbrltype": "domainItemType" }, "us-gaap_UnrealizedGainLossOnInvestments": { "auth_ref": [ "r90" ], "calculation": { "http://www.tenonmed.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 25.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of unrealized gain (loss) on investment.", "label": "Unrealized Gain (Loss) on Investments", "negatedLabel": "Unrealized loss on investments" } } }, "localname": "UnrealizedGainLossOnInvestments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r143", "r144", "r145", "r146", "r151", "r152", "r153" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates, Policy [Policy Text Block]", "terseLabel": "Use of estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/SummaryOfSignificantAccountingPrinciplesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_WarrantMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.", "label": "Warrant [Member]", "verboseLabel": "Outstanding warrants [Member]" } } }, "localname": "WarrantMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/SummaryOfSignificantAccountingPrinciplesScheduleOfSecuritiesExcludedDueToAntiDilutiveEffectDetail" ], "xbrltype": "domainItemType" }, "us-gaap_WarrantsAndRightsOutstandingMeasurementInput": { "auth_ref": [ "r383" ], "lang": { "en-us": { "role": { "documentation": "Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.", "label": "Warrants and Rights Outstanding, Measurement Input" } } }, "localname": "WarrantsAndRightsOutstandingMeasurementInput", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/StockholdersEquityAdditionalInformationDetail" ], "xbrltype": "decimalItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r127", "r134" ], "lang": { "en-us": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number of Shares Outstanding, Diluted", "terseLabel": "Diluted" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]", "terseLabel": "Weighted-Average Shares of Common Stock Outstanding" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "stringItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r126", "r134" ], "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Basic" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.tenonmed.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "sharesItemType" } }, "unitCount": 6 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(f))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(k)(1))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(2)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690" }, "r108": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "https://asc.fasb.org/topic&trid=2122369" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=SL124452830-107794" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.M.Q2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693" }, "r125": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "250", "URI": "https://asc.fasb.org/topic&trid=2122394" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1278-109256" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "55", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2626-109256" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(18))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6327-108592" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6442-108592" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592" }, "r154": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "https://asc.fasb.org/topic&trid=2134479" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27405-111563" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(24))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL120269820-111563" }, "r183": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "320", "URI": "https://asc.fasb.org/topic&trid=2196928" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "321", "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "321", "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "321", "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714" }, "r187": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "321", "URI": "https://asc.fasb.org/topic&trid=75115024" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27)(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "323", "URI": "https://asc.fasb.org/topic&trid=2196965" }, "r191": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "325", "URI": "https://asc.fasb.org/topic&trid=2197064" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(3)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(4)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "340", "URI": "https://asc.fasb.org/extlink&oid=126905020&loc=d3e5879-108316" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "340", "URI": "https://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r212": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "360", "URI": "https://asc.fasb.org/topic&trid=2155823" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "410", "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r217": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "https://asc.fasb.org/topic&trid=2144648" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751" }, "r225": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "https://asc.fasb.org/topic&trid=2127136" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "460", "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12021-110248" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "460", "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12053-110248" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(i)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031898-161870" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "69E", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "69F", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612" }, "r275": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "https://asc.fasb.org/topic&trid=2208564" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Topic": "480", "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(7))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "50", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775" }, "r298": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "https://asc.fasb.org/topic&trid=2208762" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=77885760&loc=SL35686385-199418" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(8))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5047-113901" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5047-113901" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(04)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a),20,24)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(v)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4568447-111683" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569643-111683" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4613674-111683" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(3)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "4J", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r370": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "https://asc.fasb.org/topic&trid=2197479" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(b)(2)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(2))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "2C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL7498348-110258" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(1)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.27(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(4)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971" }, "r413": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/subtopic&trid=77888251" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(01)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864" }, "r424": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "850", "URI": "https://asc.fasb.org/topic&trid=2122745" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "855", "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-30)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r430": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "855", "URI": "https://asc.fasb.org/topic&trid=2122774" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(i)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(ii)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)(i)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.31)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(5)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(6)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(7)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(b)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "730", "Topic": "912", "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447" }, "r465": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447" }, "r466": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447" }, "r467": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447" }, "r468": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447" }, "r469": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313" }, "r470": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447" }, "r471": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447" }, "r472": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447" }, "r473": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447" }, "r474": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(1)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447" }, "r475": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(2)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447" }, "r476": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(10))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r477": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r478": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r479": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(15)(5))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313" }, "r480": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r481": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(22))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r482": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r483": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(4))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r484": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(5))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r485": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.15(3),(4))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r486": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.15(5))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r487": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r488": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r489": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(24))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580" }, "r490": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(25))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r491": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(26))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r492": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r493": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884" }, "r494": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630" }, "r495": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r496": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(1)(g))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r497": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(10))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r498": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r499": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(15)(a))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580" }, "r500": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r501": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r502": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(24))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r503": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r504": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r505": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r506": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.15(a))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r507": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.17)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r508": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r509": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(20))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580" }, "r510": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(21))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r511": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(22))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r512": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r513": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439" }, "r514": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441" }, "r515": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r516": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r517": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r518": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(1)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r519": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580" }, "r520": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r521": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iii)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r522": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iv)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r523": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(1)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r524": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r525": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(e)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124508989&loc=d3e19393-158473" }, "r526": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195" }, "r527": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "205", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=118262037&loc=d3e9915-115836" }, "r528": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(13))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=120401414&loc=d3e603758-122996" }, "r529": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-05(4))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=120401414&loc=d3e604008-122996" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580" }, "r530": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(6))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=120401555&loc=SL114874367-224272" }, "r531": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(7))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=120401555&loc=SL114874367-224272" }, "r532": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Topic": "954", "URI": "https://asc.fasb.org/extlink&oid=126942805&loc=d3e3115-115594" }, "r533": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(a)", "Topic": "954", "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629" }, "r534": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Subparagraph": "(d)", "Topic": "958", "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99779-112916" }, "r535": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99893-112916" }, "r536": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=SL120174063-112916" }, "r537": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663" }, "r538": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691" }, "r539": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580" }, "r540": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r541": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r542": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r543": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r544": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r545": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402" }, "r546": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(1)" }, "r547": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)" }, "r548": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(3)" }, "r549": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(i)" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580" }, "r550": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(ii)" }, "r551": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(iii)" }, "r552": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r553": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(1))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(22))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(23))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(24))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(4))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1,2)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7(c),9(a))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.8)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3000-108585" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(27)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4313-108586" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(c))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" } }, "version": "2.1" } ZIP 63 0001575872-22-001085-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001575872-22-001085-xbrl.zip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end